



European
Crohn's and Colitis
Organisation

Barcelona
Spain

Inflammatory Bowel Diseases

Final Programme



12th Congress of ECCO
CCIB Barcelona
February 15-18, 2017

www.ecco-ibd.eu



European
Crohn's and Colitis
Organisation

Barcelona
Spain

e-CCO Learning

Open access
preview @ the
ECCO Booth

e-CCO



Congress special: Open access preview

Are you looking for educational material? Check out...

Latest e-Courses

- Malignancies
- Extra-intestinal Manifestations
- Surgery in CD

Upcoming e-Courses

- Use of exclusive enteral nutrition in CD
- Transition

IBD Blue Book

- Disease monitoring in IBD
- Emergencies in IBD
- Imaging modalities in IBD

ECCO e-Library

- Congress Abstracts
- Congress Webcasts
- Congress Presentations

Latest Talking Heads

- When and if to stop biological therapy
- Understanding Cancer Risk
- Nursing perspective: Stoma & Pouch

New

- ECCO IBD Curriculum



Scan and visit

www.e-learning.ecco-ibd.eu



Word of welcome

Dear Colleagues,

It is my pleasure to welcome you to the ECCO Congress 2017 held in the charming city of Barcelona, Spain, on February 15-18, 2017. This is already the 12th Congress of the European Crohn's and Colitis Organisation. Barcelona is a city of design and creativity, and these components are an essential part of our congress programme for 2017.

The ECCO Congress 2017 is marked in our calendar year as a great opportunity for scientists and medical experts from a broad range of fields related to IBD, including gastroenterology, internal medicine, surgery, paediatrics, epidemiology, endoscopy, imaging, nursing, pathology and nutrition, to come together from around the world and learn about the latest trends in IBD research and clinical care. The annual congress attracts more than 6,000 delegates from all over the world, becoming the world's first IBD event for the presentation and dissemination of advances in the field.

The Organising Committee designed a programme that is attractive and indispensable for all the professionals related to IBD. For 2017 the theme of the congress is "Advancing knowledge, improving care". As the ECCO Congress has become the main world event for the presentation of new studies, the number of original oral presentations during the congress has expanded, and integrates new and functional formats in the sessions, with very dynamic presentations covering new treatment paradigms, and active focus on research.

Thanks to the generosity of our sponsors, and also to collaboration with other scientific societies (IOIBD, AOCC), the number of fellowships and grants awarded in Barcelona in 2017 is also increased. Around the congress, a wide offer of educational activities is deployed as usual, devoted to young specialists, nurses, colleagues from the industry, and in general to all those for whom IBD is a main focus and who are willing to gain deep insights into development of clinical trials, histology, imaging, surgical treatment and many other evolving topics in IBD.

On behalf of the whole ECCO Team I extend a warm welcome to you all, and wish you a very successful ECCO Congress 2017 in Barcelona!

Yours sincerely,

A handwritten signature in black ink, appearing to read "Panés", written in a cursive style.

Julián Panés
ECCO President & Chair of Organising Committee




Julián Panés

Table of contents

Word of welcome.....	3
ECCO Structure	5
Scientific Information: A-Z	11
Scientific programme day by day.....	19
Abstract presentation format	37
Poster exhibition	38
Digital oral presentations.....	43
Poster presentation.....	69
Educational programme	159
15 th IBD Intensive Advanced Course	159
8 th N-ECCO School.....	162
2 nd School for Clinical Trialists.....	164
4 th N-ECCO Research Forum.....	166
2 nd ECCO Endoscopy Workshop	167
3 rd Advanced ECCO: EduCational COurse for Industry.....	168
3 rd Y-ECCO Basic Science Workshop	169
10 th Y-ECCO Career Workshop.....	170
6 th S-ECCO IBD Masterclass in collaboration with ESCP....	171
4 th ECCO Ultrasound Workshop.....	172
2 nd ECCO-AOCC Forum: Learning from the Masters	176
5 th SciCom Workshop: Methodology on Research.....	177
11 th N-ECCO Network Meeting	178
4 th P-ECCO Educational Course	180
2 nd H-ECCO IBD Masterclass	181
2 nd D-ECCO Workshop	182
Industry sponsored satellite symposia	186
Congress information.....	195
ECCO Business meetings	203
Industry exhibition.....	204
Corporate Members.....	206
ECCO Interaction: Hearts and Minds	207
Floor plans.....	208
Index of authors	212

ECCO Structure



Governing Board

President
 President-Elect
 Past-President and Liaison Officer
 Secretary
 Treasurer
 Education Officer
 Scientific Officer

Julián Panés (Spain)
 Silvio Danese (Italy)
 Séverine Vermeire (Belgium)
 Laurent Peyrin-Biroulet (France)
 Tibor Hlavaty (Slovakia)
 Gerassimos Mantzaris (Greece)
 Filip Baert (Belgium)

ClinCom

Chair	Alessandro Armuzzi (Italy)
Members	Marc Ferrante (Belgium) Edyta Sylwia Zagorowicz (Poland) John Mansfield (United Kingdom) Javier Gisbert (Spain)

EduCom

Chair	Peter Irving (United Kingdom)
Members	Antonio López San Román (Spain) Kostas Katsanos (Greece) Peter Lakatos (Hungary/Canada) Giovanni Maconi (Italy) Pascal Juillerat (Switzerland)

EpiCom

Chair	Ebbe Langholz (Denmark)
Members	Vito Annese (Italy) Marieke Pierik (The Netherlands) Laurent Beaugerie (France) Nynne Nyboe Andersen (Denmark)

GuiCom

Chair	Andreas Sturm (Germany)
Members	Christian Maaser (Germany) Gionata Fiorino (Italy) Stephan Vavricka (Switzerland) Glen Doherty (Ireland)

N-ECCO

Chair	Karen Kemp (United Kingdom)
Members	Palle Bager (Denmark) Kay Greveson (United Kingdom) Usha Chauhan (Canada) Kathleen Sugrue (Ireland)

P-ECCO

Chair	Dan Turner (Israel)
Members	Richard Russell (United Kingdom) Salvatore Cucchiara (Italy) Patrick van Rheenen (The Netherlands) Jaroslaw Kierkus (Poland)

SciCom

Chair	Gerhard Rogler (Switzerland)
Members	Janneke van der Woude (The Netherlands) Florian Rieder (United States) Charlie Lees (United Kingdom) Britta Siegmund (Germany)

S-ECCO

Chair	Oded Zmora (Israel)
Members	Janindra Warusavitarne (United Kingdom) Paulo Kotze (Brazil) Antonino Spinelli (Italy) Yves Panis (France)

Y-ECCO

Chair	Tim Raine (United Kingdom)
Members	Isabelle Cleynen (Belgium) Nuha Yassin (United Kingdom) Nik Sheng Ding (Australia) Dominik Bettenworth (Germany)

D-ECCO Working Group

Chair	Rotem Sigall-Boneh (Israel)
Members	Nicolette Wierdsma (The Netherlands) Konstantinos Gerasimidis (United Kingdom) Miranda Lomer (United Kingdom) Arie Levine (Israel)

H-ECCO Working Group

Chair	Roger Feakins (United Kingdom)
Members	Vincenzo Villanacci (Italy) Paula Borralho Nunes (Portugal) Magali Svrcek (France)

Organising Committee - 12th Congress of ECCO

Chair	Julián Panés (Spain)
Members	Silvio Danese (Italy) Laurent Peyrin-Biroulet (France) Charlie Lees (United Kingdom) Peter Lakatos (Hungary/Canada)

National Representatives



Christoph Högenauer
Gottfried Novacek



Péter Lakatos
Tamás Molnár



Cathérine Reenaers
Peter Bossuyt



Jane McCarthy
Glen Doherty



Ante Bogut
Emil Babić



Shomron Ben-Horin
Matti Waterman



Zoya Spassova
Iskren Kotzev



Emma Calabrese
Sandro Ardizzone



Brankica Mijandrušić-Sinčić
Željko Krznarić



Aleksejs Derovs
Jelena Derova



Ioannis Kaimakliotis
Theodora Demetriou



Limas Kupčinskas
Gediminas Kiudelis



Martin Bortlík
Tomáš Douda



Pierre Ellul



Jørn Brynskov
Torben Knudsen



Vlada Dumbravă
Svetlana Turcan



Karin Kull
Benno Margus



Kristin Kaasen Jørgensen
Marte Lie Høivik



Clas-Göran af Björkesten
Pauliina Molander



Edyta Zagórowicz
Jarosław Kierkuś



Arnaud Bourreille
Xavier Roblin



Paula Ministro
Ana Isabel Vieira



Britta Siegmund
Torsten Kucharzik



Mihai Mircea Diculescu
Adrian Goldis



Ioannis Koutroubakis
Giorgos Bamias



Elena Belousova
Alexander Potapov



Mirjana Cvetkovic
Marijana Protić



Martin Huorka
Mária Zakuciová



Ivan Ferkolj
David Drobne



Pilar Nos
Javier Perez Gisbert



Hans Strid
Ann-Sofie Backman



Pierre Michetti
Frank Seibold



Andrea van der Meulen-de Jong
Dirk de Jong



Yusuf Ziya Erzincan
Filiz Akyüz



Tetyana Zvyagintseva
Andrey Dorofeyev



Tariq Ahmad
Barney Hawthorne

Honorary Members

Renzo Caprilli (Italy)
Yehuda Chowers (Israel)
Jean-Frédéric Colombel (United States)
Geert D'Haens (The Netherlands)
Axel Dignass (Germany)
Daniel Hommes (United States)

Miquel Gassull (Spain)
Pierre Michetti (Switzerland)
Pia Munkholm (Denmark)
Walter Reinisch (Austria)
Simon Travis (United Kingdom)
Boris Vucelić (Croatia)

Corporate Members

AbbVie
Biogen
Bühlmann Laboratories
Celgene
Celltrion
Cosmo Pharmaceuticals
Dr. Falk Pharma
J&J Ethicon
Eli Lilly and Company
Ferring

Grifols
Gilead
Hospira
Janssen
MSD
Mundipharma
Nestlé Health Science
Nographarma
Otsuka Pharmaceuticals
Pfizer

Roche
Sandoz
Shield Therapeutics
Shire
Takeda Pharmaceuticals Europe
Tigenix
Tillotts Pharma
Vifor Pharma



European
Crohn's and Colitis
Organisation

Announcement
2018

Inflammatory Bowel Diseases



13th Congress of ECCO
February 14-17, 2018

- Reed Messe Vienna
- EACCME applied
- Register at the 12th Congress of ECCO in Barcelona or at www.ecco-ibd.eu/ecco18

Scan and contact the ECCO Office
www.ecco-ibd.eu



Scientific Information: A-Z

Awards – ECCO Fellowships & Grants

On Friday, February 17, 2016, 15:00-15:20 ECCO officially announces the following prizes:

- ECCO Pioneer Award 2017
- ECCO Grants 2017
- ECCO-Vifor Pharma Grant 2017
- ECCO-AOCC Visiting Travel Grant 2017
- ECCO Travel Awards 2017

The awarded candidates will officially be handed over their prize by naming the title of their fellowship / grant research project.

A major part of this session is dedicated to the presentation of the research projects of Ferdinando Bonfiglio and Jesús Cosín who were awarded with ECCO Fellowships in 2016.

For further information and guidelines for these awards please refer to www.ecco-ibd.eu.

Business meetings

Attendance of business meetings is upon invitation only (please refer to page 203).

Compliance

According to the European Legislation (Directive 2001/83/CE), EFPIA Code (European Federation of Pharmaceuticals Industries & Associations), Farmaindustria Code (Spanish Code of Practice for the Pharmaceutical Industry), and EUCOMED Code of Practice the promotion of prescription-only medicines should be limited to those HCPs able to prescribe or dispense medicines.

The organiser of the 12th Congress of ECCO has done its utmost best to comply with the prevalent legislation and to keep all stakeholders participating at the Congress informed about the relevant regulations. ECCO has adopted several measures that allow compliance with applicable regulations:

- Exhibitors have been asked to respect the Code of Practice in the context of the ECCO'17 Exhibitor & Sponsor Prospectus.
- Exhibitors have been alerted to the regulations about the promotion of prescription-only medicine, explaining that non-prescribing congress delegates can be identified with the NP sign on the congress badge.
- In the course of the online and onsite registration, the congress delegates will also be informed about the regulations regarding publicity and promotion of medicine and are asked to indicate their prescriber/non-prescriber status accordingly.

Disclosure policy

ECCO has diligently maintained a disclosure policy of potential Conflicts of Interests (CoI) and its aim is to foster transparency and to ensure scientific rigour and objectivity in all of its scientific and educational activities. Therefore, all presenters, including invited faculty members and abstract presenters, are required to disclose any relevant financial support or relationship that may lead to a potential conflict. Please note that the responsibility for the content of each presentation lies with the presenting author.

All presenters are required to complete a Conflict of Interest form to disclose any financial support as well as advisory and consultancy roles in the biomedical industry. All submitted forms are open to public scrutiny on the ECCO Website (www.ecco-ibd.eu/about-ecco/ecco-disclosures) providing

a comprehensive overview of potential conflicts of interest of presenters. As soon as the Col Forms are online, the IBD Community is also notified by the ECCO eNewsletter about the online access to the up-to date disclosure information. In addition, these conflicts are requested to be shown at the beginning of each presentation on a PowerPoint slide.

In order to facilitate the process and reinforce the 2nd slide policy, faculty speakers are reminded to disclose their potential conflicts of interest in their PowerPoint slides in line with UEMS regulations. Based on the submitted Col form of each speaker, a draft Col slide has been prepared and is made available in the Speakers' centre with a reminder that if the respective presentation does not yet include a disclosure form, the slide draft should be checked/amended and included in the PowerPoint slides.

Conflicts of Interest may include financial relationships or when the individual has the opportunity to influence the content of a presentation, and can comprise grants, honoraria, shares, paid positions on advisory boards etc. ECCO expects many presenters to have some Conflicts of Interest, which do not prevent them from presenting their work given that the conflict is disclosed.

EACCME – Continuing Medical Education

The 12th Congress of ECCO in Barcelona is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The **12th Congress of ECCO** in Barcelona is designated for European external CME credits. Full congress days count 6 credits, half congress days for 3 credits. Thus, a maximum of **12 CME credits** can be obtained for the scientific sessions of the core programme.



For the **15th IBD Intensive Advanced Course** for Junior Gastroenterologists (upon invitation only) **9 CME credits** will be accredited. Please refer to page 159.

For the **2nd School for Clinical Trialists** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 164.

For the **2nd ECCO Endoscopy Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 167.

For the **3rd Y-ECCO Basic Science Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 169.

For the **10th Y-ECCO Career Workshop** for Regular Members of ECCO (pre-registered participants only) **2 CME credits** will be accredited. Please refer to page 170.

For the **6th S-ECCO IBD Masterclass** for Regular Members of ECCO (pre-registered participants only) **6 CME credits** will be accredited. Please refer to page 171.

For the **4th ECCO Ultrasound Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 175.

For the **5th SciCom Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 177.

For the **4th P-ECCO Educational Course** for Regular Members of ECCO (pre-registered participants only) **2 CME credits** will be accredited. Please refer to page 180.

For the **2nd H-ECCO IBD Masterclass** for Regular Members of ECCO (pre-registered participants only) **6 CME credits** will be accredited. Please refer to page 181.

For the **2nd D-ECCO Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 183.

In order to obtain CME credits ECCO requires feedback on its educational activities. Therefore, you will receive an e-mail with a link to the online evaluation platform at the end of the congress. You will be able to evaluate the Scientific Programme and any educational activities you attended. Once you have submitted your surveys, your CME Certificates will be available for download or print.

Plenary session

The plenary session is held from Thursday, February 16 to Saturday, February 18, 2017 and starts off with the official welcome & opening of the core scientific programme. The programme includes all official speeches, with a mixture of invited speakers and oral presentations of the best submitted abstracts. Please be informed that this year the Scientific Programme will also be broadcasted in Room 116+117 (Overflow Room) on Level 1. Kindly note that Scientific Session 9 will be held in Room 111, Level 1.

Oral presentations – Best abstracts

Out of 1,239 submitted abstracts the 38 best submitted abstracts have carefully been chosen by a panel of referees and selected for oral presentation during the scientific programme. For the presentation schedule please refer to the scientific programme (page 19).

Digital oral presentations

Abstracts have been selected from the ranking by taking 90 abstracts after those 38 selected for presentation in the scientific programme. These abstracts will be presented as digital oral presentations, with a 5 minute oral presentation in several rooms on Level 1 of the CCIB on Thursday, February 16, 2017 from 17:45-18:45 and on Friday, February 17, 2017 from 17:20-18:20. Please find the schedule and selected abstracts for each digital oral presentation room on page 43.

Poster exhibition

The remaining accepted abstracts will be displayed as hard copy posters throughout the congress in the Banquet Hall. For further details on all posters included in the poster exhibition please refer to page 69.

Scientific congress theme

This year's congress theme is "Advancing knowledge, improving care".

Top tips for chairs

All chairs are kindly asked to attend the closed session on "Top tips for chairs" which takes place on Thursday, February 16, 2017 at 10:45-11:15 in the Plenary Hall on the Ground Level of the CCIB. During this session, Laurence Egan will give essential information on how to chair scientific sessions in a highly humorous manner – do not miss out on it!



European
Crohn's and Colitis
Organisation

Research Grants and Fellowships 2018



Fund your innovative scientific research
with ECCO's Fellowships and Grants

ECCO Fellowships

- EUR 60,000 for young and enthusiastic scientists to research in a host institute abroad

ECCO Grants

- EUR 40,000 for innovative, and original research projects

ECCO Travel Awards

- EUR 1,500 for young doctors and nurses to enable visits of European IBD centres

N-ECCO Research Grant

- Up to EUR 20,000 for research projects in IBD nursing

Application deadline: September 1, 2017

ECCO Pioneer Award

- EUR 200,000 for innovative and collaborative research projects between at least 3 IBD centres

First Application deadline: June 1, 2017

Scan and visit

www.ecco-ibd.eu





European
Crohn's and Colitis
Organisation

ECCO Pioneer Award



Awarded for the first time in 2017

The ECCO Pioneer Award aims to enhance visionary, collaborative, and interdisciplinary scientific research in IBD centres.

2018: Open to all topics in IBD

- EUR 200,000 prize
- 1 exceptional award per year
- Fund up to 24 months of basic/clinical research in IBD
- For innovative and collaborative research projects between at least 3 participating institutions

Application deadline (1st phase): June 1, 2017

Scan and contact the ECCO Office
www.ecco-ibd.eu





European
Crohn's and Colitis
Organisation

Barcelona
Spain

Abstracts 2017



Look out for your voucher in your
congress bag!

ECCO Key USB Drive

- Contains all ECCO'17 Abstracts
- Pick up at ECCO Booth

Scan and contact the ECCO Office
www.ecco-ibd.eu



Educational programme

WED Feb 15, 2017	Room	08:00-08:30	08:30-10:30	10:30-11:30	11:30-11:45	11:45-12:30	12:30-12:45	12:45-13:00	13:00-14:00	14:00-15:00	15:00-15:30	15:30-15:45	15:45-16:00	16:00-16:15	16:15-17:00	17:00-18:00
	111 (Level 1)	15 th IBD Intensive Advanced Course p. 159											IBD Intensive Advanced Course ISSS p.194			
	131 + 132 (Level 1)	8 th N-ECCO School p. 162														
	120 + 121 (Level 1)									3 rd Y-ECCO Basic Science Workshop p. 169			10 th Y-ECCO Career Workshop p. 170			
	124 + 125 (Level 1)	2 nd School for Clinical Trialists p. 164								4 th N-ECCO Research Forum p. 166						
	122 + 123 (Level 1)					Endoscopy Workshop ISSS p. 194				2 nd ECCO Endoscopy Workshop p. 167						
	113 (Level 1)									3 rd Advanced ECCO: EduCational COURSE for Industry p. 168						

THU Feb 16, 2017	Room	07:30-08:00	08:00-08:30	08:30-09:00	09:00-10:00	10:00-11:30	11:30-12:00	12:00-12:15	12:15-12:30	12:30-12:45	12:45-13:30	13:30-13:45	13:45-14:00	14:00-17:00	17:00-17:10	17:15-18:15	
	122 + 123 (Level 1)	4 th ECCO Ultrasound Workshop p. 175															
	113 (Level 1)	6 th S-ECCO IBD Masterclass p. 171															
	111 (Level 1)	15 th IBD Intensive Advanced Course p. 161															
	118 + 119 (Level 1)				2 nd ECCO-AOCC Forum p. 176												
	112 (Level 1)				11 th N-ECCO Network Meeting p. 178						N-ECCO Network Meeting ISSS p. 194		11 th N-ECCO Network Meeting p. 179				
	131 + 132 (Level 1)				5 th SciCom Workshop p. 177												
	120 + 121 (Level 1)				4 th P-ECCO Educational Course p. 180										2 nd H-ECCO IBD Masterclass p. 181		

FRI Feb 17, 2017	Room	08:00-08:30	08:30-11:40	11:40-12:30	12:30-15:00	15:00-18:00
	129 + 130 (Level 1)	2 nd H-ECCO IBD Masterclass p. 182				
118 + 119 (Level 1)	2 nd D-ECCO Workshop p. 183					

Programme overview Congress theme: “Advancing knowledge, improving care”

Scientific programme

THU Feb 16, 2017	Room	10:45-11:15	11:15-11:30	11:30-12:00	12:00-12:30	12:30-12:45	12:45-13:00	13:00-14:30	14:30-15:00	15:00-16:30	16:30-17:00	17:00-17:30	17:30-17:45	17:45-18:00	18:00-18:45
	Plenary Hall (Ground level)	Top tips for chairs p. 19		ISSS 1a p. 186		Welcome and opening p. 19	SS 1: Pathways of environmental factors or everyday poisons and IBD p. 19		SS 2: Evolving therapeutic algorithms in 2017 p. 20	SS 3: Vulnerable patients: 10 burning questions in IBD p. 21				ISSS 2a p. 187	
	Parallel Hall (116+117, Level 1)			ISSS 1b p. 187	Overflow room – Scientific programme								ISSS 2b p. 187		
	Exhibition Hall (Ground level)			Industry Exhibition p. 205					Coffee break	Industry Exhibition p. 205					
	111, 113, 114, 115, 118+119, (Level 1)													DOP Sessions 1-5 p. 44-57	
Banquet Hall (Level 2)			Poster Exhibition p. 69					Poster Exhibition p. 69							

FRI Feb 17, 2017	Room	07:15-08:15	08:15-08:30	08:30-09:30	09:30-10:30	10:30-11:00	11:00-12:30	12:30-12:40	12:40-13:20	13:20-13:30	13:30-15:00	15:00-15:40	15:40-16:10	16:10-17:10	17:10-17:20	17:20-18:00	18:00-18:20	18:20-18:30	18:30-19:30	
	Plenary Hall (Ground level)	ISSS 3a p. 188		SS 4: Clinical trials versus real life p. 23		SS 5: Managing bowel damage in IBD: Surgical or medical treatment? p. 24		ISELSS LS 1 p. 188		SS 6: Intestinal inflammation – not always IBD p. 26	SS 7: ECCO Fellowships & Grants p. 27		SS 8: IBD Horizons p. 27							ISSS 4a p. 190
	Parallel Hall (116+117, Level 1)	ISSS 3b p. 188	Overflow room – Scientific programme								ISELSS LS 2 p. 189	Overflow room – Scientific programme								ISSS 4b p. 190
	Exhibition Hall (Ground level)			Ind exhib. p. 205	Coffee break	Industry exhib. p. 205	Lunch break		Industry exhibition p. 205	Coffee break	Industry exhibition p. 205									
	111, 113, 114, 115, 118+119 (Level 1)																			DOP Sessions 6-10 p. 57-67
	111 (Level 1)							ISELSS LS 3 p. 189		SS 9: Basic Science meets the clinic p. 289	SS 9: Basic Science meets the clinic p. 29									
113 (Level 1)							ISELSS LS 4 p. 189													
Banquet Hall (Level 2)			Poster Exhibition p. 69					Guided poster session	Poster Exhibition p. 69											

SAT Feb 18, 2017	Room	07:15-08:15	08:15-08:30	08:30-9:30	9:30-10:20	10:20-10:50	10:50-12:20	12:20-12:50	12:50-12:55	12:55-13:00
	Plenary Hall (Ground level)	ISSS 5a p. 191		SS 10: New compounds in the treatment of IBD p. 32			SS 11: Gut luminal content – more than just bacteria p. 34	SS 12: ECCO Lecture p. 345	Awards and closing remarks p. 35	The ECCO Film 2017 p. 35
	Parallel Hall (116+117, Level 1)	ISSS 5b p. 191								
	Exhibition Hall (Ground level)			Industry exhibition p. 205	Coffee break	Industry exhibition p. 205				
Banquet Hall (Level 2)			Poster Exhibition p. 69	Poster Exhibition p. 69						

SS = Scientific session

ISSS = Industry sponsored satellite symposium

ISELSS = Industry sponsored educational lunchtime satellite symposium

DOP = Digital oral presentation



European
Crohn's and Colitis
Organisation

Become a member!

3-year membership:
Regular & Y-ECCO
Members save up to 20%



Be a bee in our hive to experience
the ECCO Spirit

To reach our objectives, our members can access the following ECCO Initiatives:

- Reduced Congress fee
- JCC – Journal of Crohn's and Colitis (12 online issues/year)*
- e-CCO Learning Platform incl. e-Courses & e-Library
- Monthly eNewsletter
- Access to online members' area
- Voting rights in General Assembly (President-Elect, Treasurer, Secretary)
- Quarterly ECCO News – The society's magazine
- Educational and networking activities
- Guidelines, ECCO Fellowships, Grants and Travel Awards
- Access to ECCO UR-CARE - United Registries for Clinical Assessment and Research

Scan and contact the ECCO Office
www.ecco-ibd.eu



*For Regular Members (incl. Y-ECCO) only; online access only



European
Crohn's and Colitis
Organisation

Video recordings of the ECCO Congress



Missed an excellent presentation at the
ECCO Congress? No time to attend?

- Watch video recordings of ECCO'17 and past Congresses on the e-CCO Learning Platform
- Accessible for all ECCO Members
- Presentation availability is subject to speaker authorisation

Scan and visit
www.e-learning.ecco-ibd.eu



“Advancing knowledge, improving care”

Thursday, February 16, 2017

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

10:45 - 11:15	Top Tips for chairs (closed session) Laurence Egan, Galway, Ireland
11:30 - 12:30	Industry sponsored satellite symposia 1a & 1b Please refer to pages 186-187
12:45 - 12:50	1: Welcome Javier Gisbert, Madrid, Spain
12:50 - 13:00	2: Opening Julián Panés, Barcelona, Spain
13:00 - 14:30	Scientific session 1: Pathways of environmental and genetic factors in IBD Stephan Vavricka, Zurich, Switzerland Nynne Nyboe Andersen, Copenhagen, Denmark
	3: Nutrition and food additives Charlie Lees, Edinburgh, United Kingdom
	4: OP001: Whole genome sequencing and imputation in Inflammatory Bowel Disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insights L. Moutsianas¹, K. De Lange¹, Y. Luo^{1,2,3}, J. Lee⁴, L. Jostins⁵, C. Lamb⁶, N. Kennedy⁷, J. Mansfield⁸, M. Parkes⁴, J. Barrett¹, C. Anderson¹, UK Inflammatory Bowel Disease Genetics Consortium⁹ ¹ Wellcome Trust Sanger Institute, Human Genetics, Hinxton, Cambridge, United Kingdom, ² Broad Institute of Harvard and MIT, Program in Medical and Population Genetics, Cambridge, United States, ³ Harvard Medical School, Division of Genetics and Rheumatology, Boston, United States, ⁴ Addenbrooke's Hospital, Inflammatory Bowel Disease Research Group, Cambridge, United Kingdom, ⁵ Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom, ⁶ Newcastle University, Newcastle upon Tyne, United Kingdom, ⁷ University of Exeter, Precision Medicine Exeter, Exeter, United Kingdom, ⁸ University of Newcastle, Human Genetics, Newcastle upon Tyne, United Kingdom, ⁹ UK IBD Genetics Consortium, Various, United Kingdom
	5: Everyday poisons: Smoking, pollution, stress, sedentary lifestyle Stephan Vavricka, Zurich, Switzerland
	6: OP002: Epigenetic biomarkers to detect UC associated neoplasia: Results from phase I of the ENDCAP-C study T. Iqbal¹, A. Beggs¹, P. Taniere², Y. Wallis³, S. Mehta⁴, L. Magill⁴, J. Deeks⁴, G. Matthews¹, D. Morton¹, EndCAP-C Consortium ¹ University of Birmingham, Institute of Cancer & Genomic Sciences, Birmingham, United Kingdom, ² University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³ West Midlands Regional Genetics Centre, Birmingham, United Kingdom, ⁴ University of Birmingham, Birmingham Clinical Trials Unit, Birmingham, United Kingdom



Y-ECCO
Abstract Award

OP = Oral presentation – Best abstracts

Thursday, February 16, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

14:00 - 14:10	<p>7: OP003: Increased risk of acute arterial events in young patients with severely active Inflammatory Bowel Disease: A nationwide French cohort study J. Kirchgesner^{1,2}, L. Beaugerie¹, F. Carrat^{3,4}, N. Nyboe Andersen⁵, T. Jess^{5,6}, M. Schwarzinger^{7,8}, For the BERENICE Study Group ¹Saint-Antoine Hospital, AP-HP, Gastroenterology, Paris, France, ²INSERM, University Paris 06, UMR S 1136, Paris, France, ³Hopital Saint Antoine, Department of Public Health, Paris, France, ⁴INSERM, University Paris 06, UMR S 1136, Paris, France, ⁵Statens Serum Institute, Department of Epidemiology Research, Copenhagen, Denmark, ⁶Frederiksberg Hospital, Institute of Preventive Medicine, Frederiksberg, Denmark, ⁷INSERM, UMR 1137, Paris, France, ⁸THEN, Translational Health Economics Network, Paris, France</p>
14:10 - 14:30	<p>8: Environmental factors as therapy (diet modification, EEN feeding) Pierre Ellul, Sliema, Malta Arie Levine, Tel Aviv, Israel</p>
14:30 - 15:00	Coffee break
15:00 - 16:30	<p>Scientific session 2: Evolving therapeutic algorithms in 2017 Jane Andrews, Adelaide, Australia Jarosław Kierkuś, Warsaw, Poland</p>
15:00 - 15:20	<p>9: Placing new molecules in the treatment pathway Gerhard Rogler, Zurich, Switzerland</p>
15:20 - 15:30	<p>10: OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's Disease L. Le Bourhis¹, A. Corraliza², C. Auzolle¹, E. Ricart², C. Hawkey³, J.O. Lindsay⁴, M. Clark³, G. Rogler⁵, J. Satsangi⁶, D. Haller⁷, J. Panes², A. Salas², M. Allez¹ ¹Hôpital Saint-Louis INSERM, U1160 - Intestinal Immunity in Inflammation and Cancer, Paris, France, ²IDIBAPS, Hospital Clínic, Gastroenterology, Barcelona, Spain, ³University of Nottingham, Gastroenterology, Nottingham, United Kingdom, ⁴Barts and The London, Queen Mary University of London, Centre for Immunology, The Blizard Institute, London, United Kingdom, ⁵University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland, ⁶Western General Hospital, Gastrointestinal Unit, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom, ⁷Technical University Munich, Department of Nutrition and Immunology, Freising, Germany</p>
15:30 - 15:50	<p>11: Maximising the bang for your buck: How to manage IBD on a minimum budget Peter Irving, London, United Kingdom</p>

OP = Oral presentation – Best abstracts

Thursday, February 16, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

15:50 - 16:00	<p>12: OP005: The PROSIT cohort of infliximab biosimilar in IBD: A prolonged follow-up on the efficacy and safety across Italy L. Guidi¹, G. Fiorino², A. Variola³, N. Manetti⁴, W. Fries⁵, G. Rizzuto⁶, F. Bossa⁷, M. Cappello⁸, L. Biancone⁹, R. D'Incà¹⁰, L. Cantoro¹¹, F. Castiglione¹², M. Principi¹³, M.L. Annunziata¹⁴, M. Di Girolamo¹⁵, M.M. Terpin¹⁶, C.C. Cortelezzi¹⁷, F. Costa¹⁸, A. Amato¹⁹, A. Di Sabatino²⁰, S. Saibeni²¹, G. Meucci²², C. Petruzzellis²³, R. Tari²⁴, F.W. Gugliemi²⁵, A. Armuzzi²⁶, S. Danese², A. Geccherle³, F. Rogai⁴, A. Ventra⁵, A. Orlando⁶, A. Andriulli⁷, B. Scivo⁸, E. Troncone⁹, R. Caccaro¹⁰, A. Kohn¹¹, O. Nardone¹², V. Annese²⁷ ¹Complesso Integrato Columbus, Fondazione Policlinico Gemelli Università Cattolica, Internal Medicine and Gastroenterology, Rome, Italy, ²Humanitas Research Hospital and University, Gastroenterology and IBD Center, Rozzano, Italy, ³Sacro Cuore Don Calabria Hospital, Gastroenterology and Hepatology, Negrar, Italy, ⁴AOU Careggi, DEA, Gastroenterology, Florence, Italy, ⁵University of Messina, Clinical Unit for Chronic Bowel Disorders, Messina, Italy, ⁶Riuniti Villa Sofia - Cervello Hospital, Internal Medicine ², Palermo, Italy, ⁷IRCCS-CSS Hospital, Gastroenterology, San Giovanni Rotondo, Italy, ⁸University Hospital, Gastroenterology, Palermo, Italy, ⁹Tor Vergata, Gastroenterology, Roma, Italy, ¹⁰University of Padova, Gastroenterology, Padova, Italy, ¹¹S. Camillo-Forlanini Hospital, Gastroenterology, Rome, Italy, ¹²Federico II University, Gastroenterology, Naples, Italy, ¹³University Bari, Gastroenterology, Bari, Italy, ¹⁴IRCCS Policlinico, Gastroenterology & Digestive Endoscopy Unit, San Donato, Milano, Italy, ¹⁵University Hospital, Gastroenterology, Modena, Italy, ¹⁶AO Hospital, Gastroenterology and Endoscopy, Legnano, Italy, ¹⁷AOU di Circolo Fondazione Macchi, Gastroenterology, Varese, Italy, ¹⁸AOU, Gastroenterology, Pisa, Italy, ¹⁹Ospedale Valduce, Gastroenterology, Como, Italy, ²⁰S. Matteo Hospital Foundation, University of Pavia, First Department of Medicine, Pavia, Italy, ²¹ASST Rhodense, Gastroenterology Unit, Rho, Italy, ²²S. Giuseppe Hospital, Gastroenterology, Milano, Italy, ²³Poliambulanza Hospital, Gastroenterology and Digestive Endoscopy, Brescia, Italy, ²⁴AOU Maggiore, Gastroenterology, Novara, Italy, ²⁵S. Pellegrino Hospital, Gastroenterology, Trani, Italy, ²⁶Complesso Integrato Columbus - Catholic University, Internal Medicine and Gastroenterology, Rome, Italy, ²⁷Valiant Clinic, Gastroenterology, Dubai, United Arab Emirates</p>
16:00 - 16:10	<p>13: OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: Long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial L. Pouillon¹, M. Ferrante¹, G. Van Assche¹, P. Rutgeerts¹, M. Noman¹, N. Vande Castele², A. Gils³, S. Vermeire¹ ¹University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ²University of California San Diego, Department of Medicine, La Jolla, CA, United States, ³University of Leuven, Department of Pharmaceutical Sciences, Leuven, Belgium</p>
16:10 - 16:30	<p>14: Personalised medicine: Dream or reality? Iris Dotan, Tel Aviv, Israel</p>
16:30 - 17:30	<p>Scientific session 3: Vulnerable patients: 10 burning questions in IBD Pierre Michetti, Lausanne, Switzerland Triana Lobatón, Barcelona, Spain</p>
16:30 - 16:42	<p>15: The child with IBD: Should anti-TNF be used as a mono-therapy in children (safety risk)? Who should (be allowed to) operate on the children in IBD? Dan Turner, Jerusalem, Israel</p>



Y-ECCO
Abstract Award

OP = Oral presentation – Best abstracts

Thursday, February 16, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

16:42 - 16:54	16: Treating the pregnant woman with IBD: Should anti-TNF be stopped during pregnancy? Should vedolizumab be stopped during pregnancy? Janneke van der Woude, Rotterdam, The Netherlands
16:54 - 17:06	17: The elderly patient with IBD: Should azathioprine ever be used in the elderly? Should the type of surgery be different in an elderly patient? Jean-Frédéric Colombel, New York, United States
17:06 - 17:18	18: The use of IBD medicine in patients with cancer: Which treatment should be stopped when cancer is diagnosed? Which treatment to use in a patient with a prior diagnosis with cancer? Laurent Beaugerie, Paris, France
17:18 - 17:30	19: The patient with psychological comorbidities: How to wean off opiates in these patients? Is there any preference in drugs? Jane Andrews, Adelaide, Australia
17:45 - 18:45	Industry sponsored satellite symposia 2a & 2b Please refer to pages 187
17:45 - 18:45	Digital oral presentations Please refer to page 43-67

OP = Oral presentation – Best abstracts

Friday, February 17, 2017

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

07:15 - 08:15	Industry sponsored satellite symposia 3a & 3b Please refer to page 188
08:30 - 10:30	Scientific session 4: Clinical trials versus real life Janneke van der Woude, Rotterdam, The Netherlands Pascal Juillerat, Bern, Switzerland
08:30 - 08:50	20: Trial endpoints vs. therapeutic objectives Filip Baert, Roeselare, Belgium
08:50 - 09:00	21: OP007 A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitis I.C. Lawrence^{1,2}, A. Baird¹, D. Lightowler², G. Radford-Smith³, J.M. Andrews⁴, S. Connor⁵ ¹ University of Western Australia, Medicine and Pharmacology, Perth, Australia, ² Saint John of God Hospital, Centre for Inflammatory Bowel Diseases, Subiaco, Australia, ³ University of Queensland School of Medicine, IBD Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia, ⁴ University of Adelaide, School of Medicine, Adelaide, Australia, ⁵ University of NSW Medicine, South Western Sydney Clinical School, Sydney, Australia
09:00 - 09:10	22: OP008: An innovative treatment for refractory perianal fistulas in Crohn's Disease: Local micro reinjection of autologous fat and adipose derived stromal vascular fraction (ClinicalTrials.gov NCT02520843, Eudract: 2013-002602-31) M. Serrero¹, C. Philandrianos², C. Visee³, J. Veran², P. Orsoni³, F. Sabatier², J.C. Grimaud¹ ¹ Hopital Nord, Gastroenterology, Marseille, France, ² Aix-Marseille, Marseille, France, ³ Hopital Nord, Visceral Surgery, Marseille, France
09:10 - 09:20	23: OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's Disease: 52-week results of a phase III randomised controlled trial J. Panes¹, D. García-Olmo², G. Van Assche³, J.F. Colombel⁴, W. Reinisch⁵, D.C. Baumgart⁶, M. Nachury⁷, M. Ferrante³, L. Kazemi-Shirazi⁵, J.C. Grimaud⁸, F. de la Portilla⁹, E. Goldin¹⁰, M.P. Richard¹¹, M.C. Diez¹, S. Danese¹² ¹ Hospital Clínic de Barcelona, Dept of Gastroenterology, Barcelona, Spain, ² Hospital U. Fundación Jiménez-Díaz, Madrid, Spain, ³ University Hospitals Leuven, KU Leuven, Leuven, Belgium, ⁴ Icahn School of Medicine at Mount Sinai, New York, United States, ⁵ Medical University of Vienna, Vienna, Austria, ⁶ Charité Medical School - Humboldt-University of Berlin, Berlin, Germany, ⁷ CHU Lille, Lille, France, ⁸ Hôpital Nord, Marseille, France, ⁹ Hospital Virgen del Rocío, Sevilla, Spain, ¹⁰ Sharee Zedek MC, Jerusalem, Israel, ¹¹ TiGenix, Madrid, Spain, ¹² Istituto Clinico Humanitas, Milano, Italy
09:20 - 09:40	24: The long-term efficacy outside clinical trials Stefan Schreiber, Kiel, Germany

OP = Oral presentation – Best abstracts

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

09:40 - 09:50	<p>25: OP010: Long term efficacy and safety of Ustekinumab for Crohn's Disease: Results from IM-UNITI long-term extension through 2 years W. Sandborn¹, P. Rutgeerts², C. Gasink³, D. Jacobstein³, L.-L. Gao³, J. Johanss³, B. Sands⁴, S.B. Hanauer⁵, S. Targan⁶, S. Ghosh⁷, D.V. Willem J.S.⁸, J.-F. Colombel⁴, B.G. Feagan⁹ ¹University of California San Diego, La Jolla, United States, ²University Hospital, Gasthuisberg, Leuven, Belgium, ³Janssen Research & Development, LLC, Spring House, United States, ⁴Icahn School of Medicine at Mt Sinai, New York, United States, ⁵Northwestern University Feinberg School of Medicine, Chicago, United States, ⁶Cedars-Sinai Medical Center, Los Angeles, United States, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸University of Stellenbosch, Stellenbosch, South Africa, ⁹Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada</p>
09:50 - 10:00	<p>26: OP011: Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study L. Peyrin-Biroulet¹, B.G. Feagan², J. Mansfield³, D.T. Rubin⁴, U. Arulmani⁵, R. Maciuc⁵, H. Tyrrell⁶, J. Thommes⁵, S. Tole⁶ ¹Université de Lorraine, Vandœuvre-lès-Nancy, France, ²University of Western Ontario, London, Canada, ³Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴University of Chicago Medicine, Chicago, United States, ⁵Genentech, South San Francisco, United States, ⁶Roche, Welwyn Garden City, United Kingdom</p>
10:00 - 10:10	<p>27: OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with Ulcerative Colitis undergoing (procto)colectomy with ileal pouch-anal anastomosis M. Ferrante¹, N. Schils¹, A. de Buck van Overstraeten², S. Vermeire¹, G. Van Assche¹, A. Wolthuis², A. D'Hoore² ¹University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ²University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium</p>
10:10 - 10:30	<p>28: The long-term safety outside clinical trials Gert van Assche, Leuven, Belgium</p>
10:30 - 11:00	Coffee break
11:00 - 12:30	<p>Scientific session 5: Managing bowel damage in IBD: Surgical or medical treatment? Antonino Spinelli, Milan, Italy Edyta Zagórowicz, Warsaw, Poland</p>
11:00 - 11:20	<p>29: Are we truly changing disease course with current strategies? Yves Panis, Clichy, France</p>

OP = Oral presentation – Best abstracts

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

11:20 - 11:30	<p>30: OP013: Disease management and outcomes of patients with Crohn's Disease at high risk of recurrence. Results from PRACTICROHN study M. Iborra¹, M.D. Martín Arranz², E. Domènech³, V. García⁴, A. Gutiérrez⁵, M. Barreiro-de Acosta⁶, L. Cea-Calvo⁷, C. Romero⁷, B. Juliá⁷ ¹Servicio de Gastroenterología, Hospital La Fe, Valencia, Spain, ²Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain, ³Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, ⁴Hospital Universitario Reina Sofía, Unidad Clínica de Aparato Digestivo, Córdoba, Spain, ⁵Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain, ⁶Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, ⁷MSD Spain, Medical Department, Madrid, Spain</p>
11:30 - 11:50	<p>31: Combined approach for intestinal sparing in CD? Paulo Kotze, Curitiba, Brazil</p>
11:50 - 12:00	<p>32: OP014: Histological remission is predictive of improved clinical outcomes in patients with Ulcerative Colitis: Results from the TOUCHSTONE OLE W. Sandborn¹, B. Feagan², G. D'Haens³, B. Levesque², R. Pai⁴, S. Hanauer⁵, D. Wolf⁶, S. Vermeire⁷, S. Ghosh⁸, C. Li⁹, D. Penenberg⁹, R. Aranda⁹, A. Olson⁹ ¹University of California San Diego, San Diego, United States, ²Robarts Research, London, Canada, ³Academic Medical Center, Amsterdam, Netherlands, ⁴Mayo Clinic, Department of Laboratory Medicine and Pathology, Scottsdale, United States, ⁵Feinberg School of Medicine, Chicago, United States, ⁶Atlanta Gastroenterology Associates, Atlanta, United States, ⁷University of Leuven, Leuven, Belgium, ⁸University of Calgary, Calgary, Canada, ⁹Receptos, a wholly owned subsidiary of Celgene, San Diego, United States</p>
12:00 - 12:10	<p>33: OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn's Disease: THE LIRIC TRIAL J. de Groof^{1,2}, W. Bemelman¹, E. Eshuis², T. Gardenbroek¹, P. Bossuyt³, J. Bosmans⁴, H. van Dongen⁴, B. van Wageningen⁵, M. Brink⁶, E. Consten⁷, C. Buskens¹, G. D'Haens², P. Stokkers⁸, C. Ponsioen², LIRIC study group ¹Academic Medical Center, Surgery, Amsterdam, Netherlands, ²Academic Medical Center, Gastroenterology, Amsterdam, Netherlands, ³Academic Medical Center, Epidemiology, Amsterdam, Netherlands, ⁴VU, Health Sciences, Amsterdam, Netherlands, ⁵OLVG West, Surgery, Amsterdam, Netherlands, ⁶Meander Medical Center, Gastroenterology, Amersfoort, Netherlands, ⁷Meander Medical Center, Surgery, Amersfoort, Netherlands, ⁸OLVG West, Gastroenterology, Amsterdam, Netherlands</p>
12:10 - 12:30	<p>34: The ileorectal anastomosis in UC: Time for a comeback? Oded Zmora, Tel Aviv, Israel</p>
12:30 - 13:30	<p>Lunch & Guided Poster Session Please refer to page 40</p>
12:40 - 13:20	<p>Educational Lunchtime Satellite Symposia Please refer to pages 188-189</p>

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

13:30 - 15:00	Scientific session 6: Intestinal inflammation - not always IBD	
	Chairs: Eugeni Domènech, Badalona, Spain Dror Shouval, Tel Aviv, Israel	
Carousel:		
Epidemiologist – Vito Annese, Florence, Italy		
Basic Science – Britta Siegmund, Berlin, Germany		
Pathologist – Roger Feakins, London, United Kingdom		
Physician – James Lindsay, London, United Kingdom		
13:30 - 13:50	35: Microscopic colitis	Carousel
13:50 - 14:00	36: OP016: Potential role of bile acid receptor FXR in microscopic colitis	C. Palmela¹ , J. Torres ¹ , P. Gomes de Sena ² , M.P. Costa Santos ¹ , C. Gouveia ¹ , M.H. Oliveira ² , C. M. P. Rodrigues ³ , M. Cravo ¹ , P. Borralho ^{4,5} ¹ Hospital Beatriz Ângelo, Gastroenterology Department, Loures, Portugal, ² Hospital Beatriz Ângelo, Pathology Department, Loures, Portugal, ³ Faculty of Pharmacy, Universidade de Lisboa, Research Institute for Medicines, Lisboa, Portugal, ⁴ Hospital Cuf Descobertas, Pathology Department, Lisboa, Portugal, ⁵ Universidade de Lisboa, Faculty of Medicine, Lisboa, Portugal
14:00 - 14:20	37: IBDU	Carousel
14:20 - 14:30	38: OP017: Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoach	M. de Jong^{1,2} , A. van der Meulen-de Jong ³ , M. Romberg-Camps ⁴ , M. Becx ⁵ , M. Cilissen ¹ , J. Maljaars ³ , A. van Bodegraven ⁴ , N. Mahmmod ⁵ , T. Markus ⁶ , W. Hameeteman ¹ , G. Dijkstra ⁷ , A. Masclee ^{1,2} , A. Boonen ^{8,9} , D. Jonkers ^{1,2} , A. van Tubergen ^{8,9} , M. Pierik ^{1,2} ¹ Maastricht University Medical Center (MUMC), Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, Netherlands, ² Maastricht University Medical Center (MUMC), NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³ Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, ⁴ Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen, Netherlands, ⁵ St. Antonius Hospital, Department of Gastroenterology and Hepatology, Nieuwegein, Netherlands, ⁶ CCUVN, Woerden, Netherlands, ⁷ University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ⁸ Maastricht University Medical Center (MUMC), Department of Internal Medicine, Division of Rheumatology, Maastricht, Netherlands, ⁹ Maastricht University Medical Center (MUMC), CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands
14:30 - 14:40	39: OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF type	S. Kanis , A. de Lima, C. van der Woude Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands
14:40 - 15:00	40: Eosinophilic enteritis	Carousel



Y-ECCO
Abstract Award



Y-ECCO
Abstract Award

OP = Oral presentation – Best abstracts

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB (Scientific sessions 7 & 8)

Room 111, Level 1, CCIB (Scientific session 9)

EITHER:

15:00 - 15:40		<p>Scientific session 7: ECCO Fellowships and Grants Britta Siegmund, Berlin, Germany Gionata Fiorino, Milan, Italy Plenary Hall, Ground level, CCIB</p>
15:00 - 15:07		<p>41: Outcomes from the 2015-2016 Fellowships: Post-genomic application in general, and the establishment of computational approaches relevant to translational medicine Ferdinando Bonfiglio, Stockholm, Sweden</p>
15:07 - 15:14		<p>42: Outcomes from the 2015-2016 Fellowships: Hypoxia, antophagy and inflammasome Jesús Cosín, Valencia, Spain</p>
15:14 - 15:20		<p>43: Announcement of ECCO Fellowships & Grants 2017</p>
15:20 - 15:30		<p>44: OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn's Disease treated with mongersen (GED-0301) B. Feagan¹, J.-F. Colombel², G. Rossiter³, X. Li³, K. Usiskin³, X. Zhan³, B. Sands² ¹Robarts Clinical Trials and University of Western Ontario, London, Canada, ²Icahn School of Medicine at Mount Sinai, New York, United States, ³Celgene Corporation, Summit, United States</p>
15:30 - 15:40		<p>45: OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn Disease A. Gíls¹, E. Dreesen¹, G. Compernelle¹, M. Peeters¹, E. Brouwers¹, S. Tops¹, V. Ballet¹, M. Noman², M. Ferrante², G. Van Assche², S. Vermeire² ¹KU Leuven, P.O. Box 820 Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ²UZ Leuven, Campus Gasthuisberg, Department of Gastroenterology and Hepatology, Leuven, Belgium</p>
15:40 - 16:10		Coffee break
16:10 - 17:10		<p>Scientific session 8: IBD Horizons Bruce Sands, New York, United States Herbert Tilg, Innsbruck, Austria Plenary Hall, Ground level, CCIB</p>
16:10 - 16:20		<p>46: OP021: Hyperbaric oxygen therapy is safe and effective for hospitalised Ulcerative Colitis patients suffering from moderate-severe flares: A multi-center, randomised, double-blind, sham-controlled trial P. Dulai^{1,2}, J. Buckley Jr.², L. Raffals³, J. Swoger⁴, P. Claus³, K. O'Toole⁴, J. Ptak², M. Gleeson², C. Widjaja¹, J. Adler², N. Patel², L. Skinner², S. Haren³, K. Goldby-Reffner⁴, K. Thompson², R. Knight¹, J. Chang¹, C. Siegel² ¹University of California San Diego, La Jolla, CA, United States, ²Dartmouth Hitchcock Medical Center, Lebanon, NH, United States, ³Mayo Clinic, Rochester, MN, United States, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, United States</p>

OP = Oral presentation – Best abstracts

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB (Scientific sessions 7 & 8)

Room 111, Level 1, CCIB (Scientific session 9)

16:20 - 16:30	<p>47: OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character study R. Kalla¹, A. Adams¹, S. Vatn², D. Bergemalm³, P. Ricane⁴, J. Lindstrom², A. Ocklind⁵, N. Nordberg⁵, N. Kennedy¹, N. Ventham¹, IBD Character Consortium⁶, M. Vatn⁴, J. Söderholm⁷, M. Pierik⁸, L. Törkvist⁹, F. Gomollón¹⁰, J. Jahnsen², J. Halfvarson³, J. Satsangi¹</p> <p>¹University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, ²Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, ³Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, ⁴University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ⁵Olink Proteomics, Uppsala, Sweden, ⁶IBD Character Consortium, Edinburgh, United Kingdom, ⁷Linköping University, Gastroenterology, Linköping, Sweden, ⁸Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ⁹Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Karolinska, Sweden, ¹⁰HCU "Lozano Blesa", IIS Aragón, CIBEREHD, Zaragoza, Spain</p>
16:30 - 16:40	<p>48: OP023: Maintenance of clinical effect in patients with Moderate-to-Severe Crohn's Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY study S. Vermeire¹, S. Schreiber², R. Petryka³, T. Kuehbacher⁴, X. Hebuterne⁵, X. Roblin⁵, M. Klopocka⁶, A. Goldis⁸, M. Wisniewska-Jaroszinska⁹, A. Baranovsky¹⁰, R. Sike¹¹, K. Stoyanova¹², L. Meuleners¹³, C. Tasset¹³, A. Van der Aa¹³, P. Harrison¹³</p> <p>¹University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, ²University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany, ³Vivamed, Warsaw, Poland, ⁴Asklepios Hospital West Hamburg, Department of Gastroenterology, Hamburg, Germany, ⁵CHU Nice Hopital l'Archet, Department of Gastroenterology and Nutrition, Nice Cedex 3, France, ⁶North Hospital, Department of Gastroenterology, Saint Priez en Jarez, France, ⁷NC University in Toruń, Collegium Medicum, Bydgoszcz, Poland, ⁸Dr. Goldis Center for Gastroenterology, Ltd., Timisoara, Romania, ⁹Santa LLC, Santa Familia Research, Prevention and Treatment Centre, Lodz, Poland, ¹⁰City Clinical Hospital #31, St. Petersburg, Russian Federation, ¹¹Szent Margit Hospital, Budapest, Hungary, ¹²PSI Pharma Support EOOD, Sofia, Bulgaria, ¹³Galapagos NV, Mechelen, Belgium</p>
16:40 - 16:50	<p>49: OP024: Childhood-onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014 O. Olén^{1,2}, J. Askling¹, P. Frumento³, M.C. Sachs³, M. Neovius¹, J. Eriksson¹, K.E. Smedby¹, A. Ekbohm¹, P. Malmberg^{1,2}, J.F. Ludvigsson^{4,5,6,7}</p> <p>¹Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Unit, Stockholm, Sweden, ²Sachs' Children's Hospital, Department of Pediatric Gastroenterology and Nutrition, Stockholm, Sweden, ³Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden, ⁴Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ⁵Örebro University Hospital, Department of pediatrics, Örebro, Sweden, ⁶University of Nottingham, Division of Epidemiology and Public Health, School of Medicine, Nottingham, United Kingdom, ⁷Columbia University College of Physicians and Surgeons, Department of Medicine, New York, Sweden</p>

OP = Oral presentation – Best abstracts

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB (Scientific sessions 7 & 8)

Room 111, Level 1, CCIB (Scientific session 9)

16:50 - 17:00	<p>50: OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's Disease in clinical practice S. Steiner¹, E. King², K. Park³, D. Pashankar⁴, H. Shashidhar⁵, B. Sudel⁶, S. Eichner⁷, S. Chen², J. Pratt², R. Colletti⁸, ImproveCareNow Network⁹ ¹Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, United States, ²Cincinnati Children's Hospital Medical Center, Cincinnati, United States, ³Lucile Salter Packard Children's Hospital, Stanford University, Palo Alto, United States, ⁴Yale-New Haven Children's Hospital, New Haven, United States, ⁵New Hampshire's Hospital for Children, Manchester, United States, ⁶University of Minnesota Masonic Children's Hospital, Minneapolis, United States, ⁷AbbVie, North Chicago, United States, ⁸University of Vermont Children's Hospital, Burlington, United States, ⁹ImproveCareNow, Burlington, United States</p>
17:00 - 17:10	<p>51: OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with Inflammatory Bowel Disease C. Lahiff¹, L.M. Wang², S.P.L. Travis¹, J.E. East¹ ¹Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Translational Gastroenterology Unit, Experimental Medicine Division, Oxford, United Kingdom, ²John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Department of Cellular Pathology, Oxford, United Kingdom</p>

OR:

15:00 - 17:10	<p>Scientific session 9: Basic Science meets the clinic Arthur Kaser, Cambridge, United Kingdom Azucena Salas, Barcelona, Spain Room 111, Level 1, CCIB</p>
---------------	---

 Y-ECCO Abstract Award	15:00 - 15:20	<p>52: IL-23 and beyond Fiona Powrie, Oxford, United Kingdom</p>
	15:20 - 15:30	<p>53: OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in Colitis-associated colorectal cancer L.R. Lopetuso^{1,2}, C. De Salvo³, L. Di Martino³, W. Goodman³, F. Scalfaferrri⁴, A. Gasbarrini⁴, T.T. Pizarro³ ¹Catholic University of the Sacred Heart, Internal Medicine, Gastroenterology Division, Rome, Italy, ²Case Western Reserve University, Pathology, Cleveland, United States, ³Case Western Reserve University, Pathology, Cleveland, United States, ⁴Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy</p>
	15:30 - 15:40	<p>54: OP028: Gut specific regulatory T cells – a new frontier for Crohn's Disease therapy R. Goldberg^{1,2,3,4}, C. Scotta^{3,4,5}, D. Cooper⁶, E. Eliraz⁷, E. Nir⁷, P. Irving^{1,8}, J. Sanderson^{1,8}, N. Shpigel⁷, F. Marelli-Berg⁶, G. Lombardi^{3,4,5}, G. Lord^{2,3,4} ¹Guy's and St Thomas' NHS Trust, Gastroenterology, London, United Kingdom, ²King's College London, Experimental Immunobiology, London, United Kingdom, ³King's College London, Medical Research Council Centre for Transplantation, London, United Kingdom, ⁴Guy's and St Thomas' NHS Trust, National Institute for Health Research Biomedical Research Centre, London, United Kingdom, ⁵King's College London, Immunoregulation and Immune Intervention, London, United Kingdom, ⁶Bart's and the London Queen Mary School of Medicine and Dentistry, William Harvey Research Institute, London, United Kingdom, ⁷Hebrew University of Jerusalem, Koret School of Veterinary Medicine, Rehovot, Israel, ⁸King's College London, Diabetes and Nutritional Sciences, London, United Kingdom</p>

OP = Oral presentation – Best abstracts

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB (Scientific sessions 7 & 8)

Room 111, Level 1, CCIB (Scientific session 9)

15:40 - 16:10		Coffee break
16:10 - 16:30	55: Genetics and function in IBD: The missing link?	Sebastian Zeissig, Dresden, Germany
16:30 - 16:40	56: OP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's Disease A. Lewis¹, C. Felice^{1,2}, A. Nihhuis¹, S. Iqbal¹, S. Mehta¹, R. Feakins³, A. Armuzzi², A. Silver¹, J. Lindsay⁴	¹ Queen Mary's University London, Centre for Genomics and Child Health, Blizard Institute, London, United Kingdom, ² Gemelli Hospital Catholic University Foundation, IBD Unit, Presidio Columbus, Rome, Italy, ³ The Royal London Hospital, Department of pathology, London, United Kingdom, ⁴ Queen Mary's University
16:40 - 16:50	57: OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation A. Metwaly¹, L. F. Buttó¹, N. Waldschmitt¹, I. Lagkouvardos², A.M. Corraliza³, A. Mayorgas³, M. Martinez-Medina⁴, M. Allez⁵, J. Panes³, A. Salas³, D. Haller^{1,2}	¹ Technical University Munich, Chair of Nutrition and Immunology, Freising, Germany, ² ZIEL-Institute for Food and Health, Technical University of Munich, Freising, Germany, ³ Instituto de Investigaciones Biomédicas de Barcelona CSIC, IDIBAPS, CIBERehd, Department of Experimental Pathology, Barcelona, Spain, ⁴ Laboratory of Molecular Microbiology, Universitat de Girona, Biology Department, Girona, Spain, ⁵ APHP, Hôpital Saint Louis, INSERM UMR5 1160, Paris Diderot, Sorbonne Paris-Cité University, Department of Gastroenterology, Paris, France
16:50 - 17:10	58: Epigenetics in complex diseases	Manel Esteller, Barcelona, Spain
17:20 - 18:20	Digital oral presentations Please refer to pages 43-67	
18:30 - 19:30	Industry sponsored satellite symposia 4a & 4b Please refer to page 190	
20:30	ECCO Interaction: Hearts & Minds Please refer to page 207	

OP = Oral presentation – Best abstracts



European
Crohn's and Colitis
Organisation

ECCO UR-CARE



United **Registries** for Clinical
Assess**ment and RE**search

Your IBD Database for patient records
and research studies

What to expect

- Comprehensive registry capturing demographics, environmental factors, clinical characteristics, examinations and therapeutic interventions in IBD
- Ground-breaking cross-project cooperation and comparison of results
- Independent data management software offered to study groups
- Quality of care assessment
- High mobility & continuity of care for patients
- Retro- & prospective data collection and evaluation
- Sophisticated, user friendly data export and report function
- Precise data ownership rules

Scan and visit
www.ecco-ibd.eu/ur-care



Saturday, February 18, 2017

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

07:15 - 08:15	Industry sponsored satellite symposia 5a & 5b Please refer to page 192
08:30 - 10:20	Scientific session 10: New compounds in the treatment of IBD John Mansfield, Newcastle upon Tyne, United Kingdom Pieter Hindryckx, Ghent, Belgium
08:30 - 08:50	59: JAK-inhibitors Séverine Vermeire, Leuven, Belgium
08:50 - 09:00	60: OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn's Disease: Results from a phase 2 open-label 48-week extension study J. Panés¹ , G.R. D'Haens ² , P.D.R. Higgins ³ , L. Mele ⁴ , M. Moscariello ⁴ , G. Chan ⁴ , W. Wang ⁴ , W. Niezychowski ⁵ , C. Su ⁴ , E. Maller ⁴ ¹ Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ² Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands, ³ University of Michigan, Ann Arbor, MI, United States, ⁴ Pfizer Inc, Collegeville, PA, United States
09:00 - 09:10	61: OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with Moderate to Severe Ulcerative Colitis: Results from a phase 3 randomised controlled trial W.J. Sandborn ¹ , B.E. Sands ² , S. Danese ³ , G.R. D'Haens ⁴ , S. Vermeire ⁵ , S. Schreiber ⁶ , B. Feagan ⁷ , W. Reinisch ^{8,9} , G. Friedman ¹⁰ , D. Woodworth ¹⁰ , H. Zhang ¹⁰ , N. Lawendy ¹⁰ , W. Niezychowski ¹⁰ , C. Su ¹⁰ , J. Panés¹¹ ¹ Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States, ² Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States, ³ IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy, ⁴ Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands, ⁵ Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, ⁶ Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, ⁷ Robarts Clinical Trials, Inc., Robarts Research Institute, Western University, London, ON, Canada, ⁸ McMaster University, Hamilton, ON, Canada, ⁹ Medical University of Vienna, Vienna, Austria, ¹⁰ Pfizer Inc, Collegeville, PA, United States, ¹¹ Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
09:10 - 09:20	62: OP033: Reduction of tissue pSTAT3 in Crohn's Disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor S. Vermeire ¹ , G. De Hertogh² , G. Chen ³ , D. French ⁴ , E. Huntzicker ⁴ , A. Van der Aa ⁵ , T. Van Kaem ⁵ , P. Harrison ⁵ , C. Tasset ⁵ , R. Galien ⁶ , Y. Pan ⁴ , B. Feagan ⁷ , W. Sandborn ⁸ ¹ University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, ² University Hospitals Leuven, Department of Pathology, Leuven, Belgium, ³ Gilead Sciences, Department of Biostatistics, Foster City, United States, ⁴ Gilead Sciences, Biomarker Sciences, Foster City, United States, ⁵ Galapagos NV, Mechelen, Belgium, ⁶ Galapagos SASU, Romainville, France, ⁷ Robarts Research Institute, Ontario, Canada, ⁸ University of California, Division of Gastroenterology, San Diego, United States
09:20 - 09:40	63: S1P modulators Arthur Kaser, Cambridge, United Kingdom



European
Crohn's and Colitis
Organisation



United We Stand

ECCO-EFCCA Patient Guidelines - CD and UC



Now in 30 languages

Available for download at: www.ecco-ibd.eu and www.efcca.org

ECCO and EFCCA Country Members' languages in which the guidelines are translated:

Bosnian	English	Hungarian	Norwegian	Slovakian
Bulgarian	Estonian	Hebrew	Polish	Slovenian
Croatian	Finnish	Icelandic	Portuguese	Spanish
Czech	French	Italian	Romanian	Swedish
Danish	German	Latvian	Russian	Turkish
Dutch	Greek	Lithuanian	Serbian	Ukrainian

Scan and visit

www.ecco-ibd.eu/ecco-efcca-patient-guidelines



Saturday, February 18, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

09:40 - 09:50	<p>64: OP034: Efficacy and safety of abrilumab in subjects with Moderate to Severe Ulcerative Colitis: Results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study</p> <p>W.J. Sandborn¹, M. Cyrille², M.B. Hansen³, B.G. Feagan⁴, E.V. Loftus Jr⁵, G. Rogler⁶, S. Vermeire⁷, M.L. Cruz², J. Yang², B.A. Sullivan², W. Reinisch⁸</p> <p>¹University of California San Diego, Department of Gastroenterology, La Jolla, United States, ²Amgen, Thousand Oaks, United States, ³University of Copenhagen, Copenhagen, Denmark, ⁴Robarts Clinical Trials, Robarts Research Institute, Western University, London, Canada, ⁵Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, ⁶Universitätsspital Zurich, Zurich, Switzerland, ⁷University Hospital Gasthuisberg, Leuven, Netherlands, ⁸Medical University of Vienna, Vienna, Austria</p>
09:50 - 10:00	<p>65: OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for Moderate to Severe Crohn's Disease</p> <p>W.J. Sandborn¹, M. Cyrille², M. Berner Hansen³, B.G. Feagan⁴, E.V. Loftus Jr⁵, S. Vermeire⁶, M.L. Cruz², M. Mo², B.A. Sullivan², W. Reinisch⁷</p> <p>¹University of California San Diego, United States, ²Amgen Inc., Thousand Oaks, United States, ³University of Copenhagen, Copenhagen, Denmark, ⁴Robarts Research Institute, University of Western Ontario, London, Canada, ⁵Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, ⁶University Hospitals Leuven, Leuven, Belgium, ⁷Medical University Vienna, Vienna, Austria</p>
10:00 - 10:20	<p>66: Anti IL12/IL23 compounds</p> <p>Bruce Sands, New York, United States</p>
10:20 - 10:50	Coffee break
10:50 - 12:20	<p>Scientific session 11: Gut luminal content – more than just bacteria</p> <p>Isabelle Cleynen, Leuven, Belgium Miquel Gassull, Barcelona, Spain</p>
10:50 - 11:10	<p>67: The forgotten populations in the gut</p> <p>Patricia Lepage, Jouy-En-Josas, France</p>
11:10 - 11:20	<p>68: OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active Ulcerative Colitis: A randomised controlled trial</p> <p>S. Costello^{1,2,3}, O. Waters⁴, R. Bryant^{2,3}, R. Katsikeros³, J. Makanyanga⁴, M. Schoeman^{2,3}, R. Mountfield⁵, D. Tee⁶, S. Howell⁷, P. Hughes², M. Conlon⁷, I. Roberts-Thomson^{1,2}, J. Andrews^{2,3}</p> <p>¹The Queen Elizabeth Hospital, Gastroenterology, Woodville, Australia, ²University of Adelaide, School of Medicine, Adelaide, Australia, ³The Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia, ⁴Fiona Stanley Hospital, Gastroenterology, Murdoch, Australia, ⁵Flinders Medical Centre, Gastroenterology, Bedford Park, Australia, ⁶Lyell McEwin Hospital, Gastroenterology, Elizabeth Vale, Australia, ⁷CSIRO, Health and Biosecurity, Adelaide, Australia</p>
11:20 - 11:40	<p>69: Metabolic activity</p> <p>Dirk Haller, Freising, Germany</p>



IIS
Abstract Award

Saturday, February 18, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

11:40 - 11:50	<p>70: OP037: Infants born to mothers with Inflammatory Bowel Disease exhibit distinct microbiome features that persist up to 3 months of life J. Torres¹, J. Hu², C. Eisele², N. Nair², H. Panchal², X. Bao², X. Niu², J. Coté-Daigneault¹, B. Jharap¹, E. Maser¹, A. Kornbluth¹, P. Legnani¹, J. George¹, M. Dubinsky³, J. Stone⁴, C.-L. Chen⁴, J. Clemente^{2,5}, J.-F. Colombel¹, I. Peter²</p> <p>¹Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, ²Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences, New York, United States, ³Icahn School of Medicine at Mount Sinai, Department of Pediatrics, New York, United States, ⁴Icahn School of Medicine at Mount Sinai, Obstetrics, Gynecology and Reproductive Science, New York, United States, ⁵Icahn School of Medicine at Mount Sinai, Immunology, New York, United States</p>
11:50 - 12:00	<p>71: OP038: Impact of ileocecal resection in Crohn's Disease patients on mucosal microbiota K. Machiels¹, M. Pozuelo del Río², J. Sabino¹, A. Santiago², D. Campos², A. Wolthuis³, A. De Buck Van Overstraeten³, A. D'Hoore³, G. Van Assche¹, M. Ferrante¹, P. Rutgeerts¹, G. De Hertogh³, S. Vermeire¹, C. Manichanh²</p> <p>¹University Hospitals Leuven, KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ²Vall d'Hebron Research Institute, Barcelona, Spain, ³University Hospitals Leuven, KU Leuven, Leuven, Belgium</p>
12:00 - 12:20	<p>72: Microbiome reality check – looking beyond the hype Jeroen Raes, Ghent, Belgium</p>
12:20 - 12:50	<p>Scientific session 12: ECCO Lecture Julián Panés, Barcelona, Spain Silvio Danese, Milan, Italy</p>
12:20 - 12:50	<p>73: Best individualised IBD care – optimising drugs, psychology, diet and microbes Michael Kamm, Melbourne, Australia</p>
12:50 - 12:55	<p>74: Awards and closing remarks Julián Panés, Barcelona, Spain</p>
12:55 - 13:00	<p>75: The ECCO Film</p>



European
Crohn's and Colitis
Organisation

Barcelona
Spain

ECCO IBD Curriculum

Pick up your
copy @ the
ECCO Booth



Congress special: Open access preview

- Concise yet complete: What gastroenterologists need to know to develop expertise in the IBD field
- Developed in part by ECCO Officers and ECCO National Representatives
- Provides a future framework for ECCO Educational Activities
- 275 items from the e-CCO Learning Platform are already mapped to the ECCO IBD Curriculum
 - e-Courses
 - Talking Heads
 - Webcasts from the ECCO Congress Scientific Programme and Educational Activities



Scan and visit

www.e-learning.ecco-ibd.eu





Abstract presentation format

Oral presentations (OP)

Out of 955 accepted abstracts the 38 best submitted abstracts have been chosen for oral presentation by a panel of referees and will be presented during the scientific programme of the ECCO Congress. For the presentation title and schedule please refer to the scientific congress programme per day.

Note: Oral poster presentations will not be displayed as hard copy posters.

Digital oral presentations (DOP)

Abstracts have been selected from the ranking by taking 90 abstracts after those 38 selected for presentation in the scientific programme. These abstracts will be presented as digital oral presentations, with a 5 minute oral presentation in several rooms on Level 1 of the CCIB on Thursday, February 16, 2017 from 17:45-18:45 and on Friday, February 17, 2017 from 17:20-18:20.

The schedule and selected abstracts for each digital oral presentation room can be found on pages 43-67.

Note: Digital oral presentations will not be displayed as hard copy posters.

Hard copy poster presentations (P)

All remaining accepted abstracts are selected for "hard copy poster presentation" and are listed on pages 69-158. Hard copy posters will be installed on poster walls in the poster exhibition area in the Banquet Hall on Level 2 and will be available for viewing throughout the Congress.

Poster award ceremony:

On Saturday, February 18, 2017 from 12:50 to 12:55 the poster prizes will be awarded for the ten 'Best Posters'. One abstract of each digital oral presentation room has been nominated by the chairs of the respective session.

Please note that this year for the seventh time the ECCO Congress hosts a separate nurses poster section in the Banquet Hall on Level 2 at the CCIB. Please find the list of nurses posters on page 156-158.

Poster award ceremony is chaired by:

Julián Panés (Spain)

Silvio Danese (Italy)

Laurent Peyrin-Biroulet (France)

Charlie Lees (United Kingdom)

Peter Lakatos (Hungary/Canada)

Reviewers

ECCO gratefully thanks the following reviewers for their valuable time and efforts in reviewing abstracts:

(i) Basic Science

Ingrid Arijis (Belgium), Giorgio Bamias (Greece), Dominik Bettenworth (Germany), Mathilde Body (France), Flavio Caprioli (Italy), Gwenny Fuhler (The Netherlands), Alessandra Geremia (United Kingdom), Pieter Hindryckx (Belgium), Michel Maillard (Switzerland), Giovanni Monteleone (Italy), Maikel Peppelenbosch (The Netherlands), Theresa Pizarro (United States), Nick Powell (United Kingdom), Gerhard Rogler (Switzerland), Franco Scaldaferrì (Italy), Michael Schumann (Germany), Britta Siegmund (Germany), Harry Sokol (France), Markus Tschurtschenthaler (Austria), Holm Uhlig (United Kingdom), Dominique Velin (Switzerland)

(ii) Clinical: Diagnosis & outcome

Ayesha Akbar (United Kingdom), Xavier Aldeguer (Spain), Vito Annese (Italy), Raja Atreya (Germany), Oliver Bachmann (Germany), Filip Baert (Belgium), Marko Banic (Croatia), Andrea Cassinotti (Italy), Fabiana Castiglione (Italy), Aykut F. Celik (Turkey), Jacques Cosnes (France), Silvio Danese (Italy), Marco Daperno (Italy), Mircea Diculescu (Romania), Axel Dignass (Germany), Iris Dotan (Israel), Tomas Douda (Czech Republic), Roger Feakins (United Kingdom), Richard Gearry (New Zealand), Kristina Gecse (Hungary), Corinne Gower-Rousseau (France), Richard Hansen (United Kingdom), Marcus Harbord (United Kingdom), Njegica Jovic (Serbia), Ioannis Karagiannis (Greece), Konstantinos Karmiris (Greece), Iskren Kotzev (Bulgaria), Ioannis Koutroubakis (Greece), Arie Levine (Israel), Scott Levison (United Kingdom), Jimmy Limdi (United Kingdom), Loris Riccardo Lopetuso (Italy), Edouard Louis (Belgium), Tom Moreels (Belgium), Bjorn Moum (Norway), Siew Ng (China), Bas Oldenburg (The Netherlands), Claudia Ott (Germany), Florian Rieder (United States), Richard Russell (United Kingdom), Guillaume Savoye (France), Murat Törüner (Turkey)

(iii) Clinical: Therapy and Clinical Observation

Matthieu Allez (France), Jorge Amil Dias (Portugal), Alessandro Armuzzi (Italy), Manuel Barreiro de Acosta (Spain), Shomron Ben-Horin (Israel), Bernd Bokemeyer (Germany), Martin Bortlik (Czech Republic), Carsten Büning (Germany), Daniel Burger (United Kingdom), Franck Carbonnel (France), Cristina Cijevschi (Romania), Mario Cottone (Italy), Marilia Cravo (Portugal), Vincenza Di Leo (Italy), Lesley Dibley (United Kingdom), Glen Doherty (Ireland), Laurence Egan (Ireland), Rami Eliakim (Israel), Marc Ferrante (Belgium), Gionata Fiorino (Italy), Mayur Garg (Australia), Daniel Ginard Vicens (Spain), Javier Perez Gisbert (Spain), Adrian Goldis (Romania), Fernando Gomollón García (Spain), Daniel Hommes (United States), Samuel Huber (Germany), Peter Irving (United Kingdom), Guru lyngkaran (Australia), Kostas Katsanos (Greece), Karen Kemp (United Kingdom), Satish Keshav (United Kingdom), Sanja Kolacek (Croatia), David Laharie (France), Ebbe Langholz (Denmark), Ian Lawrance (Australia), James Lindsay (United Kingdom), Milan Lukas (Czech Republic), Christian Maaser (Germany), Fernando Magro (Portugal), Jeroen Maljaars (The Netherlands), Gerassimos Mantzaris (Greece), Paula Ministro (Portugal), Tamas Molnar (Hungary), Irl L. K. Monstad (Norway), Tom Oresland (Norway), Remo Panaccione (Canada), Konstantinos Papadakis (Greece), Pavol Papay (Austria), Laurent Peyrin-Biroulet (France), Guillaume Pineton de Chambrun (France), Valérie Pittet (Switzerland), Francisco Portela (Portugal), Zhihua Ran (China), Catherine Reenaers (Belgium), Walter Reinisch (Austria),

Xavier Roblin (France), Iago Rodríguez Lago (Spain), Gianluca Sampietro (Italy), Nik Sheng Ding (Australia), Dino Tarabar (Serbia), Herbert Tilg (Austria), Simon Travis (United Kingdom), John Triantafyllidis (Greece), Gert van Assche (Belgium/Canada), Manuel Van Domselaar (Spain), Niels Vande Castele (Belgium), Stephan Robert Vavricka (Switzerland), Severine Vermeire (Belgium), Janindra Warusavitarne (United Kingdom), Sebastian Zeissig (Germany)

(iv) Epidemiology

Luc Biedermann (Switzerland), Renata D'Inca (Italy), David Drobne (Belgium), Hannah Gordon (United Kingdom), Peter Lakatos (Hungary/Canada), Pierre Michetti (Switzerland), Wolfgang Miehsler (Austria), Selwyn Odes (Israel), Morten Vatn (Norway), Gabor Veres (Hungary), Ida Vind (Denmark), David Wilson (United Kingdom)

(v) Genetics

Shay Ben-Shachar (Israel), Andre Franke (Germany), Jack Satsangi (United Kingdom)

(vi) Microbiology

Natalia Borrueal (Spain), Paolo Gionchetti (Italy), Gregor Gorkiewicz (Austria), Dirk Haller (Germany), Shaji Sebastian (United Kingdom), Philippe Seksik (France)

(vii) Nurses

Palle Bager (Denmark), Kay Greveson (United Kingdom), Nienke Ipenburg (The Netherlands), Jochen Maul (Germany)

Poster exhibition

Opening hours

<i>Industry and Poster exhibition</i>	
Thursday, February 16, 2017	12:00 – 18:00
Friday, February 17, 2017	09:30 – 18:00
Saturday, February 18, 2017	09:30 – 13:00

Guided poster session

The guided poster session is scheduled on Friday, February 17, 2017 from 12:30 to 13:30 in the Banquet Hall on Level 2 at the CCIB.

At least one of the authors of the abstracts will be present in order to give a 1-2 minute summary of the major findings described in the poster. Poster session chairs will guide through the poster exhibition in pairs. Congress delegates being present during that time will enjoy the possibility to engage in poster discussions.

Please choose one of the below listed poster groups and follow the respective poster chairs (they will carry a button with the words “ECCO Poster Chair” as well as a sign indicating the poster group number and the topic). The starting poster of each group is indicated below – please make sure to be there at 12:30.

Guided poster sessions are chaired by:

(i) **Basic Science:**

- Group 1** (starts at **P001**): Sebastian Zeissig, Dresden, Germany
Fiona Powrie, Oxford, United Kingdom
- Group 2** (starts at **P031**): Jesús Rivera-Nieves, San Diego, United States
Azucena Salas, Barcelona, Spain
- Group 3** (starts at **P061**): Arthur Kaser, Cambridge, United Kingdom
Gerhard Rogler, Zurich, Switzerland
- Group 4** (starts at **P091**): Ferdinando Bonfiglio, Stockholm, Sweden
Nik Sheng Ding, Melbourne, Australia

(ii) **Clinical: Diagnosis & outcome:**

- Group 5** (starts at **P121**): Filip Baert, Roeselare, Belgium
Jimmy Limdi, Manchester, United Kingdom
- Group 6** (starts at **P151**): Fernando Magro, Porto, Portugal
John Mansfield, Newcastle upon Tyne, United Kingdom
- Group 7** (starts at **P180**): Boris Vucelic, Zagreb, Croatia
Giovanni Maconi, Milan, Italy
- Group 8** (starts at **P209**): Florian Rieder, Cleveland, United States
Torsten Kucharzik, Lüneburg, Germany
- Group 9** (starts at **P238**): Yehuda Chowers, Haifa, Israel
Miquel Gassull, Barcelona, Spain

- Group 10** (starts at **P267**): Christianne Buskens, Amsterdam, The Netherlands
Matthieu Allez, Paris, France
- Group 11** (starts at **P296**): Bruce Sands, New York, United States
Johan Burisch, Frederikssund, Denmark

(iii) Clinical: Therapy and observation:

- Group 12** (starts at **P325**): Janneke van der Woude, Rotterdam, The Netherlands
Andreas Sturm, Berlin, Germany
- Group 13** (starts at **P353**): Glen Doherty, Dublin, Ireland
Pieter Hindryckx, Ghent, Belgium
- Group 14** (starts at **P381**): Laurence Egan, Galway, Ireland
Marieke Pierik, Maastricht, The Netherlands
- Group 15** (starts at **P409**): Randi Opheim, Oslo, Norway
Tom Øresland, Lorenskog, Norway
- Group 16** (starts at **P437**): Pierre Michetti, Lausanne, Switzerland
Herbert Tilg, Innsbruck, Austria
- Group 17** (starts at **P465**): Daniel Hommes, Los Angeles, United States
Charlie Lees, Edinburgh, United Kingdom
- Group 18** (starts at **P493**): Jaroslaw Kierkus, Warsaw, Poland
Paulo Kotze, Curitiba, Brazil
- Group 19** (starts at **P521**): Konstantinos Katsanos, Ioannina, Greece
Michael Kamm, Melbourne, Australia
- Group 20** (starts at **P549**): Pascal Juillerat, Bern, Switzerland
Peter Irving, London, United Kingdom
- Group 21** (starts at **P577**): Javier Gisbert, Madrid, Spain
Janindra Warusavitarne, London, United Kingdom
- Group 22** (starts at **P605**): Lesley Dibley, London, United Kingdom
Pierre Ellul, Sliema, Malta
- Group 23** (starts at **P633**): Rami Eliakim, Tel Aviv, Israel
Laurent Beaugerie, Paris, France
- Group 24** (starts at **P661**): Gerassimos Mantzaris, Athens, Greece
Michel Adamina, Winterthur, Switzerland

(iv) Epidemiology:

- Group 25** (starts at **P688**): Vito Annese, Florence, Italy
Naila Arebi, Harrow, United Kingdom
- Group 26** (starts at **P720**): Peter Lakatos, Budapest, Hungary; Montreal, Canada
Nynne Nyboe Andersen, Copenhagen, Denmark

(v) Genetics:

- Group 27** (starts at **P752**): Miles Parkes, Cambridge, United Kingdom
Isabelle Cleynen, Leuven, Belgium

(vi) Microbiology:

- Group 28** (starts at **P766**): Dirk Haller, Freising, Germany
Jeroen Raes, Ghent, Belgium



European
Crohn's and Colitis
Organisation

Why submit your research to JCC?



JCC publishes scholarship that has undergone rigorous peer review, including an initial screening by one of the Editors and recommendation by independent reviewers. The average time from submission to first decision is two weeks.

Fast publication speeds

- Fast Advance Access publication of the author manuscript version within one week of acceptance making your work discoverable faster.

Increased Impact Factor

- JCC's latest Impact Factor increased by 5.6% to 6.585, again ranked eighth in Gastroenterology & Hepatology.

Wide dissemination

- Publishing in JCC will ensure that your article will be seen, read and cited by your research community.

Scan and visit


<https://academic.oup.com/ecco-jcc>





CCIB, Level 1

- Digital oral presentations



Digital oral presentation

For details please refer to p. 35.

Please find below an overview of all DOP sessions. The schedule and selected abstracts for each digital oral presentation room can be found on pages 43-67. Please make sure to be there on time.

Digital Oral Presentation Session 1 (please refer to page 44-47)	Epidemiology, environment and nutrition Ebbe Langholz, Hellerup, Denmark Peter Lakatos, Budapest, Hungary; Montreal, Canada
Digital Oral Presentation Session 2 (please refer to page 47-50)	New tips for clinical practice Jane Andrews, Adelaide, Australia Glen Doherty, Dublin, Ireland
Digital Oral Presentation Session 3 (please refer to page 50-53)	Vedolizumab and ustekinumab therapies Pieter Hindryckx, Ghent, Belgium Laurent Peyrin-Biroulet, Vandoeuvre-les-Nancy, France
Digital Oral Presentation Session 4 (please refer to page 53-54)	Immunogenicity and pharmacokinetics of biologics Gionata Fiorino, Milan, Italy Florian Rieder, Cleveland, United States
Digital Oral Presentation Session 5 (please refer to page 55-57)	Surgical treatment Paulo Kotze, Curitiba, Brazil Oded Zmora, Tel Aviv, Israel
Digital Oral Presentation Session 6 (please refer to page 57-58)	Towards personalised medicine Axel Dignass, Frankfurt, Germany Britta Siegmund, Berlin, Germany
Digital Oral Presentation Session 7 (please refer to page 59-61)	Management of perianal and luminal disease Willem Bemelman, Amsterdam, The Netherlands Tom Øresland, Lorenskog, Norway
Digital Oral Presentation Session 8 (please refer to page 61-63)	Endoscopy in IBD: assessment of activity and surveillance Rami Eliakim, Tel Aviv, Israel Nik Sheng Ding, Melbourne, Australia
Digital Oral Presentation Session 9 (please refer to page 64-66)	New therapies Jean-Frédéric Colombel, New York, United States Joana Torres, Lisbon, Portugal
Digital Oral Presentation Session 10 (please refer to page 66-67)	Translational IBD Dominik Bettenworth, Münster, Germany Gerhard Rogler, Zurich, Switzerland

Please find the detailed schedule for each session on the following pages:

Thursday, February 16, 2017

<p>Digital Oral Presentation Session 1 - Epidemiology, environment and nutrition Room 115, Level 1 Ebbe Langholz, Hellerup, Denmark Peter Lakatos, Budapest, Hungary; Montreal, Canada</p>	
<p>17:45 - 18:45</p>	<p>DOP001: European Crohn's and Colitis Organisation topical review on environmental factors in IBD C. Maaser¹, E. Langholz², H. Gordon³, J. Burisch⁴, P. Ellul⁵, V. Hernández⁶, T. Karakan⁷, K.H. Katsanos⁸, E. Krustins⁹, A. Levine¹⁰, G.J. Mantzaris¹¹, C. O'Morain¹², E.S. Yuksel¹³, H. Strid¹⁴, V. Annese¹⁵ ¹Klinikum Lueneburg, Lueneburg, Germany, ²Department C, Gastroenterology Section, Herlev and Gentofte University Hospital, Hellerup, Denmark, ³Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom, ⁴Department of Gastroenterology, North Zealand University Hospital, Fredrikssund, Denmark, ⁵Department of Gastroenterology, Division of Gastroenterology, Mater Dei Hospital, Msida, Malta, ⁶Department of Gastroenterology, Hospital Álvaro Cunqueiro, Vigo, Spain, ⁷Department of Gastroenterology, Ankara, Turkey, ⁸Department of Gastroenterology and Hepatology, University and Medical School of Ioannina, Ioannina, Greece, ⁹Department of Gastroenterology, Hepatology and Nutrition Therapy, Pauls Stradins Clinical University Hospital, Riga, Latvia, ¹⁰Paediatric Gastroenterology & Nutrition Unit, Wolfson Medical Center, Tel Aviv, Israel, ¹¹Department of Gastroenterology, Evangelismos Hospital, Athens, Greece, ¹²Department of Gastroenterology, Dublin, Ireland, ¹³Department of Gastroenterology, Izmir Katip Celebi University, Izmir, Turkey, ¹⁴Department of Internal Medicine, Södra Älvsborgs Hospital, Borås, Sweden, ¹⁵Department of Emergency, Division of Gastroenterology, University Hospital Careggi, Florence, Italy</p>
<p>17:45 - 17:51</p>	<p>DOP002: Trends in small bowel resections for Crohn's Disease with and without short bowel syndrome in the era of biologics B. Limketkai¹, A. Parian², J.-F. Colombel³ ¹Stanford University School of Medicine, Gastroenterology & Hepatology, Stanford, California, United States, ²Johns Hopkins University School of Medicine, Gastroenterology & Hepatology, Baltimore, Maryland, United States, ³Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York, United States</p>
<p>17:51 - 17:57</p>	<p>DOP003: Proximal disease extension in patients with limited Ulcerative Colitis: A Danish population-based inception cohort J. Burisch¹, I. Vind², M. Prosborg², J.-F. Colombel³, R. Ungaro³, F. Bendtsen², M. Vester-Andersen^{2,4} ¹North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark, ²Hvidovre University Hospital, Gastroint, medical section, Hvidovre, Denmark, ³Susan and Leonard Feinstein IBD Clinical Center Icahn School of Medicine at Mount Sinai, Departments of Medicine and Pediatrics, New York, United States, ⁴Zealand University Hospital, Department of Medical Gastroenterology, Køge, Denmark</p>
<p>17:57 - 18:03</p>	

Thursday, February 16, 2017, cont.

18:03 - 18:09	<p>DOP004: Ethnicity and country of birth are associated with phenotypic differences in patients with Inflammatory Bowel Disease L. Spekhorst^{1,2}, M. Severs³, N.K.H. de Boer⁴, E.A.M. Festen^{1,2}, H.H. Fidder³, F. Hoentjen⁵, F. Imhann^{1,2}, D.J. de Jong⁵, A.E. van der Meulen-de Jong⁶, M. Pierik⁷, C.J. van der Woude⁸, G. Dijkstra¹, C.Y. Ponsioen⁹, M. Lowenberg⁹, B. Oldenburg³, R.K. Weersma¹</p> <p>¹University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ²University of Groningen and University Medical Center Groningen, Department of Genetics, Groningen, Netherlands, ³University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ⁴VU University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, ⁵University Medical Center St. Radboud, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands, ⁶Leiden University Medical Center, Department of Gastroenterology and Hepatology, Leiden, Netherlands, ⁷University Medical Center Maastricht, Division of Gastroenterology and Hepatology, Maastricht, Netherlands, ⁸Erasmus Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, ⁹Amsterdam Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands</p>
18:09 - 18:15	<p>DOP005: Proximal disease extension in limited Ulcerative Colitis: A systematic review and meta-analysis G. Roda¹, N. Narula², R. Pinotti³, A. Skamnelos⁴, K. Katsanos⁴, J. Torres⁵, R. Ungaro⁶, J.-F. Colombel⁷</p> <p>¹University of Bologna, Gastroenterology, BOLOGNA, Italy, ²University of Toronto, Canada, Gastroenterology, Toronto, Canada, ³Icahn School of Medicine, Levy Library, New York, United States, ⁴University Hospital of Ioannina – Greece, Department of Gastroenterology, Ioannina, Greece, ⁵Icahn School of Medicine, Gastroenterology, New York, United States, ⁶Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States, ⁷Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York, United States</p>

Thursday, February 16, 2017, cont.

<p>18:15 - 18:21</p>	<p>DOP006: Research gaps in diet and nutrition in Inflammatory Bowel Disease. A topical review by ECCO R. Sigall Boneh¹, A. Levine^{1,2}, M. Lomer³, N. Wierdsma⁴, P. Alan⁵, G. Fiorino⁶, S. Gatti⁷, D. Jonkers⁸, J. Kierkus⁹, K. H. Katsanos¹⁰, S. Melgar¹¹, E. Saritas Yuksel¹², K. Whelan¹³, E. Wine¹⁴, K. Gerasimidis¹⁵ ¹Wolfson Medical Center, Pediatric Gastroenterology and Nutrition Unit, Tel Aviv, Israel, ²Tel Aviv University, Tel Aviv, Israel, ³Guy's and St Thomas' NHS Foundation Trust and King's College London, Department of Nutrition and Dietetics, London, United Kingdom, ⁴U University Medical Centre, Department of Nutrition and Dietetics, Amsterdam, Netherlands, ⁵John Radcliffe Hospital, Department of Translational Gastroenterology, Oxford, United Kingdom, ⁶Humanitas Research Hospital, Department of Gastroenterology, IBD Center, Rozzano, Italy, ⁷Polytechnic University of Marche, Department of Paediatrics, Ancona, Italy, ⁸NUTRIM School for Nutrition and Translation Research in Metabolism, Maastricht University Medical Center, Division Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht, Netherlands, ⁹Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland, ¹⁰University and Medical School of Ioannina, Department of Gastroenterology and Hepatology, Ioannina, Greece, ¹¹APC Microbiome Institute, University College Cork, Cork, Ireland, ¹²Izmir Katip Celebi University Atatürk Teaching and Research Hospital, Department of Gastroenterology, Izmir, Turkey, ¹³King's College London, Division of Diabetes and Nutritional Sciences, London, United Kingdom, ¹⁴University of Alberta, Department of Paediatrics, Edmonton, Canada, ¹⁵University of Glasgow, Human Nutrition, School of Medicine, Dentistry and Nursing, Glasgow, United Kingdom</p>
<p>18:21 - 18:27</p>	<p>DOP007: Crohn's Disease exclusion diet and partial enteral nutrition (CDED+PEN) vs. exclusive enteral nutrition (EEN): Microbiome changes of a randomised clinical trial (RCT) in paediatric CD: Remission is associated with similar structural + functional profiles K.A. Dunn¹, R. Sigall-Boneh², J.P. Bielawski¹, D. Turner³, J. Van Limbergen⁴, A. Levine² ¹Dalhousie University, Biology, Halifax, Canada, ²Edith Wolfson Medical Centre, Pediatrics, Tel Aviv, Israel, ³Shaare Zedek Medical Center, Department of Gastroenterology and Digestive Diseases, Jerusalem, Israel, ⁴IWK Health Centre - Dalhousie University, Pediatric Gastroenterology, Halifax, Canada</p>
<p>18:27 - 18:33</p>	<p>DOP008: Dietary manipulation of the healthy human and colitic murine gut microbiome by CD-TREAT diet and exclusive enteral nutrition; a proof of concept study V. Svolos¹, R. Hansen², U.Z. Ijaz³, C. Quince⁴, D. Watson⁵, A. Alghamdi⁵, A. Brejnrod⁴, C. Ansalone⁶, S. Milling⁶, D. Gaya⁷, R. Russell², K. Gerasimidis¹ ¹Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom, ²Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, United Kingdom, ³School of Engineering, University of Glasgow, Glasgow, United Kingdom, ⁴Warwick Medical School, University of Warwick, Warwick, United Kingdom, ⁵Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom, ⁶Institute of Infection, Immunity and Inflammation, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁷Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, United Kingdom</p>

Thursday, February 16, 2017, cont.

18:33 - 18:39	<p>DOP009: Choice of corticosteroids or exclusive enteral nutrition as the first induction of remission therapy does not affect disease behavior within two years of diagnosis N. Cohen-Dolev¹, M. Sladek², R. Sigall Boneh¹, G. Veres³, S. Hussey⁴, A. Staiano⁵, F. Nuti⁶, P. Lionetti⁷, S. Koletzko⁸, A. Levine¹</p> <p>¹The E.Wolfson medical Center, Pediatric Gastroenterology and Nutrition Research Unit, Holon, Israel, ²Jagiellonian University Medical College, Krakow, Poland, ³Semmelweis University, 1st Dept. of Pediatrics, Budapest, Hungary, ⁴National Children's Research Centre, UCD and RCSJ, Dublin, Ireland, ⁵University of Naples "Federico II", Department of Translational Medical Science, Section of Pediatrics, Napoli, Italy, ⁶Sapienza University, Rome, Italy, ⁷University of Florence, Florence, Italy, ⁸Dr. v Haunersches Kinderspital, Ludwig Maximilians University Munich, Department of Pediatric Gastroenterology and Hepatology, Munich, Germany</p>
---------------	---

<p>Digital Oral Presentation Session 2 - New tips for clinical practice Room 114, Level 1 Jane Andrews, Adelaide, Australia Glen Doherty, Dublin, Ireland</p>	
17:45 - 18:45	<p>DOP10: ECCO Topical Review on transitional care in Inflammatory Bowel Disease P. van Rhee^{en}, ECCO Transition Topical Review Consensus Group University Medical Center Groningen, Pediatric Gastroenterology, Groningen, Netherlands</p>
17:51 - 17:57	<p>DOP11: Risk of opportunistic infection in healthcare personnel with Inflammatory Bowel Disease: A case-control study of the GETAID C. Gagniere¹, A. Bourrier², P. Seksik², J.-M. Gornet³, O. Dewit⁴, S. Nancey⁵, R. Altwegg⁶, V. Abitbol⁷, D. Laharie⁸, C. Reenaers⁹, A. Buisson¹⁰, M. Nachury¹¹, S. Viennot¹², L. Vuitton¹³, C. Stefanescu¹⁴, P. Marteau¹⁵, G. Bouguen¹⁶, J. Cosnes², A. Amiot¹</p> <p>¹Henri Mondor Hospital, Gastroenterology, Creteil, France, ²APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France, ³Hospital Saint-Louis, Department of Gastroenterology, Paris, France, ⁴UCL Saint-Luc, Department of Gastroenterology, Brussels, Belgium, ⁵Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France, ⁶CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, ⁷Cochin Hospital, Department of Gastroenterology, Paris, France, ⁸CHU Bordeaux, Department of Gastroenterology, Bordeaux, France, ⁹CHU Liège, Sart Tilman, Department of Gastroenterology, Liège, Belgium, ¹⁰CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, ¹¹CHRU Lille, Department of Gastroenterology, Lille, France, ¹²Hospital Cote de Nacre, Department of Gastroenterology, Caen Cede, France, ¹³CHU Besancon, Department of Gastroenterology and Hepatology, Besançon, France, ¹⁴APHP Beaujon, Department of Gastroenterology, Clichy, France, ¹⁵Hospital Lariboisière, Department of Gastroenterology, Paris, France, ¹⁶CHU Pontchaillou, Department of Gastroenterology, Rennes, France</p>
17:57 - 18:03	<p>DOP12: Impact on clinical practice of Epstein-Barr virus infection in patients with Inflammatory Bowel Disease R. de Francisco¹, S. Riestra¹, I. Pérez-Martínez¹, A. Castaño¹, S. Martínez-González¹, S. Jiménez², A.J. González³, L.R. Morais³, A. Suárez¹</p> <p>¹Hospital Universitario Central de Asturias, Gastroenterology, Oviedo, Spain, ²Hospital Universitario Central de Asturias, Pediatrics, Oviedo, Spain, ³Hospital Universitario Central de Asturias, Hematology, Oviedo, Spain</p>

Thursday, February 16, 2017, cont.

18:03 - 18:09	<p>DOP013: Definition of therapeutic response criteria using MRI in Crohn's Disease patients treated with anti-TNF therapy: A multicenter prospective study (the IRMA study) A. Buisson^{1,2}, L. Messadeg³, G. Bouguen⁴, F. Goutorbe^{1,5}, J.-M. Reimund⁶, M. Goutte^{1,2}, C. Sautel⁷, C. Duron⁸, J. Scanzi¹, M. Reymond¹, C. Allimant¹, M. Dapoigny¹, G. Bommelaer^{1,2}, B. Pereira⁹, C. Hordonneau³</p> <p>¹University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, ²UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, ³University Hospital Estaing, Radiology Department, Clermont-Ferrand, France, ⁴University Hospital, Rennes, France, ⁵Hospital of Bayonne, Gastroenterology Department, Bayonne, France, ⁶University Hospital Hautepierre, Gastroenterology Department, Strasbourg, France, ⁷Hospital of Issoire, Gastroenterology Department, Issoire, France, ⁸Hospital of Montluçon, Department of Gastroenterology, Montluçon, France, ⁹University Hospital, Biostatistics Unit, DRCI, Clermont-Ferrand, France</p>
18:09 - 18:15	<p>DOP014: Transmural healing is better than mucosal healing in Crohn's Disease S. Raimundo Fernandes¹, R. Vale Rodrigues², S. Bernardo¹, J. Cortez Pinto², I. Rosa², L. Correia¹, P. Moura Santos³, A. Rita Gonçalves³, A. Valente³, C. Baldaia³, J. Pereira da Silva², A. Dias Pereira², J. Velosa¹</p> <p>¹Hospital de Santa Maria, Serviço de Gastreenterologia e Hepatologia, Lisboa, Portugal, ²Instituto Português de Oncologia de Lisboa, Serviço de Gastreenterologia, Lisboa, Portugal, ³Centro Hospitalar Lisboa Norte, Gastreenterology, Lisbon, Portugal</p>
18:15 - 18:21	<p>DOP015: International differences in gastroenterologists' perspective on stopping therapy for patients with Crohn's Disease C.A. Siegel¹, K.D. Thompson¹, D. Walls², J. Gollins³, J.-F. Colombel⁴, E. Louis⁵, - On behalf of the BIOCYCLE group⁵</p> <p>¹Dartmouth-Hitchcock Medical Center, Lebanon, United States, ²BDJ Solutions, Boston, United States, ³Delta Modelling, Chicago, United States, ⁴Icahn School of Medicine at Mount Sinai, New York, United States, ⁵University Hospital CHU of Liège, Liège, Belgium</p>

Thursday, February 16, 2017, cont.


 IIS
Abstract Award

18:21 - 18:27

DOP016: Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of Inflammatory Bowel Diseases: Results from the multicenter European TEDDY study

M. Chaparro¹, A. Verreth², T. Lobaton³, E. Gravito-Soares⁴, M. Julsgaard⁵, E. Savarino⁶, F. Magro⁷, I. Avni Biron⁸, P. López-Serrano⁹, M. Casanova¹, M. Gompertz¹⁰, S. Vitor¹¹, M. Arroyo¹², D. Pugliese¹³, Y. Zabana¹⁴, R. Vicente¹⁵, M. Aguas¹⁶, A. Bar-Gil Shitrit¹⁷, A. Gutierrez¹⁸, G. Doherty¹⁹, L. Fernández-Salazar²⁰, J. Martínez Cadilla²¹, J. Huguet²², A. O'Toole²³, E. Stasi²⁴, N. Manceñido Marcos²⁵, A. Villoria²⁶, K. Karmiris²⁷, J. Rahier²⁸, C. Rodriguez²⁹, M. Diz-Lois Palomares³⁰, G. Fiorino³¹, J. Benítez³², M. Principi³³, T. Naftali³⁴, C. Taxonera³⁵, G. Mantzaris³⁶, L. Sebkova³⁷, B. Iade³⁸, D. Lissner³⁹, I. Ferrer Bradley⁴⁰, A. López-San Román⁴¹, I. Marín-Jiménez⁴², O. Merino⁴³, M. Sierra⁴⁴, M. Van Domselaar⁴⁵, F. Caprioli⁴⁶, I. Guerra⁴⁷, P. Peixe⁴⁸, M. Piqueras⁴⁹, I. Rodríguez-Lago⁵⁰, Y. Ber⁵¹, K. Van Hoesel⁵², P. Torres⁵³, E. Gravito-Soares⁵⁴, D. Rudbeck-Thomsen⁵⁵, O. Bartolo⁵⁶, A. Peixoto⁵⁷, G. Martín⁵⁸, J. Pérez⁵⁹, A. Garre⁶⁰, M. G Donday⁶¹, J. Martín de Carpi⁶², J.P. Gisbert¹, Gastroenterology Units. On behalf of the TEDDY study group investigators

¹Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Madrid, Spain, ²University Hospitals Leuven, Leuven, Belgium, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶University of Padua, Padua, Italy, ⁷Centro Hospitalar Sao Joao, Porto, Portugal, ⁸Rabin Medical Center, Petaj Tikva, Israel, ⁹Hospital Universitario Fundación Alcorcón, Alcorcón, Spain, ¹⁰Hospital Clinic Barcelona, Barcelona, Spain, ¹¹Hospital de Santa Maria de Lisboa, Lisboa, Portugal, ¹²Hospital Clínico de Zaragoza, Zaragoza, Spain, ¹³Complejo Integrato Columbus Catholic University, Roma, Italy, ¹⁴Hospital Universitari Mútua de Terrassa, Terrassa, Spain, ¹⁵Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁶Hospital Universitario La Fe, Valencia, Spain, ¹⁷Shaare Zedek Medical Center Jerusalem, Jerusalem, Israel, ¹⁸Hospital General Universitario de Alicante, Alicante, Spain, ¹⁹St. Vincents University Hospital, Dublin, Ireland, ²⁰Hospital Clínico Universitario de Valladolid, Spain, ²¹Hospital Universitario Alvaro Cunqueiro, Vigo, Spain, ²²Hospital General Universitario de Valencia, Valencia, Spain, ²³Beaumont Hospital, Dublin, Ireland, ²⁴IRCCS Saverio de Bellis, Castellana Grotte, Italy, ²⁵Hospital Infanta Sofia, Madrid, Spain, ²⁶Hospital Parc Taulí, Sabadell, Spain, ²⁷Venizeleio General Hospital, Heraklion, Greece, ²⁸CHU Dinant Godinne, Dinant, Belgium, ²⁹Complejo Universitario de Navarra, Pamplona, Spain, ³⁰Hospital Universitario A Coruña, Coruña, Spain, ³¹Humanitas Research Hospital, Milan, Italy, ³²Hospital Reina Sofia, Córdoba, Spain, ³³Azienda Ospedaliera Policlinico de Bari, Bari, Italy, ³⁴Meir Hospital Kfar saba Tel Aviv University, Tel Aviv, Israel, ³⁵Hospital Clínico San Carlos, Madrid, Spain, ³⁶Evangelismos, Ophthalmiatreion Athinon and Polyclinic Hospitals, Athens, Greece, ³⁷Azienda Ospedaliera, Pugliese-Ciaccio", Catanzaro, Italy, ³⁸Hospital de Clínicas, Montevideo, Uruguay, ³⁹Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ⁴⁰Hospital de Manises, Manises, Spain, ⁴¹Hospital Ramón y Cajal, Madrid, Spain, ⁴²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴³Hospital Universitario de Cruces, Baracaldo, Spain, ⁴⁴Hospital de León, León, Spain, ⁴⁵Hospital de Torrejón, Torrejón de Ardoz, Spain, ⁴⁶IRCCS Ospedale Ca Granda Policlinico di Milano, Milano, Italy, ⁴⁷Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain, ⁴⁸Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal, ⁴⁹Consorcio Sanitari de Terrasa, Terrasa, Spain, ⁵⁰Hospital de Galdakao, Vizcaya, Spain, ⁵¹Hospital San Jorge, Huesca, Spain, ⁵²Hospital San Joan de Déu, Barcelona, Spain

Thursday, February 16, 2017, cont.

18:27 - 18:33	<p>DOP017: Patterns of anti-TNF use and associated treatment outcomes in Inflammatory Bowel Disease patients: Results from an analysis of Dutch health insurance claims data S. Bots¹, D. Hoekman^{1,2}, M. Benninga², C. Ponsioen¹, H. Smeets³, G. D'Haens¹, M. Löwenberg¹</p> <p>¹Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, ²Academic Medical Center (AMC), Department of Pediatric Gastroenterology and Nutrition, Amsterdam, Netherlands, ³Achmea Health Insurance, Amersfoort, Netherlands</p>
18:33 - 18:39	<p>DOP018: Effect of adalimumab on extraintestinal manifestations among patients with Ulcerative Colitis in a clinical practice setting: Results from INSPIRADA S. Travis¹, B. Feagan², L. Peyrin-Biroulet³, R. Panaccione⁴, S. Danese⁵, A. Lazar⁶, A. Robinson⁷, R. Thakkar⁷, B. Pappalardo⁷, J. Petersson⁷, M. Bereswill⁶, N. Chen⁷, M. Skup⁷</p> <p>¹Oxford University Hospitals, Oxford, United Kingdom, ²Robarts Research Institute, London, Canada, ³University Hospital of Nancy, Les Nancy, France, ⁴University of Calgary, Calgary, Canada, ⁵Istituto Clinico Humanitas, Milan, Italy, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, United States</p>

17:45 - 18:45

Digital Oral Presentation Session 3 - vedolizumab and ustekinumab therapies

Room 113, Level 1

Pieter Hindryckx, Ghent, Belgium

Laurent Peyrin-Biroulet, Vandoeuvre-les-Nancy, France

17:45 - 17:51	<p>DOP019: Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn's Disease: A GEMINI 2 post hoc analysis B.G. Feagan¹, W.J. Sandborn², J.-F. Colombel³, S. O'Byrne⁴, J.M. Khalid⁵, N. Brayshaw⁶, P. Geransar⁷, D.T. Rubin⁸</p> <p>¹Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials Inc, London, Canada, ²University of California San Diego, Division of Gastroenterology, La Jolla, United States, ³Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, ⁴Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, United Kingdom, ⁵Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom, ⁶Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom, ⁷Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland, ⁸University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States</p>
17:51 - 17:57	<p>DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn's Disease and Ulcerative Colitis on maintenance therapy with vedolizumab A. Yarur¹, A. Bruss¹, A. Jain², V. Kondragunta², K. Hester², T. Luna², D. Agrawal¹, A. Patel¹, C. Fox¹, S. Werner¹, S. Naik², D. Stein¹</p> <p>¹Medical College of Wisconsin, Gastroenterology and Hepatology, Milwaukee, United States, ²Prometheus Laboratories, San Diego, United States</p>

Thursday, February 16, 2017, cont.

17:57 - 18:03	<p><i>DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn's Disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study</i> S. Vermeire¹, E.V. Loftus², J.-F. Colombel³, B. Feagan⁴, W. Sandborn⁵, B. Sands⁶, S. Danese⁷, G. D'Haens⁸, A. Kaser⁹, R. Panaccione¹⁰, D. Rubin¹¹, I. Shafraan¹², S. O'Byrne¹³, P. Geransar¹³, A. Previtali¹⁴, J.M. Khalid¹⁵, A. Kaviya¹⁶</p> <p>¹University Hospitals Leuven, Dpt of Gastroenterology, Leuven, Belgium, ²Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, United States, ³Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, ⁴Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada, ⁵University of California - San Diego, Division of Gastroenterology, La Jolla, United States, ⁶Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, ⁷Humanitas University, Italy, Gastrointestinal Immunopathology, Milan, Italy, ⁸Academic Medical Centre, Dept. of Gastroenterology, Amsterdam, Netherlands, ⁹University of Cambridge, Division of Gastroenterology and Hepatology, Cambridge, United Kingdom, ¹⁰University of Calgary, Department of Medicine, Calgary, Canada, ¹¹University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States, ¹²Shafran Gastroenterology Research center, Gastroenterology, Winter Park, United States, ¹³Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland, ¹⁴Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom, ¹⁵Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom, ¹⁶Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom</p>
18:03 - 18:09	<p><i>DOP022: Vedolizumab (VDZ) and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: A retrospective chart review</i> R. Ehehalt¹, S. Schubert², D. Stein³, D. Lambrelli⁴, M. Bassel⁵, H.-D. Orzechowski⁶, K. Minda⁷, J.M. Khalid⁸</p> <p>¹Gastroenterology Outpatient Clinic, Heidelberg, Germany, ²Gastroenterologist in Private Practice, Berlin, Germany, ³Evidera, Montreal, Canada, ⁴Evidera, Hammersmith, United Kingdom, ⁵UBC: An Express Scripts Company, Montreal, Canada, ⁶Takeda Pharma GmbH, Berlin, Germany, ⁷Takeda Pharmaceuticals International AG, Zurich, Switzerland, ⁸Takeda Development Centre Europe Ltd, London, United Kingdom</p>
18:09 - 18:15	<p><i>DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active Ulcerative Colitis: Results from the US VICTORY consortium</i> P. Dulai¹, J. Meserve¹, J. Hartke², P. Chilukuri², K. Chaudrey³, J. L. Koliiani-Pace⁴, G. Kochhar⁵, M. P. Parikh⁵, E. Shmidt⁶, R. Hirten⁶, M. Luo⁷, M. Barocas⁷, K. Lasch⁷, K. Sultan⁸, A. Swaminath⁹, M. Bohm¹⁰, D. Lukin¹¹, D. Hudesman¹², B. Shen⁵, C. A. Siegel⁶, B. E. Sands⁶, J.-F. Colombel⁶, S. Kane³, E. V. Loftus Jr³, S. Singh¹, W. J. Sandborn¹, B. S. Boland¹</p> <p>¹University of California - San Diego, La Jolla, United States, ²Indiana University School of Medicine, Indianapolis, United States, ³Mayo Clinic, Rochester, United States, ⁴Dartmouth-Hitchcock Medical Center, Lebanon, United States, ⁵Cleveland Clinic Foundation, Cleveland, United States, ⁶Icahn School of Medicine at Mount Sinai, New York, United States, ⁷Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States, ⁸North Shore University Hospital, Manhasset, United States, ⁹Lenox Hill Hospital, New York, United States, ¹⁰Indiana University Hospital, Indianapolis, United States, ¹¹Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States, ¹²New York University School of Medicine, New York, United States</p>

Thursday, February 16, 2017, cont.

18:15 - 18:21	<p>DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infections S.C. Ng¹, W. Palo², A. Blake³, Q. Rana-Khan⁴, F. Bhayat⁵ ¹Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, Hong Kong, ²Takeda Development Center Americas, Inc., Global Statistics and Statistical Programming, Deerfield, United States, ³Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom, ⁴Takeda Pharmaceutical International AG Singapore, Emerging Markets Medical Affairs, Singapore, Singapore, ⁵Takeda Development Centre Europe Ltd, Global Pharmacovigilance, London, United Kingdom</p>
18:21 - 18:27	<p>DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with Inflammatory Bowel Disease: A post-hoc analysis of the OBSERV-IBD cohort from the GETAID S. Tadbiri¹, J.C. Grimaud², L. Peyrin-Biroulet³, J. Filippi⁴, B. Pariente⁵, X. Roblin⁶, A. Buisson⁷, C. Stefanescu⁸, C. Trang-Poisson⁹, R. Altwegg¹⁰, P. Marteau¹¹, T. Vaysse¹², A. Bourrier¹³, S. Nancey¹⁴, D. Laharie¹⁵, M. Allez¹⁶, Y. Bouhnik⁸, A. Amiot¹⁷ ¹CHU Henri Mondor, Department of Gastroenterology, Creteil, France, ²Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France, ³CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France, ⁴Archet 2 Hospital, Department of Gastroenterology, Nice, France, ⁵CHRU Lille, Department of Gastroenterology, Lille, France, ⁶University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, ⁷CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, ⁸APHP Beaujon, Department of Gastroenterology, Clichy, France, ⁹CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, ¹⁰CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, ¹¹Hospital Lariboisière, Department of Gastroenterology, Paris, France, ¹²CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France, ¹³APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France, ¹⁴Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France, ¹⁵CHU Bordeaux, Department of Gastroenterology, Bordeaux, France, ¹⁶Hospital Saint-Louis, Department of Gastroenterology, Paris, France, ¹⁷Henri Mondor Hospital, Gastroenterology, Creteil, France</p>
18:27 - 18:33	<p>DOP026: Sustained remission with vedolizumab in patients with Moderately to Severely active Ulcerative Colitis: A GEMINI 1 post hoc analysis of week 14 remitters A. Stallmach¹, B. Bokemeyer², J. Axler³, R. Curtis⁴, R. Ehehalt⁵, B. Feagan⁶, P. Geransar⁷, A. James⁸, A. Kaviya⁹, J.M. Khalid¹⁰, D. Wolf¹¹, S. Schreiber¹² ¹University hospital Jena, Department of Internal Medicine IV, Jena, Germany, ²Gastroenterology Practice, Private practice, Minden, Germany, ³TDDA (Toronto Digestive Disease Associates Inc.), Toronto, Canada, ⁴Takeda Development Centre Europe Ltd, Global Medical Affairs, London, United Kingdom, ⁵Praxis für Gastroenterologie, Gastroenterology, Heidelberg, Germany, ⁶Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada, ⁷Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland, ⁸Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom, ⁹Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom, ¹⁰Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom, ¹¹Atlanta Gastroenterology Associates, Emory Saint Joseph's, Atlanta, United States, ¹²University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany</p>

Thursday, February 16, 2017, cont.

18:33 - 18:39	<p>DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn's Disease patients: A multicenter retrospective experience P. Wils¹, Y. Bouhnik², P. Michetti³, B. Flourie⁴, H. Brixis⁵, A. Bourrier⁶, M. Allez⁷, B. Duclos⁸, M. Serrero⁹, A. Buisson¹⁰, A. Amiot¹¹, M. Fumery¹², X. Roblin¹³, L. Peyrin-Biroulet¹⁴, J. Filippi¹⁵, G. Bouguen¹⁶, V. Abitbol¹⁷, B. Coffin¹⁸, M. Simon¹⁹, D. Laharie²⁰, B. Pariente¹</p> <p>¹University of Lille, Department of Gastroenterology, Lille, France, ²Beaujon Hospital, Gastroenterology Unit, Clichy, France, ³University Hospital Lausanne, Division of Gastroenterology & Hepatology, Lausanne, Switzerland, ⁴Centre Hospitalier Lyon-Sud, Service d'Hépatogastro-entérologie, Lyon, France, ⁵CHU de Reims, Gastroentérologie, Reims, France, ⁶University Hospital of Saint Antoine, APHP, Gastroenterology, Paris, France, ⁷APHP, Hôpital Saint Louis, Department of Gastroenterology, Paris, France, ⁸Université de Strasbourg, Gastroenterology, Strasbourg, France, ⁹Hôpital Nord Assistance Publique de Marseille, Department of Gastroenterology, Marseille, France, ¹⁰Clermont-Ferrand University, Clermont-Ferrand, France, ¹¹Hôpital Henri-Mondor, Department of Gastroenterology, Creteil, France, ¹²Amiens University Hospital, Gastroenterology, Amiens, France, ¹³University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, ¹⁴CHU Nancy, Department of Gastroenterology, Nancy, France, ¹⁵CHU de Nice, Department of Gastroenterology, Nice, France, ¹⁶CHU Rennes, Department of HepatoBiliary Surgery and Digestive, Rennes, France, ¹⁷Cochin University Hospital, Gastroenterology, Paris, France, ¹⁸Hôpital Louis-Mourier, Gastroentérologie, Colombes, France, ¹⁹Institut Mutualiste Montsouris, Gastroentérologie, Paris, France, ²⁰CHU de Bordeaux, Gastroentérologie, Pessac, France</p>
---------------	---

<p>Digital Oral Presentation Session 4 - Immunogenicity and pharmacokinetics of biologics 17:45 - 18:45 Room 111, Level 1 Gionata Fiorino, Milan, Italy Florian Rieder, Cleveland, United States</p>	
17:45 - 17:51	<p>DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatment S. Bian¹, H.T. Tang¹, M. Peeters¹, G. Compennolle¹, E. Dreesen¹, G. Van Assche², M. Ferrante², S. Vermeire², A. Gils¹</p> <p>¹KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ²University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium</p>
17:51 - 17:57	<p>DOP029: Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: Post-hoc analysis of the taxit trial T. Van Stappen¹, N. Vande Castelee¹, G. Van Assche², M. Ferrante², S. Vermeire², A. Gils¹</p> <p>¹KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ²UZ Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium</p>
17:57 - 18:03	<p>DOP030: Anti-TNF re-induction is as effective, simpler and cheaper compared with dose interval shortening following secondary loss of response in Crohn's Disease: A dual centre 'real world' study A. Srinivasan¹, A. Vasudevan^{1,2,3}, A. McFarlane¹, P. Gibson^{2,3}, M. Sparrow^{2,3}, D. van Langenberg^{1,2}</p> <p>¹Eastern Health, Gastroenterology, Melbourne, Australia, ²Monash University, Melbourne, Australia, ³Alfred Health, Gastroenterology, Melbourne, Australia</p>

Thursday, February 16, 2017, cont.

18:03 - 18:09	<p>DOP031: Subtherapeutic serum infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab discontinuation in Paediatric Crohn's Disease patients B. Kang¹, K. Lee¹, K. Kim², J.H. Lee³, Y.H. Choe¹ ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea, ²Samsung Medical Center, Biostatistics and Clinical Epidemiology Center, Seoul, South Korea, ³Chungbuk National University Hospital, Chungbuk National University College of Medicine, Department of Pediatrics, Cheongju, South Korea</p>
18:09 - 18:15	<p>DOP032: Hydrocortisone premedication withdrawal in patients on stable infliximab maintenance: Clinical and pharmacokinetic outcomes M.-L. Tran-Minh¹, M. Mailet¹, C. Auzolle^{1,2}, M. Simon³, A.L. Cathala¹, T. Aparicio^{1,2}, C. Baudry¹, J. Bonnet¹, N. Lourenco¹, P. Houze⁴, J.-M. Gornet¹, M. Allez^{1,2} ¹Saint Louis Hospital, Gastroenterology, Paris, France, ²INSERM, U940, Paris, France, ³Institut Montsouris, Gastroenterology, Paris, France, ⁴Saint Louis Hospital, Pharmacology, Paris, France</p>
18:15 - 18:21	<p>DOP033: Severely active Ulcerative Colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomes N. Vande Casteele^{1,2}, V. Jairath^{3,4}, B. Levesque^{1,2}, B. Feagan^{3,4}, W. Sandborn^{1,2} ¹University of California, San Diego, United States, ²Robarts Clinical Trials, Inc., San Diego, United States, ³University of Western Ontario, London, Canada, ⁴Robarts Clinical Trials, Inc., London, Canada</p>
18:21 - 18:27	<p>DOP034: Serum adalimumab concentration 3 months after surgery is correlated with endoscopic recurrence in Crohn's Disease patients treated with adalimumab for prevention of postoperative recurrence L. Boivineau¹, J.F. Bourgaux², G. Pineton de Chambrun¹, L. Caillo², G. Danan¹, J. Boitard¹, J. Liautard¹, F. Guillon¹, R. Altwegg¹ ¹CHU St Eloi, Hepato-gastro-enterology, Montpellier, France, ²CHU Nimes, Hepato-gastro-enterology, Nimes, France</p>
18:27 - 18:33	<p>DOP035: High gammaglobulin and low albumin serum levels independently predict secondary loss of response to anti-TNFa therapy in IBD F. Schoenefuss, P. Hoffmann Kliniken Essen Mitte, Gastroenterology, Essen, Germany</p>
18:33 - 18:39	<p>DOP036: The therapeutic efficacy of anti-TNF requires Fc-gamma receptors and can be improved by antibody hypo-fucosylation F. Bloemendaal¹, A. Levin², M. Wildenberg², P. Koelink², R. Visser³, J. Claassens⁴, M. Bradford⁵, G. D'Haens², S. Verbeek⁴, G. Vidarsson³, G. van den Brink² ¹University of Amsterdam, Gastroenterology, Amsterdam, Netherlands, ²Academic Medical Center, Gastroenterology, Amsterdam, Netherlands, ³Sanquin Research, Department of Experimental Immunohematology, Amsterdam, Netherlands, ⁴Leiden University Medical Center, Department of Human Genetics, Leiden, Netherlands, ⁵Abbvie Bioresearch Center, Worcester, United States</p>

Thursday, February 16, 2017, cont.

Digital Oral Presentation Session 5 - Surgical treatment
17:45 - 18:45

 Room 118+119, Level 1
 Paulo Kotze, Curitiba, Brazil
 Oded Zmora, Tel Aviv, Israel

17:45 - 17:51

DOP037: A model for prediction of early surgery and complications in Paediatric Crohn's Disease; results of the prospective GROWTH CD study
A. Levine^{1,2}, S. Hussey³, K.L. Kolho⁴, M. Sladek⁵, J.M. de Carpi⁶, D. Turner⁷, R.K. Russell⁸, N. Cohen-Dolev⁹, J. Escher¹⁰, Porto - ECCO GROWTH CD study group

¹Edith Wolfson Medical Center, Department of Paediatric Gastroenterology and Nutrition Unit, Holon, Israel, ²Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel, ³National Children's Research Centre, UCD and RCSI, Dublin, Ireland, ⁴Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland, ⁵Jagiellonian University Medical College, Krakow, Poland, ⁶Hospital Sant Joan de Deu, Department of Paediatric Gastroenterology, Barcelona, Spain, ⁷Shaare Zedek Medical Center, Department of Paediatric Gastroenterology, Jerusalem, Israel, ⁸The Royal Hospital for Children, Department of Paediatric Gastroenterology, Glasgow, United Kingdom, ⁹Edith Wolfson Medical Center, PIBD Research Center, Department of Paediatric Gastroenterology and Nutrition Unit, Holon, Israel, ¹⁰Children's Hospital Erasmus MC Sophia, Department of Paediatric Gastroenterology, Rotterdam, Netherlands

17:51 - 17:57

DOP038: Increased number of enteric glial cells in proximal margin of resection is associated with postoperative recurrence of Crohn's Disease
Y. Li, W. Zhu, J. Gong, Z. Guo

Jinling Hospital, Medical School of Nanjing University, Department of General Surgery, Nanjing, China

17:57 - 18:03

DOP039: Postoperative infectious complications in Crohn's Disease: Results from PRACTICROHN study
A. Gutiérrez¹, C. Taxonera², V. García³, M. Minguéz⁴, M.D. Martín Arranz⁵, M. Castro⁶, M. Barreiro-de Acosta⁷, B. Juliá⁸, L. Cea-Calvo⁸, C. Romero⁸, E. Domènech⁹
¹Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain, ²Hospital Clinico San Carlos, Gastroenterology Unit, Madrid, Spain, ³Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain, ⁴Unidad de Gastroenterología, Hospital General de Valencia, Valencia, Spain, ⁵Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain, ⁶Unidad de Gastroenterología, Hospital de Valme, Sevilla, Spain, ⁷Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, ⁸MSD Spain, Medical Department, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain

Thursday, February 16, 2017, cont.

18:03 - 18:09	<p>DOP040: Postoperative surgical recurrence in Crohn's Disease decreases significantly in the biologic era E.M.J. Beelen¹, W.R. Schouten², B. Oldenburg³, A.E. van der Meulen-de Jong⁴, C.I.J. Ponsioen⁵, G. Dijkstra⁶, M.J. Pierik⁷, D.J. de Jong⁸, N.K.H. de Boer⁹, C.J. van der Woude¹, A.C. de Vries¹</p> <p>¹Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, ²Erasmus MC, Department of General Surgery, Rotterdam, Netherlands, ³University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ⁴Leiden University Medical Center, Department of Gastroenterology and Hepatology, Leiden, Netherlands, ⁵Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, ⁶University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ⁷Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ⁸Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands, ⁹VU University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands</p>
18:09 - 18:15	<p>DOP041: Prepouch ileitis after ileal pouch anal anastomosis for Ulcerative Colitis: Patterns of presentation and risk factors for failure of treatment M. Rottoli¹, C. Vallicelli, E. Bigonzi, M. Di Simone, P. Gionchetti, L. Boschi, G. Poggioli</p> <p>Alma Mater Studiorum University of Bologna, Sant'Orsola - Malpighi Hospital, Digestive Disease, Bologna, Italy</p>
18:15 - 18:21	<p>DOP042: Omentectomy is not necessary during laparoscopic total colectomy and ileal pouch-anal anastomosis for Inflammatory Bowel Disease. A comparative study in 247 consecutive patients from 4 expert centres D. Mege¹, A. Germain², M. Stellingwerf³, F. Colombo⁴, L. Maggiori¹, A. de Buck van Overstraeten², C. Buskens⁵, D. Foschi⁴, G. Sampietro⁶, W. Bemelman³, A. D'Hoore², Y. Panis¹</p> <p>¹Beaujon Hospital, Colorectal Surgery, Clichy, France, ²Leuven, Digestive Surgery, Leuven, Belgium, ³AMC, Digestive Surgery, Amsterdam, Netherlands, ⁴ASST, Digestive Surgery, Milan, Italy</p>
18:21 - 18:27	<p>DOP043: High risk of Pouch dysplasia in IBD-PSC patients following total proctocolectomy C. Palmela^{1,2}, D. Castaneda³, S. Shah¹, J. ten Hove⁴, T. Ullman¹, S. H. Itzkowitz¹, J. Torres^{1,2}</p> <p>¹Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, ²Hospital Beatriz Ângelo, Department of Gastroenterology, Loures, Portugal, ³Mount Sinai St. Luke's and Mount Sinai West Hospitals, Division of Internal Medicine, New York, United States, ⁴University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands</p>
18:27 - 18:33	<p>DOP044: Relationship between microbiota and development of early postoperative Crohn's Disease recurrence K. Machiels¹, V. Pascal², J. Sabino¹, A. Santiago², D. Campos², A. Wolthuis³, A. de Buck van Overstraeten³, A. D'Hoore³, G. Van Assche¹, M. Ferrante¹, P. Rutgeerts¹, C. Manichanh², S. Vermeire¹</p> <p>¹University Hospitals Leuven, KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ²Vall d'Hebron Research Institute, Barcelona, Spain, ³University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium</p>

Thursday, February 16, 2017, cont.

18:33 - 18:39	<p>DOP045: Post-operative complications in elderly-onset Inflammatory Bowel Disease: A population-based study S.-C. Sacleux¹, C. Charpentier¹, H. Sarter², M. Fumery³, N. Guillon-Dellac⁴, E. Laberenne⁵, B. Pariente⁶, L. Peyrin-Biroulet⁷, C. Gower-Rousseau⁸, G. Savoye¹</p> <p>¹CHU Rouen, Department of Gastroenterology and Hepatology, Rouen, France, ²CHRU Lille, Department of Biostatistics EA 2694, Lille, France, ³Amiens University Hospital, Department of Gastroenterology and Hepatology, Amiens, France, ⁴CHRU Lille, Department of Epidemiology, Lille, France, ⁵CH Seclin, Department of Gastroenterology, Seclin, France, ⁶CHRU Lille, Department of Gastroenterology, Lille, France, ⁷CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France, ⁸CHRU Lille, Department of Epidemiology, EPIMAD Registry, Lille, France</p>
---------------	---

Friday, February 17, 2017

17:20 - 18:20	<p>Digital Oral Presentation Session 6 - Towards personalised medicine Room 115, Level 1 Axel Dignass, Frankfurt, Germany Britta Siegmund, Berlin, Germany</p>
17:20 - 17:26	<p>DOP046: Genome-wide association study of baseline disease characteristics and response to ustekinumab in moderate to severe Crohn's Disease A. Hart, K. Li, C. Gasink, D. Jacobstein, C. Brodmerkel Janssen Research & Development, LLC, Spring House, United States</p>
17:26 - 17:32	<p>DOP047: Early fibrostenosis in Crohn's Disease is associated with multiple susceptibility loci on Immunochip analysis T. Holvoet¹, P. Bossuyt^{2,3}, I. Cleynen³, I. De Kock⁴, P. Hindryckx¹, S. Vermeire^{3,5}, D. Laukens¹, M. De Vos¹</p> <p>¹Ghent University Hospital, Department of Gastroenterology, Ghent, Belgium, ²Imelda GI Clinical Research Center, Department of Gastroenterology, Bonheiden, Belgium, ³University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, ⁴Ghent University Hospital, Radiology, Ghent, Belgium, ⁵Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium</p>
17:32 - 17:38	<p>DOP048: PROFILE trial: Predicting outcomes for Crohn's Disease using a molecular biomarker J. Lee^{1,2}, D. Biasci¹, N. Noor^{1,2}, E. McKinney¹, T. Ahmad^{3,4}, N. Lewis⁵, A. Hart^{6,7}, P. Lyons¹, M. Parkes^{1,2}, K. Smith¹</p> <p>¹University of Cambridge, School of Clinical Medicine, Cambridge, United Kingdom, ²Addenbrooke's Hospital NHS Trust, Department of Gastroenterology, Cambridge, United Kingdom, ³University of Exeter, Exeter IBD and Pharmacogenetics Research Group, Exeter, United Kingdom, ⁴Royal Devon and Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom, ⁵Nottingham University Hospitals NHS Trust, Department of Gastroenterology, Nottingham, United Kingdom, ⁶St Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom, ⁷Imperial College, Faculty of Medicine, Department of Surgery & Cancer, London, United Kingdom</p>

Friday, February 17, 2017, cont.

17:38 - 17:44	<p>DOP049: Inflammatory dyskinesia: Defects of NF-κB dynamic behaviour as a new potential biomarker for personalised medicine in Inflammatory Bowel Disease G. Sellge¹, S. Papoutsopoulou², J. Verdier¹, C. Trautwein¹, F. Bergey³, M. Burkitt⁴, M. Burkitt⁴, R. Sheibani⁵, M. Pierik⁶, D. Jonkers⁶, M. White², P. Paszek², V. Martins dos Santos³, P. Rosenstiel⁵, W. Müller², C. Probert⁴, SysmedIBD consortium²</p> <p>¹University Hospital RWTH Aachen, Dep. of Internal Medicine III, Aachen, Germany, ²University of Manchester, Faculty of Life Sciences, Manchester, United Kingdom, ³LifeGlimmer GmbH, Berlin, Germany, ⁴University of Liverpool, Cellular and Molecular Physiology, Liverpool, United Kingdom, ⁵Kiel University, Institute of Clinical Molecular Biology, Kiel, Germany, ⁶Maastricht University Medical Centre, Division Gastroenterology-Hepatology, Maastricht, Netherlands</p>
17:44 - 17:50	<p>DOP050: Serum proteomic analysis defines novel circulating inflammatory markers for Crohn's Disease and response to anti-TNF therapy H. Korfi^{1,2}, J. Sabino¹, V. Ballet³, M. de Bruyn^{1,4}, G. Van Assche³, M. Ferrante³, S. Vermeire³</p> <p>¹KULeuven, Translational Research in Gastrointestinal Disorders (TARGID), Clinical and Experimental Medicine, Leuven, Belgium, ²KULeuven, Laboratory of Hepatology, Clinical and Experimental Medicine, Leuven, Belgium, ³UZLeuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ⁴KULeuven, Rega Institute for Medical Research, Department of Microbiology and Immunology, Leuven, Belgium</p>
17:50 - 17:56	<p>DOP051: Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn's Disease W.T. van Haaften^{1,2}, J.H. Mortensen³, M.L. Olesen^{3,4}, M.A. Karsdal³, P. Olinga², A.-C. Bay-Jensen³, G. Dijkstra¹</p> <p>¹University Medical Center Groningen, University of Groningen, Department of Gastro-enterology and Hepatology, Groningen, Netherlands, ²University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, Netherlands, ³Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ⁴Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark</p>
17:56 - 18:02	<p>DOP052: Molecular response to ustekinumab in Moderate-to-Severe Crohn's Disease by serum protein and biopsy gene expression analysis: Results from ustekinumab phase 3 studies K. Li, K. Hayden, E. Wadman, S. Bhagat, S. Emrich, D. Jacobstein, C. Gasink, C. Brodmerkel</p> <p>Janssen Research & Development, LLC, Spring House, United States</p>
18:02 - 18:08	<p>DOP053: The fecal microbiome as a tool for monitoring and predicting response outcomes in ustekinumab-treated, anti-TNFa refractory Crohn's Disease patients: Results from the CERTIFI study M.K. Doherty¹, C. Koumpouras¹, S.E. Telesco², C. Monast², C. Brodmerkel², P.D. Schloss¹</p> <p>¹University of Michigan Medical School, Department of Microbiology and Immunology, Ann Arbor, United States, ²Janssen Research & Development, LLC, Spring House, United States</p>
18:08 - 18:14	<p>DOP054: High-throughput sequencing of T cell receptors from pediatric Ulcerative Colitis patients reveals distinct tissue-specific repertoires L. Werner¹, M. Nunberg¹, Y. Haberman¹, A. Lahad¹, D. Turner², B. Weiss¹, D. Shouval¹</p> <p>¹Safra Children's Hospital, Pediatric Gastroenterology, Tel Hashomer, Israel, ²Shaare Zedek Medical Center, Jerusalem, Israel</p>

Friday, February 17, 2017, cont.

17:20 - 18:20	<p>Digital Oral Presentation Session 7 - Management of perianal and luminal disease Room 114, Level 1 Willem Bemelman, Amsterdam, The Netherlands Tom Øresland, Lorenskog, Norway</p>
17:20 - 17:26	<p>DOP055: Results of the Fifth Scientific Workshop of ECCO (III): Clinical aspects of perianal fistulising Crohn's Disease - The unmet needs K. Gecke¹, S. Sebastian², G. de Hertogh³, N. Yassin⁴, P. Kotze⁵, W. Reinisch⁶, A. Spinelli⁷, I. Koutroubakis⁸, K. Katsanos⁹, A. Hart¹⁰, G. van den Brink¹¹, G. Rogler¹², W. Bemelman¹³ ¹Semmelweis University, First Department of Medicine, Budapest, Hungary, ²Hull & East Yorkshire NHS Trust, Inflammatory Bowel Disease Unit, Hull, United Kingdom, ³University of Leuven, Department of Pathology, Leuven, Belgium, ⁴St Mark's Hospital and Academic Institute, Department of Colorectal Surgery, London, United Kingdom, ⁵Catholic University of Paraná, Colorectal Surgery Unit, Curitiba, Brazil, ⁶Medical University of Vienna, Department of Gastroenterology, Vienna, Austria, ⁷Humanities University, Colorectal Surgery Unit, Humanitas Research Hospital, Milano, Italy, ⁸University Hospital Heraklion, Department of Gastroenterology, Heraklion, Greece, ⁹School of Health Sciences, Division of Gastroenterology, Department of Medicine, Ioannina, Greece, ¹⁰St. Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom, ¹¹Academic Medical Centre, University of Amsterdam, Department of Gastroenterology, Amsterdam, Netherlands, ¹²University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, ¹³Academic Medical Centre, University of Amsterdam, Department of Surgery, Amsterdam, Netherlands</p>
17:26 - 17:32	<p>DOP056: Pathophysiology of perianal Fistulising Disease B. Siegmund¹, R.M. Feakins², G. Barmias³, J. Coelho Ludvig⁴, F. Vieira Teixeira⁵, G. Rogler⁶, M. Scharl⁷ ¹Charite Berlin, Berlin, Germany, ²Royal London Hospital, London, United Kingdom, ³Ethnikon and Kapodistriakon University of Athens, Athens, Greece, ⁴Santa Isabel Hospital Blumenau, Santa Catarina, Brazil, ⁵Gastrosaude Clinic, Sao Paulo, Brazil, ⁶University Hospital Zurich, Zurich, Switzerland, ⁷University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland</p>
17:32 - 17:38	<p>DOP057: Perianal paediatric Crohn's Disease is associated with a distinct phenotype and greater inflammatory burden A. Assa¹, M. Amitai², M.-L. Greer³, D. Castro³, R. Cytter Kuint⁴, M. Martínez-León⁵, I. Herman-Sucharska⁶, E. Copenrath⁷, S. Anupindi⁸, A. Towbin⁹, D. Moote¹⁰, O. Konen¹¹, L.-T. Pratt¹², A. Griffiths³, D. Turner⁴ ¹Schneider Children's medical Center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, ²Sheba Medical Center, Department of Radiology, Ramat Gan, Israel, ³Hospital for Sick Children, Toronto, Canada, ⁴Shaare Zedek Medical Center, Jerusalem, Israel, ⁵Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁶Jagiellonian University in Cracow, Cracow, Poland, ⁷University of Munich, Munich, Germany, ⁸The Children's Hospital of Philadelphia, Philadelphia, United States, ⁹Cincinnati Children's Hospital, Cincinnati, United States, ¹⁰Connecticut Children's Medical Center, Hartford, United States, ¹¹Schneider Children's medical Center, Petach Tikva, Israel, ¹²Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel</p>
17:38 - 17:44	<p>DOP058: Does biologic therapy increase the risk for fistula-associated mucinous adenocarcinoma in long standing perianal Crohn's Disease? S. Laureti¹, M. Coscia, L. Gentilini, P. Gionchetti, N. Renzi, F. Rizzello, M. Tanzanu, G. Poggioli University of Bologna, Department of Gastroenterology and Surgical Sciences, Bologna, Italy</p>

Friday, February 17, 2017, cont.

<p>17:44 - 17:50</p>	<p>DOP059: New human gut xenograft mouse model for intestinal fistulas R.S. Bruckner^{1,2}, N. Marsiano³, E. Nissim-Eliraz³, E. Nir³, S. Lang^{1,2}, M. Spalinger^{1,2}, G. Rogler^{1,4}, S. Yagel⁵, SysmedBD EU research consortium, M. Scharl^{6,1,4}, N.Y. Shpigel^{6,3}. *Authors contributed equally ¹University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, ²University of Zurich, Zurich, Switzerland, ³Hebrew University of Jerusalem, Koret School of Veterinary Medicine, Rehovot, Israel, ⁴University of Zurich, Zurich Center for Integrative Human Physiology, Zurich, Switzerland, ⁵Hadassah University Hospital, Obstetrics and Gynecology, Jerusalem, Israel</p>
<p>17:50 - 17:56</p>	<p>DOP060: Real-world treatment pathway visualisations show low use of biologic therapies in Crohn's Disease and Ulcerative Colitis in the United States C. Siegel¹, F. Yang², S. Eslava², J. Cai² ¹Dartmouth-Hitchcock Medical Center, Lebanon, United States, ²Celgene Corporation, Summit, United States</p>
<p>17:56 - 18:02</p>	<p>DOP061: Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with Innovator Infliximab (INX) in patients with active Crohn's Disease: Early efficacy and safety results Y.H. Kim¹, B.D. Ye², M. Pesegova³, O. Alexeeva⁴, M. Osipenko⁵, A. Lahat⁶, A. Dorofeyev⁷, A. Salamon⁸, S. Fishman⁹, O. Levchenko¹⁰, J.H. Cheon¹¹, M.L. Scribano¹², R.-B. Mateescu¹³, K.M. Lee¹⁴, C.S. Eun¹⁵, S.J. Lee¹⁶, S.Y. Lee¹⁶ ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Krasnoyarsk Regional clinical hospital, Krasnoyarsk, Russian Federation, ⁴Nizhny Novgorod Regional Clinical Hospital n.a. N.A.Semashko, Nizhny Novgorod, Russian Federation, ⁵Novosibirsk State Medical University, Novosibirsk, Russian Federation, ⁶Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel and Sackler Faculty of Medicine, Tel Aviv University, Ramat-Gan, Israel, ⁷Medical Center LLC Ukrainian German Antiulcer Gastroenterology Center BIK Kyiv, Kyiv, Ukraine, ⁸Tolna Megyei Balassa János Kórház, Szekszárd, Hungary, ⁹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹⁰Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine, ¹¹Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ¹²Azienda Ospedaliera San Camillo Forlanini, Roma, Italy, ¹³Gastroenterology Dept. at Colentina Clinical Hospital AND „Carol Davila“ University of Medicine and Pharmacy, Bucharest, Romania, ¹⁴St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, South Korea, ¹⁵Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, South Korea, ¹⁶CELLTRION, Inc., Incheon, South Korea</p>

Friday, February 17, 2017, cont.

18:02 - 18:08	<p>DOP062: Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: Explorative IBD subgroup-analyses in Crohn's Disease and Ulcerative Colitis from the NOR-SWITCH trial K.K. Jørgensen¹, I.C. Olsen², G.L. Goll², M. Lorentzen³, N. Bolstad⁴, I.P. Berset⁵, E.A. Haavardsholm^{2,6}, K.E. Lundin^{6,7,8}, C. Mørk⁹, T.K. Kvien^{2,6}, J. Jahnsen^{1,6}, The Nor-Switch Study Group ¹Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ³Oslo University Hospital, Rikshospitalet, Department of Dermatology, Oslo, Norway, ⁴Oslo University Hospital, Radiumhospitalet, Department of Medical Biochemistry, Oslo, Norway, ⁵Ålesund Hospital, Department of Gastroenterology, Ålesund, Norway, ⁶University of Oslo, Faculty of Medicine, Oslo, Norway, ⁷Oslo University Hospital, Rikshospitalet, Department of Gastroenterology, Oslo, Norway, ⁸Centre for Immune Regulation, Department of Immunology, Oslo, Norway, ⁹Norwegian University of Science and Technology, Faculty of Medicine, Trondheim, Norway</p>
18:08 - 18:14	<p>DOP063: Serial tuberculin skin test improves the detection of latent tuberculosis infection in Inflammatory Bowel Disease patients C. Taxonera¹, A. Ponferrada², F. Bermejo³, J.P. Gisbert⁴, S. Riestra⁵, C. Saro⁶, J.L. Cabriada⁷, M. Barreiro-de Acosta⁸, J. Barrio⁹, E. Flores¹⁰, I. Ferrer¹¹, A. Hernandez¹², M. Van Domselaar¹³, D. Olivares¹, C. Alba¹, L. Fernández-Salazar¹⁴, O. Merino¹⁵, B. Botella¹⁶, D. Ceballos¹⁷, I. Moral¹⁸, M. Peñate¹⁹, A. Algaba³, on behalf of the SEGURTB study group from GETECCU ¹Hospital Clinico San Carlos, IdISSC, Madrid, Spain, ²Hospital Infanta Leonor, Madrid, Spain, ³Hospital de Fuenlabrada, Madrid, Spain, ⁴Hospital Universitario de La Princesa, CIBERehd, Madrid, Spain, ⁵Hospital Central De Asturias, Oviedo, Spain, ⁶Hospital De Cabuñes, Gijón, Spain, ⁷Hospital San Eloy, Baracaldo, Spain, ⁸Hospital de Santiago De Compostela, Santiago de Compostela, Spain, ⁹Hospital Río Hortega, Valladolid, Spain, ¹⁰Hospital Universitario Reina Sofía, CIBERehd, Córdoba, Spain, ¹¹Hospital de Manises, Manises, Spain, ¹²Hospital Universitario De Canarias, Santa Cruz De Tenerife, Spain, ¹³Hospital de Torrejón, Madrid, Spain, ¹⁴Hospital Clinico de Valladolid, Valladolid, Spain, ¹⁵Hospital De Cruces, Bilbao, Spain, ¹⁶Hospital Universitario Infanta Cristina, Madrid, Spain, ¹⁷Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ¹⁸Hospital Príncipe De Asturias, Madrid, Spain, ¹⁹Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain</p>

17:20 - 18:20	<p>Digital Oral Presentation Session 8 - Endoscopy in IBD: Assessment of activity and surveillance Room 113, Level 1 Rami Eliakim, Tel Aviv, Israel Nik Sheng Ding, Melbourne, Australia</p>
17:20 - 17:26	<p>DOP064: High rate of advanced neoplasia after detection of low-grade dysplasia in Inflammatory Bowel Disease patients with primary sclerosing cholangitis J.R. Ten Hove¹, J. Torres², D. Castaneda², C. Palmela², E. Mooiweer¹, S.C. Shah², J.-F. Colombel², T. Ullman², S.H. Itzkowitz², B. Oldenburg¹ ¹University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ²Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology, New York, United States</p>
17:26 - 17:32	<p>DOP065: Use of chromoendoscopy versus white light endoscopy for colorectal cancer surveillance in Inflammatory Bowel Disease patients with primary sclerosing cholangitis; a six year experience K. Hartery¹, K. Williamson, R. Chapman, N. Atkinson, J. East John Radcliffe Hospital, Translation Gastroenterology Unit, Oxford, United Kingdom</p>

Friday, February 17, 2017, cont.

17:32 - 17:38	<p>DOP066: Strict surveillance colonoscopy should be performed for the Ulcerative Colitis patients who underwent ileorectal anastomosis</p> <p>H. Anzai, K. Hata, S. Ishihara, J. Kishikawa, K. Muroho, M. Kaneko, K. Sasaki, K. Yasuda, K. Otani, T. Nishikawa, T. Tanaka, T. Kiyomatsu, K. Kawai, H. Nozawa, T. Watanabe The University of Tokyo, Department of Surgery, Tokyo, Japan</p>
17:38 - 17:44	<p>DOP067: Risk of malignant and non-malignant complications of the rectal stump in patients with Inflammatory Bowel Disease</p> <p>J. Bogaerts¹, J.R. Ten Hove¹, M.M. Laclé², V. Meij³, B. Oldenburg¹ ¹University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ²University Medical Center Utrecht, Department of Pathology, Utrecht, Netherlands, ³University Medical Center Utrecht, Department of Surgery, Utrecht, Netherlands</p>
17:44 - 17:50	<p>DOP068: The virtual electronic chromoendoscopy (VEC) score in Ulcerative Colitis exhibits very good inter-rater agreement in scoring mucosal and vascular changes after computerised module training: A study across academic and community practice</p> <p>T. Trivedi^{1,2,3,4}, J. Hodson³, N. Bhalra⁴, R. Cooney⁴, R. Boulton⁴, X. Gui⁵, T. Iqbal⁴, K.-k. Li⁶, S. Mumtaz⁷, S. Pathmakanthan⁴, M.N. Quraishi⁴, V.M. Sagar¹, A. Shah⁷, N. Sharma⁸, K. Siau⁷, S. Smith⁴, S. Ward⁹, M.M. Widlak^{10,11}, S. Ghosh^{3,4}, M. Iacucci^{3,4} ¹University of Birmingham, NIHR Birmingham Liver Biomedical Research Unit, Birmingham, United Kingdom, ²Queen Elizabeth Hospital, Liver Unit, Birmingham, United Kingdom, ³University of Birmingham, Institute of Translational Medicine, Birmingham, United Kingdom, ⁴Queen Elizabeth Hospital, Department of Gastroenterology, Birmingham, United Kingdom, ⁵University of Calgary and Calgary Laboratory Services, Department of Pathology and Laboratory Medicine, Calgary, Canada, ⁶Leicester Royal Infirmary, Department of Gastroenterology and Hepatology, Leicester, United Kingdom, ⁷New Cross Hospital, Department of Gastroenterology, Wolverhampton, United Kingdom, ⁸University Hospitals Birmingham Heart of England Foundation Trust, Department of Gastroenterology, Birmingham, United Kingdom, ⁹University Hospitals Coventry and Warwickshire, Department of Colorectal Surgery, Coventry, United Kingdom, ¹⁰University Hospitals Coventry and Warwickshire, Department of Gastroenterology, Coventry, United Kingdom, ¹¹University of Warwick, Warwick Medical School, Coventry, United Kingdom</p>
17:50 - 17:56	<p>DOP069: Natural history of dysplasia and colorectal cancer in IBD patients in Belgium tertiary care centers</p> <p>A. Cremer¹, C. Liefferinckx¹, M. De Vos², J.-F. Rahier³, F. Baert⁴, T. Moreels⁵, E. Macken⁵, E. Louis⁶, J. Devière¹, A. Van Gossum¹, S. Vermeire⁷, D. Franchimont¹ ¹University Hospital Erasme, Gastroenterology, Brussels, Belgium, ²University Hospital Gent, Gastroenterology, Brussels, Belgium, ³University Hospital Mont-Godinne, Gastroenterology, Yvoir, Belgium, ⁴AZ Delta, Roeselare, Belgium, ⁵University Hospital Antwerp, Edegem, Belgium, ⁶University Hospital Liège, Liège, Belgium, ⁷University Hospital Leuven, Gastroenterology, Leuven, Belgium</p>
17:56 - 18:02	<p>DOP070: Endoscopic response to induction therapy with TNF inhibitors is the best predictor of long term mucosal healing in Crohn's Disease</p> <p>I. Alfaro¹, M. Masamunt¹, N. Planell², A. López-García¹, J. Castro¹, M. Gallego¹, R. Barastegui¹, A. Giner¹, A. Vara¹, A. Salas², E. Ricart¹, J. Panés¹, I. Ordás¹ ¹Hospital Clínic, Gastrointestinal Disease, Barcelona, Spain, ²Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</p>

Friday, February 17, 2017, cont.

18:02 - 18:08	<p><i>DOP071: Comparison of endoscopic responses to adalimumab monotherapy and combination therapy with azathioprine in patients with Crohn's Disease: A sub-analysis of DIAMOND trial</i> K. Watanabe¹, T. Matsumoto², S. Motoya³, T. Hisamatsu⁴, H. Nakase⁵, N. Yoshimura⁶, T. Ishida⁷, S. Kato⁸, T. Nakagawa⁹, M. Nagahori¹⁰, M. Esaki¹¹, T. Matsui¹², Y. Naito¹³, T. Kanai¹⁴, Y. Suzuki¹⁵, M. Nojima¹⁶, M. Watanabe¹⁰, T. Hibi¹⁷</p> <p>¹Osaka City General Hospital, Gastroenterology, Osaka, Japan, ²Waste Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan, ³Sapporo Kosei General Hospital, Inflammatory Bowel Disease Centre, Sapporo, Japan, ⁴Kyorin University School of Medicine, Department of Internal Medicine, Tokyo, Japan, ⁵School of Medicine, Sapporo Medical University, Department of Gastroenterology and Hepatology, Sapporo, Japan, ⁶Tokyo Yamate Medical Centre, Department of Medicine, Division of Gastroenterology, Tokyo, Japan, ⁷Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, ⁸Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan, ⁹Graduate School of Medicine, Chiba University, Department of Gastroenterology and Nephrology, Chiba, Japan, ¹⁰Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, ¹¹Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, ¹²Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan, ¹³Kyoto Prefectural University of Medicine, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan, ¹⁴School of Medicine, Keio University, Department of Internal Medicine, Tokyo, Japan, ¹⁵Toho University Sakura Medical Center, Department of Internal Medicine, Chiba, Japan, ¹⁶Institute of Medical Science Hospital, University of Tokyo, Centre for Translational Research, Tokyo, Japan, ¹⁷Kitasato University Kitasato Institute Hospital, Centre for Advanced IBD Research and Treatment, Tokyo, Japan</p>
18:08 - 18:14	<p><i>DOP072: Assessment of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) using central video review of colonoscopies in paediatric patients with Ulcerative Colitis: Data from the Canadian Children IBD Network</i> N. Carman¹, H. Huynh², M. Mouzaki³, E. Crowley³, C.M. Walsh³, A. Ricciuto³, T.D. Walters³, P.C. Church³</p> <p>¹The Hospital for Sick Children, Toronto, Canada, ²University of Alberta, Edmonton, Canada, ³The Hospital for Sick Children, University of Toronto, Gastroenterology Department, Toronto, Canada</p>

Friday, February 17, 2017, cont.

<p>Digital Oral Presentation Session 9 - New therapies Room 111, Level 1 Jean-Frédéric Colombel, New York, United States Joana Torres, Lisbon, Portugal</p>	
<p>17:20 - 18:20</p>	<p>DOP073: Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided Ulcerative Colitis patients with Moderate-to-Severe disease R. Atreya¹, T. Kühbacher^{2,3}, M.J. Waldner¹, S. Hirschmann¹, O. Drvarov², R. Abu Hashem², C. Maaser⁴, T. Kucharzik⁴, J. Dinter⁵, C. Schramm⁵, J. Mertens⁵, B. Holler⁶, J. Mössner⁶, K. Suzuki⁷, J. Yokoyama⁷, S. Terai⁷, H. Yoneyama⁸, H. Asakura⁷, T. Hibi⁹, M.F. Neurath¹ ¹Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany, ²Asklepios Westklinikum, Department of Internal Medicine/Gastroenterology, Hamburg, Germany, ³Christian Albrechts University Kiel, Department of Internal Medicine/Gastroenterology, Kiel, Germany, ⁴Klinikum Lüneburg, Klinik für Allgemeine Innere Medizin und Gastroenterologie, Lüneburg, Germany, ⁵Uniklinik Köln, Klinik für Gastroenterologie und Hepatologie, Köln, Germany, ⁶Universitätsklinikum Leipzig, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Leipzig, Germany, ⁷Niigata University Medical and Dental Hospital, Niigata, Japan, ⁸Stelic Institute & Co., Tokyo, Japan, ⁹Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan</p>
<p>17:20 - 17:26</p>	<p>DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in Ulcerative Colitis patients A. Mukherjee¹, G.R. D'Haens², W.J. Sandborn³, S. Tsuchiawata⁴, C. Vong⁵, C. Deng⁶, R. Xie⁶, A. Hazra¹, S.W. Martin⁵, G. Friedman⁷, W. Niezychowski⁷, C. Su⁷ ¹Pfizer Inc, Groton, CT, United States, ²Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands, ³Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States, ⁴Pfizer Japan Inc, Tokyo, Japan, ⁵Pfizer Inc, Cambridge, MA, United States, ⁶Pfizer Inc, Shanghai, China, ⁷Pfizer Inc, Collegeville, PA, United States</p>
<p>17:26 - 17:32</p>	<p>DOP075: Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: Subgroup analysis of the phase 2 FITZROY study in Moderate-to-Severe Crohn's Disease G. D'Haens¹, S. Schreiber², R. Petryka³, T. Kuehbacher⁴, X. Hebuterne⁵, X. Roblin⁶, M. Klopocka⁷, A. Goldis⁸, M. Wisniewska-Jarosinska⁹, A. Baranovsky¹⁰, R. Sike¹¹, K. Stoyanova¹², L. Meuleners¹³, C. Tasset¹³, A. Van der Aa¹³, P. Harrison¹³, S. Vermeire¹⁴ ¹Academic Medical Center (AMC), Department of Gastroenterology, Amsterdam, Netherlands, ²University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany, ³Vivamed, Warsaw, Poland, ⁴Asklepios Hospital West Hamburg, Department of Gastroenterology, Hamburg, Germany, ⁵CHU Nice Hopital l'Archet, Department of Gastroenterology and Nutrition, Nice Cedex 3, France, ⁶North Hospital, Department of Gastroenterology, Saint Prieux en Jarez, France, ⁷NC University in Toruń, Collegium Medicum, Bydgoszcz, Poland, ⁸Dr. Goldis Center for Gastroenterology, Ltd., Timisoara, Romania, ⁹Santa LLC, Santa Familia Research, Prevention and Treatment Centre, Lodz, Poland, ¹⁰City Clinical Hospital #31, St. Petersburg, Russian Federation, ¹¹Szent Margit Hospital, Budapest, Hungary, ¹²PSI Pharma Support EOOD, Sofia, Bulgaria, ¹³Galapagos NV, Mechelen, Belgium, ¹⁴University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium</p>
<p>17:32 - 17:38</p>	

Friday, February 17, 2017, cont.

17:38 - 17:44	<p>DOP076: A Phase 2B, multicenter, randomised, placebo-controlled dose-ranging trial of peficitinab, an Oral JAK Inhibitor, in patients with Moderately to Severely active Ulcerative Colitis B. Sands¹, W. Sandborn², B.G. Feagan³, G. Lichtenstein⁴, H. Zhang⁵, P. Szapary⁵, J. Panes⁵, S. Vermeire⁷, C. O'Brien⁵, J. Dewey⁵, Z. Yang⁵, J. Johanns⁵, R. Strauss⁵, C. Marano⁵</p> <p>¹Icahn School of Medicine at Mt Sinai, New York, United States, ²University of California San Diego, La Jolla, United States, ³Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ont., Canada, ⁴University of Pennsylvania, Philadelphia, United States, ⁵Janssen Research & Development, LLC, Spring House, United States, ⁶Hospital Clinic Barcelona, IDIBAPS, CIVERehd, Barcelona, Spain, ⁷Uz Leuven, Campus Gasthuisberg, Leuven, Belgium</p>
17:44 - 17:50	<p>DOP077: Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator S.D. Lee¹, R. Christopher², L. Trokan², C. Lassen², J. Adams², M. Chiorean³</p> <p>¹University of Washington Medical Center, Seattle, United States, ²Arena Pharmaceuticals, Inc., San Diego, United States, ³Virginia Mason, Digestive Disease Institute, Seattle, United States</p>
17:50 - 17:56	<p>DOP078: Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator T. Kühbacher¹, R. Christopher², L. Trokan², C. Lassen², J. Adams², L. Peyrin-Biroulet³</p> <p>¹Asklepios Westklinikum Hamburg and Christian Albrechts University, Department of Internal Medicine/Gastroenterology, Kiel, Germany, ²Arena Pharmaceuticals, Inc., San Diego, United States, ³Nancy University Hospital and Lorraine University, Department of Gastroenterology, Nancy, France</p>
17:56 - 18:02	<p>DOP079: The role of intestinal transplant in patients with complicated Inflammatory Bowel Disease (IBD): The Cambridge experience S.P. Yeap¹, L.M. Sharkey¹, J.M. Woodward¹, D.C. Massey¹, S.J. Middleton¹, N.K. Russell², A.J. Butler²</p> <p>¹Addenbrooke's Hospital, Gastroenterology, Cambridge, United Kingdom, ²Addenbrooke's Hospital, Transplant Surgery, Cambridge, United Kingdom</p>
18:02 - 18:08	<p>DOP080: Low viral richness at baseline in Ulcerative Colitis associated with faecal microbiota transplantation success N. Conceição-Neto¹, W. Deboutte¹, T. Dierckx¹, K. Machiels², J. Wang^{1,3}, C. Yinda¹, P. Maes¹, M. Van Ranst¹, M. Joossens^{1,3}, J. Raes^{1,3}, S. Vermeire², J. Matthijnsens¹</p> <p>¹KU Leuven, Rega Institute, Department of Microbiology and Immunology, Leuven, Belgium, ²KU Leuven, TARGID, Department of Translational Research Centre for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ³VIB, Center for the Biology of Disease, Leuven, Belgium</p>

Friday, February 17, 2017, cont.

18:08 - 18:14	<p>DOP081: Glycosylation of T cells: A novel targeted-specific therapeutic strategy in IBD A. M. Dias^{1,2}, A. Correia³, M. Pereira¹, C. R. Almeida⁴, I. Alves¹, M. Lima^{5,6}, R. Marcos-Pinto^{2,7,8}, C. A. Reis^{1,2,9}, M. Vilanova^{2,3}, P. Lago⁹, S. S. Pinho^{1,9}</p> <p>¹Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & i3S – Instituto de Investigação e Inovação em Saúde, Glycobiology in Cancer, Porto, Portugal, ²Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Porto, Portugal, ³Instituto de Investigação e Inovação em Saúde (I3S)/Institute for Molecular and Cell Biology (IBMC), Immunobiology Group, Porto, Portugal, ⁴Instituto de Investigação e Inovação em Saúde (I3S)/ Institute of Biomedical Engineering (INEB), NEWTherapies Group, University of Porto, Porto, Portugal, ⁵Centro Hospitalar do Porto, Multidisciplinary Unit for Biomedical Research (UMIB), Porto, Portugal, ⁶Centro Hospitalar do Porto, Hematology Department, Porto, Portugal, ⁷Medical Faculty, Centre for Research in Health Technologies and Information Systems (CINTESIS), Porto, Portugal, ⁸Centro Hospitalar do Porto, Department of Gastroenterology, Porto, Portugal, ⁹University of Porto, Medical Faculty, Porto, Portugal</p>
---------------	---

<p>Digital Oral Presentation Session 10 - Translational IBD Room 118+119, Level 1 Dominik Bettenworth, Münster, Germany Gerhard Rogler, Zurich, Switzerland</p>	
17:20 - 18:20	<p>DOP082: Enhanced TH17 responses in patients with IL10 receptor deficiency and history of infantile-onset IBD D. Shouval¹, L. Konnikova², L. Werner¹, M. Nunberg¹, B. Weiss¹, S. Glover³, S. Snapper²</p> <p>¹Safra Children's Hospital, Pediatric Gastroenterology, Tel Hashomer, Israel, ²Boston Children's Hospital, Boston, United States, ³University of Florida, Gainesville, United States</p>
17:26 - 17:32	<p>DOP083: Recombinant subcutaneous human beta-Defensin 2 (hBD2) ameliorates experimental Colitis in different in vivo models D. Mailänder-Sánchez¹, S. Kjaerulf², K. Sidelmann Brinch², B. Andersen², E.F. Stange¹, N. Malek¹, P. Nordkild³, J. Wehkamp¹</p> <p>¹University Hospital Tuebingen, Internal Medicine I, Tuebingen, Germany, ²Novozymes, Bagsvaerd, Denmark, ³Defensin Therapeutics, Copenhagen, Denmark</p>
17:32 - 17:38	<p>DOP084: Peripheral T cell repertoire reconstitution in Crohn's Disease patients undergoing autologous HSCT A.M. Corraliza¹, M.C. Masamunt¹, E. Ricart¹, A. López-García¹, L. Le Bourhis², M. Allez², J. Panés¹, A. Salas¹</p> <p>¹IDIBAPS, Hospital Clínic, Gastroenterology, Barcelona, Spain, ²Hôpital Saint-Louis, Inserm U1160, Paris, France</p>
17:38 - 17:44	<p>DOP085: Tight NADPH oxidase regulation is a prerequisite for gut health G. Aviello^{1,2}, E. Conroy³, B. Bourke¹, U.G. Knaus^{1,3}</p> <p>¹National Children's Research Centre, Our Lady's Children's Hospital, Dublin, Ireland, ²University of Aberdeen, The Rowett Institute, Aberdeen, United Kingdom, ³University College Dublin, Conway Institute, Dublin, Ireland</p>

Friday, February 17, 2017, cont.

17:44 - 17:50	<p>DOP086: Macrophages from Crohn's Disease patients showed a defect to control adherent-invasive E. coli replication influenced by genetic host factors A. Buisson^{1,2}, E. Vazeille^{1,2}, L. Ouchchane³, M. Goutte^{1,2}, J.-P. Hugot⁴, A. Dubois², R. Minet Quinard⁵, D. Bouvier⁵, G. Bommelaer^{1,2}, N. Barnich² ¹University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, ²UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, ³University Hospital G Montpied, Biostatistics unit, Clermont-Ferrand, France, ⁴Assistance Publique Hôpitaux de Paris et Université, Paris Diderot, Paris, UMR843, Inserm, Paris, France, ⁵University Hospital G. Montpied, Biochemistry laboratory, Clermont-Ferrand, France</p>
17:50 - 17:56	<p>DOP087: Microbial colonisation at weaning period determines Colitis severity in adult mice Z. Al Nabhani, S. Dulauroy, B. Polomack, G. Eberl Institut Pasteur, Immunology Department, Paris, France</p>
17:56 - 18:02	<p>DOP088: Somatic and visceral hypersensitivity associated to acute intestinal inflammation are absent in sigma 1 receptor knockout mice S. López-Estévez¹, G. Gris², B. de la Puente², X. Codony², M. Merlos², V. Martínez¹ ¹Universitat Autònoma de Barcelona, Cell Biology, Physiology and Immunology, Bellaterra, Spain, ²Esteve, Department of Pharmacology, Drug Discovery & Preclinical Development, Barcelona, Spain</p>
18:02 - 18:08	<p>DOP089: PTPN2 controls intestinal inflammation and promotes Colitis-associated tumour formation via control of inflammasome activation and IL-1alpha release M. Spalinger¹, L. Hering¹, R. Manzini¹, J.B. Riggs¹, C. Gottier¹, K. Atrott¹, A. Fettelschoss², T. Kündig², M. Fried^{1,3}, G. Rogler^{1,3}, M. Scharl^{1,3} ¹University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, ²University Hospital Zurich, Clinic for Dermatology, Zurich, Switzerland, ³University of Zurich, Zurich Center for Integrative Human Physiology, Zurich, Switzerland</p>
18:08 - 18:14	<p>DOP090: The $\alpha 7$ nicotinic acetylcholine receptor agonist GTS-21 attenuate DSS-induced Colitis by improving intestinal mucosal barrier function H. Zhang¹, Y. Zhu² ¹the First Affiliated Hospital of Nanjing Medical University, Gastroenterology, Nanjing, China, ²the First Affiliated Hospital of Nanjing Medical University, Nanjing, China</p>



European
Crohn's and Colitis
Organisation

New ECCO Guidelines & Topical Reviews



Stay tuned with JCC online 2017

ECCO Guidelines

- ECCO Crohn's Disease Consensus Update
- ECCO-ESCP Consensus on Surgery in CD
- ECCO Ulcerative Colitis Consensus Update

ECCO Topical Reviews

- IBD in Elderly
- Environmental Factors in IBD
- Research Gaps in Diet in IBD
- Transition in IBD

ECCO is looking forward to your visit to JCC online, which also provides free access to all Guidelines publications!

Andreas Sturm
ECCO GuiCom Chair

Laurence Egan
JCC Editor-in-Chief

Scan and contact the ECCO Office
www.ecco-ibd.eu



Basic Science

■ P001

The biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, tracks with efficacy in a preclinical model of IBD

X. Cheng, R. Taranath, L. Mattheakis, A. Bhandari, D. Liu

Protagonist Therapeutics, Milpitas, United States

■ P002

Inhibition of axl signaling by BGB324 reduces fibrogenesis in human intestinal cells and human intestinal organoids

C. Steiner, E. Rodansky, L.A. Johnson, S. Huang, J. Spence, **P.D. Higgins**

University of Michigan, Internal Medicine - Gastroenterology, Ann Arbor, United States and others

■ P003

Withdrawn

■ P004

Stimulation of CYP450-mediated ω -3 docosahexaenoic acid (DHA) metabolism via MFSD2A as a novel therapy for Inflammatory Bowel Disease

F. Ungaro, C. Tacconi, C. Correale, L. Massimino, P. Corsetto, A. Piontini, P. Fonteyne, F. Calcaterra, S. Della Bella, A. Spinelli, M. Carvello, A. Rizzo, S. Vetrano, G. Fiorino, F. Furfaro, K.R. Maddipati, S. D'Alessio, S. Danese

Humanitas Research Institute, Laboratory of Immunology in Gastroenterology, Rozzano, Italy and others

■ P005

Establishing a porcine model to translate anorectal stem cell organoid models to elucidate the aetiology of perianal Crohn's fistulae.

S. Adegbola, J. Moore, K. Sahnun, P. Tozer, R. Phillips, J. Warusavitarne, O. Faiz, A. Hart

St Mark's Academic Institute, Surgery, London, United Kingdom and others

■ P006

Transcriptomic profiling of intestinal macrophages isolated from patients reveals a profound gene expression reprogramming underlying IBD pathogenesis

S. Dharmasiri, E.M. Garrido Martin, T. Sanchez-Elsner, J.R.F. Cummings

Southampton General Hospital, Department of Gastroenterology, Southampton, United Kingdom and others

■ P007

Oral tyrosine kinase 2 inhibitor ameliorates T cell transfer Colitis

L. De Vries, M. Wildenberg, P. van Hamersveld, O. Welting, C. Verseijden, G. D'Haens, W. De Jonge

Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands and others

■ P008

Common and different inflammatory features in Inflammatory Bowel Disease and colon cancer

E. Lo Presti, R. Di Mitri, F. Dieli, F. Mocchiari, M.G. Cilluffo, G.M. Pecoraro, G. Russo, S. Meraviglia

University of Palermo, Department of Biopathology and Medical Biotechnologies (DIBIMED, CLADIBOR), Palermo, Italy and others

■ P009

Autophagy stimulation reduces mucosal NF- κ B protein levels and ameliorates murine colitis

D.C. Macias Ceja, J. Cosin-Roger, D. Ortiz-Masià, P. Salvador, L. Gisbert-Ferrándiz, C. Hernandez, J.V.

Esplugues, S. Calatayud, M.D. Barrachina
Fisabio Hospital Peset, Valencia, Spain and others

■ P010

Effects of cigarette smoke on the DSS-induced Colitis model in C57Bl/6 mice

B. Phillips, **G. Lo Sasso**, M. Talikka, E. Veljkovic, F. Martin, A. Elamin, E. Guedj, N. Ivanov, M. Peitsch, J. Hoeng

Philip Morris International Research Laboratories, Department of Reduced-Risk Products, Singapore, Singapore and others

■ **P011**

Evaluation of the intestinal barrier function patients with Inflammatory Bowel Disease

D. Abdulganieva, D. Mukhametova, S. Koshkin, O. Zinkevich, N. Saphina, S. Abdulkhakov, A. Odintsova, M. Koporulina
Kazan State Medical University, Kazan, Russian Federation and others

■ **P012**

Ral activation exacerbates colonic inflammation through the impairment of intestinal barrier function in experimental murine Colitis

N. Minami, M. Matsuura, S. Yamamoto, Y. Honzawa, S. Yamada, Y. Koshikawa, M. Okabe, H. Seno, H. Horiuchi, H. Nakase
Graduate School of Medicine, Kyoto University, Gastroenterology and Hepatology, Kyoto, Japan and others

■ **P013**

Decreased fibrogenesis in CH25H knockout mice in a mouse model of intestinal fibrosis

T. Raselli, A. Wyss, M.N. Gonzalez Alvarado, C. Mamie, G. Rogler, M. Hausmann, B. Misselwitz
University of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland

■ **P014**

Mucosal lymphocyte subsets in Ulcerative Colitis at diagnosis and during follow-up

C. Smids, C. Horjus Talabur Horje, M. Groenen, E. van Koolwijk, P. Wahab, E. van Lochem
Rijnstate Hospital, IBD Centre, Gastroenterology and Hepatology, Arnhem, Netherlands and others

■ **P015**

Wnt10b promotes fibrosis in murine Colitis

D. Ortiz-Masia, P. Salvador, D.C. Macias-Ceja, L. Gisbert-Ferrández, C. Hernandez, S. Calatayud, J.V. Esplugues, D. Barrachina
Universidad de Valencia-CIBERehd, Pharmacology, Valencia, Spain and others

■ **P016**

Pregnancy in IBD: Direct effect of sex-hormones on epithelial barrier function

J. van der Giessen, C. van der Woude, M. Peppelenbosch, G. Fuhler
Erasmus Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands

■ **P017**

OGR1 (GPR68) expression is increased in intestinal inflammation and correlates with disease activity in patients with IBD

J. Cosin-Roger, S. Bengs, S. Lang, M. Turina, A. Rickenbacher, K. Seuwen, P.A. Ruiz, B. Misselwitz, G. Rogler, **C. de Vallière**
University Hospital Zurich, University of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland and others

■ **P018**

Complete metabolomic and microbiota profiling identifies biomarkers for anti-TNF therapy response

N.S. Ding, M. Sarafian, A. Perdones-Montero, R. Misra, P. Hendy, L. Penez, E. Holmes, A. Hart
St Vincent's Hospital, Inflammatory Bowel Disease, Melbourne, Australia and others

■ **P019**

Anti-TNF-alpha therapy induces microbial and immunological changes in dextran sodium sulphate chronic Colitis

V. Petito, C. Graziani, L. Lopetuso, G. Quaranta, F. Paroni Sterbini, L. Masucci, A. Sgambato, G. Cammarota, M. Sanguinetti, A. Gasbarrini, F. Scaldaferri
Fondazione Policlinico Universitario Gemelli, Catholic University of Sacred Heart, Gastroenterological Area, Gastroenterological and Endocrino-Metabolical Sciences Department, Rome, Italy and others

■ **P020**

Wnt5b could contribute to regeneration of the epithelium in Inflammatory Bowel Disease by potentiating epithelial mesenchymal transition

I. Dotti, E. Ferrer-Picón, N. Planell, E.H. van Herk, M. Cuatrecasas, J. Panés, A. Salas
IDIBAPS, Experimental Gastroenterology, Barcelona, Spain and others

■ **P021**

Utility of therapeutic anti-TNF drug monitoring in hospitals with different degree of experience in the treatment of inflammatory Bowel Disease

M. Vila, A. Bahi, J.O. Miquel, D. Busquets, J. Saló, X. Aldeguer

Dr. Josep Trueta University Hospital, Institute of biomedical investigation of Girona, Girona, Spain and others

■ **P022**

MET deletion in MRP8+ neutrophils is protective during DDS-induced Colitis via Th17 pathway

M. Stakenborg, E. Meroni, G. Govere, **G. Matteoli**

KU Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium

■ **P023**

Fatigue in quiescent Inflammatory Bowel Disease is associated with low GM-CSF levels and metabolomic alterations

N. Borren, G. Goel, K. Lassen, K. Devaney, T. Cleland, J. Garber, H. Khalili, V. Yajnik, R. Xavier, A. Ananthakrishnan

Massachusetts General Hospital, Department of Gastroenterology, Boston, United States and others

■ **P024**

Stratification of Ulcerative Colitis patients according to distinctive tissue cytokine profiles

A. Butera, D. De Nitto, B. Ciambelano, A. Giuliani, R. Pica, A. Pronio, M. Boirivant

Istituto Superiore di Sanità, Dept Infectious, Parasitic and Immune-mediated Diseases, Roma, Italy and others

■ **P025**

Transcriptional and molecular pathways activated in mesenteric adipose tissue and intestinal mucosa of Crohn's Disease patients

A. Coope, L.B. Pascoal, F.A.R. Silva, J.D. Botezelli, M.L.S. Ayrizono, M. Milanski, M.G. Camargo, N. Planell, M. Portovedo, C.B. Dias, J.J. Fagundes, **R.F. Leal**

University of Campinas, Department of Surgery, IBD Research Laboratory, Campinas, Brazil and others

■ **P026**

The role of fibrocytes in mesenteric Crohn's Disease

M.G. Kiernan, S.M. Sahebally, P.A. Kiely, D. Waldron, M. Moloney, M. Skelly, P.N. Faul, D.P. O'Leary, A.J. Lowery, L.G. Walsh, C.P. Dunne, J.C. Coffey

University of Limerick, Graduate Entry Medical School and Centre for Interventions in Infection, Inflammation and Immunity (4i), Limerick, Ireland and others

■ **P027**

Comparing the immunological signatures of inflammatory diseases

E. McDonald, P. Wright, T. Zangerle-Murray, J. Jung, D. Gaya, S. Siebert, I. McInnes, S. Milling

University of Glasgow, Infection, Immunity and Inflammation, Glasgow, United Kingdom and others

■ **P028**

Oligonol attenuates dextran sulfate sodium-induced Colitis and reduces flare-UP in mice by enhancing host defense mechanism

K.-J. Kim, J.-M. Park, Y.-M. Han, S.G. Lee, S.A. Shin, K.-B. Hahm

Asan Medical Center, Gastroenterology, Seoul, South Korea and others

■ **P029**

Azelnidipine, a novel calcium channel blocker, ameliorates severity of Colitis in DSS induced Colitis in mice possibly by modulating tissue levels of TNF alpha and IL-6

T. Kav, A. Akyol, E. Aksoy, C. Ozer, M. Torgutalp, B. Sivri

Hacettepe University, Gastroenterology, Ankara, Turkey

■ **P030**

Inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory cell adhesion and recruitment to colon epithelium

B.-S. Jeong, S. Banskota, H.-E. Kang, J.-A. Kim, T.-G. Nam

Yeungnam University, College of Pharmacy, Gyeongsan, South Korea and others

■ **P031**

Identification of alternative splicing in transcript isoforms in patients with Ulcerative Colitis: Effects of disease duration

E.N.D. Low, Z. Wong, C.S. Ngiu, A.H. Nazefah, A.R. Rafiz, N. Mokhtar, R.A. Raja Ali
Universiti Kebangsaan Malaysia, Medicine, Kuala Lumpur, Malaysia and others

■ **P032**

The pharmacological profile of TOP1288, a narrow spectrum kinase inhibitor (NSKI) in clinical development as an anti-inflammatory treatment for Ulcerative Colitis

M. Foster, P. Biancheri, M. Fyfe, T. MacDonald, A. Rowley, S. Sirohi, Y. Solanke, S. Webber, C. Walshe
Topivert Pharma Ltd, London, United Kingdom and others

■ **P033**

DSS-induced Colitis is attenuated in sigma 1 receptor knockout mice

S. López-Estévez, M. Aguilera, G. Gris, B. de la Puente, X. Codony, D. Zamanillo, V. Martínez
Universitat Autònoma de Barcelona, Cell Biology, Physiology and Immunology, Bellaterra, Spain and others

■ **P034**

Altered microbiota and host-bacterial interactions during the spontaneous development of Colitis in IL-10 knockout mice

S. López-Estévez, M. Aguilera, V. Martínez
Universitat Autònoma de Barcelona, Cell Biology, Physiology and Immunology, Bellaterra, Spain

■ **P035**

TNF-driven pathways are increased at baseline in Crohn's Disease patients not responding to infliximab

B. Verstockt, I. Arijis, M. de Bruyn, S. Verstockt, G. Van Assche, C. Breynaert, S. Vermeire, M. Ferrante
KU Leuven, Department of Clinical and Experimental Medicine, TARGID-IBD, Leuven, Belgium and others

■ **P036**

Human peripheral blood monocytes and intestinal macrophage populations activate transforming growth factor beta via expression of the integrin alpha v beta 8

E. Shuttleworth, A. Kelly (joint first author), T. Fenton, C. Smedley, S. Levison, M. Travis
University of Manchester, MCCIR, Manchester, United Kingdom and others

■ **P037**

MDR1-deficiency unmasks mitochondrial dysfunction as a pathogenic mechanism in IBD

G.-T. Ho, R. Aird, R. Boyapati, B. Liu, N. Kennedy, T. Shimizu, B. Sartor, J. Satsangi
University of Edinburgh, MRC Centre for Inflammation Research, Edinburgh, United Kingdom and others

■ **P038**

Tissue differences in the pro-inflammatory activation of ER stress of patients with Crohn's Disease

A. Coope, J.D. Botezelli, L. Bitencourt Pascoal, F. Ramos Silva, M.L.S. Ayrizono, M. Milanski, L.A. Velloso, R.F. Leal
University of Campinas, Coloproctology Unit, Surgery Department, Campinas, Brazil and others

■ **P039**

Suppression of phospholipase A2 of intestinal microbiota by the phospholipid-bile acid conjugate ursodeoxycholate-lysophosphatidylethanolamide ameliorates mucosal inflammation in a genetic mouse model of Ulcerative Colitis

W. Stremmel, S. Staffer, N. Stuhmann, A. Gauss, N. Burger, D. Hornuss
University Hospital of Heidelberg, Internal Medicine IV, Dept. of Gastroenterology, Heidelberg, Germany

■ **P040**

Intestinal EP4 receptor is required for homeostasis of the colon in mice

Y. Matsumoto, A. Fukuda, H. Seno
Kyoto University Graduate School of Medicine, Gastroenterology and Hepatology, Kyoto, Japan

■ **P041**

C-jun n-terminal kinase 2 promotes enterocyte survival and goblet cell differentiation in the inflamed intestine

A.D. Mandić, E. Bennek, J. Verdier, K. Zhang, S. Roubrocks, R.J. Davis, B. Denecke, N. Gassler, K. Streetz, A. Kel, M. Hornef, F.J. Cubero, C. Trautwein, **G. Sellge**
University Hospital RWTH Aachen, Dep. of Internal Medicine III, Aachen, Germany and others

■ **P042**

Expression of IL-38 and their antagonists in patients with Inflammatory Bowel Disease

G. Fonseca Camarillo, J. Furuzawa Carballeda, E. Iturriaga Goyon, J.K. Yamamoto Furusho
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Mexico City, Mexico and others

■ **P043**

Ulcerative Colitis is characterised by an exaggerated onset of acute inflammation with delayed resolution

D. Marks, R. Wysoczanski, A. Kendall, M. Motwani, R. Vega, F. Rahman, S. McCartney, S. Bloom, A. Nicolaou, D. Gilroy, A. Segal
University College London, Molecular Medicine, London, United Kingdom and others

■ **P044**

Therapeutic effects of mesenchymal stem cells induced regulatory dendritic cells on chronic Colitis model in mice

H.-S. Kim, H. Jo, Y.W. Eom, M.Y. Cho
Yonsei University Wonju College of Medicine, Internal medicine, Wonju, South Korea and others

■ **P045**

5-Aminosalicylates promote inflammation resolution in Ulcerative Colitis through generation of anti-inflammatory hydroxy fatty acids

R. Wysoczanski, A. Kendall, M. Motwani, R. Vega, F. Rahman, S. McCartney, S. Bloom, A. Nicolaou, D. Gilroy, A. Segal, D. Marks
University College London, Molecular Medicine, London, United Kingdom and others

■ **P046**

Starch consumption is associated with serologic responses in patients with Ulcerative Colitis and an ileo-anal Pouch

I. Goren, L. Godny, N. Maharshak, H. Tulchinsky, **I. Dotan**
Tel Aviv Medical center, IBD unit, Department of Gastroenterology and Hepatology, Tel Aviv, Israel and others

■ **P047**

Therapeutic dosing of filgotinib (GS-6034, GLPG0634) is efficacious in the mouse DSS model of Colitis

S. Kim, J. Zheng, B. Lu, D. Alonzo, **B. Kanwar**, V. Smith
Gilead Sciences, Inc, Foster City, United States

■ **P048**

Decreased expression of aquaporins in colonic biopsies from collagenous colitis patients. A novel diarrhoeal pathomechanism?

A. Holm, A. Mancebo Giménez, V. Loitto, E. Vikström, K.-E. Magnusson, **A. Münch**
Linköping University, Department of Clinical and Experimental Medicine, Linköping, Sweden and others

■ **P049**

Lewis Score: A useful tool for the diagnosis but not for the definition of prognosis in suspected Crohn's Disease

M. Silva, H. Cardoso, A. Peixoto, M. Marques, E. Rodrigues-Pinto, A.C.-R. Nunes, S. Lopes, F. Magro, G. Macedo
Centro Hospitalar São João, Department of Gastroenterology, Porto, Portugal

■ **P050**

Centrally-determined standardisation of flow cytometry methods reduces inter-laboratory variation in a prospective multicenter study

L. Westera, T. van Viegen, J. Jeyarajah, A. Azad, J. Bilsborough, G. van den Brink, S. Danese, G. D'Haens, L. Eckmann, W. Faubion, H. Korf, D. McGovern, J. Panes, A. Salas, W. Sandborn, M. Silverberg, M. Smith, S. Vermeire, S. Vetrano, L. Shackelton, L. Stitt, V. Jairath, B. Levesque, D. Spencer, B. Feagan, **N. Vande Castele**

Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands and others

■ **P051**

Use of digital technology to boost patient recruitment in Inflammatory Bowel Disease clinical trials

Y. Bouhnik, A. Amiot, N. Alexandre, A. Attar, P.K. Kondamudi, C. Stéfanescu
Beaujon Hospital, Gastroenterology, Clichy, France and others

■ **P052**

The role of TDAG8 in intestinal inflammation

I. Tcymbarevich, **C. de Valliere**, M. Spalinger, J. Cosin-Roger, K. Atrott, S. Richards, K. Seuwen, I. Frey-Wagner, G. Rogler

University of Zurich, Zurich, Switzerland and others

■ **P053**

Circulating non-classical monocytes are reduced in patients with active IBD but increase after vedolizumab: A role for $\alpha 4\beta 7$ in myeloid cell recruitment to the inflamed intestine

H. Gordon, I. Hoti, J.O. Lindsay, A. Stagg

Royal London Hospital, Gastroenterology, London, United Kingdom and others

■ **P054**

Metformin protects against intestinal barrier disruption via AMPK $\alpha 1$ -dependent inhibition of JNK signaling pathway

J. Deng, Y. Chen, L. Zeng

Nanfang Hospital, Southern Medical University, Department of Gastroenterology, Guangzhou, China

■ **P055**

Mitochondrial DNA is a damage-associated molecular pattern (DAMP) released during active IBD promoting TLR9-mediated inflammation

R. Boyapati, D. Dorward, A. Tamborska, R. Kalla, N. Ventham, A. Rossi, J. Satsangi, **G.-T. Ho**

University of Edinburgh, MRC Centre for Inflammation Research, Edinburgh, United Kingdom

■ **P056**

Gut microbiota characterisation in South Asian IBD patients resident in the UK

M.N. Quraishi, A. Rossiter, N. Bhal, M. Beaumont, S. Pathmakanthan, S. Ghosh, T.H. Iqbal

University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom and others

■ **P057**

IL-6 induces NLRP3 inflammasome activation through JAK/STAT3-dependent NOX2 induction in colon epithelial cells

J.-A. Kim, P. Grung, S. Banskota, B.-S. Jeong, T.-G. Nam

Yeungnam University, College of Pharmacy, Gyeongsan, South Korea and others

■ **P058**

Comparison of Calprotectin levels in stool and rectal mucus in subjects with suspected or confirmed Inflammatory Bowel Disease

J. McLaughlin, A.D. Hedley, P. Treasure, C.M. Collins, R.A. Craven

University of Manchester, School of Medical Sciences, Manchester, United Kingdom and others

■ **P059**

Mucosal inflammation promotes activation of circulating V $\delta 2+$ T-cells in Crohn's Disease

N. McCarthy, H. Gordon, S. Rahman, P. Harrow, A. Stagg, J. Lindsay

The Blizard Institute, Queen Mary University of London, Centre for Immunobiology, London, United Kingdom and others

■ **P060**

Role of innate lymphoid cells in the chronic Colitis under anti-il-17a therapy

C.S. Eun, D.S. Han, C.H. Park, A.R. Lee, Y.R. Lee
Hanyang University Guri Hospital, Gastroenterology, Guri, South Korea

■ **P061**

Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in Inflammatory Bowel Disease - IBD Character

A. Adams, R. Kalla, S. Vatn, F. Bonfiglio, E. Nimmo, N. Kennedy, N. Ventham, IBD Character Consortium, M. Vatn, P. Ricaneck, D. Bergemalm, J. Halfvarson, J. Söderholm, M. Pierik, L. Törkvist, F. Gomollón, I. Gut, J. Jahnsen, J. Satsangi
University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom and others

■ **P062**

The narrow spectrum kinase inhibitor (NSKI) TOP1288 demonstrates potent anti-inflammatory effects in a T cell adoptive transfer Colitis model through a topical mode of action

Y. Solanke, **M. Foster**, M. Fyfe, A. Rowley, S. Sirohi, S. Webber, C. Walshe
Topivert Pharma Ltd, London, United Kingdom

■ **P063**

HDAC as versatile regulators of the intestinal epithelial barrier in Inflammatory Bowel Disease

M. Friedrich, J. Ganther, T. Breiderhoff, R. Rosenthal, R. Glauben, B. Siegmund
Charité - Universitätsmedizin Berlin, Medical department for Gastroenterology, Infectious Diseases and Rheumatology, Berlin, Germany

■ **P064**

EBI2 and oxysterols in the development of intestinal lymphoid structures and Colitis

A. Wyss, T. Raselli, G. Schmelczler, M. Spalinger, K. Atrott, I. Frey-Wagner, A.W. Sailer, G. Rogler, B. Misselwitz
University of Zurich, Zurich, Switzerland and others

■ **P065**

Effects of gut bacteria on the intestinal immune cell composition and barrier function

F. Schmidt, K. Dahlke, A. Batra, C. Ring, J. Keye, G. Loh, M. Schumann, A. Kühl, M. Blaut, B. Siegmund
Charité - Universitätsmedizin Berlin, Medical Department for Gastroenterology, Infectious Diseases and Rheumatology, Berlin, Germany and others

■ **P066**

Fibrostenotic phenotype of fibroblasts in Crohn's Disease is dependent on tissue stiffness and reversed by LOX inhibition

J. de Bruyn, G. van den Brink, J. Steenkamer, C. Buskens, W. Bemelman, S. Meisner, V. Muncan, A. te Velde, G. D'Haens, M. Wildenberg
Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands and others

■ **P067**

Molecular profiling of early Crohn's Disease reveals a prominent role for WNT5A

S. Verstockt, J. Van der Goten, M. Vancamelbeke, B. Verstockt, L. Van Lommel, F. Schuit, P. Rutgeerts, M. Ferrante, S. Vermeire, I. Arijis, I. Cleynen
KU Leuven, Department of Human Genetics, Leuven, Belgium and others

■ **P068**

Evaluation of the therapeutic potential of metformin-pretreated tonsil-derived mesenchymal stem cells in a chronic colitis model

K.E. Lee, S.-A. Jung, Y.-H. Joo, C.H. Tae, C.M. Moon, S.-E. Kim, H.-K. Jung, K.-N. Shim, K. Yoo, Y.s. Yu, I.h. Jo
Ewha Womans University School of Medicine, Department of Internal Medicine, Seoul, South Korea and others

■ **P069**

Sympathetic but not vagal intestinal innervation regulates murine dextran sodium sulphate (DSS)-induced Colitis

R. Willemze, O. Welting, P. van Hamersveld, A. Sridhar, M. Vervoordeldonk, J. Seppen, W. de Jonge Academic Medical Center (AMC), Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands and others

■ **P070**

TNF α production by classical monocytes is poorly controlled by IL-10 in patients with IBD

I. Hoti, N.E. McCarthy, E.M. Giles, I. Ayada, H. Gordon, A.J. Stagg, J.O. Lindsay Blizard Institute, London, United Kingdom

■ **P071**

The mesentery in Crohn's Disease displays mesenchymal abnormalities

L. Walsh, M. Kiernan, S. Sahebally, P. Kiely, D. Waldron, M. Moloney, M. Skelly, H. Hidayat, P. Faul, D.P. O'Leary, A. Lowery, C. Dunne, J.C. Coffey University of Limerick, Department of Surgery, Limerick, Ireland and others

■ **P072**

The role of the rs8005161 polymorphism on pH-sensing G protein-coupled receptor GPR65 (TDAG8) signalling in intestinal inflammation

I. Tcymbarevich, N. Obialo, J. Cosin-Roger, K. Seuwen, G. Rogler, B. Misselwitz, **C. de Valliere** University of Zurich, Zurich, Switzerland and others

■ **P073**

Age dependent decrease in gut-homing CD4 lymphocytes

S. Oh, C.H. Lee, P. Hsu, M. Hu, B. Nanan, K. Gaskin, R. Leong, R. Nanan University of New South Wales, Kensington, Australia and others

■ **P074**

Decreased levels of circulating Protein S (PROS1) in patients with active Crohn's Disease

A. Sambuelli, P. Chavero, G. de Larrañaga, A. Errasti, A. Carrera Silva, L. Tessone, S. Peres, S. Negreira, A. Gil, M. Bellicoso, S. Goncalves, S. Huernos, P. Tirado, C. Rothlin Hospital Bonorino Udaondo, IBD Section - Medicine, Buenos Aires, Argentina and others

■ **P075**

Calponin 2 protects against Colitis associated cancer in mice through mediating inflammatory responses

B. Xu, M. Jiang, Z. Qiu, X. Li, D. Chen, Y. Chu, W. Wang, J. Liang, K. Wu The Fourth Military Medical University, State Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xi'an, Shaanxi, China

■ **P076**

IL-26 genetic polymorphisms impair cytokine response to bacterial DNA translocation and increase anti-TNF consumption in patients with Crohn's Disease

P. Piñero, O. Juanola, A. Gutiérrez, P. Zapater, P. Giménez, A. Steinert, L. Sempere, J.M. Gonzalez-Navajas, J. Niess, R. Francés CIBERehd - Hospital General Universitario de Alicante, Alicante, Spain and others

■ **P077**

Histological remission in UC: An analysis of two independent cohorts

K. Li, R. Strauss, C. Marano, L. Greenbaum, C. Brodmerkel, G. De Hertogh Janssen Research & Development, LLC, Spring House, United States and others

■ **P078**

Gut microbiome profiling of MMP-9 deficient mice and their wild-type littermates in a model of acute DSS-induced Colitis

M. de Bruyn, J. Sabino, D. Vandeputte, S. Vermeire, J. Raes, G. Opendakker Rega Institute for Medical Research, KU Leuven, Department of Microbiology and Immunology, Laboratory of Immunobiology, Leuven, Belgium and others

■ **P079**

Association of gut microbiota with mucosal inflammation in Ulcerative Colitis

M.N. Quraishi, A. Rossiter, B. Chung, M. Beaumont, E. Liaskou, R. Horniblow, A. Beggs, D. Withers, S. Ghosh, C. Tselepis, G. Hirschfield, T.H. Iqbal
University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom and others

■ **P080**

IL-10 induction properties of the TLR-9 agonist cobitolimod – a candidate for treatment of active Ulcerative Colitis in late stage of clinical development

C. Admyre, A. Zargari, R. Atreya, **T. Knittel**
Index Pharmaceuticals, Stockholm, Sweden and others

■ **P081**

10 years of the UK Inflammatory Bowel Disease (IBD) audit and the journey is just beginning

A. Protheroe, S. Murray
Royal College of Physicians, Clinical Effectiveness and Evaluation Unit, London, United Kingdom

■ **P082**

An investigation of azathioprine on autophagy pathway activity

K. Hooper, P. Barlow, P. Henderson, C. Stevens
Edinburgh Napier University, Edinburgh, United Kingdom and others

■ **P083**

The protective role of vitamin D3 on Colitis-associated colorectal cancer in a mouse model

L. Ma, Y. Xin, H. Lv, H. Wang, J. Qian
Peking Union Medical College Hospital, Gastroenterology, Beijing, China and others

■ **P084**

Investigation of non-coding RNAs as molecular markers during glucocorticoid treatment in children with Inflammatory Bowel Disease

M. Lucafo, A. Di Silvestre, M. Romano, S. Martellosi, S. Naviglio, A. Tommasini, G. Stocco, A. Ventura, G. Decorti, S. De Iudicibus
University of Trieste, Department of Medicine, Surgery and Health Sciences, Trieste, Italy and others

■ **P085**

The effect of vitamin D on macrophage function and polarisation in Crohn's Disease

S. Dionne, C.-F. Duchatellier, **E. Seidman**
Research Institute of the McGill University Hospital, Gastroenterology, Montreal, Canada

■ **P086**

MMP-12, a novel mediator of nociception in Crohn's Disease

M. Tranter, F. Barakat, H. Dogra, J. Lindsay, N. Croft, **D. Bulmer**
Queen Mary University of London, London, United Kingdom

■ **P087**

Increased wnt ligands expression in M2c macrophages is associated with fibrosis in Stat6 knockout mice

D. Ortiz-Masia, P. Salvador, D.C. Macias-Ceja, L. Gisbert-Ferrándiz, C. Hernandez, S. Calatayud, J.V. Esplugues, D. Barrachina
Universidad de Valencia-CIBERehd, Pharmacology, Valencia, Spain and others

■ **P088**

Evaluation of free Vitamin D levels in IBD paediatric patients: The role of inflammation

C. Strisciuglio, S. Cenni, F.P. Giugliano, E. Miele, G. Cirillo, M. Martinelli, A. Vitale, A. Staiano, E. Miraglia del Giudice, L. Perrone
Second University of Naples, Department of Woman, Child and General and Specialistic Surgery, Naples, Italy and others

■ **P089**

Extracellular matrix fragments as markers of cytokine driven intestinal damage or protection; test in a novel intestinal ex vivo model

M.L. Olesen, A. Krag, M. Karsdal, J. Kjeldsen, A.-C. Bay-Jensen, J.H. Mortensen
Nordic Bioscience A/S, Biomarkers and Research, Herlev, Denmark and others

■ **P090**

Metformin induces late apoptosis and modulates dysbiosis in western-style diet induced colitic cancer

E.J. Chung, E.J. Do, S.-J. Myung
Asan Medical Center, Seoul, South Korea and others

■ **P091**

Usefulness of transcriptional whole blood biomarkers as a non-invasive surrogate marker of mucosal healing and endoscopic response in Ulcerative Colitis

N. Planell, M.C. Masamunt, R. Franco Leal, L. Rodríguez, M. Esteller, J.J. Lozano, A. Ramírez, M.d.L. Setsuko Ayrrizono, C. Saddy Rodrigues Coy, I. Alfaro, I. Ordás, S. Visvanathan, E. Ricart, J. Guardiola, J. Panés, A. Salas
IDIBAPS, Hospital Clínic, CIBER-EHD, Gastroenterology, Barcelona, Spain and others

■ **P092**

Exogenous administration of IL-4-treated macrophages prevents intestinal fibrosis in Stat6 knockout mice

P. Salvador, D. Ortiz-Masià, D.C. Macias-Ceja, L. Gisbert-Ferrándiz, C. Hernández, J.V. Esplugues, M.D. Barrachina-Sancho, S. Calatayud
University of Valencia, Valencia, Spain and others

■ **P093**

Dysregulation of cellular vs humoral immunity to the intestinal microbiota in Inflammatory Bowel Disease

A. Noble, L. Durant, L. Hoyles, A.L. McCartney, R. Man, S.P. Costello, P. Hendy, D. Reddi, J. Segal, D. Lim, M. Bolton, A.L. Hart, S.R. Carding, S.C. Knight
Imperial College London, Antigen Presentation Research Group, Harrow, United Kingdom and others

■ **P094**

DNA methylation patterns in Crohn's Disease mucosal-derived fibroblasts

A.A. te Velde, A.Y. Li Yim, J.R. de Bruyn, N.W. Duijvis, W. de Jonge, M.E. Wildenberg, M.M. Mannens, G.R. D'Haens, P. Henneman
Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands and others

■ **P095**

The genetic risk in ER stress and autophagy translates into quantifiable epithelial ER stress levels in IBD patients

W. Vanhove, K. Nys, I. Arijis, I. Cleyen, M. de Bruyn, H. Korf, M. Ferrante, G. Van Assche, S. Vermeire
KU Leuven, Translational Research in Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, Leuven, Belgium and others

■ **P096**

Combined detection variants of NUDT15 could highly predict thiopurine-induced leukopenia in Chinese patients with Inflammatory Bowel Disease: A multi-center analysis

K. Chao, X. Zhu, Q. Cao, H. Yang, J. Liang, L. Lin, Z. Huang, Y. Zhang, Y. Huang, Y. Sun, X. Xue, M. Huang, P. Hu, K. Wu, P. Lan, X. Wang, J. Qian, X. Gao
The Sixth Affiliated Hospital, Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China and others

■ **P097**

Th2 cytokines are potent stimulators of pro-fibrotic responses by human intestinal subepithelial myofibroblasts

E. Filidou, V. Valatas, I. Drygiannakis, K. Arvanitidis, S. Vradelis, G. Kolios
Democritus University of Thrace, Laboratory of Pharmacology, Faculty of Medicine, Alexandroupolis, Greece and others

■ **P098**

Oregonin inhibits intestinal epithelial injury by modulating Heme oxygenase-1

G.S. Seo, J.-H. Chi, H. Jin, S.H. Lee

Wonkwang University Hospital, Digestive Disease Research Institute, Department of Gastroenterology, Iksan, South Korea and others

■ **P099**

Altered intrinsic brain function in Crohn's Disease

A. Thomann, M. Griebel, P. Thomann, W. Reindl, C. Wolf

Universitätsmedizin Mannheim, Department of medicine II, Mannheim, Germany and others

■ **P100**

Intestinal epithelial cells under endoplasmic reticulum stress boosts serine proteolytic activity and modulates barrier function

N. Solà Tapias, A. Denadai-Souza, C. Rolland-Fourcade, C. Blanpied, G. Dietrich, C. Bonnart, A. Edir, C. Rolland, C. Deraison, N. Vergnolle, F. Barreau

Institut de Recherche en Santé Digestive (IRSD), toulouse, France

■ **P101**

Interleukin-13 induces polarity defects in the intestinal epithelia

L. Lebenheim, A. Kühnel, N. Hering, C. Bojarski, J.-D. Schulzke, B. Siegmund, M. Schumann

Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology and Medicine I, Berlin, Germany

■ **P102**

Hypoxia reduces inflammation through the downregulation of NLRP3/mTOR signaling and the activation of autophagy

J. Cosin-Roger, S. Simmen, H. Melhem, K. Atrott, I. Frey-Wagner, M. Hausmann, C. De Valliere, M.R. Spalinger, P. Spielmann, R.H. Wagner, J. Zeitz, S.R. Vavricka, G. Rogler, P.A. Ruiz

University of Zurich, Gastroenterology, Zurich, Switzerland and others

■ **P103**

Evaluation of efficacy of new vectors for siRNA CYCLIN D1 and E2F1 delivery in control of cancer progression in Inflammatory Bowel Disease

I. Russo, S. Bochicchio, O. Piazza, A.A. Barba, G. Lamberti, A. Carrizzo, P. Zeppa, C. Vecchione, P. Iovino, C. Ciacci

University of Salerno, Department of Medicine and Surgery, Baronissi Campus (Salerno), Italy and others

■ **P104**

Rebamipide, sucralfate, and rifaximin have the suppressive effects on radiation-induced inflammation in the intestine of mouse

W. Moon, S.J. Park, J.H. Kim, M.I. Park, S.E. Kim, K.W. Jung

Kosin University College of Medicine, Department of Internal Medicine, Busan, South Korea

■ **P105**

An experimental examination of appetite and disordered eating in Crohn's Disease patients

R. Wardle, G. Thapaliya, A. Nowak, M. Dalton, G. Finlayson, **G. Moran**

University Hospitals Nottingham, NIHR Biomedical Research Unit in Gastrointestinal and Liver Diseases, Nottingham, United Kingdom and others

■ **P106**

Binding properties of human TLR-9 receptor to cobitolimod – a candidate for treatment of active Ulcerative Colitis in late stage of clinical development

A. Zargari, C. Admyre, T. Knittel

Index Pharmaceuticals, Stockholm, Sweden

■ **P107**

Lactobacillus plantarum 06CC2 induces intestinal IL-10-producing dendritic cells to ameliorate acute experimental Colitis in mice

A. Tanaka, S. Kanmura, S. Arima, F. Sasaki, Y. Nasu, S. Tanoue, S. Hashimoto, H. Setoyama, A. Ido

Kagoshima University Graduate School of Medical and Dental Sciences, Digestive and Lifestyle Diseases, Kagoshima, Japan and others

■ **P108**

Oleuropein decreases interleukin (IL)-17 and attenuates inflammatory damage in colonic mucosa from Ulcerative Colitis patients

T. Larussa, M. Oliverio, E. Suraci, M. Greco, R. Placida, S. Gervasi, R. Marasco, M. Imeneo, D. Paolino, L. Tucci, E. Gulletta, M. Fresta, A. Procopio, F. Luzza
University of Catanzaro Magna Graecia, Health of Sciences, Catanzaro, Italy and others

■ **P109**

Profiling of Receptor for Advanced Glycation End Products (RAGE) expression in cases of primary sclerosing cholangitis (PSC) with Ulcerative Colitis (UC)

V. Udupa, A. Baird, **D. Winter**
St Vincent's University Hospital, Dept of Surgery, Dublin, Ireland and others

■ **P110**

Characterisation of human intestinal macrophage subsets in health and Inflammatory Bowel Disease

D. Bernardo, I. Mora-Gutierrez, A.C. Marin, A. Díaz-Guerra, R. Caminero-Fernández, M. Caldas, F. De la Morena, M. Jiménez, M. Chaparro, J.P. Gisbert
Hospital Universitario de La Princesa, CIBERehd, Madrid, Spain and others

■ **P111**

The anti-inflammatory effect of a serine protease inhibitor in a chronic Colitis transfer model is mediated by the suppression of Th1 cell differentiation

H. Van Spaendonk, S. Francque, J. De Man, B. De Winter
University of Antwerp, Laboratory of Experimental Medicine and Pediatrics, Antwerp, Belgium and others

■ **P112**

Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development

Y. Tian, K. Wang, G. Ji
The Second Affiliated Hospital of Nanjing Medical University, Department of Oncology, Nanjing, China and others

■ **P113**

Model based predictions of the PTG-100 pharmacodynamic responses in Ulcerative Colitis patients

L. Mattheakis, C. Fossier, R. Saralaya, K. Horsch, N. Rao, L. Bai, L. Zhao, T. Annamalai, D. Liu
Protagonist Therapeutics, Milpitas, United States and others

■ **P114**

Fecal loss of infliximab is underestimated due to proteolysis

A. Strik, J. Brandse, P. Koelink, M. Wildenberg, A. de Vries, R. Boshuizen, G. van den Brink, G. D'Haens
Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands and others

■ **P115**

Escherichia Coli Nissle 1917 modulate gut microbiota composition in Ulcerative Colitis patients

C. Graziani, V. Petito, F. Del Chierico, F. Mangiola, S. Pecere, E. Schiavoni, M. Pizzoferrato, L.R. Lopetuso, L. Putignani, A. Gasbarrini, **F. Scaldaferri**
Fondazione Policlinico Gemelli, Università Cattolica del Sacro Cuore, Gastroenterological Area, Gastroenterological and Endocrino-Metabolic Sciences Department, Rome, Italy and others

■ **P116**

E. coli Nissle 1917 distinctively regulates apoptosis and cell cycling of Caco-2 cells

A. Schirbel, A. Sturm
Charité Campus Virchow Klinikum, Berlin, Germany and others

■ P117***Functional implications of microRNAs in Crohn's Disease revealed by integrating microRNA and messenger RNA expression profiling***

O. Palmieri, T. Creanza, F. Bossa, T. Latiano, G. Corritore, O. Palumbo, G. Martino, G. Biscaglia, D. Scimeca, M. Carella, N. Ancona, A. Andriulli, A. Latiano
IRCCS, Casa Sollievo della Sofferenza, Hospital, UOC Gastroenterology, San Giovanni Rotondo, Italy and others

■ P118***Balancing JAK/STAT-signaling with Tofacitinib in monocytes of healthy controls and IBD patients***

A.F. Cordes, E. Lenker, T. Weinhage, G. Varga, D. Foell
University Hospital Münster, Department of Gastroenterology, Münster, Germany and others

■ P119***Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohn's Disease: A SONIC post hoc analysis***

J.-F. Colombel, O.J. Adedokun, C. Gasink, K. Tang, F. Cornillie, G. D'Haens, P. Rutgeerts, W. Reinisch, W. Sandborn, S. Hanauer
Icahn School of Medicine at Mt Sinai, New York, United States and others

■ P120***A single-nucleotide polymorphism in the vitamin D receptor gene is associated with a B3-penetrating phenotype in Crohn's Disease***

L. Gisbert-Ferrándiz, P. Salvador, D. Ortiz-Masiá, D.C. Macias-Ceja, S. Calatayud, J. Hinojosa, L. Oltra-Camps, M.D. Barrachina, C. Hernández
University of Valencia, Valencia, Spain and others

Clinical: Diagnosis and outcome

■ P121

Antimicrobial antibodies and inflammatory markers are present in the serum of patients with IBD years before diagnosis and can predict disease

J. Torres, P. Wang, F. Princen, T. Stockfisch, F. Petralia, R.S. Choung, S. Telesco, R. Strauss, C. Porter, J. Murray, M. Riddle, J.-F. Colombel
Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States and others

■ P122

Magnetic resonance index of activity (MaRIA) and Clermont score are two MRI indices which are highly and equally effective in detecting mucosal healing in Crohn's Disease

A. Buisson, B. Pereira, M. Goutte, M. Reymond, C. Allimant, G. Bommelaer, C. Hordonneau
University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France and others

■ P123

MRI remission after therapeutic intervention is associated with more time spent in clinical corticosteroids-free remission and decreased risk of surgery in Crohn's Disease

A. Buisson, C. Hordonneau, F. Goutorbe, C. Allimant, M. Goutte, M. Reymond, G. Bommelaer
University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France and others

■ P124

Disagreement among gastroenterologists in the endoscopic evaluation using the Mayo endoscopic score and the Rutgeerts postoperative score

S. Raimundo Fernandes, J. Pinto, P. Marques da Costa, L. Correia, Grupo de Estudos de Doença Inflamatória Intestinal
Hospital de Santa Maria, Serviço de Gastreenterologia e Hepatologia, Lisboa, Portugal and others

■ P125

Rapid increase in pan-treatment refractory Crohn's Disease after transition to adult services: A regional cohort study

V. Merrick, P. Henderson, P. Rogers, I. Arnott, J. Satsangi, D. Wilson
University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom and others

■ P126

Experience of 3D modelling in perianal Fistula Disease and survey of international surgical interest

K. Sahnan, S. Adegbola, P.J. Tozer, D. Burling, J. Warusavitarne, O.D. Faiz, R.K. Phillips, A.L. Hart, P.F. Lung
St Mark's Hospital, Colorectal Surgery, London, United Kingdom and others

■ P127

An assessment of a pancolonc adaptation of the Ulcerative Colitis endoscopic index of severity in comparison to clinical and biochemical markers of disease activity in Paediatric UC

A. Ricciuto, J. Fish, N. Carman, E. Crowley, A. Muise, P. Church, T. Walters, B.M. Kamath, A. Griffiths
Hospital for Sick Children, University of Toronto, Toronto, Canada

■ P128

Diagnostic accuracy of faecal calprotectin in Crohn's Disease - does disease location matter?

E. Simon, R. Wardle, A.A. Thi, J. Eldridge, S. Samuel, G. Moran
Christian Medical College, Gastroenterology, Vellore, India and others

■ P129

Persistent intestinal inflammation leads to surgical intervention in Crohn's patients: A nested case-control study

P. Pavlidis, A. Cockroft, S. Chatu, L.M. Choong, L. Medcalf, J. Tumova, R. Srirajakanthan, G. Chung-Faye, P. Dubois, R. Sherwood, I. Bjarnason, B.H. Hayee
King's College Hospital, Department of Gastroenterology, London, United Kingdom and others

P130
Ingestion of 100ml and 300ml blood mimicking upper GI bleeding leads to significant Calprotectin elevation in healthy volunteers – results from the ‘Vampire Study’

S. Vavricka, H. Heinrich, B. Misselwitz, S. Buetikofer, E. Burri, G. Rogler, F. Breitenmoser, X. Schneider, J. Zeitz, L. Biedermann, M. Sauter
 Triemli Hospital, Division of Gastroenterology, Zurich, Switzerland and others

P131
Fecal micro-RNAs indicate disease activity in Ulcerative Colitis

J. Verdier, I. Breunig, M.C. Ohse, S. Roy, S. Groner, S. Roubrocks, K. Streetz, C. Trautwein, C. Roderburg, **G. Sellge**
 University Hospital RWTH Aachen, Dep. of Internal Medicine III, Aachen, Germany and others

P132
Cooperation to improve quality of IPAA surgery in IBD: South Netherlands experience

L. Stassen, B. Sahari, T. Lubbers, A. van Bodegraven, M. Pierik, J. Stoot, E. Belgers
 Maastricht University Medical Center (MUMC), Department of GI surgery, Maastricht, Netherlands and others

P133
A novel candidate pathway for development of neoplasms with serrated morphology in patients with Ulcerative Colitis

M. Nishio, W. Shibata, Y. Ajioka, K. Hirasawa, W. Ueda, K. Okawa, H. Otake, T. Ogashiwa, A. Takase, S. Chiba, Y. Inayama, H. Kimura, R. Kunisaki, S. Maeda
 Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan and others

P134
Point of care ultrasound accurately distinguishes inflammatory from non inflammatory disease in patients presenting with abdominal pain and diarrhea

H. Al-Farhan, A. Al-Darmaki, H. Shim, C.H. Seow, G.G. Kaplan, R. Panaccione, S.R. Wilson, J. Halasz, K.L. Novak
 University of Calgary, Gastroenterology, Calgary, Canada and others

P135
The early course of Crohn’s Disease: Prognostic and treatment modalities during the first year of disease

S. Raimundo Fernandes, L. Correia, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, J. Velosa
 Hospital de Santa Maria, Serviço de Gastreenterologia e Hepatologia, Lisboa, Portugal and others

P136
Sporadic adenomas in IBD patients over 50 years old and average risk population – is there a difference?

S. Monteiro, T. Cúrdia Gonçalves, P. Boal Carvalho, F. Dias de Castro, S. Leite, M.J. Moreira, J. Cotter
 Hospital da Senhora da Oliveira-Guimarães, Gastroenterology, Guimarães, Portugal and others

P137
Ulcerative Colitis in the elderly - different disease course?

C. Teixeira, C. Martins, S. Ribeiro, D. Trabulo, A.L. Alves, I. Cremers, A.P. Oliveira
 Centro Hospitalar de Setúbal, Gastroenterology, Setúbal, Portugal

P138
Does depression at IBD diagnosis impact on disease outcomes in Crohn’s?

C. Alexakis, S. Saxena, V. Chhaya, E. Cecil, R. Pollok
 St George’s University Hospital, Gastroenterology, London, United Kingdom and others

P139
Articular manifestations in Inflammatory Bowel Disease - results from Northeastern Romania

A. Cardoneanu, E. Rezus, O. Gavrilescu, C. Cijevschi Prelipcean, M. Dranga, A. Badescu, V. Drug, C. Stanciu, A. Trifan, C. Mihai
 University of Medicine and Pharmacy Gr.T.Popa Iasi, Rheumatology, Iasi, Romania and others

■ **P140**

Use of vedolizumab in a transplanted liver patient: A case report of the first experience in a liver transplant referral center in Argentina

P.R. Daffra, M.J. Etchevers, M.J. Sobrero, R.C. Gonzalez Sueyro, G. Rainero, F. Carbonnel, T. Vaysse, M.M. Marcolongo, J.A. De Paula
Hospital Italiano de Buenos Aires, Gastroenterology, Buenos Aires, Argentina and others

■ **P141**

Characteristics and outcomes of Acute Colitis presenting via the emergency department in an Irish academic medical centre

J. O'Connell, S. Keohane, A. McGreal-Bellone, S. Naimimohasse, S. McKiernan, F. MacCarthy, D. O'Toole, J. Meaney, D. Kevans
St James Hospital, Gastroenterology, Dublin, Ireland and others

■ **P142**

Postoperative course of laparoscopic subtotal colectomy is not affected by preoperative medical treatment in patients with Acute Colitis complicating Inflammatory Bowel Disease

D. Mege, M. Monsinjon, L. Maggiori, X. Tréton, Y. Bouhnik, Y. Panis
Beaujon Hospital, Colorectal Surgery, Clichy, France and others

■ **P143**

From biopsies to fecal samples: challenging *F. prausnitzii* and related phylogroups as potential biomarkers for IBD

J. Amoedo, M. Serra-Pagès, M. Serrano, A. Bahí, M. Malagón, P. Gilabert, J. Guardiola, D. Busquets, X. Aldeguer, J. Garcia-Gil
Universitat de Girona, Microbiologia, Girona, Spain and others

■ **P144**

Protozoa and bacterial infections are relevant for clinical outcomes in Ulcerative Colitis: A study from Latin America

Y. Gutierrez-Grobe, C. Barrera-Ochoa, **J. Yamamoto-Furusho**
IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico

■ **P145**

Measuring access and quality of care indicators in Inflammatory Bowel Disease in a tertiary referral center

P.A. Golovics, L. Gonczi, Z. Kurti, B.D. Lovasz, K.B. Gecse, Z. Vegh, P.L. Lakatos
Semmelweis University, First Department of Medicine, Budapest, Hungary

■ **P146**

Primary intestinal Epstein-Barr virus-associated NK/T-Cell lymphoproliferative disorder: A disease mimicking IBD

Z. Wang, M. Zhu, C. Luo, J. Mu, Z. Yu, **H. Zhang**
West China Hospital, Sichuan University, Department of Gastroenterology, Chengdu, China

■ **P147**

Metabolomics discriminate children with Crohn's Disease from Ulcerative Colitis and from healthy controls - preliminary study

U. Daniluk, M. Ciborowski, **J. Daniluk**, K. Pietrowska, A. Kretowski, D. Lebensztejn
Medical University of Bialystok, Department of Pediatrics, Gastroenterology and Allergology, Bialystok, Poland and others

■ **P148**

Fecal calprotectin as a noninvasive indicator for Ulcerative Colitis disease activity in the Korean cohort

S.-H. Lee, H. Seo, K. Chang, E.M. Song, G.-U. Kim, M. Seo, E.J. Kwon, S.W. Hwang, S.H. Park, D.-H. Yang, K.-J. Kim, J.-S. Byeon, S.-J. Myung, S.-K. Yang, B.D. Ye
University of Ulsan College of Medicine, Asan Medical Center, Department of Gastroenterology, Seoul, South Korea and others

P149***Urban life is an independent risk factor for psychological symptoms of the Chinese patients with Crohn's Disease***

H. He, M. Zhi, M. Zhang, Y. Zhang, J. Hu, J. Tang, M. Su, X. Gao, P. Hu
the Sixth Affiliated Hospital of Sun Yat-sen University, Gastroenterology, Guangzhou, China and others

P150***Pregnancy complications and outcomes in patients with Inflammatory Bowel Disease***

Y. Yokoyama, H. Tanaka, A. Nishio, T. Sato, M. Kawai, K. Kamikozuru, Y. Kita, T. Miyazaki, N. Hida, K. Hori, S. Nakamura
Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine, Nishinomiya, Japan and others

P151***Spinal disorders in IBD patients 20 years after diagnosis. Results from the IBSEN study***

A. Ossum, Ø. Palm, M. Cvanarova, B. Moum, M. Høivik
Oslo University hospital, Gastroenterology, Oslo, Norway and others

P152***Reconsidering the prognostic value of traditional serologic antibodies in Crohn's Disease – immunoglobulin classes to take the centre stage***

N. Sipeki, G.L. Norman, Z. Shums, G. Veres, P.L. Lakatos, P. Antal-Szalmás, **M. Papp**
University of Debrecen, Clinical Center, Institute of Internal Medicine, Department of Gastroenterology, Debrecen, Hungary and others

P153***Role of 3D endoanal ultrasound in perianal fistulising Crohn's Disease. Preliminary results***

G. Luglio, M.C. Giglio, A. Rispo, N. Imperatore, V. Sollazzo, R. Peltrini, M. Sacco, F. Castiglione, G.D. De Palma, L. Bucci
University of Naples Federico II - Italy, Clinical Medicine and Surgery - Surgical Coloproctology Unit, Naples, Italy and others

P154***Complete sequence-based NUDT15 and TPMT variants for predicting thiopurine-induced leukopenia in patients with Crohn's Disease***

T.J. Kim, E.R. Kim, S.N. Hong, D.K. Chang, Y.-H. Kim
Samsung Medical Center, Seoul, South Korea

P155***A retrospective analysis of Clostridium difficile infection in patients with Ulcerative Colitis***

H. Xu, Y. Li, T. Xu, J. Li, H. Yang, H. Lv, J. Qian
Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Department of Gastroenterology, Beijing, China and others

P156***Microbiota diversity at time of surgery predict endoscopic recurrence in Crohn's Disease: Results of a prospective study of the REMIND group***

H. Sokol, L. Brot, C. Stefanescu, C. Auzolle, N. Barnich, A. Buisson, M. Fumery, M. Nachury, X. Treton, S. Nancey, M. Allez, P. Seksik, REMIND
APHP INSERM INRA, Paris, France and others

P157***Fecal calprotectin correlates to endoscopic and histologic remission in Ulcerative Colitis: A prospective study***

L. Hart, O. Kherad, C. Lemieux, J. Laneuville, M. Chavannes, V. Marcus, C. Maedler, W. Afif, A. Bitton, P. Brassard, T. Bessissow
McGill University, Gastroenterology, Montreal, Canada and others

■ **P158**

Pouchitis in paediatric UC: A multicentre longitudinal cohort study from the Porto IBD working group of ESPGHAN

C. Topf-Olivestone, E. Orlanski Meyer, O. Ledder, M. Friedman, I. Dotan, L.-F. Hansen, A. Kindermann, A. Assa, K.-L. Kolho, S. Kolaček, E. Wine, C. Strisciuglio, M. Aloï, R. Hansen, H.S. Winter, V.M. Navas-López, L. de Ridder, F. Smets, D. Turner
Shaare Zedek Medical Center, The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel and others

■ **P159**

Real-time endoscopic-guided measurement of rectal mucosal admittance: A novel and safety method for prediction of relapse in Ulcerative Colitis

T. Taida, T. Nakagawa, M. Fujie, Y. Ohta, S. Hamanaka, K. Okimoto, K. Saito, D. Maruoka, T. Matsumura, M. Arai, T. Katsuno
Chiba University, Department of Gastroenterology and Nephrology, Chiba, Japan and others

■ **P160**

Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound for evaluation of small bowel Crohn's Disease; a systematic review and meta-analysis

U. Kopylov, D. Young, T. Engel, S. Vijayan, O. Har-Noy, L. Katz, T. Avni, R. Eliakim, S. Ben-Horin, A. Koulaouzidis
Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel and others

■ **P161**

Crohn's Disease risk prediction model appropriately stratifies patients' risk for developing disease related complications

K.D. Thompson, L.S. Siegel, T. MacKenzie, M.C. Dubinsky, **C.A. Siegel**
Dartmouth-Hitchcock Medical Center, Lebanon, United States and others

■ **P162**

Early onset of disease and higher risk for colorectal dysplasia in IBD patients with coincidental primary sclerosing cholangitis – evidence from a large cohort study

A.F. Cordes, T. Laumeyer, J. Gerß, T. Kucharzik, D. Bettenworth
University Hospital Münster, Department of Gastroenterology, Münster, Germany and others

■ **P163**

Performance of ASAS criteria for inflammatory back pain in patients with Inflammatory Bowel Disease

E. Belousova, D. Abdulganieva, A. Odintsova, R. Zakirov, B. Nagornyykh, M. Protopopov
Kazan State Medical University, Hospital Therapy, Kazan, Russian Federation and others

■ **P164**

FOXO4 gene expression in colonic mucosa is a potential marker associated with histological remission in patients with Ulcerative Colitis

J. Yamamoto-Furusho, E. Iturriaga-Goyon, G. Fonseca-Camarillo
IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico

■ **P165**

Impact of double balloon endoscopy on management of small bowel Crohn's Disease

A. Madian, M. Matsuura, A. El Bahrawy, H. Nakase, T. Chiba, M.N. Rafaat
Al Azhar University, Faculty of Medicine, Internal Medicine, Assiut, Egypt and others

■ **P166**

Decreased expression of elafin in peripheral blood and intestinal mucosa in Inflammatory Bowel Disease

W. Zhang, G. Teng, H. Wang, Y. Tian, Y. Zheng
Peking University First Hospital, Gastroenterology, Beijing, China

■ **P167**

Diagnostic accuracy of neutrophil-lymphocyte ratio in suspected paediatric Inflammatory Bowel Disease

I. Chalmers, D. Wilson, P. Henderson

Royal Hospital for Sick Children, Edinburgh, Department of Paediatric Gastroenterology, Edinburgh, United Kingdom and others

■ **P168**

Validation of the red flags index for early referral of patients with symptoms and signs suggestive of Crohn's Disease

S. Raimundo Fernandes, J. Rita Carvalho, P. Santos, P. Marques da Costa, C. Moura, L. Correia, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, J. Velosa

Hospital de Santa Maria, Serviço de Gastroenterologia e Hepatologia, Lisboa, Portugal and others

■ **P169**

Usability of a home-based test for the measurement of fecal calprotectin in IBD patients

C. Bello, A. Roseth, J. Guardiola, C. Reinhard, **E. Louis**

CHU Liège, Gastroenterology, Liège, Belgium and others

■ **P170**

Integrated psychological care in outpatients with Inflammatory Bowel Disease

T. Lores, C. Goess, C. Hrycek, R. Grafton, J. Hughes, L. Cronin, A. Mikocka-Walus, A. Chur-Hansen, A.L. Burke, K.L. Collins, J.M. Andrews

Royal Adelaide Hospital, Gastroenterology, Adelaide, Australia and others

■ **P171**

Reliable assessment of ultrasound parameters during transabdominal ultrasonography in Inflammatory Bowel Disease

M. Bittl, F. Petersen, C. Maaser, S. Rath, A. Roessler, I. Fischer, D. Bettenworth, T. Kucharzik

Klinikum Lueneburg, Gastroenterology, Lueneburg, Germany and others

■ **P172**

Withdrawn

■ **P173**

Risk stratification of patients with Crohn's Disease: A retrospective analysis of clinical decision-making and its impact on long-term outcome

M. Mosli, H. Sabbahi, H. Alyousef, M. Abdullhaq, A. Hadadi, **H. Jawa**, E. Aljahdli, S. Bazarah, Y. Qari

King Abdulaziz University, Medicine, Jeddah, Saudi Arabia

■ **P174**

Optimal time interval required for correlation between fecal calprotectin test and endoscopy

S.R. Jeon, H.G. Kim, J.-O. Kim, Y. Jung, B.M. Ko, M.S. Lee

Soonchunhyang University College of Medicine, Seoul, South Korea

■ **P175**

A novel small-caliber deep enteroscope can overcome technical difficulty of insertion in patients with Crohn's Disease

Y. Endo, K. Ohtsuka, A. Yoshida, F. Ueno, K. Takenaka, M. Watanabe

Ofuna Chuo Hospital, Center for Gastroenterology and Inflammatory Bowel Disease, Kamakura, Kanagawa, Japan and others

■ **P176**

Correlation of biomarkers to PET/MRI and endoscopy in patients with Crohn's Disease with special focus on small bowel involvement

J. Langhorst, J. Boone, A. Koch, A. Rueffer, G. Dobos, K. Beiderwellen, T. Lauenstein

University of Duisburg-Essen, Integrative Gastroenterology, Essen, Germany and others

■ **P177**

Histological features in paired ileal resections in Crohn's Disease patients

C. Palmela, J. Torres, R. Huang, N. Vyas, X. Zhang, M. Suarezfarinas, J. Cho, J.-F. Colombel, N. Harpaz, H.M. Ko
Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States and others

■ **P178**

Validation of the clinical utility of IFI16-based markers in IBD

V. Caneparo, L. Pastorelli, E. Vanni, D. Roggenbuck, R. Boldorini, M. Astegiano, M. Vecchi, S. Landolfo, M. Gariglio, **M. De Andrea**
University of Turin, Medical School, Department of Public Health and Pediatric Sciences, Viral Pathogenesis Unit, Turin, Italy and others

■ **P179**

Diagnostic performance of low haemoglobin density (LDH %) for detecting iron deficiency in IBD patients

E. Banerjee, A. Dienethal, **J. Stein**
DGD Clinics Sachsenhausen, Frankfurt/Main, Germany and others

■ **P180**

Investing in workability of patients with IBD: Results of a pilot project Activ84work (Activate for work)

S. Coenen, M.-N. Schmickler, D. Staes, F. Wieme, T. Swinnen, X. Dekeuleneer, T. Van Hooland, K. Van den Cruys, S. Vermeire
UZ Leuven, Gastroenterology, Leuven, Belgium and others

■ **P181**

Home smart-phone based measurement of fecal calprotectin by IBD patients: Correlation with laboratory assay and applicability as patient-friendly monitoring tool

B. Ungar, A. Lahat, L. Selinger, N. Levhar, S. Neuman, U. Kopylov, M. Yavzori, E. Fudim, M. Bubis, O. Picard, R. Eliakim, **S. Ben-Horin**
Sheba Medical Center & Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel

■ **P182**

Assessing the effect of ethnicity on urinary metabolic profiles in Inflammatory Bowel Disease

L. Hicks, S. Powles, J. Swann, L. Chong, E. Holmes, H. Williams, T. Orchard
Imperial College Healthcare NHS Trust St. Mary's Hospital, Department of Gastroenterology, London, United Kingdom and others

■ **P183**

Psychosocial impact of Inflammatory Bowel Disease and its practice management as perceived by patients and physicians in Spain. The ENMENTE Project

M. Barreiro-de Acosta, M. Gobbo Montoya, M. Cañas, A. Panadero, Y. Modino, J. Guardiola, L. Cea-Calvo, B. Juliá, C. Romero, L. Carmona, I. Marín-Jiménez
Complejo Universitario de Santiago de Compostela, Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Santiago de Compostela, Spain and others

■ **P184**

Photoprotective behaviours in Inflammatory Bowel Disease patients on azathioprine and TNF- α inhibitors

C. Gallagher, A. Ridge, A.M. Tobin, D. Kevans, D. McNamara
Adelaide & Meath Hospital, Dublin, Incorporating The National Children's Hospital, Department of Clinical Medicine, Dublin, Ireland and others

■ **P185**

Validity of contrast enhanced ultrasonography and dynamic contrast enhanced MR enterography in the assessment of Crohn's Disease

R. Wilkens, R. Hagemann-Madsen, D.A. Peters, A.H. Nielsen, C.B. Nørager, H. Glerup, K. Krogh
Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark and others

■ **P186**

Association between anti-TNF serum levels and mucosal healing (MH) in Inflammatory Bowel Disease (IBD)

M. Chaparro, M. Barreiro-de Acosta, A. Echarri, R. Almendros, J. Barrio, J. Llao, F. Gomollón, M. Vera, J.L. Cabriada, J. Guardiola, I. Guerra, B. Beltrán, O. Roncero, D. Busquets, C. Taxonera, X. Calvet, R. Ferreira, V. Ollero Pena, M. G Donday, A. Garre, A. Godino, A. Díaz, J.P. Gisbert
Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Madrid, Spain and others

■ **P187**

Differential distribution of Epstein-Barr virus and Cytomegalovirus in colonic mucosa in patients with active Ulcerative Colitis

S. Yamada, M. Matsuura, Y. Honzawa, M. Okabe, Y. Koshikawa, N. Minami, S. Yamamoto, H. Seno, H. Nakase
Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan and others

■ **P188**

Crohn's Disease of the terminal Ileum: PET-MRE results correlate well with biomarkers

H. Leibovitzh, I. Avni-Biron, L. Lichtenstein, D. Groshar, H. Bernstine, L. Domachevsky, G. M. Fraser, **O. Ben-Bassat**
Rabin Medical Center, The Gastroenterology Dept, Petach Tikva, Israel and others

■ **P189**

Serum neutrophil gelatinase-associated lipocalin (NGAL) correlates with Mayo Clinic score in Ulcerative Colitis but fails to predict activity in Crohn's Disease

A. Budzyńska, E. Nowakowska-Duława, M. Gawron-Kiszka, J. Śpiewak, M. Hartleb
Medical University of Silesia, Dept of Gastroenterology & Hepatology, Katowice, Poland

■ **P190**

Comparison of two endoscopic scores of inflammatory activity in small-bowel Crohn's Disease and its correlation with clinical activity and biomarkers

A. Ponte, R. Pinho, A. Rodrigues, J. Silva, J. Rodrigues, M. Sousa, A.P. Silva, L. Alberto, J. Carvalho
Centro Hospitalar Vila Nova de Gaia/Espinho, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova Gaia, Portugal

■ **P191**

The robotic surgery in the treatment of Crohn's Disease: Our experience

M.V. Marino, G. Salamone, G. Gulotta
University of Palermo, Emergency and General Surgery, Palermo, Italy

■ **P192**

Heartburn in Crohn's Disease is associated with increased disease activity, poor sleep quality and prior ileocecectomy

M.A. Sofia, A.M. Lipowska, E.Y. Perez, N. Zmeter, R.T. Kavitt, D.T. Rubin
The University of Chicago, Department of Medicine - Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States

■ **P193**

Faecal calprotectin differentially predicts postoperative endoscopic recurrence in Crohn's Disease according to therapy. A prospective multicenter study.

C. Verdejo Gil, A.J. Lucendo Villarín, D. Hervías Cruz, Ó. Roncero García-Escribano, A. Bouhmidi, R. Salmoral Luque, T. Angueira, L. Rincón, I. Salueña, R. Lorente Poyatos
Hospital General Universitario de Ciudad Real, Gastroenterology, Ciudad Real, Spain and others

■ **P194**

Anti-TNF α treatment following surgical resection for Crohn's Disease is effective despite previous pharmacodynamic failure

A. Assa, J. Bronsky, K.-L. Kolho, K. Zarubova, T. de-Meij, O. Ledder, M. Sladek, S. van Biervliet, C. Strisciuglio, R. Shamir
Schneider Children's Medical Center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel and others

■ **P195**

The utility of fecal microRNAs in the diagnosis of Inflammatory Bowel Disease

F. Yi

Second affiliated hospital of Nanchang University, Department of Oncology, Nanchang, China

■ **P196**

Patients with UC and concomitant PSC have more subclinical endoscopic and histologic disease activity in the right colon compared to UC patients without PSC

N. Krugliak Cleveland, **D. Rubin**, **K. Meckel**, **A. Tran**, **A. Aelvoet**, **A. Gonsalves**, **J.N. Gaetano**, **K. Williams**, **B. Jabri**, **K. Wroblewski**, **J. Pekow**

University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States and others

■ **P197**

Improved maternal and neonatal outcomes in a clinic dedicated to pregnant patients with Inflammatory Bowel Disease

A.B.-G. Shitrit, **B. Koslowsky**, **D.M. Livovsky**, **E. Goldin**, **B. Mazuz**, **S. Granovsky-Grisaru**

Shaare Zedek Medical Center, Digestive Diseases Institute, Jerusalem, Israel and others

■ **P198**

Dipeptidyl peptidase 4 (DPP-4): A strong predictive marker of disease activity and treatment escalation in Inflammatory Bowel Diseases

P. Pinto-Lopes, **J. Afonso**, **G. Macedo**, **F. Magro**

Faculty of Medicine, University of Porto, Department of Biomedicine – Pharmacology and Therapeutics Unit, Porto, Portugal and others

■ **P199**

PET/MR for evaluating subclinical inflammation of Ulcerative Colitis in remission

S.C. Wei, **I.-L. Shih**, **B.-R. Lin**, **R.-F. Yen**, **Y.-C. Chang**, **J.-M. Wong**

National Taiwan University Hospital and College of Medicine, Department of Internal Medicine, Taipei, Taiwan and others

■ **P200**

Faecal calprotectin as a marker of relapse in Inflammatory Bowel Disease - its place in the management algorithm and cost effectiveness in Poland

P. Petryszyn, **N. Wieckowska**, **A. Trznadel**, **P. Ekk-Cierniakowski**, **A. Staniak**, **R. Dudkowiak**, **P. Piotrowski**

Wroclaw Medical University, Clin Pharmacology, Wroclaw, Poland and others

■ **P201**

Faecal bacterial markers correlate with calprotectin in IBD activity monitoring

J. Amoedo, **M. Serra-Pagès**, **M. Serrano**, **A. Bahí**, **M. Malagón**, **P. Gilabert**, **J. Guardiola**, **D. Busquets**, **J. Garcia-Gil**, **X. Aldeguer**

Universitat de Girona, Microbiologia, Girona, Spain and others

■ **P202**

Diagnosis of Inflammatory Bowel Disease in asymptomatic subjects: Disease characteristics, natural history and treatment requirements

I. Rodríguez-Lago, **O. Merino**, **I. Azagra**, **A. Maiz**, **E. Zapata**, **R. Higuera**, **M. Fernández-Calderón**, **A. Iriarte**, **P. Arreba**, **J. Carrascoa**, **I. Montalvo**, **I. Portillo**, **U. Aguirre**, **J.L. Cabriada**, **IBD Study Group of the Basque - Navarre Society of Gastrointestinal Diseases**,

Hospital de Galdakao, Gastroenterology, Galdakao, Spain and others

■ **P203**

Factors associated with restless legs syndrome in patients with Ulcerative Colitis: A study in a tertiary care center in Romania

R.C. Popa, **A. Savin**, **I. Ungureanu**, **O. Gavrilescu**, **M. Dranga**, **A.M. Chiosa**, **A.O. Jigararu**, **I. Popa**, **C. Mihai**, **C. Cijevschi Prelipcean**

Gastroenterology and Hepatology Institute, Iasi, Romania and others

■ **P204**

Lipid profile in Inflammatory Bowel Disease under maintenance with anti-TNF: A prospective longitudinal cohort study

R. Ferreira, J. Lopez-Diaz, A. Lorenzo, J.E. Dominguez-Munoz, M. Barreiro de Acosta
University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain

■ **P205**

A telemanagement system web in patients with complex Inflammatory Bowel Disease: Design and implementation of a randomised clinical trial

M. Aguas, J. Del Hoyo, D. Muñoz, R. Faubel, A. Barrios, B. Navarro, G. Bastida, B. Valdivieso, P. Nos
La Fe University and Politechnic Hospital, Gastroenterology, Valencia, Spain and others

■ **P206**

Celiac disease and Inflammatory Bowel Disease, a rare association

A. Boutaleb, H. Saoula, M. Aissaoui, D. Hamidouche, Y. Aissat, H. Mahiou, R. Osmane, Y. Zmiri, A. Mitiche, M. Nakmouche, F. Hamchaoui
CHU of Bab El Oued, Gastroenterology, Algiers, Algeria and others

■ **P207**

Prevalence and characteristics of Romanian patients with upper GI tract involvement in Crohn's Disease

A. Dimitriu, S. Ichim, M. Cojocaru, C. Gheorghe, M. Diculescu, R. Iacob, L. Gheorghe
Clinical Institute Fundeni, Department of Digestive Diseases and Liver Transplantation, Bucharest, Romania

■ **P208**

Long term follow up of lymphocytic colitis patients

G. Mohamed, P. Crotty, D. Mc Namara, N. Breslin, B.M. Ryan
Tallaght Hospital and Trinity College Dublin, Gastroenterology, Dublin, Ireland and others

■ **P209**

Long-term effectiveness and safety of vedolizumab in patients with Ulcerative Colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study

E.V. Loftus, J.-F. Colombel, B. Feagan, **S. Vermeire**, W. Sandborn, B. Sands, S. Danese, G. D'Haens, A. Kaser, R. Panaccione, D. Rubin, I. Shafran, S. O'Byrne, P. Geransar, A. James, A. Kaviya, J.M. Khalid
Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, United States and others

■ **P210**

The associations of optimism, social support, and coping strategies with health-related quality of life in a cohort of patients after proctocolectomy with ileal pouch-anal anastomosis

I. Cohen, Y. Benyamini, H. Tulchinsky, I. Dotan
Tel Aviv Sourasky Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Department of Gastroenterology and Liver Diseases, Tel-Aviv, Israel and others

■ **P211**

Differences in therapeutic approaches and outcomes in paediatric and adult onset Crohn's Disease with Perianal fistula (CD-PAF): Comparison of 2 multicentre fistula cohorts

S. Sebastian, C. Black, M.V. Nair, T. Drskova, O. Hradsky, C. Tzivinikos, K. Sahnan, R. Muhammed, D. Devadason, R.S. Parmar, K. Crook, A. Akbar, M. Thomson, D. Pugliese, A. Armuzzi, K.H. Katsanos, D.K. Christodoulou, C. Selinger, G. Maconi, G. Fiorino, U. Kopylov, M.M. Bosca-Watts, K. Karmiris, P. Ellul, S. Ben-Horin, S. Danese, A.L. Hart
Hull & East Yorkshire NHS Trust, Hull, United Kingdom and others

■ **P212**

Location and Kudo pit pattern reflect neoplastic histology of lesions detected at surveillance colonoscopy in Inflammatory Bowel Disease

M. Iacucci, A. Oluseyi, R. Panaccione, X. Gui, S. Urbanski, P. Minoo, G.G. Kaplan, K. Novak, M.W. Lowerison, B.C. Lethebe, Y. Leung, C.H.-T. Seow, S. Ghosh
University of Birmingham, Institute of Translational Medicine, Birmingham, United Kingdom and others

■ **P213**

Agreement between Crohn's Disease endoscopy severity scores derived from live local, delayed local video-recorded and central readings

J. Côté-Daigneault, F. Peerani, K. Katsanos, T. Ullman, J.F. Marion, P. Legnani, B.L. Cohen, J.-F. Colombel
Centre Hospitalier de l'Université de Montréal (CHUM), Medicine department, Montreal, Canada and others

■ **P214**

What is the diagnostic accuracy of faecal calprotectin regarding endoscopic relapse in Crohn's Disease patients following ileocecal resection? A tertiary single center experience

S. Yildirim, N. Demir, S. Bozcan, Y. Erzin, I. Hatemi, A.F. Celik
Istanbul University Cerrahpasa School of Medicine, Gastroenterology, Istanbul, Turkey

■ **P215**

Clinical features of chronic enteropathy associated with *SLCO2A1* gene (CEAS)

J. Umeno, M. Esaki, A. Hirano, T. Hisamatsu, K. Watanabe, F. Hirai, T. Matsui, T. Hibi, T. Kitazono, T. Matsumoto
Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan and others

■ **P216**

Mesenteric disease is directly related to mucosal disease in Crohn's Disease

M.G. Kiernan, S.M. Sahebally, D. Waldron, M. Moloney, M. Skelly, H. Hidayat, D.P. O'Leary, A.J. Lowery, L.G. Walsh, C.P. Dunne, J.C. Coffey
University of Limerick, Graduate Entry Medical School and Centre for Interventions in Infection, Inflammation and Immunity (4i), Limerick, Ireland and others

■ **P217**

The relationship between thiopurine use during pregnancy and anemia in the offspring during the first year of life

A.B.-G. Shitrit, S. Granovsky-Grissar, E. Goldin, B. Koslowsky
Shaare Zedek Medical Center, Digestive Diseases Institute, Jerusalem, Israel and others

■ **P218**

Venous thromboembolism in a Finnish IBD cohort

H. Sairo, **A. Jussila**, P. Collin, H. Huhtala, P. Oksanen
Tampere University, Tampere, Finland and others

■ **P219**

Inflammatory Bowel Disease in children is a challenging diagnosis when overlaps with coeliac disease

A. Zambrano Perez, R. Shergill-Bonner, F. Kiparissi, N. Acton, K. Lindley, N. Shah, M. Baycheva
Great Ormond Street Hospital for Children, Department of Gastroenterology, London, United Kingdom

■ **P220**

Current practices in Ileal Pouch surveillance for Ulcerative Colitis patients in three London IBD referral centres

M. Kabir, **S. Morgan**, M.A. Samaan, K. Forsyth, J.P. Segal, S. Elkady, A.P.Z. Arenaza, K. Kok, E. Seward, R. Vega, S. Di Caro, E. Westcott, S. Mehta, F. Rahman, S. McCartney, S.L. Bloom, M. Northover, A. Darakhshan, A. Williams, S. Anderson, J. Sanderson, A. Hart, P.M. Irving
University College London, Gastroenterology, London, United Kingdom and others

■ **P221**

Natural history of perianal Crohn's Disease in patients with elderly-onset disease: A population-based study

M. Danielou, C. Mamona, M. Barthoulot, B. Pariente, M. Fumery, h. sarter, C. Charpentier, J.-L. Dupas, G. Savoye, C. Gower-Rousseau
CHU Rouen, Department of Gastroenterology and Hepatology, Rouen, France and others

P222
Sequential MRI volume measurements of perianal fistulae in Crohn's Disease

C. Black, A. Razack, S. Sebastian

Hull & East Yorkshire NHS Trust, IBD Unit, Hull, United Kingdom and others

P223
C-reactive protein improvement after vedolizumab induction phase is associated with remission after 6 months of treatment in Ulcerative Colitis patients

P. Zezos, B. Kabakchiev, A.V. Weizman, G.C. Nguyen, N. Narula, K. Croitoru, A.H. Steinhart, M.S. Silverberg
Mount Sinai Hospital, University of Toronto, Division of Gastroenterology, Toronto, Canada and others

P224
Virtual chromoendoscopy with i-Scan as alternative to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic Inflammatory Bowel Disease

A. López-Serrano, J.M. Paredes, A. Polanco, C. García, J. Hervás, C. Amurrio, A. Pascual, M.J. Suárez, M. Barrachina, E. Moreno-Osset

Hospital Universitari Dr. Peset, Gastroenterology Department, Valencia, Spain

P225
Clinical characteristics of patients who have Inflammatory Bowel Disease associated with hyperamylasemia and pancreatitis

K. Kawagishi, K. Yokoyama, K. Kobayashi

Kitasato University School of Medicine, Gastroenterology, Sagamihara, Japan

P226
Comparison of four different immunoassays for measuring golimumab and anti-golimumab antibody concentration in patients with Ulcerative Colitis

S. Paul, G. Duru, A. de Vries, J.C. Marini, D. Aoucheta, F. Cornillie, S. Nancey, I. Detrez, A.-E. Berger, A. Gils, X. Roblin

CHU Saint-Etienne, Immunology Department, Saint-Priest en Jarez, France and others

P227
Outcomes of anti-TNF versus vedolizumab therapy for Ulcerative Colitis: The Leeds experience

M.V. Lenti, A. Johnston, A. O'Connor, C. Selinger, A.C. Ford, P.J. Hamlin

Leeds Gastroenterology Institute, Leeds Teaching hospitals, United Kingdom and others

P228
Prevalence and risk factor of CMV infection among hospitalised patients with Ulcerative Colitis

G.A. Song, D.H. Baek, I.S. Han, S.Y. Han

Pusan National University Hospital, Department of Internal Medicine, Gastroenterology, Busan, South Korea

P229
The modified postoperative endoscopic recurrence score for Crohn's Disease: Does it really make a difference in predicting clinical recurrence?

P. Rivière, S. Vermeire, G. Van Assche, P. Rutgeerts, A. de Buck Van Overstraeten, A. d'Hoore, M. Ferrante
Bordeaux University Hospital, Bordeaux, France and others

P230
Methotrexate in the treatment of Crohn's Disease: A Portuguese real-life single center experience

A. Peixoto, M. Silva, R. Morais, R. Liberal, S. Lopes, F. Magro, G. Macedo

Centro Hospitalar São João, Gastroenterology, Porto, Portugal

P231
Backgrounds and D-dimer on admission are useful factors for predicting venous thromboembolic complications in hospitalised patients with Inflammatory Bowel Disease

Y. Ohta, T. Taida, T. Nakagawa, S. Hamanaka, H. Koseki, K. Okimoto, D. Maruoka, T. Matsumura, M. Arai, T. Katsuno

Chiba University, Department of Gastroenterology and Nephrology, Chiba City, Japan

■ **P232**

Atherosclerosis in Ulcerative Colitis

I.V. Popa, O. Gavrilescu, R.C. Popa, M. Dranga, A. Didita, A.O. Jigaranu, I.O. Ungureanu, C. Mihai, C. Cijevschi-Prelipcean
Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania and others

■ **P233**

Diagnostic delay in a large cohort of patients with Inflammatory Bowel Disease - results of a multicenter study of the Austrian IBD Study Group (ATISG)

G. Novacek, H.P. Gröchenig, T. Waldhör, G. Eckhardt, T. Feichtenschlager, T. Haas, A. Kirchgatterer, R. Koch, O. Ludwiczek, A. Mayer, W. Miehsler, P. Papay, P. Peters, R. Platzer, G. Reicht, P. Steiner, H. Wenzl, H. Fuchssteiner, J. Gartner, H. Vogelsang, C. Dejaco
Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria and others

■ **P234**

Recent trends in microscopic Colitis: Demographics, clinical features and outcomes in a Portuguese cohort

M. Silva, A. Peixoto, S. Lopes, A.C.-R. Nunes, F. Magro, G. Macedo
Centro Hospitalar São João, Department of Gastroenterology, Porto, Portugal

■ **P235**

Endoscopic, clinical, and surgical recurrence of Crohn's Disease: In which direction are we going?

L. Campanati, A. Indriolo, M. Giulii Capponi, G. Panyor, M. Lotti, F. Rubertà, M. Giussani, E. Poiasina, P. Cosimo, L. Ansaloni, P. Ravelli
Papa Giovanni XXIII Hospital, Bergamo, Italy

■ **P236**

Fecal calprotectin as suitable biomarker in evaluation of histological disease activity

T. Knezevic Ivanovski, S. Knezevic Usaj, V. Gligorijevic, S. Markovic, P. Svorcan, M. Nedeljkovic Protic
University Hospital Zvezdara, Gastroenterology and Hepatology, Belgrade, Serbia and others

■ **P237**

Hair mineral and trace element contents as reliable markers of nutritional status compared to serum levels in children with Inflammatory Bowel Disease

H.R. Yang, J.M. Cho
Seoul National University Bundang Hospital, Department of Pediatrics, Seongnam, South Korea and others

■ **P238**

Mental health issues and healthcare utilisation in outpatients with Inflammatory Bowel Disease

T. Lores, C. Goess, C. Hrycek, R. Grafton, J. Hughes, L. Cronin, A. Mikocka-Walus, A. Chur-Hansen, A.L. Burke, K.L. Collins, J.M. Andrews
Royal Adelaide Hospital, Gastroenterology, Adelaide, Australia and others

■ **P239**

A novel user friendly model to identify key predictors of corticosteroid utilisation in newly diagnosed patients with Ulcerative Colitis

D. Patel, Y. Shah, N. Khan
Mercy Catholic, Philadelphia, United States and others

■ **P240**

Presentation and surgical interventions for Crohn's Disease with perianal fistula in the biologics era: Results from a multicentre study

C. Black, D. Pugliese, K. Sahnan, A. Armuzzi, S.M. Elkady, A.L. Hart, K.H. Katsanos, D.K. Christodoulou, C. Selinger, G. Maconi, G. Fiorino, Y. Davidov, U. Kopylov, S. Ben-Horin, P. Navarro, M.M. Bosca-Watts, M. Muscat, P. Ellul, K. Karmiris, V. Allgar, S. Danese, N.S. Fearnhead, **S. Sebastian**
Hull & East Yorkshire NHS Trust, IBD Unit, Hull, United Kingdom and others

■ **P241**

Defining patient-centered outcomes for IBD – an international, cross-disciplinary consensus

A. Kim, C. Roberts, B. Feagan, R. Banerjee, W. Bemelman, K. Bodger, M. Derieppe, A. Dignass, R. Driscoll, R. Fitzpatrick, P. Higgins, P. Kotze, J. Meissner, M. O'Connor, Z.-H. Ran, C. Siegel, H. Terry, W. van Deen, C. van der Woude, A. Weaver, S.-K. Yang, B. Sands, S. Vermeire, S. Travis
Translational Gastroenterology Unit, Oxford, United Kingdom and others

■ **P242**

Phenotypic characterisation of elderly onset Inflammatory Bowel Disease – IBD at the extremes

U. Nosegbe, J.A. Scott, B. Crooks, B. Miller, J. Limdi

The Pennine Acute Hospitals NHS Trust, Manchester UK, Gastroenterology Dept, Bury, United Kingdom and others

■ **P243**

Complications of newly diagnosed Crohn's Disease can be predicted by mathematical modeling of serologic responses

H. Yanai, S. Ben-Shachar, N. Maharshak, Y. Ron, M. Leshno, I. Dotan

Tel Aviv Sourasky Medical Center, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel and others

■ **P244**

Diffusion-weighted MRI enables to accurately grade inflammatory activity in patients of ileocolonic Crohn's Disease: Results from an observational study

R. Mao, X. Li, Z. Li, **M. Chen**

The first affiliated hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China and others

■ **P245**

A systematic review of outcomes reported in studies on Fistulising Perianal Crohn's Disease

K. Sahnan, S.O. Adegbola, P.J. Tozer, B.S.R. Allin, M.J. Lee, N. Heywood, A.G.K. McNair, A.J. Lobo, S.R. Brown, S. Sebastian, R.K. Phillips, P.F. Lung, O.D. Faiz, S. Blackwell, A. Verjee, N.S. Fearnhead, A.L. Hart
St Mark's Hospital, Colorectal Surgery, London, United Kingdom and others

■ **P246**

Risk factors associated with low ovarian reserve in young women of reproductive age with Crohn's Disease

R. Mao, Y. Zhao, Y. He, S. Ben-Horin, **M.-H. Chen**

First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China and others

■ **P247**

Fungal infections in children with Inflammatory Bowel Disease

E. Majorová, I. Šusterová, P. Kolarčík, I. Fandakova, S. Majlingová, K. Gombošová, M. Petrášová

Detská fakultná nemocnica, Paediatric Department, Košice, Slovakia and others

■ **P248**

The new infliximab point-of-care quantitative test can equally be used for therapeutic drug monitoring of biosimilars of infliximab

J. Afonso, F. T. Sousa, I. Rosa, J. Carvalho, C.C. Dias, F. Magro

Faculty of Medicine, University of Porto, Department of Biomedicine, Unit of Pharmacology and Therapeutics, Porto, Portugal and others

■ **P249**

Usefulness of abdominal ultrasonography for patency assessment using the patency capsule

M. Ishii, M. Nasuno, H. Tanaka, S. Motoya, M. Miyakawa, K. Sugiyama, K. Honda, H. Matsumoto, M. Fujita, N. Manabe, J. Hata, A. Shiotani

Kawasaki Medical School, Division of Gastroenterology Department of Internal Medicine, Kurashiki, Japan and others

■ **P250**

DUBLIN (Degree of Ulcerative Colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis

C.R. Rowan, P. Twomey, G. Cullen, J. Sheridan, H. Mulcahy, E. Ryan, G.A. Doherty

St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland and others

■ **P251**

The contribution of clinical and psychosocial factors to fatigue in 182 patients with Inflammatory Bowel Disease: a cross-sectional study

M. Artom, W. Czuber-Dochan, J. Sturt, T. Murrells, C. Norton

King's College London, Florence Nightingale Faculty of Nursing & Midwifery, London, United Kingdom

■ **P252**

Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients Crohn's Disease

K. Oh, E.H. Oh, E.M. Song, G.-U. Kim, M. Seo, S.W. Hwang, S.H. Park, D.-H. Yang, K.-J. Kim, J.-S. Byeon, S.-J. Myung, S.-K. Yang, B.D. Ye

University of Ulsan College of Medicine, Asan Medical Center, Internal Medicine, Seoul, South Korea and others

■ **P253**

Effects of time on urinary metabolic signatures in Inflammatory Bowel Disease

L. Hicks, S. Powles, J. Swann, L. Chong, E. Holmes, H. Williams, T. Orchard

Imperial College Healthcare NHS Trust St. Mary's Hospital, Department of Gastroenterology, London, United Kingdom and others

■ **P254**

Relationship between severe endoscopic lesions and plasmatic and fecal infliximab levels in acute severe Ulcerative Colitis: A case control study

F. Poullenot, D. Nivet, S. Paul, J. Ricard, X. Roblin, D. Laharie

CHU Bordeaux, Department of Gastroenterology, Bordeaux, France and others

■ **P255**

Predictors of negative C-reactive protein in active Crohn's Disease

P. Sousa, **D. Martins**, J. Pinho, E. Cancela, R. Cardoso, R. Araújo, A. Castanheira, A. Silva, P. Ministro

Centro Hospitalar Tondela-Viseu, Gastroenterology, Viseu, Portugal

■ **P256**

Correlation of fecal calprotectin levels with endoscopic severity evaluated with balloon-assisted endoscopy in patients with Crohn's Disease

K. Matsuoka, F. Iwamoto, M. Kimura, K. Takenaka, T. Fujii, M. Nagahori, N. Enomoto, K. Ohtsuka, M. Watanabe

Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan and others

■ **P257**

Evaluation of serum ICAM-1 and VCAM-1 as biomarkers for disease progression in Crohn's Disease

I. Bar Orr, J. Martin de Carpi, J. Amil Dias, A. Levine, F. Nuti, P. Lionetti, J. Escher

E. Wolfson Medical Center, Pediatric Gastroenterology, Holon, Israel and others

■ **P258**

Disease course and operative risk after diagnosis of ileal penetrating Crohn's Disease: A cohort study

P. Bossuyt, C. Debeuckelaere, M. Ferrante, A. de Buck van Overstraeten, T. Billiet, D. Vanbeckevoort, A. Wolthuis, A. D'Hoore, G. Van Assche, S. Vermeire

University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium and others

■ **P259**

The clinical course of UC after orthotopic liver transplantation in context of HLA-DR mismatch

L. Bajer, A. Slavcev, P. Macinga, M. Roder, J. Brezina, P. Trunecka, J. Spicak, P. Drastich

Institute for Clinical and Experimental Medicine, Prague, Czech Republic

■ **P260**

Endoscopic surveillance in Ulcerative Colitis: An Algerian prospective study

H. Saoula, A. Boutaleb, H. Mahiou, K. Belhocine, M. Aissaoui, I. Gamar, D. Hamidouche, A. Mitiche, Y.

Aissat, R. Osmane, Y. Zmiri, N. Bounab, L. Kecili, S. Berkane, T. Boucekkine, Z.c. Amir, M. Nakmouche
CHU of Bab El Oued, Gastroenterology, Algiers, Algeria and others

P261
Grading post-operative recurrence in Crohn's Disease: A comparison between MRE and ileocolonoscopy

A. Lavelle, D. Keegan, K. Byrne, J. Sheridan, H. Mulcahy, G. Cullen, S. Skehan, G.A. Doherty
Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland and others

P262
Evaluation of zinc as a biomarker of a complicated course in paediatric Crohn's Disease

S. Ben Avraham, R. Sigall Boneh, N. Cohen-Dolev, C. Sarbagili-Shabat, A. Levine, S. Hussey, J. Escher, J.M. de Carpi, R.K. Russell, Porto - ECCO GROWTH CD study group
Edith Wolfson Medical Center, PIBD Research Center, Department of Paediatric Gastroenterology and Nutrition Unit, Holon, Israel and others

P263
De-novo Inflammatory Bowel Disease after bariatric surgery: A novel association

M.B. Braga Neto, E. Loftus, D. Bruining, B. Bazerbachi, B. Abu Dayyeh, L. Raffals, P. Deepak
Mayo Clinic, Rochester, United States

P264
Relation of inflamed resection margins to postoperative complications in Crohn's Disease

G. Aaltonen, A. Ristimäki, I. Keränen, M. Carpelan-Holmström, A. Lepistö
Helsinki University Hospital, Colorectal Surgery, Helsinki, Finland and others

P265
Comparison of two faecal calprotectin assays in monitoring children with Inflammatory Bowel Disease

M. Meglicka, M. Szczepanski, J. Bierla, M. Dadalski, B. Cukrowska, J. Kierkus
The Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland and others

P266
Risk factors for colorectal neoplasia in Ulcerative Colitis

H. Saoula, A. Boutaleb, M. Aissaoui, A. Salah, K. Belhocine, I. Gamar, D. Hamidouche, H. Mahiou, Y. Aissat, A. Mitiche, Y. Zmiri, R. Osmane, N. Bounab, L. Kecili, S. Berkane, T. Boucekine, Z.C. Amir, M. Nakmouche
CHU of Bab El Oued, Epidemiology, Algiers, Algeria and others

P267
Candidate serum markers in newly diagnosed Crohn's Disease patients

C. Smids, C. Horjus Talabur Horje, S. Nierkens, J. Drylewicz, M. Groenen, P. Wahab, E. van Lochem
Rijnstate Hospital, IBD Centre, Gastroenterology and Hepatology, Arnhem, Netherlands and others

P268
Faecal calprotectin correlates more highly with endoscopic disease activity than symptom-based disease activity markers in paediatric PSC-IBD

A. Ricciuto, J. Fish, N. Carman, E. Crowley, A. Muike, P. Church, T. Walters, B.M. Kamath, A. Griffiths
Hospital for Sick Children, University of Toronto, Toronto, Canada

P269
Phenotypic predictors of endoscopic recurrence after ileal resection for Crohn's Disease: An NIDDK IBD Genetics Consortium prospective study

K. Boland, T. Haritunians, L.P. Schumm, D. McGovern, S.R. Brant, J.L. Rioux, Y. Sharma, R. Duerr, J. Cho, M. Silverberg
Mount Sinai Hospital, Zane Cohen Center for Digestive Diseases, Toronto, Canada and others

P270
Correlation between endoscopic and histological activity in Ulcerative Colitis using validated indices

N.R. Irani, L.M. Wang, G.S. Collins, S.P.L. Travis
Translational Gastroenterology Unit, Oxford University Hospitals Trust, Oxford, United Kingdom and others

■ **P271**

Complications of primary sclerosing cholangitis in patients with Ulcerative Colitis and normal liver function tests: A prospective magnetic resonance cholangiographic study with long-term follow-up

E.L. Culver, H. Bungay, M. Betts, C. Manganis, O. Buchel, E. Shrumphf, J.F. Cummings, S. Keshav, S.P. Travis, R.W. Chapman
John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, United Kingdom and others

■ **P272**

Faecal calprotectin and magnetic resonance imaging are highly accurate to detect endoscopic postoperative recurrence in Crohn's Disease

P. Baillet, G. Cadiot, M. Goutte, F. Goutorbe, C. Allimant, M. Reymond, H. Obritin, G. Bommelaer, B. Pereira, C. Hordonneau, **A. Buisson**
University Hospital Estaing, Radiology Department, Clermont-Ferrand, France and others

■ **P273**

Prediction of treatment response in Crohn's Disease patients using contrast enhanced ultrasound: A pilot study

P. Zazos, M. Atri, E. Zittan, A. Nazarian, A.H. Steinhart, M.S. Silverberg
Mount Sinai Hospital, University of Toronto, Division of Gastroenterology, Toronto, Canada and others

■ **P274**

Assessing the individual risk of Acute Severe Colitis at diagnosis in a South Asian population

S. Powles, L. Chong, L. Hicks, L. Han, J. Omassoli, H. Williams, T. Orchard
Imperial College Healthcare NHS Trust St. Mary's Hospital, Department of Gastroenterology, London, United Kingdom

■ **P275**

Development and reliability of the new endoscopic virtual chromoendoscopy score: The PICaSSO score (The Paddington International Virtual Chromoendoscopy ScOre) in UC

M. Iacucci, M. Daperno, M. Lazarev, R. Arsenescu, G.E. Tontini, B.C. Lethebe, M.W. Lowerison, X. Gui, V. Villanacci, O. Akinola, M. Goetz, M. Vecchi, H. Neuman, S. Ghosh, R. Bisschops, R. Kiesslich
University of Birmingham, Institute of Translational Medicine, Birmingham, United Kingdom and others

■ **P276**

A snap-shot review of small bowel capsule endoscopy in the setting of Inflammatory Bowel Disease

R. Stack, L. Ridgeway, N. Moran, N. Breslin, B. Ryan, D. Mc Namara
Adelaide & Meath Hospital, Dublin, Incorporating The National Children's Hospital, Department of Gastroenterology, Dublin, Ireland and others

■ **P277**

Comparative accuracy of US versus MRI and colonoscopy in assessing disease activity and complications and influencing the decision-making process in Crohn's Disease

M. Allocca, G. Fiorino, C. Bonifacio, F. Furfaro, S. Radice, D. Gilardi, L. Peyrin-Biroulet, S. Danese
Humanitas Research Hospital, IBD Center, Gastroenterology, Rozzano, Milan, Italy and others

■ **P278**

Short and long-term surgical outcomes and Pouch function following proctocolectomy and pouch formation in Paediatric UC: A multicentre-retrospective cohort study from the Porto IBD working group of ESPGHAN

E. Orlanski Meyer, C. Topf-Olivestone, E. Shtayer, H. Tulchinsky, L.-F. Hansen, A. Kindermann, A. Assa, K.-L. Kolho, S. Kolaček, M.W. Carroll, M. Martinelli, M. Aloï, R. Hansen, H.S. Winter, V.M. Navas-López, B. Weiss, N. Shah, D. Turner
Shaare Zedek Medical Center, The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel and others

■ **P279**

Children born to mothers with Inflammatory Bowel Disease – is there any risk for newborns' complication and development during childhood?

K. Farkas, K. Szántó, N. Vass, D. Szűcs, A. Demcsák, S. Lada, T. Nyári, A. Milassin, M. Rutka, R. Bor, A. Bálint, A. Fábrián, F. Nagy, Z. Szepes, A. Marik, T. Molnár
University of Szeged, 1st Department of Medicine, Szeged, Hungary and others

■ **P280**

Therapeutic drug monitoring of infliximab and adalimumab for detection of patients at risk of loss of response in Inflammatory Bowel Disease

J. Gonzalez-Lopez, J.M. Giráldez-Montero, R. Ferreiro, A. Lorenzo, M.J. Lamas, J.E. Dominguez-Munoz, **M. Barreiro de Acosta**
University Hospital Santiago, Department of Pharmacy, Santiago, Spain and others

■ **P281**

Factors at diagnosis associated with disabling disease course in Crohn's Disease

A. Ponte, R. Pinho, A. Rodrigues, J. Silva, J. Rodrigues, M. Sousa, A.P. Silva, L. Alberto, J. Carvalho
Centro Hospitalar Vila Nova de Gaia/Espinho, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova Gaia, Portugal

■ **P282**

Does colonoscopy alter the post-procedural fecal calprotectin results in Crohn's Disease patients with ileocecal resection?

Y. Erzin, N. Demir, S. Bozcan, S. Yildirim, I. Hatemi, A.F. Celik
Istanbul University Cerrahpasa School of Medicine, Gastroenterology, Istanbul, Turkey

■ **P283**

Quantum blue® adalimumab: Development of the first point of care rapid test for therapeutic drug monitoring of serum adalimumab levels

F.I. Bantleon, S. Kräuchi, T.B. Schuster, M. Schneider, A. Abel
Bühlmann Laboratories AG, Schönenbuch, Switzerland

■ **P284**

Ulcerative Colitis – presentation during pregnancy or puerperium

P. Sousa, **D. Martins**, J. Pinho, E. Cancela, R. Cardoso, R. Araújo, A. Castanheira, A. Silva, P. Ministro
Centro Hospitalar Tondela-Viseu, Gastroenterology, Viseu, Portugal

■ **P285**

Usefulness of a multidisciplinary approach combining both rheumatology and gastroenterology for the assessment and treatment of Inflammatory Bowel Disease patients

E. Perez-Pampin, R. Ferreiro, A. Lorenzo, A. Mera, J.E. Dominguez-Munoz, **M. Barreiro de Acosta**
University Hospital of Santiago de Compostela, Rheumatology, Santiago, Spain and others

■ **P286**

Evaluation of fecal S100A12 in patients with Inflammatory Bowel Disease

F. Yi
Second affiliated hospital of Nanchang University, Department of Oncology, Nanchang, China

■ **P287**

Lipid peroxidation levels and antioxidant status in serum, plasma and saliva of patients with active and inactive Crohn's Disease

K. Szczeklik, W. Krzysciak, R. Domagala-Rodacka, **D. Cibor**, T. Mach, D. Owczarek
Jagiellonian University Medical College, Integrated Dentistry, Cracow, Poland and others

■ **P288**

Treating beyond symptoms in Inflammatory Bowel Disease (IBD): The Kent IBD Nurse Experience with the Steroid assessment tool

G. Scott, W. Lewis, N. Roads
East Kent Hospitals University NHS Foundation Trust, Gastroenterology, Canterbury, United Kingdom and others

■ **P289**

Outcome of endoscopic ally resected dysplastic lesions in Ulcerative Colitis

H. Saoula, A. Boutaleb, H. Mahiou, M. Aissaoui, A. Salah, K. Belhocine, N. Bounab, D. Hamidouche, I. Gamar, Y. Aissat, Y. Zmiri, A. Mitiche, R. Osmane, L. Kecili, S. Berkane, T. Boucekkine, Z.C. Amir, M. Nakmouche
CHU of Bab El Oued, Epidemiology, Algiers, Algeria and others

■ **P290**

Evaluation of patients with retained patency capsule

M. Silva, H. Cardoso, A. Peixoto, M. Marques, A.C.-R. Nunes, S. Lopes, F. Magro, G. Macedo
Centro Hospitalar São João, Department of Gastroenterology, Porto, Portugal

■ **P291**

Proteinase 3-antineutrophil cytoplasmic antibodies (PR3-ANCA) would be a predictive biomarker for the clinical course of Ulcerative Colitis

M. Sono, T. Yoshino, S. Yazumi
Kitano Hospital, Division of Gastroenterology and Hepatology, Digestive Disease Center, Osaka, Japan

■ **P292**

Perianal Disease: Far beyond a simple feature of Crohn's Disease

S. Xavier, T. Gonçalves, F. Castro, J. Magalhães, M. Moreira, J. Cotter
Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal and others

■ **P293**

Histological risk factors to predict clinical relapse in Ulcerative Colitis in mucosal healing

R. Ozaki, T. Kobayashi, E. Saito, T. Toyonaga, S. Okabayashi, S. Umeda, M. Nakano, K. Matsuoka, S. Morinaga, T. Hisamatsu, T. Hibi
Kitasato University Kitasato Institute Hospital, Minato, Japan and others

■ **P294**

Iron-deficiency without anaemia in Crohn's Disease: What are the predictive factors of recovery?

T. Cúrdia Gonçalves, S. Montelro, M. Barbosa, M.J. Moreira, J. Cotter
Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal and others

■ **P295**

Absence of mucosal healing in patients undergoing assessment of mucosal healing with a normal PUCAI score in pediatric Ulcerative Colitis

C. Sarbagili-Shabat, J. Wardi, M. Boaz, A. Levine
Paediatric and Gastroenterology and Nutrition Unit, Wolfson Medical Center, Tel Aviv University, Holon, Israel and others

■ **P296**

Persistent symptoms, CRP elevation and treatment changes over time in Crohn's Disease patients are associated with bowel damage progression as expressed by deterioration of Lémann Index score

P. Zezos, T.P. Chawla, A.V. Weizman, G.C. Nguyen, N. Narula, B. Kabakchiev, R. Milgrom, K. Croitoru, A.H. Steinhart, M.S. Silverberg
Mount Sinai Hospital, University of Toronto, Division of Gastroenterology, Toronto, Canada and others

■ **P297**

Fecal calprotectin accurately predicts symptomatic relapse in children and adolescents with Inflammatory Bowel Disease in clinical remission

K. Diederer, D. Hoekman, A. Leek, V. Wolters, M. Benninga, T. Hummel, T. de Meij, B. Koot, M. Tabbers, M. Benninga, A. Kindermann
Department of Pediatric Gastroenterology and Nutrition, Academic Medical Center, Amsterdam, Netherlands and others

■ **P298**

Comparison between clinical and patient-reported symptoms among Crohn's Disease and Ulcerative Colitis patients

V. Pittet, M.H. Maillard, G. Rogler, P. Michetti
Institute of Social & Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland and others

P299
Identification of a prognostic biomarker able to predict Ulcerative Colitis patients that will not respond to standard therapy

M. Pereira, S. Carvalho, L. Azevedo, A. Albergaria, J. Lima, C. Reis, I. Pedroto, L. Maia, R. Marcos-Pinto, P. Lago, **S. S. Pinho**
 IPATIMUP/i3S, University of Porto, Porto, Portugal and others

P300
Illness perceptions and coping with health-related quality of life in patients with Inflammatory Bowel Disease

I. Cohen, Y. Benyamini, H. Tulchinsky, I. Dotan
 Tel Aviv Sourasky Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Department of Gastroenterology and Liver Diseases, Tel-Aviv, Israel and others

P301
Non-familial small bowel carcinomas in Crohn's Disease: Clinico-pathological, molecular and prognostic features

A. Di Sabatino, A. Vanoli, D. Furlan, P. Giuffrida, C. Klersy, F. Grillo, R. Fiocca, C. Mescoli, M. Ruge, G. Nesi, P. Fociani, G. Sampietro, S. Arduzzone, O. Luinetti, A. Calabrò, F. Tonelli, U. Volta, D. Santini, G. Caio, L. Elli, S. Ferrero, G. Latella, A. Ciardi, G. Solina, A. Rizzo, C. Ciacci, F.P. D'Armiento, M. Salemme, V. Villanacci, R. Cannizzaro, V. Canzonieri, L. Reggiani Bonetti, L. Biancone, G. Monteleone, A. Orlandi, G. Santeusano, M.C. Macciomei, R. D'Inca, V. Perfetti, G. Sandri, M. Silano, A.M. Florena, A.G. Giannone, C. Papi, L. Coppola, P. Usai, A. Maccioni, M. Astegiano, P. Migliora, R. Manca, M. Martino, D. Trapani, R. Cerutti, P. Alberizzi, R. Riboni, F. Sessa, M. Paulli, E. Solcia, G.R. Corazza
 Fondazione IRCCS Policlinico San Matteo, University of Pavia, First Department of Medicine, Pavia, Italy and others

P302
Cytomegalovirus infection in paediatric acute severe Ulcerative Colitis - a multicenter case-controlled study from the Pediatric IBD Porto group of ESPGHAN

S. Cohen, C. Martinez-Vinson, M. Aloï, D. Turner, A. Assa, L. de Ridder, V. M. Wolters, T. de Meij, P. Alvisi, J. Bronskey, U. Kopylov
 "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center, The Pediatric Gastroenterology unit, Tel Aviv, Israel and others

P303
Gastrointestinal infectious agents detected by Biofire FilmArray GI PCR panel stool testing in active Inflammatory Bowel Disease are common and associated with a more benign course of IBD

J. Limsrivilai, R.W. Stidham, S. Govani, A. Waljee, B. Gutermuth, A. Brown, E. Briggs, K. Rao, P.D. Higgins
 Mahidol University, Bangkok, Thailand and others

P304
Zinc levels, interplay with ATG16L1 and disease outcome in Crohn's Disease patients in the Swiss IBD Cohort Study

T. Greuter, Y. Franc, M. Kaelin, A. Schoepfer, B. Misselwitz, S. Vavricka, G. Rogler, L. Biedermann
 University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland and others

P305
Indirect comparison of two novel biologics for the treatment of Crohn's Disease (CD): Network-meta analysis of ustekinumab (UST) vs vedolizumab (VDZ)

G. Hather, R. Curtis, K. Minda, I.A. Zouraq, **J.M. Khalid**
 Takeda Development Center, Stats Innovation, Cambridge, United States and others

P306
What is the impact of perianal disease on anorectal function and quality of life of IBD patients? A prospective observational study

F. Litta, F. Scaldaferrri, A. Parello, T. Zinicola, A. Gasbarrini, C. Ratto
 Catholic University of the Sacred Heart, Proctology Unit, Rome, Italy and others

■ **P307**

Fecal lactoferrin levels are stable during pregnancy

B. Koslowsky, D.M. Livovsky, E. Goldin, A. Bar-Gil Shitrit
Shaare Zedek Medical Center, Gastroenterology, Jerusalem, Israel

■ **P308**

Safety of the given patency capsule in patients with Crohn's Disease or suspected Crohn's Disease

M. Silva, H. Cardoso, A. Peixoto, A.C.-R. Nunes, M. Marques, S. Lopes, F. Magro, G. Macedo
Centro Hospitalar São João, Department of Gastroenterology, Porto, Portugal

■ **P309**

Impact of rapid access MR on clinical decision making and patient management in Crohn's Disease in a tertiary referral center

B.D. Lovasz, L. Gonczl, Z. Kurti, Z. Vegh, P.A. Golovics, G. Rudas, K.B. Gecse, P.L. Lakatos
Semmelweis University, First Department of Medicine, Budapest, Hungary and others

■ **P310**

Development of a new clinico-biological score associated with disease activity in patients with Inflammatory Bowel Disease treated with thiopurine

N. Williet, S. Nancey, A. Boueille, R. Altwegg, G. Cadot, M. Nachury, D. Laharie, J. Filippi, M. Sparrow, S. Nahon, G. Bouguen, P. Aygalenq, S. Viennot, G. Bonnaud, M. Dupin, N. Boukhadra, E. Del Tedesco, X. Roblin
University Hospital of Saint-Etienne, Hepato-gastroenterology, Saint-Priest en Jarez, France and others

■ **P311**

Microscopic inflammation and myenteric plexitis at the margin of resection do not predict endoscopic recurrence in patients with Crohn's Disease after ileocolic resection

K. Boland, J. Stempak, A. Weizman, G. Nguyen, E. Kennedy, H. MacRae, Z. Cohen, K. Croitoru, J. Conner, M. Silverberg
Mount Sinai Hospital, Zane Cohen Center for Digestive Diseases, Toronto, Canada and others

■ **P312**

Trabecular bone score in patients with Inflammatory Bowel Diseases

A. Krajcovicova, T. Hlavaty, Z. Killinger, M. Kuzma, I. Sturdik, Z. Leskova, J. Payer
Comenius University, Faculty of Medicine and University Hospital Bratislava, 5th Department of Internal Medicine, Bratislava, Slovakia

■ **P313**

Glycan antibodies and pANCA in newly diagnosed Inflammatory Bowel Disease patients at presentation and during follow-up

C. Smids, C. Horjus Talabur Horje, M. Groenen, E. van Koolwijk, P. Wahab, E. van Lochem
Rijnstate Hospital, IBD Centre, Gastroenterology and Hepatology, Arnhem, Netherlands and others

■ **P314**

Management of perianal disease in patients with Crohn's Disease

A. Algaba, C. Rubín de Célix, I. Guerra, A. Serrano, E. Pérez-Viejo, C. Aulló, M. Hernández-Tejero, A. Granja, F. Bermejo
Hospital Universitario de Fuenlabrada, Gastroenterology, Fuenlabrada, Spain and others

■ **P315**

Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade

M. Collins, J.-M. Michot, F.-X. Danlos, S. Champiat, C. Mussini, E. Soularue, C. Mateus, D. Loirat, A. Buisson, I. Rosa, O. Lambotte, S. Laghouati, A.-L. Voisin, J.-C. Soria, A. Marabelle, C. Robert, F. Carbonnel
Paris Sud University, Le Kremlin Bicêtre, France and others

■ **P316**

New approaches for IBD management based on text mining of digitalised medical reports and latent class modelling

F. Bergey, E. Saccenti, D. Jonkers, T. van den Heuvel, S. Jeurig, M. Pierik, V. Martins dos Santos
LifeGlimmer GmbH, Berlin, Germany and others

■ **P317**

Postoperative complications, outcome, quality of life and self-image after ileal pouch-anal anastomosis in patients operated due to acute, severe or chronic, therapy refractory Ulcerative Colitis

A. Balint, V. Czinderi, M. Szucs, M. Rutka, K. Farkas, Z. Szepes, F. Nagy, A. Fábíán, R. Bor, A. Milassin, G. Lázár, T. Molnár
University of Szeged, First Department of Medicine, Szeged, Hungary and others

■ **P318**

Accuracy of magnetic resonance enterography for extraluminal complications of Crohn's Disease

G.M. Pecoraro, A. Orlando, L. Tesè, G. Solina, R. Dimitri, F. Mocciano, S. Renna, M. Cottone
ARNAS Civico-Di Cristina-Benfratelli Hospital, Department of Gastroenterology, Palermo, Italy and others

■ **P319**

Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's Disease with fecal calprotectin

J.M. Vázquez-Morón, B. Benítez-Rodríguez, H. Pallarés-Manrique, F. H. Machancoses, J.L. Robles Rodríguez, M. Ramos-Lora, C. Ruíz-Frutos
Hospital General Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain and others

■ **P320**

Utility of a semi-quantitative rapid test in diagnosis of Ulcerative Colitis

M. Dranga, C. Mihai, O. Gavrilescu, I. Ungureanu, B. Cucuteanu, C. Cijevschi Prelepcean
University of Medicine and Pharmacy "Grigore T Popa", Iasi, Romania and others

■ **P321**

Activity graph patterns recorded using a mobile monitoring system are associated with clinical outcomes of patients with Crohn's Disease

E.S. Kim, B.I. Jang, K.O. Kim, E.Y. Kim, H.S. Lee, S.G. Kwak, E.Y. Lee, Y.J. Lee, Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD)
Kyungpook National University School of Medicine, Internal Medicine, Daegu, South Korea and others

■ **P322**

A change in Δ MCV predicts mucosal healing in patients with Crohn's Disease under combination therapy

S. Bernardo, S. Fernandes, L. Correia, J. Velosa
Hospital Santa Maria, CHLN, Department of Gastroenterology and Hepatology, Lisbon, Portugal

■ **P323**

Fatty liver assessment in Inflammatory Bowel Disease patients using controlled attenuation parameter

D.V. Balaban, A. Popp, G. Robu, S. Bucurica, R.S. Costache, P. Nuta, F. Ionita Radu, M. Jinga
"Carol Davila" University of Medicine and Pharmacy, Internal Medicine and Gastroenterology, Bucharest, Romania and others

■ **P324**

Evaluation of ability to predict mucosal healing by quantitative fecal immunochemical test in Ulcerative Colitis

H.W. Kim, G.A. Song, D.H. Kang, C.W. Choi, D.G. Ryu
Pusan National University Yangsan Hospital, Internal medicine, Yangsan, South Korea and others

Clinical: Therapy and observation

■ P325

Combination therapy with adalimumab and immunomodulators decreases incidence of intestinal resection in Crohn's Disease patients previously treated with infliximab: A large, multicentre cohort study

H. Tanaka, N. Kamata, A. Yamada, T. Fujii, K. Endo, T. Yoshino, T. Sugaya, T. Kawaguchi, S. Bamba, M. Ishii, S. Shinzaki, Y. Toya, Y. Yanai, Y. Yokoyama, J. Umeno, T. Okada, T. Kobayashi, M. Nojima, T. Hibi, the ADJUST study group
Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan and others

■ P326

Efficacy of vedolizumab on patient-reported outcomes in Ulcerative Colitis patients: Results from a prospective German observational study

C. Schmidt, C. Langbein, R. Atreya, T. Bruns, A. Dignass, K. Ende, J. Hampe, F. Hartmann, M.F. Neurath, J. Maul, J.C. Preiss, R. Schmelz, B. Siegmund, H. Schulze, N. Teich, U. van Arnim, D.C. Baumgart, A. Stallmach
Jena University Hospital, Department of Gastroenterology, Jena, Germany and others

■ P327

Evolution after a "de-intensification" strategy with anti-TNF therapy in patients with Inflammatory Bowel Disease in clinical remission: Multicenter study

J.M. Benítez, M. Barreiro-de Acosta, M. Chaparro, J.M. Vázquez, E. Iglesias-Flores, J. Tosca, E. García-Planella, S. García-López, C. Taxonera, M. Muñoz-Villafranca, R. Pajares, J. Barrio, L. Arias, O. Nantes, L. Fernández-Salazar, D. Hervías, M. Martín-Arranz, F. Mesonero, I. Moraleja-Yudejo, J. Pineda, F. Argüelles-Arias, J. Huguet, A. Hernández-Martínez, J. Pérez-Calle, E. Leo, O. Merino, M. Van Domselaar, A. Gutiérrez, R. Lorente, M. Castro, A. Algaba, E. Castro, V. Robles-Alonso, D. Ceballos, R. Gómez-García, J. Domínguez, E. Fernández, A. Vega-López, A. Trapero, A. Talavera, V. Royo, J. P. Gisbert, V. García-Sánchez
Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain and others

■ P328

Patient and physician perspectives on managing iron deficiency with or without anaemia in Inflammatory Bowel Disease: Findings from a European online survey

S. Danese, J.P. Gisbert, A.J. Lobo, A. Dignass, L. Peyrin-Biroulet, **M. Kokot**, L. Avedano
Humanitas University, Department of Biomedical Sciences, Milan, Italy and others

■ P329

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with Ulcerative Colitis in a clinical practice setting: Results from INSPIRADA

S. Travis, B. Feagan, L. Peyrin-Biroulet, R. Panaccione, S. Danese, A. Lazar, A. Robinson, R. Thakkar, B. Pappalardo, J. Petersson, M. Bereswill, N. Chen, M. Skup
Oxford University Hospitals, Oxford, United Kingdom and others

■ P330

Discontinuation of corticosteroids among Ulcerative Colitis patients treated with vedolizumab in the United States (US)

H. Patel, B. Chastek, K.D. Null, D. Demuth
Immensity Consulting, Inc., Chicago, United States and others

■ P331

Final results on efficacy and safety of biosimilar infliximab after one-year: Results from a prospective nationwide cohort

K.B. Gecke, Z. Vegh, Z. Kurti, M. Rutka, K. Farkas, P.A. Golovics, B.D. Lovasz, L. Gonczji, J. Banai, L. Bene, B. Gasztonyi, T. Kristof, L. Lakatos, P. Miheller, F. Nagy, K. Palatka, M. Papp, A. Patai, A. Salamon, T. Szamosi, Z. Szepes, G.T. Toth, A. Vincze, T. Molnar, P.L. Lakatos
Simmelweis University, First Department of Medicine, Budapest, Hungary and others

P332

Treat to target in Crohn's Disease: Ultrasonographic response is associated with better outcomes
F. Zorzi, E. Lolli, S. Onali, C. Petruzzello, M.C. Fantini, L. Biancone, G. Monteleone, **E. Calabrese**
Gastroenterology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy

P333

Changing patterns of biological therapy use with the introduction of biosimilars in Inflammatory Bowel Disease (IBD)
K. Mortier, **I. Arnott**, R.K. Russell, UK inflammatory bowel disease (IBD) audit steering group
Royal College of Physicians, London, United Kingdom and others

P334

Medication adherence in diverse inner city paediatric patients with Inflammatory Bowel Disease and comparison to physician perception of adherence
J. Ferreira, S. Thomas, G. Tomer
The Children's Hospital at Montefiore/The University Hospital for Albert Einstein College of Medicine, Pediatric Gastroenterology and Nutrition, Bronx, United States

P335

Prevalence and risk factors for non alcoholic fatty liver disease in Inflammatory Bowel Disease
A. Iannone, G. Losurdo, E. Shahini, F. Albano, R.F. La Fortezza, S.F. Rizzi, A. Contaldo, M. Barone, E. Ierardi, M. Principi, A. Di Leo
University of Bari, DETO, Bari, Italy and others

P336

Safety of anti-TNF treatment in older IBD patients: A systematic review and meta-analysis
S. Waars, N. Dekkers, A. van der Meulen, T. Stijnen, **J. Maljaars**
LUMC, Gastroenterology-Hepatology, Leiden, Netherlands and others

P337

Efficacy of intravenous cyclosporine in fulminant steroid-refractory Ulcerative Colitis with massive bleeding: A retrospective, observational study
T. Ogashiwa, M. Nishio, H. Otake, E. Inoue, H. Kimura, R. Kunisaki
Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan

P338

Value of cross-sectional imaging in assessing active Crohn's Disease before stoma reversal
B. Dirrenberger, I. Clerc-Urmès, A. Germain, L. Bresler, P. Olivera, L. Martelli, C. Baumann, V. Laurent, L. Peyrin-Biroulet
Nancy University Medical Center, Department of Hepatogastroenterology, Nancy, France and others

P339

MadCAM1 expression in intestinal lamina propria endothelium varies among Inflammatory Bowel Disease patients
T. Zamborsky, K. Berakova, B. Kadleckova, D. Podmanicky, **Z. Zelinkova**
St Michael's Hospital, Department of Gastroenterology, Bratislava, Slovakia and others

P340

Prevalence and long-term effect of antiplatelet use in Inflammatory Bowel Disease
A. Mantaka, V. Renieri, I. Koutroubakis
University Hospital of Heraklion, Department of Gastroenterology, Heraklion, Greece

P341

Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active Ulcerative Colitis: A global survey of physicians' practice
S. Ben-Horin, J.M. Andrews, K.H. Katsanos, F. Rieder, F. Steinwurz, K. Karmiris, J.H. Cheon, G.W. Moran, M. Cesarini, C.D. Stone, D. Schwartz, M. Protic, X. Roblin, G. Roda, M. Chen, O. Har-Noy, C. Bernstein
Sheba Medical Center, Tel-Hashomer, Israel and others

■ **P342**

Maladaptive coping, self-efficacy and patient reported outcomes in Inflammatory Bowel Disease

C.-Y. Chao, C. Lemieux, W. Afif, A. Bitton, G. Wild, T. Bessissow

McGill University Health Centre, Department of Gastroenterology, Montréal, Canada and others

■ **P343**

Female gender, somatisation and presence of IBS-type symptoms predicts Dyspareunia in patients with IBD

A. O'Connor, D. Gracie, P.J. Hamlin, C. Selinger, A. Ford

Leeds Gastroenterology Institute, Leeds, United Kingdom and others

■ **P344**

Vitamin D-induced alterations in Cytokine levels lower the risk of clinical relapse in Ulcerative Colitis

J.M. Gubatan, S. Mitsuhashi, M.S. Longhi, T. Zenlea, L. Rosenberg, S. Robson, A. Moss

Beth Israel Deaconess Medical Center, Harvard Medical School, Division of Gastroenterology, Department of Medicine, Boston, United States

■ **P345**

Inconsistency between electronic data of patient's adherence and self reported adherence score

E. Broide, A. Ein Dor, N. Ruhimovich, A. B. Shitrit, F. Benjaminov, S. Matalon, H. Shirin, F.M. Konikoff, T. Naftali

Assaf Harofeh Medical Center, The Kamila Gonczarowski institute of Gastroenterology Assaf Harofeh Medical Center, Zerifin, Israel and others

■ **P346**

Dietary practices and beliefs among parents of children with Inflammatory Bowel Disease: Preliminary results

A. Pituch-Zdanowska, A. Stawicka, E. Jarocka-Cyrta, A. Banaszkiwicz

Medical University of Warsaw, Department of Pediatric Gastroenterology and Nutrition, Warsaw, Poland and others

■ **P347**

Evaluation of step up therapy in patients with early UC: A prospective cohort study

P. Bossuyt, F. Baert, J.-I. Coenegrachts, M. De Vos, O. Dewit, M. Ferrante, F. Fontaine, F. Mana, J. Vandervoort, T. Moreels, Belgian IBD research and development group

University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium and others

■ **P348**

Persistent hyperCKemia during infliximab therapy in patients with Inflammatory Bowel Disease

E. Theodoraki, **E. Orfanoudaki**, K. Foteinogiannopoulou, I. Koutroubakis

University Hospital of Heraklion, Greece, Gastroenterology, Heraklion, Crete, Greece

■ **P349**

The therapies influencing postoperative surgical recurrence in Crohn's Disease

M. Shinozaki

The Institute of Medical Science, The University of Tokyo, Department of Surgery, Tokyo, Japan

■ **P350**

Induction of antiphospholipid antibodies in patients with Inflammatory Bowel Disease treated with antiTNFa agents

V. Robles, C. Herrera deGuise, M.A. Guirola, N. Borruel, F. Casellas

Unitat d'Atenció Crohn-Colitis. Hospital Universitari Vall d'Hebron, Digestive Diseases Research, Barcelona, Spain

■ **P351**

Do self-selected "Non-Transitioned" referrals from paediatric services have lower treatment requirements?

O. Shaikh, **P. Harvey**, R. Cooney, R. Muhammed

University Hospital Birmingham, Gastroenterology, Birmingham, United Kingdom and others

■ **P352**

Assessment of the use of therapeutic drug monitoring of adalimumab during maintenance therapy in children with Inflammatory Bowel Disease

M. Chavannes, F. Gervais, A. Verreault, C. Deslandres, P. Jantchou

Sainte Justine University Hospital, Pediatric Gastroenterology, Montreal, Canada and others

■ **P353**

Long-term safety of adalimumab in patients with Crohn's Disease: Final data from PYRAMID registry

G. D'Haens, W. Reinisch, J. Satsangi, E. Loftus Jr, R. Panaccione, G. Alperovich, J. Kalabic, M. Bereswill, D. Arikian, J. Petersson, A.M. Robinson

Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands and others

■ **P354**

The effect of value based health care delivery for Inflammatory Bowel Diseases on outcomes of patients

A. Zand, E. Aredas, N. Duran, C. DiNicola, P. Lacey, A. Arenas, D.W. Hommes

UCLA Center for Inflammatory Bowel Diseases, Los Angeles, United States

■ **P355**

A structured care pathway improves quality of care for Acute Severe Ulcerative Colitis

B. Neary, G. Doherty, N. Rafter, D. Gibson

St Vincent's University Hospital, Gastroenterology, Dublin, Ireland

■ **P356**

Treatment with anakinra induces T cell production of IL22 and GI mucosal healing in an IL-10RA mutation patient

J. Li, D. Shouval, A. Doty, S. Snapper, **S. Glover**

University of Florida, Gainesville, United States and others

■ **P357**

A multi-institutional report of postoperative outcomes in vedolizumab-treated patients undergoing major abdominal operations for Inflammatory Bowel Disease

A. Lightner, K. Mathis, C. Sang Tse, J. Pemberton, B. Shen, G. Kocklar, A. Singh, D. Parambir, S. Eisenstein, S. Stringfield, D. Hudesman, F. Remzi, E. Loftus

Mayo Clinic, Colon and Rectal Surgery, Rochester, United States and others

■ **P358**

Efficacy of golimumab for the treatment of Ulcerative Colitis patients in clinical practice: A retrospective cohort study

G. Dufour, R. Altwegg, J.-C. Valats, M. Bismuth, N. Funakoshi, F. Gonzalez, L. Caillo, P. Poudroux, P. Blanc, G. Pineton de Chambrun

Montpellier University, Gastroenterology and Hepatology, Montpellier, France and others

■ **P359**

Correlation between physician and patient disease assessments in Ulcerative Colitis: Baseline data from the ICONIC Study of 1816 patients in 33 countries

S. Ghosh, L. Peyrin-Biroulet, T. Sensky, F. Casellas, C. O'Shea, B. Pappalardo

University of Birmingham, Birmingham, Ukraine and others

■ **P360**

Trough levels and antibodies to ustekinumab are not correlated to response to ustekinumab treatment in Crohn's Disease patients

P. Claire, B. Severine, D. Nicolas, N. Maria, D. Pierre, B. Julien, G. Romain, B. Medina, L. Myriam, P. Benjamin

Lille 2, Gastroenterology, Lille, France and others

■ **P361**

Machine learning models at week 6 of vedolizumab therapy for Ulcerative Colitis can predict week 52 corticosteroid free endoscopic remission

A. Waljee, B. Liu, K. Sauder, J. Zhu, S. Govani, R.W. Stidham, **P.D. Higgins**

University of Michigan, Internal Medicine - Gastroenterology, Ann Arbor, United States and others

■ **P362**

Magnetic resonance healing predicts long-term outcomes in patients with Crohn's Disease

S. Raimundo Fernandes, L. Correia, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, J. Velosa
Hospital de Santa Maria, Serviço de Gastrenterologia e Hepatologia, Lisboa, Portugal and others

■ **P363**

The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: The UK TRANSIT study

S. McCartney, J. Lindsay, R. Russell, D. Gaya, I. Shaw, C. Murray, T. Finney-Hayward, S. Sebastian
University College London Hospitals NHS Foundation Trust, London, United Kingdom and others

■ **P364**

A Swedish observational study (SVEAH) on vedolizumab assessing effectiveness and healthcare resource utilization in patients with IBD

C. Eriksson, **S. Rundquist**, B. Lykiardopoulos, P. Karlén, O. Grip, C. Söderman, S. Almer, E. Hertervig, J. Gunnarsson, J. Delin, H. Strid, M. Sjöberg, D. Öberg, SWIBREG SVEAH study group, H. Hjortswang, J. Halfvarson
Örebro University Hospital, Department of Gastroenterology, Örebro, Sweden and others

■ **P365**

Serum adalimumab levels predict successful remission and safe de-intensification in Inflammatory Bowel Disease patients in clinical practice

M. Aguas, V. Bosó, B. Navarro, M.R. Marqués-Miñana, G. Bastida, B. Beltrán, M. Iborra, E. Monte-Boquet, J.L. Poveda-Andrés, P. Nos
La Fe University and Polytechnic Hospital, Gastroenterology, Valencia, Spain and others

■ **P366**

The efficacy of vedolizumab for induction of clinical response and remission in anti-TNF naïve patients with Inflammatory Bowel Disease - a multicenter European real world experience

U. Kopylov, S. Sebastian, Y. Ron, P.R. Steinhagen, X. Roblin, D. Pugliese, A. Bar-Gil Shitrit, K. Katsanos, G. Fiorino, M. Allocca, T. Sipponen, B. Ungar, A. Armuzzi, R. Eliakim, D. Christodoulou, D.C. Baumgart, S. Ben-Horin, I. Dotan
Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel and others

■ **P367**

The availability of infliximab trough levels in IBD patients on maintenance therapy deeply impacts therapeutic decision-making

T. Lobaton, F. Cañete, A. Teniente, E. Cabre, M. Mañosa, E. Martínez, E. Domènech
University Hospital Germans Trias i Pujol, Gastroenterology, Badalona (Barcelona), Spain and others

■ **P368**

Treatment of Inflammatory Bowel Disease in the elderly

L. Roque Ramos, R. Barosa, I. Mocanu, M. Patita, G. Nunes, A.I. Vieira
Hospital Garcia de Orta, Gastroenterology, Almada, Portugal and others

■ **P369**

Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective 51P receptor modulator, after dose escalation in healthy volunteers

L. Peyrin-Biroulet, R. Christopher, L. Trokan, C. Lassen, J. Adams, **T. Kühbacher**
Nancy University Hospital and Lorraine University, Department of Gastroenterology, Nancy, France and others

■ **P370**

A randomised controlled trial of acceptance and commitment therapy (ACT) for the treatment of stress in Inflammatory Bowel Disease (ClinicalTrials.gov Registration No: NCT02350920)

H. Mulcahy, B. Wynne, L. McHugh, C. Rowan, K. Byrne, D. Keegan, K. Hartery, B. Dooley
St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland and others

■ **P371**

Healthcare maintenance in Inflammatory Bowel Disease patients: Need for a top down approach

K. Hazel, M. Forry, S. Patchett, A. O'Toole
Beaumont Hospital, Department of Gastroenterology, Dublin, Ireland

■ **P372**

The long term course of patients undergoing ileal pouch-anal anastomosis for Ulcerative Colitis
F.S. Macaluso, F. Rossi, A. Orlando, C. Sapienza, E. Sinagra, S. Maisano, C. Angelo, S. Renna, C. Linea, L.M. Montalbano, M. Giunta, G. Solina, P. Marchesa, M. Ventimiglia, M. Cottone
Division of Internal Medicine, "Villa Sofia-Cervello" Hospital, Palermo, Italy and others

■ **P373**

Real-life prospective experience with adalimumab in inducing remission in Ulcerative Colitis in Italian primary Inflammatory Bowel Diseases centres
A. Tursi, L. Allegretta, N. Della Valle, W. Elisei, G. Forti, R. Faggiani, R. Lorenzetti, G. Mocci, A. Penna, G. Pranzo, P. Paiano, C. Ricciardelli, S. Gallina, M. Picchio
Azienda Sanitaria Locale BAT, Servizio di Gastroenterologia Territoriale, Andria, Italy and others

■ **P374**

Home or hospital-based analysis of stool calprotectin: Assessing two methods for monitoring Inflammatory Bowel Disease
A. Heida, M. Knol, A. Muller Kobold, G. Dijkstra, P. van Rheenen
University Medical Center Groningen, Pediatric Gastroenterology, Groningen, Netherlands and others

■ **P375**

Intraoperative endoscopy is safe and helps to determine the resection extent in Crohn's Disease
D. Podmanicky, V. Stefanov, D. Harustiakova, J. Kovacs, Z. Zelinkova
St Michael's Hospital, Department of Surgery, Bratislava, Slovakia and others

■ **P376**

Assessment of nutritional status and food related experience of adult Inflammatory Bowel Disease (IBD) inpatients
K. Keetarut, S. Bloom, X. Qu, G. Grimble
University College London Hospital, Nutrition and dietetics, London, United Kingdom and others

■ **P377**

Evaluation of the pharmacokinetic profiles of SB5 and reference adalimumab
D. Shin, J.W. Kang, S. Park, S.Y. Cheong, **E. Hong**
Samsung Bioepis Co.,Ltd, Medical Team, Incheon, South Korea and others

■ **P378**

Renal AA amyloidosis associated with Crohn's Disease
N. Bibani, O. Gharbi, D. Trad, M. Sabbah, A. Ouakaa, D. Gargouri, H. Elloumi, J. Kharrat
Department of Gastroenterology, Hospital of Habib Thameur, Tunis, Tunisia

■ **P379**

Is febuxostat the solution for patients who develop side effects to low dose azathioprine and allopurinol co-therapy?
H. Johnson, K. Wade, C. Hovell, S. Weaver, S. McLaughlin
Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom

■ **P380**

Assessment of the awareness and education of vaccination in our IBD cohort: An observational Study
P. Maheshwari, S.K. Palaniappan, C. Moran, M. Forry, V. Parihar, B. Hall, M. Reilly, A. O'Toole
Beaumont Hospital Dublin, Gastroenterology, Dublin, Ireland

■ **P381**

Adalimumab efficacy and safety by disease duration: analysis of pooled studies of Crohn's Disease
R. Panaccione, P. Rutgeerts, W. Sandborn, S. Schreiber, J.-F. Colombel, S. Berg, J.-F. Maa, J. Petersson, A.M. Robinson
University of Calgary, Department of Medicine, Calgary, Canada and others

■ **P382**

A panel of serum markers for early detection of endoscopic healing with infliximab in patients with Ulcerative Colitis

M. de Bruyn, R. Ringold, M. Ferrante, G. Van Assche, G. Opendakker, A. Dukler, S. Vermeire
Rega Institute for Medical Research, KU Leuven, Department of Microbiology and Immunology, Laboratory of Immunobiology, Leuven, Belgium and others

■ **P383**

Increasing treatment time on REMICADE® (infliximab) predicts subsequent long-term retention in stable infliximab Inflammatory Bowel Disease patients in Canada

J.K. Marshall, A.M. Marrache, E. Ewara
McMaster University Medical Center, Department of Gastroenterology, Hamilton, Canada and others

■ **P384**

Long-term outcome and endoscopic healing rates following long modified side-to-side stricturoplasties

J. Van Stappen, A. de Buck van Overstraeten, M. Ferrante, D. Vanbeckevoort, G. Van Assche, A. D'Hoore, S. Vermeire
University Hospitals Leuven, Gastroenterology, Leuven, Belgium and others

■ **P385**

Assessment of long-term outcomes of patients with Ulcerative Colitis and mucosal healing under different therapies: Is all mucosal healing the same?

S. Raimundo Fernandes, L. Correia, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, J. Velosa
Hospital de Santa Maria, Serviço de Gastreenterologia e Hepatologia, Lisboa, Portugal and others

■ **P386**

A target 6-thioguanine nucleotide ≥ 125 is associated with a higher rate and longer durability of response in infliximab-thiopurine combination therapy: A retrospective study in Crohn's Disease patients

R. Luber, V. Kariyawasam, L. Dawson, S. Munari, P. Gibson, M. Sparrow, M. Ward
The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia and others

■ **P387**

The addition of an immunosuppressant is an effective optimization strategy after loss of response to anti-TNF alpha monotherapy in patients with Inflammatory Bowel Disease: A two-year experience

F.S. Macaluso, C. Sapienza, M. Ventimiglia, S. Renna, G. Rizzuto, R. Orlando, M. Affronti, E. Orlando, M. Cottone, A. Orlando
Division of Internal Medicine, "Villa Sofia-Cervello" Hospital, Palermo, Italy

■ **P388**

Risk of relapse in Ulcerative Colitis patients in clinical remission with combination therapy (anti-TNF and azathioprine) after immunomodulator discontinuation

A. Mihai, M. Dranga, O. Gavrilesco, I. Ungureanu, A. Didita, A.M. Chiosa, A. Savin, I. Popa, R. Popa, A.O. Jigaranu, C. Cijevaschi Prelipcean
University of Medicine and Pharmacy, Gastroenterology, Iasi, Romania

■ **P389**

Low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn's Disease after ileal resection

L. Glick, P.H. Sossenheimer, A. Hirsch, R.D. Hurst, R.D. Cohen, N. Hyman, D.T. Rubin
University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States and others

■ **P390**

Open-label study to evaluate the pharmacokinetics (PK) of fidaxomicin in Inflammatory Bowel Disease patients with Clostridium difficile infection (the PROFILE study): PK analysis

C. Högenauer, Y. Mahida, A. Stallmach, P. Marteau, G. Rydzewska, V. Ivashkin, P. Gargalianos-Kakolyris, I. Michon, N. Adomakoh, **W. Reinisch**
Medical University of Graz, Graz, Austria and others

P391***Differential use of vedolizumab in Ulcerative Colitis and Crohn's Disease. Real life results from 2 tertiary referral centres in the United Kingdom***

N. Kamperidis, A. Cavazza, M. Wahed, N. Arebi
St Mark's Hospital, London, United Kingdom and others

P392***Comparison of dietary nutrient and food additive intake between patients with moderately active Ulcerative Colitis (UC), healthy stool donors and the general Australian population***

S. Costello, C. Mashej, R. Bryant, R. Katsikeros, O. Waters, J. Makanyanga, P. Hughes, M. Conlon, I. Roberts-Thomson, J. Andrews
The Queen Elizabeth Hospital, Gastroenterology, Woodville, Australia and others

P393***Evaluation of pharmacokinetic profiles of SB2 as a biosimilar of reference infliximab***

D. Shin, J.W. Kang, S. Park, Y. Lee, **S. Lee**
Samsung Bioepis Co., Ltd., Incheon, South Korea

P394***Prolonged azathioprine treatment reduces the need for surgery in early Crohn's Disease***

Y. Qiu, R. Mao, S.-H. Zhang, R. Feng, Z.-rR Zeng, M.-H. Chen
The first affiliated hospital of Sun-yat sen University, Gastroenterology, Guangzhou, China and others

P395***Etolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF- α -naïve patients in a post-hoc analysis of the phase 2 Ulcerative Colitis trial (EUCALYPTUS)***

W.J. Sandborn, S. Schreiber, M.T. Tang, A.R. Tatro, **Y.S. Oh**, R. Maciucia
University of California, San Diego, La Jolla, United States and others

P396***Long-term efficacy of thiopurines as maintenance treatment in 130 patients with Ulcerative Colitis***

C. Lefevre, G. Fotsing, M. Wangermez, P. Beau
CHU Poitiers, Poitiers, France

P397***Approach and management of psychological aspects of Inflammatory Bowel Disease described by patients and physicians in Spain. The ENMENTE Project***

I. Marín-Jiménez, A. Panadero, M. Gobbo Montoya, M. Cañas, Y. Modino, J. Guardiola, L. Cea-Calvo, B. Juliá, C. Romero, L. Carmona, M. Barreiro-de Acosta
Hospital Gregorio Marañón, Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato digestivo e Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain and others

P398***An objective measure of response to treatment for patients with Crohn's perianal fistulas on anti-TNF treatment***

K. Sahnan, P.F. Lung, S.O. Adegbola, D. Burling, J. Burn, P.J. Tozer, A. Gupta, O.D. Faiz, R.K. Phillips, A.L. Hart
St Mark's Hospital, Colorectal Surgery, London, United Kingdom and others

P399***Adverse events associated with azathioprine treatment in Korean paediatric Inflammatory Bowel Disease patients***

M. Kim
Inje University College of Medicine, Ilsan Paik Hospital, Pediatrics, Goyang-si, Gyeonggi-do, South Korea

P400***Risk-adjusted use of thiopurines prevented surgical recurrence in patients with Crohn's Disease after intestinal resection***

J. Guo, R. Mao, X. Luo, S. Ben Horin, **M. Chen**
The first affiliated hospital of Sun Yat-Sen University, Department of Radiology, Guangzhou, China and others

■ **P401**

Anti-TNF treatments in Crohn's Disease and improvement in work productivity and quality of life: An observational study from Turkey

M. Törüner, M. Başaranoğlu, Ö. Atug, Ö. Şentürk, F. Akyüz, B. Ünsal, H. Över Hamzaoğlu, F. Tekin, O. Sezgin, H. Akpınar, A.F. Çelik, A. Tezel, H.S. Göktürk, T. Kav
Ankara University School of Medicine, Gastroenterology, Ankara, Turkey and others

■ **P402**

Discontinuation of short-term infliximab maintenance therapy in patients with Crohn's Disease: Outcomes and risk factors associated with relapse

D. Zheng, R. Mao, B. Chen, T. Feng, S. Ben-Horin, **M. Chen**
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China and others

■ **P403**

Golimumab therapy for UC - An Irish multicentre experience

J. O'Connell, C. Rowan, G. Chan, G. Harkin, V. Parihar, J. Layden, S. Patchett, R. Stack, P. MacMathuna, A. O'Toole, B. Ryan, F. MacCarthy, S. McKiernan, G. Doherty, L. Egan, D. Kevans
St James Hospital, Gastroenterology, Dublin, Ireland and others

■ **P404**

Vaccinations and immunisation status in Paediatric Inflammatory Bowel Disease: Data from the VIP IBD study

M. Martinelli, C. Strisciuglio, F.P. Giugliano, V. Urbonas, D. Serban, A. Banaszkiwicz, A. Assa, T. Drskova, I. Hojsak, V.M. Navas Lopez, C. Romano, M. Sladek, M. Aloï, R. Kucinskiene, A. Staiano, E. Miele, ESPGHAN Open IBD Interest Group
University of Naples "Federico II", Translational Medical Science, Section of Pediatrics, Naples, Italy and others

■ **P405**

Toxicity of thiopurines in patients with Inflammatory Bowel Disease: Inventory and predictive factors

A. Labidi, M. Serghini, N. Ben Mustapha, M. Fekih, J. Boubaker, A. Filali
La Rabta University Hospital, Gastroenterology, Tunis, Tunisia

■ **P406**

Clinical correlations of infliximab through levels and antibodies to infliximab in Korean patients with Crohn's Disease

E.H. Oh, D.-H. Ko, H. Seo, K. Chang, G.-U. Kim, E.M. Song, M. Seo, H.-S. Lee, S.W. Hwang, D.-H. Yang, B.D. Ye, J.-S. Byeon, S.-J. Myung, S.-K. Yang, S.H. Park
University of Ulsan College of Medicine, Asan Medical Center, Department of Internal Medicine, Seoul, South Korea and others

■ **P407**

Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naïve patients with moderate to severe Ulcerative Colitis (UC): Experience from a tertiary referral centre

B. Orlandini, G. Dragoni, S. Bagnoli, S. Deiana, G. Macri, **F. Rogai**
Careggi, Gastroenterology, Florence, Italy

■ **P408**

Long-term efficacy of infliximab in patients with Ulcerative Colitis – an observational study from a single center in Norway

F. Lerang, M. Henriksen, L.-P. Jelsness-Jørgensen
Central Hospital of Østfold, Medical, Sarpsborg, Norway

■ **P409**

Mesalamine enemas for induction of remission in Paediatric Ulcerative Colitis refractory to oral Mesalamine: A prospective cohort study

A. Levine, B. Yerushalmi, M. Kori, E. Broide, Y. Mozer-Glassberg, R. Shaoul, K.-L. Kolho, E. Shteyer, H. Shamaly, O. Ledder, S. Cohen, S. Peleg, C. Sarbagili-Shabat, G. Focht, E. Shachmon, M. Boaz, A. On, D. Turner
Paediatric and Gastroenterology and Nutrition Unit, Wolfson Medical Center, Tel Aviv University, Holon, Israel and others

P410
Vedolizumab is safe and effective for IBD, but has no effect on liver biochemistry in patients with concurrent PSC

B. Christensen, D. Micic, P.R. Gibson, S. Singh, E. Bellaguarda, P. Corsello, J.N. Gaetano, J. Kinnucan, V.L. Rao, S. Reddy, A. Yarur, D.T. Rubin, J. Pekow
Alfred Hospital and Monash University, Melbourne, Australia and others

P411
Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in Inflammatory Bowel Diseases

Z. Kurti, M. Rutka, Z. Vegh, L. Gonczi, K. Farkas, B.D. Lovasz, K.B. Gecke, P.A. Golovics, B. Szalay, T. Molnar, P.L. Lakatos
Semmelweis University, First Department of Medicine, Budapest, Hungary and others

P412
The Sicilian network of biological therapy in Inflammatory Bowel Disease: Preliminary data on efficacy

A. Orlando, **F.S. Macaluso**, W. Fries, A.C. Privitera, M. Cappello, S. Siringo, G. Inserra, A. Magnano, R. Di Mitri, N. Belluardo, G. Scarpulla, G. Magri, N. Trovatiello, A. Carroccio, S. Genova, G. Calandrucio, R. Vassallo, C. Romano, S. Pellegrino, M. Citrano, S. Accomando, M. Ventimiglia, S. Renna, R. Orlando, G. Rizzuto, E. Vinci, M. Cottone
Division of Internal Medicine, "Villa Sofia-Cervello" Hospital, Palermo, Italy and others

P413
Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for Crohn's Disease

N. Heerasing, B. Thompson, P. Hendy, G. Heap, G. Walker, R. Bethune, C. Calvert, N. Kennedy, T. Ahmad, J. Goodhand
Royal Devon & Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom and others

P414
Vedolizumab in Paediatric Inflammatory Bowel Diseases: A retrospective multi-center experience from the Paediatric IBD porto group of ESPGHAN

O. Ledder, T. de Meij, J. Martín de Carpi, L. Richmond, S. Cohen, J. Bronsky, R. Shaoul, A. Levine, J. Escher, L. de Ridder, A. Assa, F. Ruemmele, N. Shah, V. Wolters, A. Rodrigues, H. Uhlig, D. Urlep, C. Posovsky, K. Kolho, D. Turner
Shaare Zedek Medical Center, Pediatric Gastroenterology, Jerusalem, Israel and others

P415
Trends in narcotic and corticosteroid prescriptions in patients with Inflammatory Bowel Disease in the United States ambulatory care setting from 2003 to 2011

N. Narula, L. Borges, A.H. Steinhart, J.-F. Colombel
McMaster University, Gastroenterology, Hamilton, Canada and others

P416
Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's Disease and Ulcerative Colitis: The Edinburgh experience

N. Plevis, T.A. Manship, A. Deekae, G.R. Jones, C.L. Noble, J. Satsangi, A.G. Shand, I.D. Arnott, C.W. Lees
NHS Lothian - Western General Hospital, Department of Gastroenterology, Edinburgh, United Kingdom

P417
Non-invasive assessment of liver fibrosis by transient elastography and AST to ALT ratio in patients with Crohn's Disease treated with methotrexate

A. Peixoto, M. Silva, R. Morais, R. Liberal, R. Gonçalves, S. Lopes, G. Macedo
Centro Hospitalar São João, Gastroenterology, Porto, Portugal

P418
Pharmacodynamic (PD) biomarkers demonstrate dose-dependent pharmacological activity of the IL-22Fc fusion protein UTR1147A in healthy volunteers in a phase 1a clinical trial

A. Lekkerkerker, B. Harder, P. Kulkarni, R. Zhao, M. Choi, A. Noyes, A. Polihrom, D. Fillos, J. Rae, D. Danilenko, E. Stefanich, A. Herman, T. Lu
Genentech, Research and Early Development, South San Francisco, United States

■ **P419**

Concentrations of anti-TNF agents in non-inflamed intestinal tissue are associated with the long-term outcome of patients with Crohn's Disease

T. Yoshihara, S. Shinzaki, S. Kawai, S. Iwatani, T. Yamaguchi, M. Araki, S. Hiyama, T. Inoue, Y. Hayashi, K. Watabe, H. Iijima, T. Takehara
Osaka university, Gastroenterology and Hepatology, Suita, Osaka, Japan

■ **P420**

Anti-TNF for post-operative prevention in Crohn's Disease: The detection of anti-drug antibodies at time of surgery is associated with an increased risk of endoscopic recurrence

C. Auzolle, P. Houze, M.-L. Tran-Minh, S. Nancey, A. Buisson, M. Fumery, B. Pariante, F. Djenidi, P. Marteau, Y. Bouhnik, P. Seksik, M. Allez
Saint-Louis Hospital, Department of Gastroenterology, Paris, France and others

■ **P421**

Comparative efficacy and impact on patient-reported outcomes of pharmacological therapies for moderate to severe Ulcerative Colitis: A systematic review and network meta-analysis

P. Paschos, A. Katsoula, **O. Giouleme**, A. Tsapas
Aristotle University, Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Thessaloniki, Greece and others

■ **P422**

Patient-near Infliximab trough-level testing by a novel quantitative rapid test; the Quantum Blue Infliximab assay

A. Roseth, I. Lindsjø, G.-H. Malmstrøm
Lovisenberg Hospital, Medicine, Oslo, Norway and others

■ **P423**

Early improvement in quality of life in patients with luminal Crohn's Disease treated with adalimumab. Data from RAPIDA trial

F. Casellas, M. Barreiro-de Acosta, M. Esteve, L. Castro-Laria, R. Vicente, D. Ceballos, A. Echarri, M.D. Martín-Arnanz, D. Busquets, J. Llaó, M. Navarro-Llavat, J.M. Huguet, F. Argüelles-Arias, J.M. Boudet, L. Rodríguez-San Pedro, G. Díaz, R. Casado, I. Marín
Hospital Universitari Vall Hebron, Barcelona, Spain, Barcelona, Spain and others

■ **P424**

Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with Inflammatory Bowel Disease on maintenance therapy

R.S. Parra, M.R. Feitosa, O. Féres, J.J.R.d. Rocha
University of São Paulo, Surgery and Anatomy, Ribeirão Preto, Brazil

■ **P425**

Biosimilar infliximab in real-life Crohn's Disease treatment in anti-TNF-alfa naïve and non - naïve patients in comparison to biologic originator: A comparative observational cohort study

M. Kaniewska, A. Moniuszko, K. Maciejewska, G. Rydzewska
Central Clinical Hospital of Ministry of Internal Affairs and Administration, Warsaw, Poland, Gastroenterology, Warsaw, Poland and others

■ **P426**

Supra-therapeutic infliximab levels are not associated with a higher risk of infection in IBD patients

T. Greener, B. Kabakchiev, M. Silverberg
Mount Sinai Hospital, Department of Gastroenterology, Toronto, Canada and others

■ **P427**

Neutrophil-to-lymphocyte ration in Ulcerative Colitis predicts sustained response to infliximab

Y. Nishida, S. Hosomi, K. Watanabe, T. Yukawa, K. Otani, Y. Nagami, F. Tanaka, K. Taira, N. Kamata, M. Shiba, H. Yamagami, T. Tanigawa, T. Watanabe, K. Tominaga, Y. Fujiwara
Osaka City University, Gastroenterology, Osaka, Japan and others

■ **P428**

Optimising thiopurines in Crohn's Disease: Low dose and low 6-TGN level are effective for maintenance of remission in Asian population

R. Mao, J. Guo, S. Ben Horin, **M. Chen**

The first affiliated hospital of Sun Yat-Sen University, Department of Radiology, Guangzhou, China and others

■ **P429**

Mucosal healing after 3 months of conventional IBD treatment: Real life data

A. Carlsen, E. Tvedt-Gundersen, K. Isaksen, K.Ø. Leitaø, L.N. Karlsen, R. Omdal, L. Aabakken, T. Grimstad Stavanger University Hospital, Department of Internal Medicine, Stavanger, Norway and others

■ **P430**

EirSwitch echos of NorSwitch: Switching biosimilar therapy in an IBD cohort an Irish experience

S. Nugent, M. Nugent, D. Mullane, C. Kelly

Whitfield Clinic, Gastroenterology, Waterford, Ireland and others

■ **P431**

Colonic Treg levels are reduced in patients with UC achieving clinical remission, but are not differentially affected by etrolizumab dose

F. Fuh, W. Tew, M. Keir, C. Looney, R. Maciuga, J. McBride, **T. Ramirez-Montagut**

Genentech, South San Francisco, United States

■ **P432**

Therapeutic approaches for perianal fistula in paediatric and adolescent onset Crohn's Disease – a multicentre cohort study

S. Sebastian, C. Tzivinikos, T. Drskova, O. Hradsky, M.V. Nair, K. Sahnan, R. Muhammed, D. Devadason, R.S. Parmar, K. Crook, A. Akbar, M. Thomson, A.L. Hart

Hull & East Yorkshire NHS Trust, Hull, United Kingdom and others

■ **P433**

Postsurgical recurrence in Crohn's Disease. Multicenter study in the region of Murcia, Spain of GEMEI group

A.M. García Albert, **R. García-Paredes**, E. Torrella Cortés, T. Martínez-Jimenez, J.M. Angel Rey, I. García-Tercero, J.M. Castillo Espinosa, M. Torregrosa Lloret, S. Chacón Martínez, J. Andreu Plaza, A. Rodríguez Lozano

Reina Sofía-Murcia Hospital, Gastroenterology, Murcia, Spain and others

■ **P434**

Combined Inflammatory Bowel Disease-Obstetric clinics: Outcomes in 95 pregnancies at a tertiary centre over a 3-year period

T.S. Chew, M.S. Carmichael, T.W. Hoare, J. Waugh, M.C. Gunn

Royal Victoria Infirmary, Department of Gastroenterology, Newcastle upon Tyne, United Kingdom and others

■ **P435**

The mean corpuscular volume flow – prognostic value for Inflammatory Bowel Disease under thiopurine treatment

J. Roseira, H. Tavares de Sousa, A. Marreiros, P. Queiros, A.M. Vaz, T. Gago, L. Contente, H. Guerreiro

Algarve Hospital Centre, Gastroenterology, Algarve, Portugal and others

■ **P436**

Secondary loss of response to antiTNF in Inflammatory Bowel Diseases. Therapeutic drug monitoring. Utility in clinical practice

M. Jimenez, M. Sierra-Ausin, N. Cano, P. Suarez, M. Fernandez-Gundin, M. Saez-Villafaña, L. Monteserin, G. Molina, N. Reyes, D. Viso, F. Jorquera

Hospital Universitario de León, Department of Gastroenterology, León, Spain and others

■ **P437**

Autologous hematopoietic stem cell transplantation for refractory Crohn's Disease: Predictive factors of relapse

A. López García, M. Rovira, A. Jauregui Amezaga, P. Marin, R. Barastegui, A. Salas, F. Feu, J. Elizalde, F. Fernández-Avilés, C. Martínez, G. Gutierrez, L. Rosiñol, E. Carreras, A. Urbano, M. Lozano, J. Cid, M. Suárez-Lledó, M.C. Masamunt, D. Comas, A. Giner, M. Gallego, I. Alfaro, I. Ordás, J. Panés, E. Ricart
Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain and others

■ **P438**

Adalimumab dose escalation and de-escalation in UC: Incidence and predictors of success: A real life Belgian cohort study

S. Van de Vondel, F. Baert, C. Reenaers, P. Bossuyt, P. Hindryckx, S. Vanden Branden, L. Amininejad, P. Dewint, J.F. Rahier, M. Ferrante, Belgian IBD research and development group
University Hospitals Leuven, Dept of Gastroenterology, Leuven, Belgium and others

■ **P439**

Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in Inflammatory Bowel Disease

A.A. Thi, S. Bouri, P. Wolfson, L. Owen, A. Abbara, L. John, R. Davidson, A. Hart
St Mark's Hospital, London, United Kingdom and others

■ **P440**

Therapeutic drug monitoring of infliximab for the management of loss of response in Inflammatory Bowel Disease: An observational multicenter study

D. Pugliese, A. Armuzzi, T. Panici Tonucci, B. Tolusso, C. Felice, A. Papa, L. Cantoro, P. Balestrieri, F. Civitelli, L. Bertani, A. Kohn, M. Cicala, F. Viola, F. Costa, G.L. Rapaccini, L. Guidi
Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, UOC Gastroenterologia Presidio Columbus, Rome, Italy and others

■ **P441**

Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's Disease: A prospective open-label study

R. Mao, Y. He, S. Ben-Horin, M.-H. Chen
First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China and others

■ **P442**

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for Inflammatory Bowel Disease: Clinical trial experience

B. Feagan, **F. Bhayat**, J.M. Khalid, W. Palo, A. Blake, M. Shetzline, S. Travis
Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada and others

■ **P443**

Systematic review of internet decision making resources for patients considering surgery for Ulcerative Colitis

D. Baker, J. Marshall, M. Lee, G. Jones, S. Brown, A. Lobo
University of Sheffield Medical School, Sheffield, United Kingdom and others

■ **P444**

Does one size truly fit all? Co-prescription of allopurinol and thiopurine therapy results in variation of TGNs outside the therapeutic range in more than half of patients

E. Johnston, B. Warner, S. Fong, M. Arenas-Hernandez, A. Marinaki, S. Anderson, J. Sanderson, P. Irving
IBD Centre, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom and others

■ **P445**

Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn's Disease undergoing right hemicolectomy with ileocolonic anastomosis

N. Schils, A. de Buck van Overstraeten, S. Vermeire, G. Van Assche, A. Wolthuis, A. D'Hoore, M. Ferrante
University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium and others

■ **P446**

Characterisation of Ulcerative Colitis patients in the Golimumab PURSUIT-Maintenance study: Post-hoc analyses of patients who maintained and did not maintain clinical response through week 54

W.J. Sandborn, P. Rutgeerts, H. Zhang, O.J. Adedokun, S. Xu, R. Shraim, C. Marano
University of California, San Diego, United States and others

■ **P447**

Vedolizumab induces significantly higher endoscopic remission rates at week 16 in Ulcerative Colitis as compared to Crohn's Disease

R.W.M. Pauwels, A.C. De Vries, C.J. Van der Woude
Erasmus MC, Gastroenterology and hepatology, Rotterdam, Netherlands

■ **P448**

Biologic therapy and immunodulators are associated with decreased risk of cardiovascular events in patients with immune-mediated Inflammatory Diseases: A systematic review and meta-analysis

M. Fumery, A. Singh, R. Khera, L. Prokop, J. Curtis, W. Sandborn, S. Singh
Amiens University Hospital, Department of Gastroenterology and Hepatology, Amiens, France and others

■ **P449**

Patient support programme for adalimumab-treated patients with Crohn's Disease in Brazil: Impact on patients' adherence and persistence

V. Teich, R. Arinelli, A. Gulart, L. Chaves, V. Garg, M. Skup
Sense Company, São Paulo, Brazil and others

■ **P450**

Reliability assessment of endoscopic scoring tools using central video review of colonoscopies in paediatric patients with Ulcerative Colitis: Data from the Canadian Children IBD Network

N. Carman, H. Huynh, C.M. Walsh, A. Ricciuto, M. Mouzaki, E. Crowley, P.C. Church, T.D. Walters
The Hospital for Sick Children, University of Toronto, Gastroenterology Department, Toronto, Canada and others

■ **P451**

Compound IBD patient profiles are related to specific information needs - an Israeli national survey

S. Daher, A. Benson, J. Walker, O. Hammerman, T. Khoury, T. Naftali, R. Eliakim, O. Ben-Bassat, C. Bernstein, E. Israeli
Hadassah-Hebrew University Medical Center, Institute of Gastroenterology and liver diseases, Jerusalem, Israel and others

■ **P452**

Silent anaemia predicts treatment change in patients with Crohn's Disease in clinical remission

K. Soufferis, N. Kafalis, A. Katsoula, G. Chatzinakos, N. Grammatikos, O. Giouleme
Ippokraton General Hospital of Thessaloniki, Second Propedeutic Department of Internal Medicine, Thessaloniki, Greece

■ **P453**

Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with Inflammatory Bowel Disease

S. Bernardo, S. Fernandes, A.R. Gonçalves, C. Baldaia, A. Valente, P. Moura Santos, L. Correia, J. Velosa
Hospital Santa Maria, CHLN, Department of Gastroenterology and Hepatology, Lisbon, Portugal

■ **P454**

Can calcineurin inhibitors induce a durable remission that is maintained with vedolizumab in IBD?

O. Kassim, D. Micic, B. Christensen, J. Pekow, A. Sakuraba, S. Dalal, D. Rubin, **R. Cohen**
University of Chicago Medical Center, Department of Gastroenterology, Chicago, United States and others

■ **P455**

Clinical features of tuberculosis infection in Inflammatory Bowel Disease patients on anti-TNF therapy

M. Estévez-Gil, M.L. De Castro, V. Hernández, J.R. Pineda, J. Martínez-Cadilla, S. Pereira, J.-I. Rodríguez-Prada

Hospital Alvaro Cunqueiro. Complejo Hospitalario Universitario de Vigo. Instituto de Investigación Biomédica., Medicine, Vigo, Spain and others

■ **P456**

Comparative analysis of oral versus intravenous iron in patients with Inflammatory Bowel Disease and iron deficiency/anaemia – impact on hospitalisation in Germany

K. Borchert, T. Hardt, J.S. Haas, S.H. Ong, E. Lechat, K. Nip, D. Foerster, S. Braun, J. Stein

Xcenda GmbH, Hannover, Germany and others

■ **P457**

Rapid faecal calprotectin test and symptom index for monitoring the disease activity in colonic IBD

A.-M. Puolanne, K.-L. Kolho, M. Färkkilä

Helsinki University Hospital, Department of Gastroenterology, Helsinki, Finland and others

■ **P458**

Sleep problems in Inflammatory Bowel Disease; when bed becomes a battleground

A. Green, A. Beale, A. Fraser, J. Potokar, C. Durrant, M. Barnes

University of Bristol, Department of Social Medicine, Bristol, United Kingdom and others

■ **P459**

Obesity in patients with an ileoanal Pouch due to Ulcerative Colitis is not associated with an increased risk for pouchitis

T. Pfeffer-Gik, S. Fishman, L. Godny, H. Tulchinsky, I. Dotan

Tel Aviv Sourasky Medical Center, IBD Center Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel and others

■ **P460**

Early use of therapeutic drug monitoring to individualize infliximab therapy in paediatric IBD: A multicentre prospective COHORT Study

E. Crowley, N. Carman, V. Arpino, K. Frost, A. Ricciuto, M. Sherlock, J. Critch, D. Mack, E. Benchimol, K. Jacobson, S. Lawrence, J. deBruyn, W. El-Matary, A. Otley, H. Huynh, P. Church, T. Walters, A. Griffiths
Hospital for Sick Children, Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, Toronto, Canada and others

■ **P461**

Comparison of efficacy of different oral 5-aminosalicylic acid doses for maintenance of remission in Ulcerative Colitis: A systematic review and meta-analysis

C.H. Choi, Y.S. Kim, W. Moon, B.I. Lee, E.S. Kim, Y. Jung, D.I. Park, Y.S. Yoon, H. Lee, D.S. Han

Chung-Ang University College of Medicine, Internal Medicine, Seoul, South Korea and others

■ **P462**

Long-term outcomes of anti-TNF therapy discontinuation in patients with penetrating Crohn's Disease

M. Gompertz, E. Ricart, I. Ordás, I. Alfaro, A. López, M. Gallego, R. Barastegui, A. Giner, A. Vara, M. Masamunt, J. Panés

Hospital Clinic Barcelona, Department of Gastroenterology, Barcelona, Spain

■ **P463**

Recurrence of Crohn's Disease after the first surgical intervention

A. Pontes García, **J.M. Gallardo Valverde**, E. Iglesias Flores, V. García Sanchez, C. Díaz López, J.L. Martínez Dueñas, J. Medina, E. Navarro, E. Torres, J. Gómez Barbadillo

Universidad de Córdoba, Córdoba, Spain and others

■ **P464**

Recurrence of Ulcerative Colitis (UC) during pregnancy in patients who became pregnant during remission

A. Ito, S. Murasugi, H. Kashiwagi, T. Hara, T. Omori, M. Yonezawa, B. Iizuka, K. Tokushige
Tokyo Women's Medical University, Department of Gastroenterology, Tokyo, Japan and others

■ **P465**

Efficacy of Ustekinumab for induction and maintenance of histological healing in patients with Crohn's Disease

K. Li, D. Chan, P. Pollack, D. Jacobstein, C. Brodmerkel, C. Gasink, B.G. Feagan, W. Sandborn, P. Rutgeerts, G. De Hertogh
Janssen Research & Development, LLC, Spring House, United States and others

■ **P466**

Real world effectiveness of vedolizumab over one year in Inflammatory Bowel Disease: A meta-analysis

S. Schreiber, **A. Dignass**, L. Peyrin-Biroulet, G. Hather, D. Demuth, J.M. Khalid, E.V. Loftus
University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany and others

■ **P467**

Maintenance of quality of life improvement in a Phase 3 study of tofacitinib for patients with moderately to severely active Ulcerative Colitis

J. Panés, D.T. Rubin, S. Vermeire, J.O. Lindsay, B.E. Sands, C. Su, G. Friedman, H. Zhang, C. Kayhan, A. Manuchehri, P. Healey
Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain and others

■ **P468**

Etrolizumab treatment improves histological activity as assessed by the Robarts histopathology index

B.G. Feagan, G. De Hertogh, L. Peyrin-Biroulet, D.T. Rubin, R. Maciucu, J. McBride, **U. Arulmani**, A. Scherl
University of Western Ontario, London, Canada and others

■ **P469**

Safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Janus kinase inhibitor TD-1473 after single and multiple oral doses in healthy subjects

B. Ferslew, C. Sherman, D. Nguyen, R. Graham
Theravance Biopharma, Clinical Pharmacology and DMPK, South San Francisco, United States and others

■ **P470**

Comparative effectiveness analysis of flares, hospitalisations, and corticosteroid use among biologic naïve patients with Inflammatory Bowel Disease within 12 months of initiation of vedolizumab or infliximab

N. Alam, M. Raluy-Callado, B. Gardstein, R. Curtis, **J.M. Khalid**
Evidera, London, United Kingdom and others

■ **P471**

Efficacy and safety of switching from reference infliximab to biosimilar infliximab in patients with Inflammatory Bowel Disease: First French experience

P.-A. Soret, C. Prieux-Klotz, J. Avouac, A. Molto, M. Dior, B. Brieau, J. Dreanic, M. Camus, M. Barret, R. Coriat, O. Conort, F. Chast, C. Goulvestre, C. Le Jeunne, M. Dougados, S. Nahon, S. Chaussade, V. Abitbol
Cochin Hospital, Department of Gastroenterology, Paris, France and others

■ **P472**

Original and biosimilar infliximab: Are they two faces of the same coin? The experience from a pioneer European center

T. Cúrdia Gonçalves, S. Monteiro, F. Dias de Castro, M.J. Moreira, J. Cotter
Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal and others

■ **P473**

How to monitor the withdrawal of maintenance treatment with azathioprine in IBD patients with deep remission: Results from a prospective study on multiple non invasive tests

A. Cassinotti, A. Massari, S. Carmagnola, P. Molteni, P. Fociani, S. Ardizzone
ASST Fatebenefratelli Sacco, Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy and others

■ **P474**

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of vedolizumab

C. Berger, J. Semmler, J. Ruppert, H. Schulze, F.-P. Armbruster, A. Dignass, **J. Stein**
Imundiagnostik AG, Bensheim, Germany and others

■ **P475**

Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: A prospective case-control study

G. Fiorino, S. Radice, D. Gilardi, C. Correale, M. Allocca, F. Furfaro, M. Alfieri, D. Nagore, L. Del Rio, J. Pascual, A. Martínez, S. Danese
Humanitas Clinical and Research Center, Department of Gastroenterology, Milan, Italy and others

■ **P476**

Sigmoidostomy or Hartman's procedure during laparoscopic subtotal colectomy for Acute Colitis complicating Inflammatory Bowel Disease? A comparative study in 129 consecutive patients

D. Mege, C. Buskens, L. Maggiori, M. Stellingwerf, W. Bemelman, Y. Panis
Beaujon Hospital, Colorectal Surgery, Clichy, France and others

■ **P477**

Withdrawn

■ **P478**

The current place of probiotics in treatment of pouchitis: Systematic review

L. Lichtenstein, I. Avni, O. Ben-Bassat
Rabin Medical Center, Gastroenterology, Petach Tikva, Israel

■ **P479**

Shifting the shunters in a Paediatric IBD population: Thiopurine dose splitting versus allopurinol and thiopurine co-therapy

S. Chadokufa, M. Baycheva, T. Sawney, N. Acton, S. Sider, N. Shah, B. Huggett, R. Dziubak, F. Kiparrissi
Great Ormond Street Hospital, Gastro, London, United Kingdom and others

■ **P480**

Characteristics of drug-induced lupus 2° to anti-TNF agents in IBD patients and evolution after switch to a second anti-TNF

M. Mañosa, G. Corrales, D. Olivares, M. Vicuña, M. Aguas, D. Busquets, J. Tosca, J. Llaó, F. Mesonero, I. García-Tejero, R. Ferreira, E. Cabre, E. Domènech
Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology, Badalona, Spain and others

■ **P481**

Serum levels of infliximab associate with early mucosal healing in Crohn's Disease: Different "therapeutic window" between post-induction and maintenance treatment

T. Feng, B. Chen, R. Mao, S. Ben-Horin, **M. Chen**
The First Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China and others

■ **P482**

Early anti-TNF/immunomodulator therapy is associated with better clinical outcomes in Asian patients with Crohn's Disease with poor prognostic factors

E.H. Oh, K. Oh, H. Seo, K. Chang, G.-U. Kim, E.M. Song, M. Seo, H.-S. Lee, E.J. Kwon, S.W. Hwang, S.H. Park, D.-H. Yang, K.-J. Kim, J.-S. Byeon, S.-J. Myung, S.-K. Yang, B.D. Ye
University of Ulsan College of Medicine, Asan Medical Center, Department of Internal Medicine, Seoul, South Korea and others

■ **P483**

Relapse after discontinuation of the maintenance drug in patients with Ulcerative proctosigmoiditis: Preliminary result of a prospective randomised trial

H. Choi, T.-G. Gweon, B.-I. Lee, K.-M. Lee, S.-W. Kim, S.-B. Kang, J.-S. Ji, S.-W. Han, M.-G. Choi
The Catholic University of Korea, Internal Medicine, Seoul, South Korea and others

■ **P484**

Dietary therapy using the Crohn's Disease exclusion diet is a successful strategy for induction of remission in children and adults failing biological therapy

R. Sigall Boneh, C. Sarbagili Shabat, M. Boaz, A. Levine, I. Chermesh, S. Ben Avraham, N. Cohen Dolev
Wolfson Medical Center, Pediatric Gastroenterology and Nutrition Unit, Tel Aviv, Israel and others

■ **P485**

Dosing infliximab in Crohn's Disease: Is adjustment for body size justified?

A.-M. Grisic, W. Huisinga, W. Reinisch, C. Kloft

Freie Universitaet Berlin, Department of Clinical Pharmacy and Biochemistry, Berlin, Germany and others

■ **P486**

Immunisation status of children and adolescents with Inflammatory Bowel Disease or autoimmune hepatitis in Germany

L. Cagol, K. Frivolt, A. Krahl, N. Förster, E. Lainka, P. Gerner, D. Ney, J. Vermehren, S. Trenkel, M. Radke, S. Koletzko, **C. Posovszky**

University Medical Center Ulm, Department for Pediatric and Adolescent Medicine, Ulm, Germany and others

■ **P487**

Effectiveness and safety of CT-P13 under routine care in paediatric patients with Inflammatory Bowel Disease

Y.H. Choe, H.R. Yang, J.S. Moon, E. Ryoo, S. Kim, J.H. Lee, H.J. Kim, J.H. Park, M.J. Kim, S.J. Lee, S.Y. Lee

Samsung medical center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Samsung, South Korea and others

■ **P488**

Does Statin use reduce the risk of J-pouch related complications in patients with Inflammatory Bowel Disease?

P. Kaimakliotis, M. Lazarev, T. Bayless, A. Parian, S. Brant, J. Melia, B. Truta

Johns Hopkins, Gastroenterology/Medicine, Baltimore, United States

■ **P489**

Double-dose infliximab therapy in Crohn's Disease: Appropriate time to evaluate the efficacy, long-term efficacy and safety

R. Kunisaki, M. Nishio, T. Ogashiwa, H. Otake, E. Inoue, H. Kimura

Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan

■ **P490**

A pilot study of the electronic patient portal "Patient Knows Best" (PKB) for monitoring biologic therapy in Inflammatory Bowel Disease (IBD)

N. Kamperidis, M. O'Connor, K. Crook, N. Arebi

St Mark's Hospital, London, United Kingdom

■ **P491**

Comparison of the durability of response to subcutaneous anti-TNF therapy between Ulcerative Colitis and Crohn's Disease

G. Mellotte, C. McShane, J. O'Connell, S. Mc Kiernan, F. Mac Carthy, D. Kevans

St James's Hospital, Dublin, Ireland and others

■ **P492**

Cumulative safety signal review confirmed the established safety profile of AsacolTM (mesalazine)

S. Timeus, P. Marchi

Tillotts Pharma, Pharmacovigilance, Rheinfelden, Switzerland and others

■ **P493**

Efficacy of anti-TNF for internal fistula in Crohn's Disease – results from a retrospective multicenter cohort study

T. Kobayashi, A. Hishida, H. Tanaka, S. Bamba, A. Yamada, F. Toshimitsu, S. Shinichiro, N. Kamata, T. Yoshino, T. Hibi, AIM Jr. Internal Fistula Study Group
Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan and others

■ **P494**

Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's Disease with perianal fistula

S. Sebastian, C. Black, D. Pugliese, A. Armuzzi, K. Sahnan, S.M. Elkady, K.H. Katsanos, D.K. Christodoulou, C. Selinger, G. Maconi, G. Fiorino, U. Kopylov, Y. Davidov, M.M. Bosca-Watts, P. Ellul, M. Muscat, K. Karmiris, N.S. Fearnhead, V. Allgar, A.L. Hart, S. Ben-Horin, S. Danese
Hull & East Yorkshire NHS Trust, Hull, United Kingdom and others

■ **P495**

Intensified infliximab rescue therapy for acute severe Ulcerative Colitis does not improve long term colectomy-free survival

A. Al Khoury, **C.-Y. Chao**, A. Aruljothy, J. Wyse, T. Bessissow
McGill University, Gastroenterology, Montreal, Canada and others

■ **P496**

Successful dose de-escalation to adalimumab 40mg every three weeks in patients with Crohn's Disease

M. Ferrante, S. Van Steenberghe, S. Bian, V. Ballet, S. Vermeire, G. Van Assche, A. Gils
University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium and others

■ **P497**

Impacts of mucosal healing on clinical outcomes in patients with refractory Ulcerative Colitis on tacrolimus or biologics

T. Yamamoto, T. Shimoyama, S. Umegae
Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

■ **P498**

Emerging role of the IL-33/ST2 axis in predicting mucosal response to anti-TNF therapy in Ulcerative Colitis

L.R. Lopetuso, V. Petito, C. Graziani, D. Scannone, F. Scaldaferrri, T.T. Pizarro, A. Gasbarrini
Catholic University of the Sacred Heart, Internal Medicine, Gastroenterology Division, Rome, Italy and others

■ **P499**

Sexual dysfunction is frequent among Inflammatory Bowel Disease patients: Results of a prospective study

P. Rivière, C. Zallot, P. Desobry, J.-M. Sabaté, J. Vergniol, F. Zerbib, L. Peyrin-Biroulet, D. Laharie, F. Poullenot
Bordeaux University Hospital, Bordeaux, France and others

■ **P500**

Effectiveness and safety in Crohn's Disease patients who were treated with CT-P13

Y.H. Choe, S.-H. Lee, D.I. Park, J.H. Lee, H.J. Kim, Y.-H. Kim, C.H. Choi, C.S. Eun, S.J. Lee, S. Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea and others

■ **P501**

Baseline characteristics of Crohn's Disease patients in the vedolizumab PASS study: A cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)

C.A. Siegel, G. Lichtenstein, B. Siegmund, J.D. Lewis, D. Wolf, E. Louis, S. Sebastian, X. Hebuterne, A. Bell, C. Söderman, S. Schubert, R. Atreya, S. Polyak, S. Hoque, A. Krummenerl, B. Bokemeyer, T. Krummenerl, S. Shulmann, P. Karlén, B. Moum, P. Dolin
Dartmouth-Hitchcock Medical Center, Department of Gastroenterology, Lebanon, United States and others

■ **P502**

Ulcerative Colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment

P. Zezos, B. Kabakchiev, A.V. Weizman, G.C. Nguyen, N. Narula, K. Croitoru, A.H. Steinhart, M.S. Silverberg
Mount Sinai Hospital, University of Toronto, Division of Gastroenterology, Toronto, Canada and others

■ **P503**

Rapid point-of-care monitoring of anti-infliximab antibodies in patients with Inflammatory Bowel Disease treated with the reference infliximab or CT-P13 in routine clinical practice

A. Ametzazurra, N. Rivera, A.M. Hernández, M.P. Arreba, E. Ruiz, J. Ortiz, M.d.C. Muñoz, N. Torres, J. Pascual, A. Martínez, M.J. Allande, **D. Nagore**
Progenika Biopharma SA, R&D Department, Derio, Spain and others

■ **P504**

Differences between paediatric and adult Inflammatory Bowel Disease presentation – analysis based on the data from multicenter, prospective cohort observational study assessing safety of anti-TNF therapy – Satimos study

J. Siczekowska-Golub, D. Jarzebička, A. Borys-Iwanicka, A. Korlatowicz-Bilar, A. Szaflarska-Popławska, U. Grzybowska-Chlebowczyk, I. Łazowska-Przeorek, U. Daniluk, B. Korczowski, B. Sordyl, M. Szczepanik, P. Landowski, A. Plocek, K. Bąk-Drabik, E. Zagorowicz, J. Kierkus
The Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland and others

■ **P505**

Efficacy of MMX-mesalamine monotherapy for maintenance of remission in UC patients after mucosal healing

J. Lopez-Diaz, R. Ferreira, D. De la Iglesia, A. Lorenzo, J.E. Dominguez-Munoz, **M. Barreiro de Acosta**
University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain

■ **P506**

Psychological factors and quality of life in IBD patients: The psycho study

E. Vegni, D. Gilardi, B.E. Corro, J. Menichetti, D. Leone, M. Allocca, S. Bonovas, F. Furfaro, S. Danese, **G. Fiorino**
University of Milan, Department of Health Sciences, Milan, Italy and others

■ **P507**

Nutrition status in pre-surgical Crohn's Disease, active Crohn's Disease, Crohn's Disease in remission and Ulcerative Colitis in remission: A cross-sectional study

A.M. Sandall, K.V. Patel, D.V. O'Hanlon, S.J. Smith, A. Darakhshan, J.D. Sanderson, M.C. Lomer
King's College London, Diabetes and Nutritional Sciences Division, London, United Kingdom and others

■ **P508**

Association between clinical outcome and post induction CT-P13 trough levels at week 14, in patients with Inflammatory Bowel Disease (IBD). Preliminary results in an observational multicentric study

A. Elosua González, D. Oyón Lara, Ó. Nantes Castillejo, M.Á. Ogueta Fernández, P. Gutiérrez Mendizábal, M.C. Muñoz Villafranca, L. Gómez Irwin, A.I. Muñagorri Santos, I. Rodríguez Lago, C. Rodríguez Gutiérrez, IBD studygroup from the Basque-Navarre Society of Gastrointestinal Diseases
Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain and others

■ **P509**

IBD cancer and serious infections in Europe (I-CARE): A European prospective observational study The I-CARE Study Group

■ **P510**

Assessment of study group - patients with Inflammatory Bowel Disease, treated with monoclonal anti-TNF alpha – a multicenter, prospective cohort observational study, Satimos – preliminary report in paediatric population

D. Jarzebicka, J. Sieczkowska, A. Borys-Iwanicka, A. Korlatowicz-Bilar, A. Szaflarska-Popławska, U. Grzybowska-Chlebowczyk, I. Łazowska-Przeorek, U. Daniluk, B. Korczowski, B. Sordyl, M. Szczepanik, P. Landowski, A. Plocek, K. Bąk-Drabik, E. Zagórowicz, J. Kierkus
The Children's Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland and others

■ **P511**

Baseline characteristics of Ulcerative Colitis patients in the vedolizumab PASS study: A cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01)

D. Wolf, J.D. Lewis, B. Siegmund, G. Lichtenstein, S. Sebastian, C.A. Siegel, E. Louis, T. Haas, K. Nedd, S. Subramanian, H. Aguilar, L. Egan, C. Gasche, G. Doherty, A. Lobo, D. Spearman, A. Patel, R. Moparty, M. Brookes, X. Hebuterne, B. Moum, P. Dolin
Atlanta Gastroenterology Associates, Atlanta, United States and others

■ **P512**

Real world use of adalimumab: Effects on corticosteroid treatment and hospital resource utilisation in UK patients with moderate/severe Ulcerative Colitis

G. Watts, R. Arasaradnam, S. Travis, A. Sharma, A. Awasthi, J. Limdi, A. Bishop-Bailey, S. Mclain-Smith, T. Finney-Hayward
University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom and others

■ **P513**

Managing IBD patients on adalimumab based on trough levels and antibodies

I. Parisi, R. Atherton, S. McCartney, R. Vega, S. Mehta, L. Whitley, M. Kabir, F. Kiparissi, S. Bloom
University College London Hospital, Department of Gastroenterology, London, United Kingdom

■ **P514**

Combination treatment with vedolizumab and anti TNF- α in Inflammatory Bowel Disease; safety data

L. Buer, M.L. Høivik, A.W. Medhus, B. Moum
Oslo University Hospital, Department of Gastroenterology, Oslo, Norway and others

■ **P515**

Evaluation of treatment persistence of vedolizumab among Finnish Inflammatory Bowel Disease (IBD) patients in real-life clinical practice (FINVEDO)

T. Ylisaukko-Oja, **A. Eberl**, J. Aaltonen, H. Nuutinen, T. Blomster, A. Jussila, M. Pajala, J. Jokelainen, S. Herrala, K. Tamminen, T. Sipponen
Takeda Oy, Helsinki, Finland and others

■ **P516**

Adrenal suppression in Inflammatory Bowel Disease patients treated with glucocorticoids: A systematic review

P. Wood, **P. Henderson**, D. Wilson
Royal Hospital For Sick Children, Department of Pediatric Gastroenterology, Edinburgh, United Kingdom and others

■ **P517**

Features of CMV infection (CMVI) in Inflammatory Bowel Disease

P. Makarchuk, E. Belousova, E. Volchkova, E. Kudriavtseva
Moscow Regional Clinical Research Institute, Moscow, Russian Federation

■ **P518**

Remission induction in corticosteroid naïve children and adolescents with Ulcerative Colitis by adsorptive leucocytapheresis as monotherapy or in combination with low dose prednisolone after failure of first-line medications

T. Tanaka, H. Goishi, T. Kajihara, M. Akagi, A. Saniabadi, T. Miura
Akitsu Hospital, Gastroenterology, Hiroshima, Japan and others

P519
Anti-tumour necrosis alpha therapy during pregnancy in patients with Inflammatory Bowel Disease: Safety in women and children

C. Bernardes, R. Loureiro, D. Carvalho, V. Borges, P. Russo, J. Saiote, J. Ramos
Hospital de Sto António dos Capuchos, Gastroenterology, Lisbon, Portugal

P520
Perspective and self-efficacy of adolescents with Inflammatory Bowel Disease post transition to adult care

A. Yadav, M. Forry, A. O'Toole, S. Patchett
Beaumont Hospital Dublin, Gastroenterology, Dublin, Ireland

P521
A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients

H. Schulze, P. Esters, F. Hartmann, J. Stein, C. Christ, M. Zorn, A. Dignass
Agaplesion Markus Hospital, Department of Medicine I, Frankfurt, Germany and others

P522
A multicenter study to validate Magnetic Resonance Enterography against histological assessments of stenotic disease in patients with Crohn's Disease

A. Coimbra, J. Rimola, M. Cuatrecasas, G. De Hertogh, G. Van Assche, R. Vanslebrouck, H. Glerup, A. Hedemann Nielsen, R. Hagemann-Madsen, Y. Bouhnik, M. Zappa, D. Cazals-Hatem, G. D'Haens, J. Stoker, S. Meijer, G. Rogler, A. Boss, A. Weber, R. Zhao, M. Keir, A. Scherl, A. deCrespigny, T. Lu, J. Panes
Genentech, Inc., South San Francisco, United States and others

P523
Association between pharmacokinetics of adalimumab and disease outcome in Japanese patients with biologics naive Crohn's Disease: A subanalysis of DIAMOND trial

S. Motoya, H. Nakase, T. Matsumoto, K. Watanabe, T. Hisamatsu, N. Yoshimura, T. Ishida, S. Kato, T. Nakagawa, M. Nagahori, M. Esaki, T. Matsui, Y. Naito, T. Kanai, Y. Suzuki, M. Nojima, M. Watanabe, T. Hibi, the DIAMOND study group
Sapporo Kosei General Hospital, Inflammatory Bowel Disease Centre, Sapporo, Japan and others

P524
Long-term outcomes after restorative proctocolectomy and ileal pouch-anal anastomosis in children compared to adults

K. Diederer, S. Sahami, M. Tabbers, M. Benninga, A. Kindermann, P. Tanis, M. Oomen, W. Bemelman, J. de Jong
Department of Paediatric Gastroenterology and Nutrition, Academic Medical Center, Amsterdam, Netherlands and others

P525
Effectiveness and safety of vedolizumab (VDZ) in IBD patients: A multicentre experience of 'real world data' from the UK

M.V. Lenti, S. Levison, E. Eliadou, R. Willert, K. Kemp, C. Stansfield, A. Assadsangabi, S. Singh, B. Crooks, S. Tattersall, C. Kenneth, S. Subramanian, C. Probert, P. Smith, E. Liu, J.K. Limdi, P.J. Hamlin, C.P. Selinger
Leeds Teaching Hospitals, Leeds Gastroenterology Institute, Leeds, United Kingdom and others

P526
A prospective 52-Week mucosal healing and deep remission assessment of small bowel and colonic Crohn's Disease as detected by Colon Capsule Endoscopy

S. Oliva, S. Cohen, F. Civitelli, M. Aloï, F. Viola, E. Casciani, F. Maccioni, C. Hassan, P. Papoff, S. Cucchiara
Sapienza - University of Rome, Department of Pediatrics, Pediatric Gastroenterology and Liver Unit, Rome, Italy and others

P527
Infliximab biosimilar switching program overseen by specialist pharmacist saves money, realises investment and optimises therapy

A. St.Clair Jones, M. Smith
Brighton and Sussex University Hospitals NHS Trust, Pharmacy, Brighton, United Kingdom and others

■ **P528**

Long-term outcome of Ulcerative Colitis patients responders to cyclosporine in the biological era
G. Bastida, L. Sargalt, V. Garcia, F. Mesonero, A.M. Braithwaite, A. Montserrat, M.D. Martín, B. Sicilia, D. Olivares, R. Vicente, E. Rodríguez, P. Navarro, T. Lobaton
La Fe University Hospital, Gastroenterology, Valencia, Spain and others

■ **P529**

Impact of stress in Inflammatory Bowel Disease. Effect of a group psychological intervention programme
P. Bernabeu, N. Buades, M. Alonso, C. Van-der Hofstadt, **A. Gutiérrez**, L. Sempere, J. Rodríguez- Marín, R. Jover
Hospital General Universitario Alicante, Psychology Department, Alicante, Spain and others

■ **P530**

Azathioprine in the maintainance of steroid-free remission in Inflammatory Bowel Disease patients: Efficacy and safety in five years of follow-up
C. Cassieri, R. Pica, E.V. Avallone, G. Brandimarte, M. Zippi, P. Crispino, D. De Nitto, G. Lecca, C. Corrado, P. Vernia, P. Paoluzi, E.S. Corazzari
"Sapienza" University, Internal Medicine and Medical Specialties, Rome, Italy and others

■ **P531**

Discontinuation of corticosteroids among Crohn's Disease patients treated with vedolizumab in the United States (US)
H. Patel, B. Chastek, K.D. Null, D. Demuth
Immensity Consulting, Inc., Chicago, United States and others

■ **P532**

Biosimilar infliximab in anti-TNF naive IBD patients – one-year clinical follow-up
M. Kolar, D. Duricova, M. Bortlik, V. Hruha, N. Machkova, K. Mitrova, M. Lukas, K. Malickova, M. Lukas
ISCARE I.V.F. a.s., IBD Clinical and Research Centre, Prague, Czech Republic and others

■ **P533**

Anaemia and iron deficiency in gastroenterology: A Scandinavian prospective, observational study of iron isomaltoiside in clinical practice
S.O. Frigstad, P. Hammarlund, O. Bonderup, T. Rannem, A. Haaber, J. Fallingborg, H. Blom, A. Bajor, P.M. Hellström
Vestre Viken Hospital Trust, Department of Medicine Baerum Hospital, Drammen, Norway and others

■ **P534**

Illness perception in IBD patients: A prospective study
E. Vegni, D. Gilardi, B.E. Corro, J. Menichetti, S. Bonovas, D. Leone, M. Allocca, F. Furfaro, S. Danese, **G. Fiorino**
University of Milan, Department of Health Sciences, Milan, Italy and others

■ **P535**

Outcomes of endoscopic resections of large non-polypoid lesions Inflammatory Bowel Disease: A single United Kingdom centre experience
S. Gulati, A. Emmanuel, M. Burt, B. Hayee, A. Haji
King's College Hospital, King's Institute of Therapeutic Endoscopy, London, United Kingdom

■ **P536**

Combination therapy of bone marrow mesenchymal stromal cells and azathioprine do not affect the clinical course of luminal Crohn's Disease
O. Knyazev, A. Parfenov, N. Fadeeva, A. Konoplyannikov, A. Kagramanova, I. Ruchkina
Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation and others

■ **P537**

Is anti-TNF therapeutic drug monitoring of value in IBD patients in clinical remission?
K. Subramaniam, R. Wathayalage, T. Neeman, P. Pavli
Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia and others

■ **P538**

Can enteral polymeric diet change the post-surgical outcome in Crohn's Disease patients? A pilot study

L. Ceccarelli, M. Franceschi, L. Bertani, C. Nieri, N. de Bortoli, G. Mumolo, G. Laino, E. Albano, G. Tapete, S. Marchi, P. Buccianti, F. Costa
Pisa University Hospital, Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy and others

■ **P539**

Does a change in therapeutic approach modify outcome in IBD patients? A comparison between two cohorts 2004-07 and 2010-2013

A. Viola, C. Ferracane, G. Costantino, A. Alibrandi, G. Inserra, W. Fries
University of Messina, Dept. of Clinical and Experimental Medicine, Messina, Italy and others

■ **P540**

Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for Ulcerative Colitis: An open-label, prospective, multicentre study

T. Yamamoto, T. Tanaka, T. Yokoyama, T. Shimoyama, H. Ikeuchi, M. Uchino, T. Watanabe
Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan and others

■ **P541**

Intestinal failure: A rare but significant outcome of restorative proctocolectomy

J. Segal, S. Oke, S. Clark, A. Hart
St Mark's Hospital, Department of Gastroenterology, Harrow, United Kingdom

■ **P542**

Long-term outcomes after switching from originator infliximab to biosimilar in paediatric-onset Inflammatory Bowel Disease patients: A single centre prospective observational study

B. Kang, K. Lee, Y.H. Choe
Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea

■ **P543**

Structured transition enhances clinical outcome without an increase in healthcare cost in adolescent patients with IBD: The UK TRANSIT Study

S. McCartney, J. Lindsay, R. Russell, D. Gaya, I. Shaw, C. Murray, T. Finney-Hayward, S. Sebastian
University College London Hospitals NHS Foundation Trust, London, United Kingdom and others

■ **P544**

Combination therapy of vedolizumab and a TNF antagonist in IBD patients with severe chronic active, therapy refractory disease course

T. Kuehbacher, R. AbuHashem, N. Langel, S. Schreiber, O. Drvarov
Asklepios Westklinikum Hamburg, Gastroenterology, Hamburg, Germany and others

■ **P545**

Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in Inflammatory Bowel Disease patients in clinical remission: Preliminary results

L.N. Guerrero Puente, E. Iglesias Flores, J.M. Benítez Cantero, M.J. Cárdenas Aranzana, R. Medina Medina, I. Salgueiro Rodríguez, P. Aguilar Melero, B. Manzanares Martin, V. García - Sánchez
Hospital Universitario Reina Sofía, Clinical Unit Of Gastroenterology, Córdoba, Spain and others

■ **P546**

Which are the optimal adalimumab trough levels associated with biological remission in patients with Inflammatory Bowel Disease?

K. Serra, L. Rodríguez-Alonso, N. Padullés, F. Rodríguez-Moranta, C. Arajol, P. Gilibert, R. Rodríguez, J. Bas, F. Morandeira-Rego, E. Santacana, A. Padullés, J. Guardiola
Hospital Universitari de Bellvitge, Department of Gastroenterology, Barcelona, Spain and others

■ **P547**

Is there an association between bariatric surgery and Crohn's Disease?

I. Brcic, A. Todoroff, K. Baumgartner, C. Langner, H.P. Gröchenig
Medical University of Graz, Institute of Pathology, Graz, Austria and others

■ **P548**

Hepatitis B virus reactivation in hepatitis B virus infected patients with Inflammatory Bowel Disease receiving anti-tumor necrosis factor-alpha therapy

J.M. Lee, K.-M. Lee, H.-S. Kim, B.D. Ye, S.J. Park, S.H. Park, J.P. Im, B.I. Jang, D.B. Kim

The Catholic University of Korea, School of Medicine, St. Vincent's Hospital, Suwon, South Korea and others

■ **P549**

Effect of maintenance ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's Disease

B.G. Feagan, C. Gasink, P. Pollack, D. Jacobstein, L.-L. Gao, J. Johanns, Y. Miao, S. Targan, S. Ghosh

Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ont., Canada and others

■ **P550**

Clinical features of demyelination following anti-TNF α therapy

P. Hendy, **N. Heerasing**, G. Walker, G. Heap, C. Bewshae, N. Kennedy, J. Goodhand, R. Martin, J. Hobart, T. Harrower, A. Coles, T. Ahmad

Royal Devon & Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom and others

■ **P551**

Smooth Seton[®] for perianal fistulas: A knot-less solution

M. Stellingwerf, J. de Groof, C. Buskens, W. Nerkens, T. Horemans, W. Bemelman

AMC, Surgery, Amsterdam, Netherlands and others

■ **P552**

An online educational portal improves concerns of Inflammatory Bowel Disease patients regarding pregnancy and medication

R. Sutton, K. Wierstra, L. Ambrosio, L. Dieleman, R.N. Fedorak, B. Halloran, K.I. Kroeker, K. Wong, K.-A. Berga, **V.W. Huang**

University of Alberta, Department of Medicine, Edmonton, Canada and others

■ **P553**

Long-term outcomes of seton drainage for perianal fistulising Crohn's Disease

E. Banayan, K. Zagihyan, **P. Fleshner**

Cedars-Sinai Medical Center, Colorectal Surgery, Los Angeles, United States

■ **P554**

Impact of real world home based remote monitoring on Quality of Care and Quality of Life in IBD patients: One year results of pragmatic randomized trial

A. Atreja, S. Khan, E. Otobo, J. Rogers, T. Ullman, A. Grinspan, S. Itzkowitz, E. Maser, B. Cohen, J.-F. Colombel, B. Sands

Icahn School of Medicine at Mount Sinai, Department of Medicine, New York City, United States

■ **P555**

Systematic review of interventions for chronic abdominal pain management in Inflammatory Bowel Disease

C. Norton, W. Czuber-Dochan, M. Artom, **L. Sweeney**, A. Hart

King's College, Faculty of Nursing and Midwifery, London, United Kingdom and others

■ **P556**

Female Crohn's Disease patients and Ulcerative Colitis patients on biologic therapy are most disabled

P. Spizzo

St Vincent's Hospital Melbourne, Victoria, Australia

■ **P557**

Utility of "trough levels" adalimumab determination in patients with Inflammatory Bowel Disease. Estimation of individual pharmacokinetic parameters (PK) through population pharmacokinetic model

G. Juan, A. Alvaríño, M. Mora, L. Oltra, N. Maroto, I. Ferrer, E. Hinojosa, M.D. Hinojosa, J. Hinojosa

Hospital de Manises, Department of Pharmacy, Manises, Spain and others

■ P558***The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive Ulcerative Colitis***

D.T. Rubin, J. Panés, J.O. Lindsay, S. Vermeire, A. Yarlás, M. Bayliss, J.C. Cappelleri, S. Maher, A.G. Bushmakín, L.A. Chen, A. Manuchehri, P. Healey
The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, United States and others

■ P559***Treatment goals in IBD: A perspective from patients and their partners***

N. Peek-Kuijt, M. Aantjes, M. Verwey, A. van der Meulen-de Jong, P. Maljaars
Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands

■ P560***Trough levels (TLs) at induction: Impact on long term response when re-initiating infliximab***

C. Liefferinckx, C. Minsart, J.-F. Toubeau, A. Cremer, L. Amininejad, E. Quertinmont, J. Deviere, A. Gils, A. Van Gossom, D. Franchimont
Université Libre de Bruxelles, Laboratory of Experimental Gastroenterology, Brussels, Belgium and others

■ P561***Can we predict adherence to treatment in IBD patients?***

T. Naftali, A. Ein Dor, N. Ruhimovich, A. B Shitrit, F. Sklerovsky Benjaminov, S. Matalon, H. Shirin, F.M. Konikoff, E. Broide
Meir medical center, Gastroenterology, Kfar Saba, Israel and others

■ P562***Real-life infliximab trough levels among Inflammatory Bowel Disease patients on maintenance therapy: Should we redefine therapeutic range based on inflammatory load?***

T. Lobaton, F. Cañete, A. Teniente, E. Cabre, M. Mañosa, E. Martínez, E. Domènech
University Hospital Germans Trias i Pujol, Gastroenterology, Badalona (Barcelona), Spain and others

■ P563***Psychotherapy experience and demand for it and their association in Inflammatory Bowel Disease – results from an internet-based survey***

T. Klag, N. Mazurak, L. Fantasia, J. Schwille-Kiuntke, A. Kirschniak, M. Goetz, N. Malek, P. Enck, J. Wehkamp
University Hospital Tuebingen, Internal Medicine I, Tuebingen, Germany and others

■ P564***Low-dose azathioprine improves long-term efficacy of infliximab maintenance treatment in Japanese patients with Crohn's Disease***

M. Nasuno, S. Motoya, K. Sugiyama, M. Miyakawa, H. Tanaka, T. Iida, K. Onodera, H. Nakase
Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan and others

■ P565***Assessments of clinical efficacy and mucosal healing in Ulcerative Colitis patients undergoing Granulomonocytapheresis at different treatment frequencies***

T. Ohmori, S. Ohmori
Ohmori Toshihide Gastrointestinal Clinic, Ageo, Japan

■ P566***Frequency and type of drug-related side effects necessitating drug cessation in the Swiss Inflammatory Bowel Disease cohort***

S. Godat, N. Fournier, E. Safroneeva, A. Marot, P. Deltenre, D. Hahnloser, A. Straumann, S. Vavricka, L. Biedermann, G. Rogler, A. Schoepfer
CHUV - Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology and Hepatology, Lausanne, Switzerland and others

■ **P567**

Cross-sectional study of the low serum concentrations of testosterone in IBD and the influence on disease activity

T. Hlavaty, A. Krajcovicova, J. Kollerova, T. Koller, Z. Leskova, I. Sturdik, J. Payer
Comenius University, Faculty of Medicine and University Hospital Bratislava, 5th Department of Internal Medicine, Bratislava, Slovakia

■ **P568**

Does infliximab therapy increase incidence of tuberculosis in patients with Inflammatory Bowel Disease in an endemic area: A nationwide study from China

L. Ye, J. Liu, Z. Lin, Q. Cao
Inflammatory Bowel Disease Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

■ **P569**

Sequential rescue treatments in steroid refractory Ulcerative Colitis: Two-year follow-up

M. Protic, F. Seibold, C. Manser, P. Frei, C. Mottet, P. Juillerat, T. Knezevic, G. Rogler, C. Beglinger, A. Schoepfer, S. Vavricka
University Hospital Zvezdara, Department of Gastroenterology, Belgrade, Serbia and others

■ **P570**

Current status of the effectiveness of infliximab in patients with Ulcerative Colitis

K. Yokoyama, K. Kawagishi, K. Kobayashi, W. Koizumi
Kitasato University School of Medicine, Department of Gastroenterology, Sagamihara, Japan and others

■ **P571**

Can Crohn's Colitis be cured by surgery?

A. Calafiore, D. Sgambato, F. Rizzello, C. Calabrese, G. Poggioli, S. Laureti, L. Calandrini, M. Mazza, C. Praticò, M. Salice, M. Campieri, P. Gionchetti
University of Bologna, Dept of Clinical and Surgical Sciences - IBD Unit, Bologna, Italy

■ **P572**

Medical therapies for stricturing Crohn's Disease: Efficacy and cross-sectional imaging predictors of therapeutic failure

C. Campos, A. Perrey, C. Lambert, B. Pereira, M. Goutte, F. Goutorbe, A. Dubois, M. Reymond, C. Allimant, M. Dapoigny, G. Bommelaer, C. Hordonneau, **A. Buisson**
University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France and others

■ **P573**

Impact of the duration of combination therapy on clinical and pharmacological efficacy of infliximab in Inflammatory Bowel Diseases

C. Vernet, X. Roblin, N. Williet
CHU, Loire, Saint Etienne, France

■ **P574**

Limitations and difficulties in using anti-TNF alpha agents in Inflammatory Bowel Disease. A survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)

S. Saibeni, C. Bezzio, A. Armuzzi, F. Bossa, E. Calabrese, F. Caprioli, M. Daperno, F. Mocchiari, A. Orlando, C. Papi, A. Rispo, F. Rizzello, IG-IBD
ASST Rhodense, Gastroenterology Unit, Rho, Italy and others

■ **P575**

AZA-related toxicity isn't aggravated by concomitant drugs in IBD patients

A. Ladic, N. Bozina, **S. Cukovic-Cavka**, Z. Krznaric
University Hospital Centre Zagreb, Zagreb, Croatia

■ **P576**

Could the hyperbaric oxygen therapy be an effective adjuvant therapy for fistulising Crohn's Disease?

G. Piotrowicz, J. Kowerzanow, P. Banaszkiwicz, A. Babicki, J. Kot, G. Rydzewska
Self-Dependent Health Care Unit of Ministry of Interior, Gastroenterology, Gdansk, Poland and others

■ **P577**

'Treat to target' recommendations in Ulcerative Colitis (UC) in practice: Clinician perceptions and potential barriers

R. Bryant, S. Costello, S. Schoeman, D. Sathananthan, S. Lau, M. Schoeman, R. Mountifield, D. Tee, S. Travis, J. Andrews
University of Adelaide, School of Medicine, Adelaide, Australia and others

■ **P578**

Evolution of Crohn's Disease treatment in clinical practice: A 25 year single centre cohort study

K. Hartery, C. Moran, J. Sheridan, D. Keegan, K. Byrne, G. Horgan, G. Doherty, G. Cullen, M. Buckley, H. Mulcahy
St.Vincent's University Hospital, Gastroenterology Department, Dublin, Ireland

■ **P579**

Complete disease resolution after allogeneic hematopoietic stem cell transplantation in children with very early onset Inflammatory Disease and no identified monogenic mutation

A. Zambrano Perez, M. Elawad, F. Kiparissi, N. Shah, S. Chadokufa, S. Sider, B. Huggett
Great Ormond Street Hospital for Children, Department of Gastroenterology, London, United Kingdom and others

■ **P580**

Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn's Disease – A multicenter 'real life' study

A. Balint, D. Torocsik, K. Palatka, Z. Szepes, M. Szucs, T. Ferenci, F. Nagy, K. Farkas, A. Fábíán, R. Bor, A. Milassin, M. Rutka, T. Molnar
University of Szeged, First Department of Medicine, Szeged, Hungary and others

■ **P581**

Highly purified eicosapentaenoic acid, as free fatty acid, reduces fecal calprotectin levels and prevents clinical relapse in Ulcerative Colitis patients: A double-blind, randomised, placebo controlled trial

E. Scafoli, A. Sartini, M. Bellanova, M. Campieri, D. Festi, F. Bazzoli, **A. Belluzzi**
S. Orsola Malpighi Hospital-University of Bologna, Department of Medical and Surgical Sciences, Gastroenterology Unit, Bologna, Italy

■ **P582**

The pharmaco-economic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016

S. Han, S. Kim, J. Kim, D.-H. Kwon, J.-S. Choi, S.-R. Yoon, S.-H. Yun, D.-S. Kim, J.-H. Bae, H.-J. Choi, H.-Y. Sung, S.-W. Yoon
Celltrion Healthcare Co., Ltd, Incheon, South Korea

■ **P583**

Trends in endoscopy management after surgery in a national cohort of Spanish Crohn's Disease patients. Results from PRACTICROHN study

M. Barreiro-de Acosta, M. Iborra, V. García, A. Gutiérrez, S. Garcia, E. Domènech, M.D. Martín Arranz, L. Cea-Calvo, C. Romero, B. Juliá
Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain and others

■ **P584**

A role for therapeutic drug-monitoring during infliximab induction treatment in Inflammatory Bowel Disease?

M. Rasmussen, J. Brynskov, M.A. Ainsworth, S. Buhl, K. Bendtzen, C. Steenholdt
Copenhagen University Hospital Herlev, Department of Gastroenterology, Herlev Copenhagen, Denmark and others

■ **P585**

Infliximab (IFX) in moderate to severe Ulcerative Colitis (UC): Comparison between scheduled treatment strategy and bridge strategy

A. Sambuelli, M. Bellicoso, S. Negreira, S. Goncalves, S. Huernos, P. Chavero, P. Tirado, A. Cabanne, A. Gil
Hospital Bonorino Udaondo, IBD Section - Medicine, Buenos Aires, Argentina and others

■ **P586**

A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: The Edinburgh experience

N. Plevris, A. Deekae, G.R. Jones, T.A. Manship, C.L. Noble, J. Satsangi, A.G. Shand, I.D. Arnott, C.W. Lees
NHS Lothian - Western General Hospital, Department of Gastroenterology, Edinburgh, United Kingdom

■ **P587**

Fermentation capacity of gut microbiota in patients with Inflammatory Bowel Disease compared to healthy controls

M. McGowan, M. Kokkorou, M. Rebull, Y. Koh, D.R. Gaya, R. Hansen, R.K. Russell, **K. Gerasimidis**
University of Glasgow, Human Nutrition, Glasgow, United Kingdom and others

■ **P588**

Ustekinumab for the treatment of Crohn's Disease patients with TNF antagonist induced psoriasis. Real life experience from a tertiary referral center through week 54

T. Kuehbacher, R. AbuHashem, N. Langel, S. Schreiber, O. Drvarov
Asklepios Westklinikum Hamburg, Gastroenterology, Hamburg, Germany and others

■ **P589**

Faecal microbiota transplantation for Inflammatory Bowel Disease: A systematic review and meta-analysis

S. Paramsothy, R. Paramsothy, M. Kamm, N. Kaakoush, H. Mitchell, D. Rubin, N. Castaño-Rodríguez
University of New South Wales, St Vincent's Clinical School, Sydney, Australia and others

■ **P590**

Reasons for discontinuation and switch of biologic therapy in IBD: Findings from a large international observational study (03)

S. Sebastian, J.D. Lewis, B. Siegmund, D. Wolf, C.A. Siegel, G. Lichtenstein, E. Louis, X. Hebuterne, P.M. Ginsburg, A. Ostrov, M.Q. Ricci, M. Bernsen, I. Shafran, S. Nancey, G. Moran, N. Teich, S. Lal, M. Kiszka-Kanowitz, S. Murugesan, B. Moum, P. Dolin
Hull Royal Infirmary, Hull & East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom and others

■ **P591**

Therapeutic drug monitoring in Paediatric Inflammatory Bowel Disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approach

S. Chadokufa, S. Sider, B. Huggett, T. Sawney, N. Shah, M. Baycheva, A. Zambrano Perez, N. Acton, F. Kiparissi
Great Ormond Street Hospital, Paediatric Gastroenterology, London, United Kingdom and others

■ **P592**

Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: Results from a prospective nationwide cohort

B.D. Lovasz, Z. Kurti, M. Rutka, Z. Vegh, K.B. Gecse, K. Farkas, J. Banai, L. Bene, P.A. Golovics, L. Gonczi, B. Gasztonyi, T. Kristof, L. Lakatos, P. Miheller, K. Palatka, A. Patai, M. Papp, A. Salamon, T. Szamosi, Z. Szepes, G.T. Toth, A. Vincze, B. Szalay, T. Molnar, P.L. Lakatos
Semmelweis University, First Department of Medicine, Budapest, Hungary and others

■ **P593**

Hospital resource use and cost associated with first-line anti-TNF therapy in patients with IBD in the UK: Comparison of subcutaneous (adalimumab) and intravenous (infliximab) therapies

J. Hickey, S. Keshav, S. Gaugris, **R. Arasaradnam**
pH Associates, Marlow, United Kingdom and others

■ **P594**

Ustekinumab treatment effectiveness in clinical practice – a multicentre retrospective review of long-term outcomes in Crohn's Disease

C.R. Rowan, A. Alakkari, C. Moran, J. O'Connell, G. Cullen, H. Mulcahy, C. O'Morain, D. McNamara, J. Leyden, P. MacMathuna, A. O'Toole, S. Patchett, S. McKiernan, D. Kevans, G.A. Doherty, B. Ryan
St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland and others

■ **P595**

The influence of vitamin D on expression of cytokines mRNA in IBD

Z. Leskova, A. Krajčovičová, K. Šoltys, S. Stuchlík, I. Šturdík, T. Koller, M. Huorka, T. Hlavatý
University hospital Bratislava and Faculty of Medicine Comenius University in Bratislava, Slovakia, 5th
Department of Internal Medicine, Bratislava, Slovakia and others

■ **P596**

FMT in patients with steroid dependant Ulcerative Colitis a single centre observational study

C.S. Grewal, A. Sood, V. Mehta, D. Kaur
Dayanand Medical College & Hospital, Gastroenterology, Ludhiana, India and others

■ **P597**

Ustekinumab use in Crohn's Disease: A tertiary centre experience

A. Greenup, **G. Rosenfeld**, B. Bressler
University of British Columbia, Gastroenterology, Vancouver, Canada

■ **P598**

Mucosal and transmural healing during anti-TNF therapy. Is fecal calprotectin a marker of therapeutic response?

L. Bertani, L. Ceccarelli, N. de Bortoli, E. Albano, G. Tapete, G. Laino, G. Mumolo, A. Ricchiuti, M. Bellini, S. Marchi, F. Costa
University of Pisa, Department of Translational Research and new Technologies in medicine and surgery, Pisa, Italy and others

■ **P599**

Home testing for faecal calprotectin: Follow-up results from the first UK trial

J. Raker, C. Ford, P. Pavlidis, L. Medcalf, L.M. Choong, G. Chung-Faye, P. Dubois, **B. Hayee**
King's College Hospital NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom

■ **P600**

Infliximab trough levels for remission induction and long term therapy management of Inflammatory Bowel Disease

D. Perdigoto, F. Portela, M. Ferreira, S. Mendes, P. Freire, M. Ferreira, S. Lopes, L. Tomé
Coimbra University Hospital Center, Gastroenterology, Coimbra, Portugal

■ **P601**

Can amitriptylin improve the quality of life (QoL) in patients with Crohn's Disease?

A.O. Jigaranu, M. Dranga, O. Gavrilescu, I. Popa, I. Ungureanu, C. Mihai, C. Cijevschi-Prelipcean
University of Medicine and Pharmacy Gr. T. Popa, IASI, Gastroenterology, Iasi, Romania

■ **P602**

Clinical/biochemical predictors of response to anti-TNFa therapies in a tertiary referral centre

D. Tighe, N. Breslin, B. Ryan, D. McNamara
AMNCH Tallaght/School of Medicine, Trinity College Dublin, Gastroenterology, Dublin, Ireland and others

■ **P603**

Hospitalisation risk and reintervention after ileocolonic resection with anastomosis in patients with Crohn's Disease. Results from the PRACTICROHN study

V. García, M. Calvo, M.D. Martín Arranz, M. Rivero, E. Domènech, M. Barreiro-de Acosta, E. García Planella, A. Gutiérrez, C. Romero, L. Cea-Calvo, B. Juliá
Hospital Universitario Reina Sofía, Unidad Clínica de Aparato Digestivo, Cordoba, Spain and others

■ **P604**

Usefulness of stool hemoglobin and fecal calprotectin for detecting of Mild to Moderate UC

J.S. Koo, D.J. Kim, D.-W. Lee, Y.J. Jeon
Korea University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul, South Korea

■ **P605**

Rapid detection of anti-infliximab antibodies in Inflammatory Bowel Disease patients treated with the reference biologic or the biosimilar CT-P13: Performance comparison with ELISA

G. Fiorino, A. Ametzazurra, **D. Nagore**, A.M. Hernández, N. Torres, S. Radice, D. Gilardi, C. Correale, M. Allocca, F. Furfaro, M. Alfieri, J. Pascual, X. Recalde, A. Martínez, S. Danese
Humanitas Clinical and Research Center, Department of Gastroenterology, Milan, Italy and others

■ **P606**

Intestinal fatty acid binding protein (I-FABP) parallels temporal changes in Harvey-Bradshaw Index and TNFa in response to infliximab in Crohn's Disease

P.M. Hellström, K.A. Al-Saffar, H. Tartera Diaz, G.V. Ram, D.-L. Webb
Uppsala University, Medical Sciences, Uppsala, Sweden

■ **P607**

Post-operative mortality and predictive factors in a cohort of severe refractory Ulcerative Colitis patients from the ENEIDA Registry (1989-2013): A multicenter nationwide study

I. Ordas, E. Domenech, M. Aguas, F. Fernandez-Bañares, S. García, M. Peñalva, C. Muñoz, V. García-Sánchez, J. Llaó, C.E. Jiménez, Ó. Merino, F. Gomollón, M. Piqueras, M. Vera, L. Márquez, M. De Castro, A. Gutiérrez, J.L. Cabriada, N. Alcaide, X. Calvet, M.A. Montoro, L. Arias, J. Panés, M. Esteve
Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain and others

■ **P608**

New anti-migration extractible metal stents for Crohn's Disease strictures: A nationwide GETAID-SFED cohort study

A. Attar, J. Branche, E. Coron, J. Privat, L. Caillo, J.-B. Chevaux, L. Vuitton, A. Amiot, H. Belkhdja, A. Buisson, X. Dray, L. Jerber, T. Ponchon, Y. Bouhnik, L. Peyrin-Biroulet
Hopital Beaujon, Gastro-entérologie - MICI- Assistance Nutritive, Clichy la Garenne, France and others

■ **P609**

A treat-to-target approach via a virtual clinic amongst Inflammatory Bowel Disease patients with secondary loss of response to anti-TNF therapy improves clinical outcomes

R. Little, K. Taylor, A. Friedman, B. Headon, P. Gibson, M. Sparrow, M. Ward
Alfred Health and Monash University, Gastroenterology, Melbourne, Australia

■ **P610**

Efficacy and safety of GLPG1205, a GPR84 antagonist, in Ulcerative Colitis: Multi-centre proof-of-concept study

S. Vermeire, W. Reinisch, D. Wasko-Czopnik, T. Van Kaem, J. Desrivot, F. Vanhoutte, J. Beetens
University Hospital Leuven, Gastroenterology, Leuven, Belgium and others

■ **P611**

Relapse risk and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy

S. Bots, S. Kuin, C. Ponsioen, G. van den Brink, M. Löwenberg, G. D'Haens
Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands

■ **P612**

Exclusive enteral nutrition in adults with active Crohn's Disease is associated with decreased disease activity

T. Pfeffer-Gik, H. Yanai, L. Godny, Y. Ron, N. Maharshak, I. Dotan
Tel Aviv Sourasky Medical Center, IBD Center Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel

■ **P613**

Mycophenolate mofetil is a valid option in patients with Inflammatory Bowel Disease resistant to TNF-alpha inhibitors and conventional immunosuppressants

F.S. Macaluso, M. Maida, S. Renna, E. Orlando, M. Affronti, C. Sapienza, M. Dimarco, R. Orlando, G. Rizzuto, M. Cottone, A. Orlando
Division of Internal Medicine, "Villa Sofia-Cervello" Hospital, Palermo, Italy and others

■ **P614**

Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's Disease: A single centre retrospective analysis

R. Gadhok, **H. Gordon**, G. Sebepos-Rogers, S. Baillie, S. Akbar, O.F. Ahmad, B. Cooper, J.O. Lindsay
Royal London Hospital, Gastroenterology, London, United Kingdom and others

■ **P615**

The unfinished symphony: Golimumab is efficient in patients with refractory Crohn's Disease

T. Greener, G. Greenberg, H. Steinhart, M. Silverberg
Mount Sinai Hospital, Department of Gastroenterology, Toronto, Canada

■ **P616**

Natural history and phenotype of Inflammatory Bowel Disease with co-existent Celiac Disease

C.S. Tse, P. Deepak, J. De La Fuente, J. Murray, K. Papadakis
Mayo Clinic, Internal Medicine, Rochester, United States and others

■ **P617**

Extraintestinal autoimmune phenomena during treatment with vedolizumab

D. Lissner, E. Sonnenberg, R. Glauben, C. Allers, J. Preiss, T. Schneider, C. Loddenkemper, B. Siegmund
Charité - Campus Benjamin Franklin, Gastroenterology, Berlin, Germany and others

■ **P618**

Rapidity of onset of response to adalimumab (ADA) in luminal Crohn's Disease (CD). Data from RAPIDA trial

I. Marin-Jimenez, F. Casellas, M. Esteve, L. Castro-Laria, S. García-López, D. Ceballos, A. Echarri, M.D. Martín-Arranz, D. Busquets, J. Llaó, M. Navarro-Llavat, J.M. Huguet, F. Argüelles-Arias, R. Vicente, L. Rodríguez-San Pedro, G. Diaz, R. Casado, M. Barreiro-de Acosta
Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain and others

■ **P619**

Tofacitinib for the treatment of resistant Ulcerative Colitis: The University of Chicago experience

R. Weisshof, M. Aharoni Golan, A. Masching, D.T. Rubin
University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States

■ **P620**

Network meta-analysis of efficacy and safety of different intravenous iron compounds for the treatment of iron deficiency anaemia in patients with Inflammatory Bowel Disease

A. Aksan, H. Işık, H.H. Radeke, A. Dignass, J. Stein
Hacettepe University, Faculty of Health Sciences, Ankara, Turkey and others

■ **P621**

Efficacy and safety of Golimumab in Ulcerative Colitis. Preliminary data from a multicenter Italian study

F. Bossa, M.R. Valvano, G. Costantino, E. Vinci, A. Rispo, M. Mendolaro, M. Patturelli, E. Shaini, S. Mazzuoli, C. Ricciardelli, A. Tursi, A. Lauria, P. Paese, A. Azzarone, L. Sebkova, G. Pranzo, W. Fries, F. Castiglione, M. Cappello, A. Privitera, B. Principi, A. Andriulli
IRCCS Casa Sollievo della Sofferenza, Gastroenterology, San Giovanni Rotondo, Italy and others

■ **P622**

Efficacy of probiotics in Inflammatory Bowel Disease: Systematic review and meta-analysis

Y. Derwa, **D.J. Gracie**, P.J. Hamlin, A.C. Ford
St. James's University Hospital, Leeds Gastroenterology Institute, Leeds, United Kingdom and others

■ **P623**

Therapeutic preferences and outcomes in newly diagnosed patient with Inflammatory Bowel Diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund database

L. Gonczi, Z. Vegh, Z. Kurti, B.D. Lovasz, P.A. Golovics, P. Fadgyas-Freyler, J. Gimesi-Orszagh, K.B. Gecse, P.L. Lakatos
Semmelweis University, First Department of Medicine, Budapest, Hungary and others

■ **P624**

Chromoendoscopy and narrow band imaging versus conventional white light endoscopy for detection of neoplasia in Ulcerative Colitis – a systematic review and meta-analysis

O. Har-Noy, L. Katz, T. Avni, T. Bessissow, D. Young, A. Koulaouzidis, T. Engel, R. Eliakim, S. Ben-Horin, **U. Kopylov**

Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel and others

■ **P625**

Ustekinumab use in Crohn's Disease: Effectiveness of dose escalation

A. Greenup, **G. Rosenfeld**, B. Bressler

University of British Columbia, Gastroenterology, Vancouver, Canada

■ **P626**

Ustekinumab for the treatment of perianal fistulas in patients with Crohn's Disease

R. Battat, T. Bessissow, M. Strohl, U. Kopylov, A. Bitton, A. Cohen, E. Seidman, W. Aff

McGill University Health Centre, Gastroenterology, Montreal, Canada and others

■ **P627**

Surrogate markers of mucosal healing in Crohn's Disease patients in clinical remission under biological/immunomodulator treatment

S. Siakavellas, A. Kostas, C. Kosmidis, M. Gizis, G. Papatheodoridis, G. Bamias

National & Kapodistrian University of Athens, Academic Dpt. of Gastroenterology, Athens, Greece

■ **P628**

Anti-TNF therapy in refractory pouchitis and Crohn's Disease-like complications of the Pouch after ileal pouch-anal anastomosis following colectomy for Ulcerative Colitis: A systematic review and meta-analysis

M. Huguet, B. Pereira, M. Goutte, F. Goutorbe, C. Allimant, M. Reymond, G. Bommelaer, **A. Buisson**

University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France and others

■ **P629**

Efficacy, safety and economic impact of the switch to biosimilar of infliximab in Inflammatory Bowel Disease patients in clinical practice: Results to one year

G.E. Rodríguez Glez., L. Díaz Hernández, J.A. Morales Barrios, M. Vela González, C.A. Tardillo Marín, M.M. Viña Romero, C.Y. Rodríguez Díaz, L. Arranz Hernández, A. Hernández Camba, F.J. Merino Alonso, F. Pérez Hernández

Hospital Universitario Ntra. Sra. Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain and others

■ **P630**

The long-term efficacy of adalimumab on Crohn's Disease comorbid with perianal lesions and poor prognostic factor analysis

R. Nozaki, H. Goto, Y. Tsuji, S. Takano, K. Yamada, M. Takano

Coloproctology Center, Takano Hospital, Kumamoto, Japan

■ **P631**

Results and predictors of outcome of endoscopic balloon dilation of colonic strictures in Inflammatory Bowel Diseases

N. Bibani, M. Yakoubi, M. Sabbah, D. Trad, A. Ouakaa, D. Gargouri, H. Elloumi, J. Kharrat

Habib Thameur Hospital, Gastroenterology, Tunis, Tunisia

■ **P632**

Comparative analysis of the pharmacokinetics of Inflectra® biosimilar with Remicade® in the induction phase of remission in patients with Crohn's Disease

G. Juan, M. Mora, A. Alvaríño, N. Maroto, I. Ferrer, E. Hinojosa, M.D. Hinojosa

Hospital de Manises, Department of Pharmacy, Manises, Spain and others

■ **P633**

Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease

G. Fiorino, M.B. Ruiz-Agüello, A. Maguregui, D. Nagore, S. Radice, D. Gilardi, C. Correale, M. Allocca, F. Furfaro, M. Alfieri, A. Martínez, S. Danese

Humanitas Clinical and Research Center, Department of Gastroenterology, Milan, Italy and others

P634
Long term risk of relapse after anti-TNF discontinuation based on mucosal healing in Inflammatory Bowel Disease

J.M. García Ortiz, M. Sáenz Gallo, C. Trigo Salado, M.D. De La Cruz Ramirez, J.L. Marquez Galan, J.M. Herrera Justiniano, J.M. Bozada García, E. Leo Carnerero
 HU Virgen del Rocío, UGC Digestive Diseases, Seville, Spain

P635
Enteral nutrition in the treatment of young adults with active Crohn's Disease

C. Wall, R. Geary, A. Day
 University of Otago Christchurch, Department of Paediatrics, Christchurch, New Zealand and others

P636
Reproducibility of the main prognostic factors for postoperative recurrence in a cohort of patients with Crohn's Disease under anti-TNF therapy

S. Raimundo Fernandes, L. Correia, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, J. Velosa
 Hospital de Santa Maria, Serviço de Gastrenterologia e Hepatologia, Lisboa, Portugal and others

P637
Anti-infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's Disease losing clinical response

E. Dreesen, T. Van Stappen, V. Ballet, S. Tops, G. Compennolle, G. Van Assche, M. Ferrante, S. Vermeire, A. Gils
 KU Leuven, P.O. Box 820 Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium and others

P638
Release of 5-aminosalicylic acid (5-ASA) from mesalazine formulations: A novel dynamic dissolution model simulating gastrointestinal pH changes

E. Demyanova, T. Vakhitov, **S. Sitkin**
 State Research Institute of Highly Pure Biopreparations, Dept. of Microbiology, St. Petersburg, Russian Federation and others

P639
Switching from originator-infliximab to biosimilar-Infliximab in IBD patients does not lead to significant changes in infliximab trough levels

A. Eberl, S. Huoponen, T. Pahikkala, P. Arkkila, M. Blom, T. Sipponen
 Helsinki University Central Hospital - Meilahti Hospital, Department of Gastroenterology, Helsinki, Finland and others

P640
Serum ustekinumab levels achieved with a subcutaneous induction regimen correlate to clinical outcome - a prospective study

C.R. Rowan, A. Kalei, A. De Vries, G. Cullen, E. Ryan, H. Mulcahy, G. D'Haens, G.A. Doherty
 St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland and others

P641
Long-term outcome of adalimumab therapy and predictors of response in 254 patients with Crohn's Disease: A hospital-based cohort study from Korea

H. Seo, B.D. Ye, S.-H. Lee, K. Chang, E.M. Song, G.-U. Kim, M. Seo, H.-S. Lee, S.W. Hwang, S.H. Park, D.-H. Yang, K.-J. Kim, J.-S. Byeon, S.-J. Myung, S.-K. Yang
 University of Ulsan College of Medicine, Asan Medical Center, Department of Gastroenterology, Seoul, South Korea and others

P642
Impact of histological and endoscopic remission in clinical recurrence and recurrence-free time in Ulcerative Colitis

A. Ponte, R. Pinho, S. Fernandes, A. Rodrigues, L. Alberto, J. Silva, J. Rodrigues, M. Sousa, S. Leite, A.P. Silva, L. Proença, T. Freitas, J. Carvalho
 Centro Hospitalar Vila Nova de Gaia/Espinho, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova Gaia, Portugal

■ **P643**

Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with Inflammatory Bowel Disease

M. Rasmussen, J. Brynskov, M.A. Ainsworth, S. Buhl, K. Bendtzen, C. Steenholdt
Copenhagen University Hospital Herlev, Department of Gastroenterology, Herlev Copenhagen, Denmark and others

■ **P644**

Factors and salvage surgery for treatment of pouch failure after restorative proctocolectomy for Ulcerative Colitis - A single-institution study

H. Kuroki, A. Sugita, K. Koganei, K. Tatsumi, R. Futatsuki, N. Obara
Yokohama Municipal Citizen's Hospital, Inflammatory Bowel Disease Center, Yokohama City, Japan

■ **P645**

The introduction of infliximab therapeutic drug level monitoring is associated with cost savings in a cohort of patients in a large district general hospital

S. Whiteoak, H. Johnson, C. Hovell, **S. Weaver**, S. McLaughlin
Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom

■ **P646**

Low FODMAPs diet as a magic bullet in reducing symptoms in different gastrointestinal diseases

A. Testa, N. Imperatore, A. Rispo, P. Capone, M. Rea, O.M. Nardone, A. Opramolla, R. Tortora, N. Caporaso, F. Castiglione
University "Federico II" of Naples, Department of Clinical Medicine and Surgery, Naples, Italy

■ **P647**

Tuberculosis in patients treated with vedolizumab: Clinical trial and post-marketing case series

M. Zerôncio, A. Blake, Q. Rana-Khan, W. Palo, F. Bhayat
Clínica de Oncologia de Natal, Gastroenterology, Natal, Brazil and others

■ **P648**

The impact of Infliximab (IFX) therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBD

C. Selinger, M. Lenti, T. Clark, H. Rafferty, A. O'Connor, T. Ahmad, P.J. Hamlin
St James University Hospital, Gastroenterology, Leeds, United Kingdom and others

■ **P649**

Does switching to low dose thiopurine and allopurinol prevent IBD patients with evidence of hypermethylation on standard dose thiopurines from developing hepatotoxicity and drug side effects?

K. Wade, **H. Johnson**, K. Slinger, C. Hovell, S. Weaver, S. McLaughlin
Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom

■ **P650**

The prognostic impact of radical resection margins on the recurrence of Crohn's Disease

J. van Amesfoort, L. Koens, W. Bemelman, C. Buskens
Academical Medical Centre, Surgery, Amsterdam, Netherlands and others

■ **P651**

Barriers to clinical research in children with Inflammatory Bowel Disease: The patients' perspective

W. El-Matary, V. Deora
University of Manitoba, Department of Paediatrics, Winnipeg, Canada

■ **P652**

Unmet needs of physicians managing Inflammatory Bowel Disease. A Survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)

S. Saibeni, C. Bezzio, A. Armuzzi, F. Bossa, E. Calabrese, F. Caprioli, M. Daperno, F. Mocciaro, A. Orlando, C. Papi, A. Rispo, F. Rizzello, IG-IBD
ASST Rhodense, Gastroenterology Unit, Rho, Italy and others

■ **P653**

The efficacy and safety of stem cell therapy for Crohn's Disease: A meta-analysis

Y. Qiu, S.-H. Zhang, R. Mao, R. Feng, Z.-R. Zeng, M.-H. Chen

The first affiliated hospital of Sun-yat sen University, Gastroenterology, Guangzhou, China and others

■ **P654**

Mucosal healing with a second anti-TNF- α in patients with Ulcerative Colitis after the failure of the previous anti-TNF- α treatment

A. Papa, D. Pugliese, F. D'Aversa, I. De Vitis, R. Landi, L. Guidi, C. Felice, V. Gerardi, A. Armuzzi, A. Gasbarrini, G.L. Rapaccini

Catholic University of Rome, Fondazione Policlinico Gemelli, Internal Medicine and Gastroenterology, Roma, Italy

■ **P655**

A study to determine factors affecting clinical decision making in outpatients with Inflammatory Bowel Disease

Y. Derwa, **D.J. Gracie**, C.J. Williams, R. Sood, S. Mumtaz, M.H. Bholah, P.J. Hamlin, A.C. Ford

St. James's University Hospital, Leeds Gastroenterology Institute, Leeds, United Kingdom and others

■ **P656**

Is there a role for additional oral mesalamine therapy in the treatment of ulcerative proctitis with skip inflammation?

Y.S. Choi, W.J. Kim, J.K. Kim, K.-H. Song, H.-J. Jung

Daehang Hospital, Gastroenterology, Seoul, South Korea and others

■ **P657**

The predictors and clinical outcomes of follow up loss of clinics in patients with Inflammatory Bowel Disease

K.O. Kim, B.I. Jang, **E.J. Koo**, M.K. Kang, C.H. Yang

Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, South Korea and others

■ **P658**

The Inflammatory Bowel Disease disability index (IBD-DI) in Ulcerative Colitis is related to disease activity, need of immunosuppressive therapy and quality of life

G.C. Morreale, V. Calvaruso, A. Sanfratello, M. Cappello

Policlinico Paolo Giaccone, Gastroenterology Section, DiBiMiS, University of Palermo, Italy, Palermo, Italy

■ **P659**

Therapeutic drug monitoring of anti-TNF α drugs in a UK tertiary IBD unit

V. Barrow, A. Innes, N. Thompson, J. Mansfield, A. Speight

Newcastle upon Tyne Hospitals Trust, Gastroenterology, Newcastle upon Tyne, United Kingdom and others

■ **P660**

Prevalence and clinical course of Cytomegalovirus Colitis (CMV) in Asian patients with acute exacerbation of Ulcerative Colitis (UC)

W.-C. Lim, H. Lin

Tan Tock Seng Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore

■ **P661**

Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade[®]) in children with established Inflammatory Bowel Disease: A multi-centre prospective observational study

M. Sladek, A. Vultaggio, S. Ghione, F. Nencini, A. Matucci, S. Pratesi, F. Zanieri, P.M. Maggi, M. Paci, K. Ponanta-Gawron, K. Kulig, A. Wasilewska, P. Lionetti

Jagiellonian University Medical College, Department of Paediatrics, Gastroenterology and Nutrition, Kraków, Poland and others

■ **P662**

Tofacitinib for induction of remission in Ulcerative Colitis: Systematic review and meta-analysis

P. Paschos, A. Katsoula, **O. Giouleme**, A. Tsapas
Aristotle University, Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Thessaloniki, Greece and others

■ **P663**

Switching from Remicade® to biosimilar CT-P13 in Inflammatory Bowel Disease patients: One year follow-up of a prospective observational cohort study

L. Smits, A. Grelack, J. Drenth, D. de Jong, R. Boshuizen, A. van Esch, L. Derikx, F. Hoentjen
Radboud university medical centre, Gastroenterology and Hepatology, Nijmegen, Netherlands and others

■ **P664**

The transitioning healthcare economy of IBD: Changes in resource allocation over time

P. Spizzo
St Vincent's Hospital Melbourne, Victoria, Australia

■ **P665**

Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with Quiescent Crohn's Disease: A prospective study

A. Strik, W. van de Vrie, Y. van Megen, J. Bloemsaat-Minekus, T. Rispens, G. D'Haens
Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands and others

■ **P666**

Short-term outcomes of adalimumab for patients with Crohn's Disease and associated prognostic factors: A multicentre retrospective cohort study

M. Nasuno, H. Tanaka, M. Miyakawa, S. Motoya, M. Ishii, A. Shiotani, M. Yamashita, F. Itoh, T. Tanuma, R. Sakemi, S. So, R. Suzuki, H. Yanagisawa, K. Onodera, H. Kaneto, M. Nojima, H. Nakase
Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan and others

■ **P667**

Safety of anti-TNF treatment in liver transplant recipients- a meta-analysis

M. Westerouen van Meeteren, A. Inderson, B. Hayee, A. van der Meulen, R. Altwegg, B. van Hoek, G.-P. Pageaux, T. Stijnen, D. Stein, **J. Maljaars**
LUMC, Gastroenterology-Hepatology, Leiden, Netherlands and others

■ **P668**

Post-marketing experience of vedolizumab in Inflammatory Bowel Disease: Analysis of pneumonia and other respiratory tract infections

F. Bhayat, **A. Blake**, S. Travis
Takeda Development Centre Europe Ltd, Global Pharmacovigilance, London, United Kingdom and others

■ **P669**

Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohn's Disease: Final data from PYRAMID registry

E. Loftus Jr, G. D'Haens, W. Reinisch, J. Satsangi, R. Panaccione, S. Berg, G. Alperovich, M. Bereswill, J. Kalabic, M. Skup, J. Petersson, A.M. Robinson
Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States and others

■ **P670**

Evaluating the management of Vitamin D in Crohn's Disease patients in a secondary care population

R. Ahmed, G. O'Connell, M. Love, J. Davis, R. Cooney, S. Pathmakanthan, T. Iqbal, N. Bhala
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Gastroenterology, Birmingham, United Kingdom

■ **P671**

Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's Disease patients

J.H. Mortensen, W.T. van Haaften, M.L. Olesen, M. Karsdal, P. Olinga, G. Dijkstra, A.-C. Bay-Jensen
Nordic Bioscience, Biomarkers & Research, Herlev, Denmark and others

■ **P672**

Surgical and anti-TNFs combined therapy prevents Crohn's perianal fistula recurrence: A systematic review and meta-analysis

P.-P. Xu, Y. Qiu, Y.-I. Jia, L. Xu, C.-Y. He, Z. Han

The First Affiliated Hospital of Wannan Medical College, Wuhu, China and others

■ **P673**

Intra-abdominal collections in Crohn's Disease: Outcomes following anti-TNF therapy

K. Subramaniam, M. Tweedale, P. Pavli

Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia and others

■ **P674**

Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term mucosal healing and histologic remission in Paediatric Crohn's Disease patients

B. Kang, K. Lee, B.-H. Choe, Y.H. Choe

Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea and others

■ **P675**

Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's Disease and Ulcerative Colitis – 54 week data

T. Molnár, K. Farkas, M. Rutka, T. Ferenci, F. Nagy, A. Bálint, R. Bor, A. Milassin, A. Fábíán, Z. Végh, Z. Kürti, P.L. Lakatos, Z. Szepes

University of Szeged, 1st Department of Medicine, Szeged, Hungary and others

■ **P676**

Comparison of real-world outcomes of adalimumab and infliximab for patients with Ulcerative Colitis in the United States

W. Sandborn, A. Sakuraba, A. Wang, D. Macaulay, L. Schemerold, M. Yang, M. Skup

University of California San Diego, La Jolla, United States and others

■ **P677**

Impact of patient reported outcomes, coping strategies and psychosocial factors on medication adherence in Inflammatory Bowel Disease

C.-Y. Chao, C. Lemieux, W. Afif, A. Bitton, G. Wild, T. Bessisow

McGill University Health Centre, Department of Gastroenterology, Montréal, Canada and others

■ **P678**

Did toxicity profile of Azathioprine changed within the last 10 years: Comperative 17 years data from a single tertiary IBD center

S. Bozcan, I. Hatemi, S. Yildirim, N. Demir, Y. Erzin, A.F. Celik

Istanbul University Cerrahpasa School of Medicine, Gastroenterology, Istanbul, Turkey

■ **P679**

Infliximab biosimilar CT-P13 in Inflammatory Bowel Disease patients that require intensification treatment

M. Gompertz, I. Alfaro, E. Ricart, A. López, J. Panés, M. Gallego, R. Barastegui, A. Giner, A. Vara, M. Masamunt, I. Ordás

Hospital Clinic Barcelona, Department of Gastroenterology, Barcelona, Spain

■ **P680**

Quality of sex life in patients with Inflammatory Bowel Disease: The gastroenterologists' perspective

P. Rivière, D. Laharie, F. Zerbib, F. Poullenot

Bordeaux University Hospital, Bordeaux, France

■ **P681**

Assessing internet based information used to aid patient decision making in surgery for perianal Crohn's fistula

J. Marshall, D. Baker, M. Lee, G. Jones, A. Lobo, S. Brown

University of Sheffield, The Medical School, Sheffield, United Kingdom and others

■ **P682**

Risk factors and clinical outcome in IBD patients with melanoma

L.H. Nissen, M. Pierik, L. Derikx, E. de Jong, W. Kievit, T. van den Heuvel, A. van Rosendaal, E. Plasmeijer, P. Dewint, I.D. Nagtegaal, F. Hoentjen, A. van der Meulen
Radboud UMC, Gastroenterology & Hepatology, Nijmegen, Netherlands and others

■ **P683**

Leishmania infantum asymptomatic infection in Inflammatory Bowel Disease patients under anti TNF- α treatment

N. Borruel, M.C. Guillen, F. Salvador, C. Herrera, M.M. Alcover, E. Sulleiro, V. Robles, D. Berenguer, A. Sánchez-Montalvá, V. Rodríguez, M. Tomás-Pérez, I. Molina, E. Navarro, L. Iniesta, R. Fisa, C. Riera, F. Casellas
Hospital Vall d'Hebron, Crohn's and Colitis attention Unit, Barcelona, Spain and others

■ **P684**

A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with Ulcerative Colitis

M. Taylor, A. Duggal, A. Rowley, M. Foster, S. Sirohi, Y. Solanke, C. Walshe, S. Webber, S. Travis, P. Irving
Topivert Pharma Ltd, London, United Kingdom and others

■ **P685**

Switching from originator-infliximab to biosimilar-infliximab has no influence on health-related quality of life and clinical disease activity among patients with Inflammatory Bowel Disease

S. Huoponen, A. Eberl, P. Räsänen, R.P. Roine, T. Sipponen, P. Arkkila, M. Blom
University of Helsinki, Helsinki, Finland and others

■ **P686**

Application of dried blood spots for pharmacokinetic profiling of Golimumab-treated patients with Ulcerative Colitis

I. Detrez, V. Ballet, G. Van Assche, S. Vermeire, M. Ferrante, A. Gils
KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium and others

■ **P687**

Fate of the rectum in anorectal Crohn's Disease

D. Zambonin, S. Scaringi, A. Di Bella, F. Giudici, P. Bechi
University of Florence, Florence, Italy

Epidemiology

■ P688

Crohn's Disease patients with a concordant family history are diagnosed earlier and are at increased risk for complicated disease

N. Borren, G. Conway, J. Garber, H. Khalili, V. Yajnik, R. Xavier, A. Ananthakrishnan
Massachusetts General Hospital, Department of Gastroenterology, Boston, United States and others

■ P689

Biologics utilisation in children with Inflammatory Bowel Diseases is higher and earlier than in adults: A report from the epi-IIRN group

M. Friedman, R. Axelrod, J. Rosenblum, N. Zigman, I. Goren, N. Lederman, N. Cohen, E. Matz, D. Dushnitsky, N. Borovsky, M. Gavish, G. Focht, M. Avitzour, I. Dotan, E. Benchimol, D. Turner
Shaare Zedek Medical Center, The Juliet Keiden Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel and others

■ P690

Ambient air quality does not affect disease course in Inflammatory Bowel Disease – a population based risk factor analysis using geographic information systems

T. van den Heuvel, E. Bijmens, B. Verhaegh, T. Nawrot, M. Zeegers, A. Masclee, L. Oostenbrug, M. Romberg-Camps, D. Jonkers, M. Pierik
Maastricht University Medical Centre+, Division of Gastroenterology and Hepatology, Maastricht, Netherlands and others

■ P691

UV exposure and skin type are more important than thiopurine exposure for non-melanoma skin cancer risk in IBD

Y. Wu, S. Ghaly, S. Kerr, K. Krishnaprasad, R. Prosser, B. Jackson, K. Hanigan, D. Martins, R. Mountfield, D. Whiteman, P. Bampton, R. Geary, G. Radford-Smith, I.C. Lawrance
St Vincent's Hospital, Department of Gastroenterology, Sydney, Australia and others

■ P692

Inflammatory Bowel Diseases in Faroese-born Danish residents and their offspring. Further evidence of the dominant role of environmental factors in IBD development

T. Hammer, S.N. Lophaven, K. Rubek Nielsen, M.C. von Euler-Chelpin, P. Weihe, P. Munkholm, J. Burisch, E. Lynge
University of Copenhagen, Department of Public Health, Copenhagen, Denmark and others

■ P693

Patients with Inflammatory Bowel Disease who are on immunosuppressive therapy perform regular gynecologic screening for uterine cervical cancer?

J.M. Vázquez-Morón, A. Cabello Fernández, H. Pallarés-Manrique, M. Ramos-Lora
Hospital General Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain

■ P694

Disease course during the first five years following diagnosis in a prospective European population-based inception cohort – The ECCO-EpiCom cohort

J. Burisch, J. Halfvarson, L. Kupcinskas, V. Hernandez, I. Kaimakliotis, D. Valpiani, N. Pedersen, D. Duricova, L. Kievit, J.F. Dahlerup, M. Fumery, R. Šalupere, N. Arebi, K.R. Nielsen, M. Giannotta, P. Oksanen, K.H. Katsanos, Z. Vegh, P. Ellul, D. Schwartz, S. Čuković-Čavka, R. D'Inca, S. Turcan, F. Magro, A. Goldis, E. Langholz, P.L. Lakatos, P. Munkholm, EpiCom studygroup
North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark and others

■ P695

The risk of proximal disease extension in patients with limited Ulcerative Colitis in a prospective European population-based inception cohort – The ECCO-EpiCom cohort

J. Burisch, J. Halfvarson, L. Kupcinskas, V. Hernandez, I. Kaimakliotis, D. Valpiani, N. Pedersen, D. Duricova, L. Kievit, J.F. Dahlerup, M. Fumery, R. Šalupere, N. Arebi, K.R. Nielsen, M. Giannotta, P. Oksanen, K.H. Katsanos, Z. Vegh, P. Ellul, D. Schwartz, S. Čuković-Čavka, R. D'Inca, S. Turcan, F. Magro, A. Goldis, E. Langholz, P.L. Lakatos, P. Munkholm, EpiCom studygroup
North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark and others

■ **P696**

Ambient air quality as risk factor for microscopic colitis – a Geographic Information System (GIS) study

B.P.M. Verhaegh, E.M. Beijnsens, T.R.A. van den Heuvel, D. Goudkade, M.P. Zeegers, T.S. Nawrot, A.A.M. Masclee, D.M.A.E. Jonkers, M.J. Pierik
Maastricht University Medical Center, Internal Medicine - Division of Gastroenterology-Hepatology, Maastricht, Netherlands and others

■ **P697**

Association of Inflammatory Bowel Disease and celiac disease. Experience in a hospital of the autonomous community of Madrid (Spain)

N. Manceñido Marcos, R. Pajares Villarroya, S. Salinas Moreno, M.R. Arribas López, C. Comas Redondo
Hospital Universitario Infanta Sofía, Gastroenterology Department, San Sebastián de los Reyes (Madrid), Spain and others

■ **P698**

The risk of developing subsequent immune mediated inflammatory diseases: A retrospective matched cohort study

R. Panaccione, D. Aletaha, M. Davis, S. Johnson, M. Skup, V. Garg
University of Calgary, Calgary, Canada and others

■ **P699**

Impact of adalimumab's patient support programme on clinical outcomes in Inflammatory Bowel Diseases: Results from the COMPANION study

J.K. Marshall, N. Narula, G. Lebovic, B. Millson, K. Charland, M. Sung, T. Gaetano, K. McHugh, M. Latour, M.-C. Laliberte
McMaster University, Department of Gastroenterology, Hamilton, Canada and others

■ **P700**

Epidemiology of genital lymphoedema as the initial presentation of paediatric Crohn's Disease

F. Jagger, A. Dall, P. Henderson, D. Wilson
University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom and others

■ **P701**

Late-onset Crohn's Disease is associated with high risk of intestinal perforation and low risk of perianal fistula as compared with early-onset Crohn's Disease: The CONNECT cohort

H.M. Kim, H.-S. Kim, J.S. Kim, Y.S. Kim, J.H. Cheon, B.D. Ye, Y.H. Kim, D.S. Han
Yonsei University Wonju College of Medicine, Division of Gastroenterology and Hepatology, Wonju, South Korea and others

■ **P702**

F-calprotectin use in Inflammatory Bowel Disease is characterised by improved diagnostic accuracy, less patient harm and decreased costs, compared with conventional serological markers and colonoscopy. A cost-effectiveness study in Italy.

B. Mascialino, A. Vora
Thermo Fisher Scientific, ImmunoDiagnostics, Uppsala, Sweden and others

■ **P703**

Risk of disease progression in patients with Crohn's Disease after 7 years of follow-up in a Danish population-based inception cohort

J. Burisch, I. Vind, M. Prosborg, M. Dubinsky, C.A. Siegel, F. Bendtsen, M. Vester-Andersen
North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark and others

■ **P704**

The impact of travel distance on disease outcomes in Inflammatory Bowel Disease

N. Borren, W. Tan, E. Andrews, H. Khalili, J. Garber, V. Yajnik, A. Ananthakrishnan
Massachusetts General Hospital, Department of Gastroenterology, Boston, United States and others

P705
Peripheral arterial disease is associated with an increased risk of elderly-onset Inflammatory Bowel Disease
F. Peerani, H. Chang, R. Ungaro, J. Torres, A. Atreja, J.-F. Colombel

University of Alberta, Department of Medicine and Division of Gastroenterology, Edmonton, Canada and others

P706
Characterisation of de novo Inflammatory Bowel Disease (IBD) diagnosed in immigrants migrating from low to high prevalence areas of IBD: A case-control study
J. Gordillo, P. Torres, A. García-García de Paredes, J. Llaó, A. López San Román, E. Domènech, E. García-Planella

Hospital de la Santa Creu i Sant Pau, Gastroenterology Department, Barcelona, Spain and others

P707
Paediatric IBD patients do not meet the daily recommendations of vitamin D and calcium intake: Survey based analysis in a tertiary centre
R. Shergill-Bonner, A. Zambrano Perez, N. Acton, S. Chadokufa, B. Huggett, F. Kiparissi, M. Baycheva, N. Shah, S. Sider

Great Ormond Street Hospital for Children, Department of Gastroenterology, London, United Kingdom

P708
H. pylori and IBD are inversely related, suggesting that individuals infected with the bacteria are less susceptible to the disease
L. Lichtenstein, D. Boltin, H. Leibovici, T. Tsadok Perets, I. Avni, D. Comaneshter, Y. Leibovici-Weissman, A. Cohen, Y. Niv, Z. Levi

Rabin Medical Center, Gastroenterology, Petach Tikva, Israel and others

P709
Inflammatory Bowel Disease and Colorectal Cancer: Analysis of a single center retrospective chart review
M. Fragaki, M. Bachlitzanaki, K. Karmiris, A. Theodoropoulou, E. Vardas, G. Paspatis

Venizelion General Hospital, Department of Gastroenterology, Heraklion, Greece

P710
Vitamin D deficiency is not associated with depression in IBD patients
S.O. Frigstad, M. Høivik, J. Jahnsen, S.R. Dahl, M. Cvancarova, T. Grimstad, I.P. Berset, G. Huppertz-Hauss, Ø. Hovde, R. Torp, T. Bernklev, B. Moum, L.-P. Jelsness-Jørgensen

Vestre Viken Hospital Trust, Department of Medicine Baerum Hospital, Drammen, Norway and others

P711
Vegetarian or gluten-free diet in patients with IBD – associated with lower psychological well-being and quality of life but no indication of beneficial effects on course of disease
P. Schreiner, J.-B. Rossel, J. Zeitz, B. Misselwitz, S. Scharl, M. Scharl, P. Frei, S. Vavricka, V. Pittet, G. Rogler, L. Biedermann

University Hospital of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland and others

P712
Risk factors for the development of fistulae and stenoses in Crohn's Disease patients in the Swiss IBD cohort
J. Zeitz, N. Fournier, C. Labenz, L. Biedermann, P. Frei, B. Misselwitz, S. Scharl, S. Vavricka, M. Sulz, M. Fried, G. Rogler, M. Scharl

University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland and others

P713
Possible explanations of the marked differences in the incidence of microscopic Colitis between Denmark and Sweden
S. Davidson, L. Munck, L. Vigren, P. Engel, K. Sjöberg

Lund University, Dept of Gastroenterology, Malmö, Sweden and others

■ **P714**

Vitamin D deficiency in Inflammatory Bowel Disease: Prevalence and relation to disease activity in a cohort of patients of a Mediterranean country

J. C. Branco, M. Cardoso, V. Anapaz, L. Lourenço, A. M. Oliveira, C. G. Rodrigues, L. Santos, J. Reis
Hospital Professor Doutor Fernando Fonseca, Gastroenterology, Lisboa, Portugal

■ **P715**

Trends in emergency department visits and hospitalisation rates for Inflammatory Bowel Disease: Results from a single-center in 2004, 2009 and 2014

G. Huh, H. Yoon, Y.J. Choi, Y.S. Park, N. Kim, D.H. Lee
Seoul National University College of Medicine, Internal Medicine, Seoul, South Korea and others

■ **P716**

Beta-blocker use is associated with a higher relapse risk of Inflammatory Bowel Disease – a Dutch retrospective cohort study

R. Willemze, T. Bakker, M. Pippias, C. Ponsioen, W. de Jonge
Academic Medical Center (AMC), Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands and others

■ **P717**

Higher Ulcerative Colitis / Crohn's Disease ratio in a central region of Argentina

D. Balderramo, P. Herrera-Najum, J. Trakal, R. Gonzalez, F. Zárate, K. Raiden, L. Ferrer, S. Balzola, M.R. Defagó, Grupo CEMEI (Cooperación para el Estudio y Manejo de la Enfermedad Inflamatoria Intestinal) Córdoba, Argentina

Hospital Privado Universitario de Cordoba, Gastroenterology Department, Cordoba, Argentina and others

■ **P718**

The epidemiology of IBD differs in South Asian migrants compared to Caucasians; results from a systematic review and meta-analysis

R. Misra, O. Faiz, J. Burisch, P. Munkholm, N. Arebi
St. Mark's Academic Institute, Gastroenterology, London, United Kingdom and others

■ **P719**

Determinants of tobacco consumption in the Swiss IBD cohort

M. Grueber, C. Clair Willi, M. Allez, L. Biedermann, N. Fournier, A. Schöpfer, S. Vavricka, P. Juillerat, A.J. Macpherson
Inselspital, Bern, Department of Gastroenterology, Bern, Switzerland and others

■ **P720**

Use of proton pump inhibitors associated with a markedly increased risk of microscopic Colitis

O. Bonderup, G. Lauge Nielsen, M. Dall, A. Pottegård, J. Hallas
University Research Clinic for Innovative Patient Pathways, Aarhus University, Denmark and others

■ **P721**

A switch in the prevalence ratio of Crohn's Disease vs. Ulcerative Colitis in Israel between 2003-2015 - a report from the epi-IIRN group

M. Friedman, S. Odes, R. Balicer, M. Hoshen, D. Cohen, J. Rosenblum, N. Zigman, I. Goren, N. Lederman, E. Matz, D. Dushnitzky, N. Borovsky, M. Gavish, G. Focht, M. Avitzour, R. Axelrod, Y. Chowers, R. Eliakim, S. Ben-Horin, I. Dotan, E. Israeli, Z. Levy, E. Benchimol, D. Turner
Shaare Zedek Medical Center, The Juliet Keiden Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel and others

■ **P722**

Prediagnostic serum vitamin D levels and risk of Inflammatory Bowel Disease: A pan-European, nested case-control study

J. Opstelen, S. Chan, A. Hart, F. van Schaik, P. Siersema, E. Lentjes, K.-T. Khaw, R. Luben, T. Key, H. Boeing, M. Bergmann, K. Overvad, D. Palli, G. Masala, A. Racine, F. Carbonnel, M.-C. Boutron-Ruault, A. Tjønneland, A. Olsen, V. Andersen, R. Kaaks, T. Kühn, R. Tumino, A. Trichopoulou, M. Verschuren, B. Witteman, B. Oldenburg
University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands and others

■ **P723**

Sex/IDI study – Sexual satisfaction in Inflammatory Bowel Disease

J. Roseira, H. Tavares de Sousa, A. Marreiros, D. Estevens, P. Queiros, A.M. Vaz, T. Gago, L. Contente, H. Guerreiro
Algarve Hospital Centre, Gastroenterology, Algarve, Portugal and others

■ **P724**

Appendectomy for appendicitis in established UC is associated with worse disease outcome

P. Myrelid, **K. Landerholm**, C. Nordenvall, T.D. Pinkney, R.E. Andersson
County Council of Östergötland, Department of Surgery, Linköping, Sweden and others

■ **P725**

The impact of an integrated model of care for patients with Inflammatory Bowel Disease in Canada

J.N. Peña-Sánchez, L.M. Lix, G.F. Teare, W. Li, S.A. Fowler, J.L. Jones
University of Saskatchewan, Department of Community Health & Epidemiology, College of Medicine, Saskatoon, Canada and others

■ **P726**

High mortality risk after first hospital admission for Inflammatory Bowel Disease: A nationwide registry linkage study

J. Opstelten, I. Vaartjes, P. Siersema, M. Bots, B. Oldenburg
University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands and others

■ **P727**

Change in Crohn's Disease behavior in a prospective European population-based inception cohort – The ECCO-EpiCom cohort

J. Burisch, J. Halfvarson, L. Kupcinskas, V. Hernandez, I. Kaimakliotis, D. Valpiani, N. Pedersen, D. Duricova, L. Kievit, J.F. Dahlerup, M. Fumery, R. Šalupere, N. Arebi, K.R. Nielsen, M. Giannotta, P. Oksanen, K.H. Katsanos, Z. Vegh, P. Ellul, D. Schwartz, S. Čuković-Čavka, R. D'Inca, S. Turcan, F. Magro, A. Goldis, E. Langholz, P.L. Lakatos, P. Munkholm, EpiCom studygroup
North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark and others

■ **P728**

Changes in the use of biologics in the treatment of IBD patients over time. Results from a comprehensive Norwegian registry study

S. Svaton Lirhus, H.O. Melberg, M. Lie Høivik, B. Moum
Universitetet i Oslo, Department of Health Management and Health Economics, Oslo, Norway and others

■ **P729**

Increased requirement for steroids, thiopurines and intestinal surgery in Crohn's patients who are smokers at IBD diagnosis; a nationwide population based study

C. Alexakis, S. Saxena, V. Chhaya, E. Cecil, R. Pollok
St George's University Hospital, Gastroenterology, London, United Kingdom and others

■ **P730**

Disease phenotype of Korean paediatric Crohn's Disease patients at diagnosis: A multicentre retrospective comparative study with EUROKIDS

B. Kang, J.-E. Kim, S. Kim, M.J. Kim, Y.M. Lee, J.H. Lee, J.-H. Lee, H.J. Lee, Y. Lee, Y.H. Choe, B.-H. Choe
Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea and others

■ **P731**

Withdrawn

■ **P732**

Clinical characteristics of Inflammatory Bowel Disease in Belgian immigrants from Moroccan and Caucasian origin

L. de Ville de Goyet, T. Moreels, M.A. Denis, B. De Vroey, N. De Suray, C. Mouradides, A. Taha, C. De Bouvere, H. Piessevaux, **O. Dewit**
Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Hépatogastroentérologie, Brussels, Belgium

■ **P733**

Past history of bariatric surgery associated with increased risk of new onset Inflammatory Bowel Disease

R. Ungaro, H. Chang, L. Roque Ramos, R. Fausel, J. Torres, J.-F. Colombel
Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States and others

■ **P734**

The sex ratio of Inflammatory Bowel Disease varies according to age at onset: Results from a worldwide survey

S.C. Shah, H. Khalili, C. Gower-Rousseau, O. Olén, E. Benchimol, E. Lynge, K. Nielsen, H. Ahn, P. Brassard, M. Vutcovici, A. Bitton, C. Bernstein, D. Leddin, H. Tamim, S. Aniwaniwan, C.-Y. Chen, T. Stefánsson, E.V. Loftus, Jr., B. Moum, W. Tang, S. Ng, R. Geary, B. Sincic, S. Bell, P.L. Lakatos, Z. Végh, C. Ott, G. Kaplan, J. Burisch, J.-F. Colombel
Mount Sinai Hospital, New York, United States and others

■ **P735**

Indirect burden of patients with moderate Inflammatory Bowel Disease in Uppsala County Council, Sweden: A retrospective study using real-world data

P.M. Hellström, J. Stålhammar, H. Beydoğan, P. Huetson, M. Skup, L. Agréus
Uppsala University, Department of Medical Sciences, Uppsala, Sweden and others

■ **P736**

Psychological impact of Inflammatory Bowel Disease: differences by gender and age. The ENMENTÉ Project

M. Gobbo Montoya, I. Marín-Jiménez, A. Panadero, Y. Modino, M. Cañas, J. Guardiola, L. Cea-Calvo, B. Juliá, C. Romero, L. Carmona, **M. Barreiro-de Acosta**
Positivamente, Centro de Psicología, Madrid, Spain and others

■ **P737**

Early life microbial exposure, lifestyle and comorbidity as risk factors for Microscopic Colitis: A case-control study

B.P.M. Verhaegh, D.M.A.E. Jonkers, M.J. Pierik, A.A.M. Masclee, D. Goudkade
Maastricht University Medical Center+, Internal Medicine - Division of Gastroenterology-Hepatology, Maastricht, Netherlands and others

■ **P738**

Assessing aCCess to investigations in IBD (ACCID) - results from an international Inflammatory Bowel Disease survey

N.S. Ding, B. Yazdanian, D. Bettenworth, I. Cleyner, N. A Yassin, A. Armuzzi, M. Ferrante, E.S. Zagorowicz, J. Mansfield, J. Gisbert, T. Raine
St Vincent's Hospital, Inflammatory Bowel Disease, Melbourne, Australia and others

■ **P739**

Characteristics of IBD related colorectal cancers observed in different Hungarian centers

M. Rutka, K. Farkas, L. Tiszlavicz, Z. Szepes, A. Balint, R. Bor, A. Fábíán, A. Milassin, P. Miheller, J. Banai, A. Salamon, J. Novák, A. Vincze, L. Lakatos, K. Palatka, T. Szamosi, A. Kovács, A. Gelléy, F. Nagy, T. Molnar
University of Szeged, I. Department of Medicine, Szeged, Hungary and others

■ **P740**

What kind of IBD patients succeed in smoking cessation? Insights from the Swiss IBD cohort study

M. Grueber, M. Allez, L. Biedermann, C. Clair Willi, N. Fournier, A. Schöpfer, S. Vavricka, P. Juillerat, A.J. Macpherson
Inselspital, Bern, Department of Gastroenterology, Bern, Switzerland and others

■ **P741**

IBD-related work disability in Brazil

R. Froes, A.T. Carvalho, A.J. Carneiro, A. Moreira, J. Moreira, R. Luiz, H. de Souza
Universidade do Estado do Rio de Janeiro, Disciplina de Gastroenterologia e Endoscopia Digestiva do Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil and others

■ **P742**

Arterial stiffness as a marker of vascular aging in IBD patients - a pilot study

R. Prijic, V. Premuzic, M. Jelakovic, A. Kunovic, D. Grgic, M. Brinar, N. Turk, Z. Krznaric, B. Vucelic, S. Cukovic-Cavka
University Hospital Center Zagreb, Division of Gastroenterology and Hepatology, Zagreb, Croatia and others

■ **P743**

What information is available on the internet and social media for faecal microbiota transplantation (FMT)?

J. Segal, **F. Abbasi**, C. Kanagasundram, A. Hart
St Mark's Hospital, Department of Gastroenterology, Harrow, United Kingdom and others

■ **P744**

Risk factors for faecal incontinence in patients with Crohn's Disease

P. Vollebregt, A. Visscher, **A. van Bodegraven**, R. Felt-Bersma
VU University Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands and others

■ **P745**

Impact of migration on IBD incidence in 8 European populations: Results from Epicom 2010 inception cohort study

R. Misra, J. Burisch, S. Shaji, R. Salupere, P. Ellul, V. Ramirez, R. D'Inca, P. Munkholm, N. Arebi
St. Mark's Academic Institute, Gastroenterology, London, United Kingdom and others

■ **P746**

Clinical characteristics of Crohn's Disease (CD) patients in Polish population

M. Lodyga, P. Eder, M. Gawron-Kiszka, M. Hartleb, J. Kierkus, M. Klopocka, M. Kukulska, K. Linke, E. Malecka-Panas, E. Poniewierka, I. Smola, T. Rawa, J. Regula, G. Rydzewska
Central Clinical Hospital of the Ministry of the Interior, Department of Internal Medicine and Gastroenterology with IBD Subdivision, Warsaw, Poland and others

■ **P747**

Extracolonic and colonic cancer risk in patients with Ulcerative Colitis and primary sclerosing cholangitis

M. Jelaković, M. Brinar, N. Turk, R. Prijic, Z. Krznaric, N. Rustemovic, S. Cukovic-Cavka
University hospital center Zagreb, Zagreb, Croatia and others

■ **P748**

High stress and significant decrease in productivity in caregivers of IBD patients

A. Zand, B.D. Kim, M. Dvorsky, D.W. Hommes
UCLA Center for Inflammatory Bowel Diseases, Los Angeles, United States

■ **P749**

Impact of psycho-social variables on the activity of Inflammatory Bowel Disease

O. Sarid, V. Slomin-Nevo, D. Schwartz, M. Friger, R. Sergienko, E. Chernin, H. Vardi, D. Greenberg, **S. Odes**
Ben-Gurion University of the Negev, Social Work, Beer Sheva, Israel and others

■ **P750**

Prevalence and risk factors of cholelithiasis in patients with Crohn's Disease

I. Sturdik, A. Krajcovicova, Z. Leskova, R. Decka, V. Cernotova, T. Koller, M. Huorka, T. Hlavaty
University Hospital, 5th Depart. Of Internal Medicine, Bratislava, Slovakia

■ P751

Trends in incidence of Inflammatory Bowel Disease in Northwest Greece

A. Skamnelos, K. Katsanos, Z. Malakos, S. Koliou, I. Mitselos, D. Politis, D. Mpalomenos, A. Kavadias, N. Tzampouras, G. Mpaltagiannis, E. Tsianos, D. Christodoulou
School of Health Sciences, University of Ioannina, Division of Gastroenterology, Ioannina, Greece and others

Genetics

■ P752

Withdrawn

■ P753

Withdrawn

■ P754

X-linked inhibitor of Apoptosis Protein (XIAP) genetic variants in paediatric-onset IBD

E. Crowley, A. Elkadri, N. Warner, S. Zhang, J. Horowitz, J. Staples, J. Overton, F. Dewey, C. Gonzaga-Jauregui, A. Griffiths, A. Muise
Hospital for Sick Children, Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, Toronto, Canada and others

■ P755

NUDT15 polymorphism is associated with thiopurine-related leukopenia independently of 6-thioguanine nucleotide levels in Korean paediatric Inflammatory Bowel Disease patients

B. Kang, J.Y. Choi, K. Lee, S.-Y. Lee, S.H. Ahn, H.J. Lee, Y.H. Choe
Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea and others

■ P756

Diagnosing rare inherited disorders using targeted next generation sequencing in patients with early-onset Inflammatory Bowel Disease: A population based study

F. Broly, M. Fumery, F. Vasseur, G. Savoye, D. Ley, H. Sarter, J.-L. Dupas, D. Turck, C. Gower-Rousseau
University of Lille, CHRU de Lille, France and others

■ P757

Genotype-serotype interactions shed light on of the pathophysiology of Inflammatory Bowel Diseases

S. Ben-Shachar, Y. Finezliber, H. Elad, H. Yanai, I. Dotan
Tel Aviv Medical Center affiliated to Tel Aviv university, Genetic Institute, Tel Aviv, Israel and others

■ P758

Elevation in ribosomal and cell cycle gene transcription in macroscopically normal colonic tissue from Icelandic patients with Ulcerative Colitis

M. Vinayaga-Pavan, M. Frampton, N. Pontikos, A. Levine, P. Smith, J. Jonasson, E. Björnsson, A. Segal, A. Smith
Eastman Dental Institute, University College London, London, United Kingdom and others

■ P759

MiRNA expression patterns in colon of active and inactive Ulcerative Colitis

S. Juzenas, J. Skieceviciene, V. Salteniene, J. Kupcinskas, G. Hemmrich-Stanisak, Z. Du, M. Hübenal, G. Kiudelis, L. Jonaitis, A. Franke, L. Kupcinskas
Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania and others

■ P760

microRNA expression profiling of Inflammatory Bowel Disease

C.F. Sibia, **R.P.L. Silva**, J.R. Ariede, F.E. Severino, E. Farinelli, F.L. Renosto, L.Y. Sasaki, P.P. Reis, R.S. Hossne
Faculdade de Medicina de Botucatu, Botucatu, São Paulo, Brazil and others

■ P761

Gene expression differences between Crohn's Disease aphthous ulcers and healthy Peyer's patches highlights potential treatment strategies

C. O'Brien, H. Patel, T. Freeman, K. Zhang, K. Peng, P. Pavli
Australian National University, Medical School, Canberra, ACT, Australia and others

■ **P762**

Gene expression profiling of immune adaptive response in the colonic mucosa from patients with Ulcerative Colitis

G. Fonseca Camarillo, E. Iturriaga Goyon, J.K. Yamamoto Furusho
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Inflammatory Bowel Disease Clinic. Department of Gastroenterology, Mexico City, Mexico

■ **P763**

Fucosyltransferase 2 (FUT2) non-secretor status in Crohn's Disease: A prospective observational analysis

R. Battat, U. Kopylov, W. Affif, T. Bessissow, J. Byer, S. Dionne, E. Zelikovic, E. Seidman, A. Bitton
McGill University Health Centre, Gastroenterology, Montreal, Canada and others

■ **P764**

Response to thiopurines is independent of ATG16L1 genotype

B. Verstockt, A.T. Matthias, K. Strongili, I. Cleynen, M. Parkes
KU Leuven, Department of Clinical and Experimental Medicine, TARGID-IBD, Leuven, Belgium and others

■ **P765**

Transcriptome of intestinal epithelial barrier genes in the colonic mucosa from patients with Ulcerative Colitis

G. Fonseca Camarillo, E. Iturriaga Goyon, J.K. Yamamoto Furusho
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Inflammatory Bowel Disease Clinic. Department of Gastroenterology, Mexico City, Mexico

Microbiology

■ P766

Combination therapy of fresh fecal microbial transplantation and antibiotics for Ulcerative Colitis

D. Ishikawa, M. Takahashi, K. Haga, T. Shibuya, T. Osada, S. Watanabe
Juntendo University, Department of Gastroenterology, Tokyo, Japan

■ P767

The FIT trial: Anti-inflammatory dietary intervention effects on the intestinal microbiota

J. Sabino, S. Vieira-Silva, K. Machiels, M. Joossens, G. Falony, M. Ferrante, G. Van Assche, S. Van Der Merwe, C. Matthys, J. Raes, S. Vermeire
University of Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium and others

■ P768

Co-housing DSS treated mice with healthy mice results in faster recovery and normalisation of the intestinal microbiota

M. Spalinger, C. Gottler, L. Hering, S. Lang, G. Rogler, M. Scharl
University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland and others

■ P769

In Crohn's Disease, an aggressive disease course is related to an increased abundance of proteobacteria; A seven year follow up study

M.K. Vester-Andersen, H.C. Mirsepasi-Lauridsen, I. Vind, M.V. Prosberg, C.O. Mortensen, C. Trager, T. Thor kilgaard, K. Skovsen, N. Sørensen, K.A. Krogfeldt, F. Bendtsen, A.M. Petersen
Hvidovre Hospital, University of Copenhagen, Denmark, Gastroint Medical division, Hvidovre, Denmark and others

■ P770

First analysis from UK IBD Twin Biobank; 16S rRNA gene sequencing identifies reduced diversity in IBD and bacterial taxa associated with disease

J. McDonald, **H. Gordon**, W. Blad, T. Orchard, J. Marchesi, M. Harbord
Imperial College London, Marchesi Laboratory, London, United Kingdom and others

■ P771

The recombinant NZ9000SHD-5 attenuates the inflammation and mucosal lesions in dextran sodium sulfate-induced Colitis

L. Zeng, Y. Chen
Nanf ang Hospital, Department of Gastroenterology, Guangzhou, China

■ P772

The presence of adherent-invasive escherichia coli strains (AIEC) on the surgical specimen is a predictor of severe endoscopic postoperative recurrence in Crohn's Disease

N. Barnich, A. Buisson, C. Auzolle, M. Rodrigues, C. Stefanescu, S. Nancey, P. Desreumaux, P. Marteau, M. Fumery, H. Sokol, X. Treton, P. Seksik, M. Allez
Université d'Auvergne, UMR Inserm U1071, Clermont-Ferrand, France and others

■ P773

Post-operative Crohn's Disease recurrence is associated with specific changes in the faecal microbiome – Potential pathogenic and protective roles

A.L. Hamilton, M.A. Kamm, S.-M. Teo, P. De Cruz, E.K. Wright, H. Feng, K.J. Ritchie, C.D. Kirkwood, M. Inouye
University of Melbourne, Department of Medicine, Melbourne, Australia and others

■ P774

Metagenomics and metabolomics of patients with Inflammatory Bowel Disease and their unaffected relatives

M. Vancamelbeke, J. Sabino, L. Deroover, G. Vandermeulen, A. Luy paerts, M. Ferrante, G. Falony, S. Vieira-Silva, K. Verbeke, J. Raes, I. Cleynen, S. Vermeire
KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, Leuven, Belgium and others

■ **P775**

Fibre intake is associated with microbiome changes in Paediatric Crohn's Disease patients following remission induction with exclusive enteral nutrition (EEN)

A. MacLellan, J. Connors, B. MacIntyre, G. Douglas, K.A. Dunn, J.P. Bielawski, A. Noble, G. Mahdi, M. Rashid, A.R. Otley, L. Cahill, M.G. Langille, J. Van Limbergen
IWK Health Centre - Dalhousie University, Pediatric Gastroenterology & Nutrition, Halifax, Canada and others

■ **P776**

Dysbiosis in Nlrp6/Asc-deficient mice does not result from inflammasome deficiency

M. Mamantopoulos, F. Ronchi, F. Van Hauwermeiren, S. Vieira-Silva, B. Yilmaz, L. Martens, Y. Saeys, S. Drexler, A. Yazdi, J. Raes, M. Lamkanfi, K. McCoy, **A. Wullaert**
Ghent University, Internal Medicine, Ghent, Belgium and others

■ **P777**

Ursodeoxycholic acid and its taurine/glycine conjugated species reduce colitogenic dysbiosis and equally suppress experimental Colitis in mice

L. Van den Bossche, P. Hindryckx, L. Devisscher, S. Devriese, S. Van Welden, T. Holvoet, R. Vilchez-Vargas, M. Vital, D.H. Pieper, J. Vanden Bussche, L. Vanhaecke, T. Van de Wiele, M. De Vos, D. Laukens
Ghent University, Department of gastroenterology, Ghent, Belgium and others

■ **P778**

Microbial characterisation of paediatric Inflammatory Bowel Disease and stratification into disease severity groups

C. Olbjørn, M. Čvancarova Småstuen, C. Casén, B. Nakstad, T. Lindahl, J. B Rove, E. Thiis-Evensen, M.H. Vatn, G. Perminow
Akershus University Hospital, Pediatric and Adolescent Medicine, Lørenskog, Norway and others

■ **P779**

CD patients in deep remission harbor a high dysbiosis index similar to active CD at diagnosis, yet both are higher in comparison to healthy controls

Y. Haberman, T. Klein, A. Di Segni, S. Neuman, N. Levhar, M. Bubis, O. Picard, M. BenShoshan, S. Farage Barhom, E. Glick Saar, K. Cesarkas, A. Lahad, D. Shouval, B. Weiss, R. Eliakim, S. Ben-Horin, U. Kopylov,
Israeli IBD Research Nucleus (IIRN)
Sheba Medical Center, Tel Hashomer, Israel and others

■ **P780**

3-oxo-C12:2-HSL, a new N-acyl-homoserine lactone identified in gut ecosystem exerts an anti-inflammatory effect and does not modify paracellular permeability

E. Le Balc'h, C. Landman, E. Tazuet, L. Brot, E. Quevrain, D. Rainteau, J.-P. Grill, S. Thenet, P. Seksik
APHP St. Antoine Hospital, ERL U1157 / UMR 7203, Paris, France and others

■ **P781**

The stability of the fecal microbiota in Crohn's Disease patients with changing disease course

D. Tedjo, P. Savelkoul, A. Masclee, A. Bodelier, M. Pierik, J. Penders, **D. Jonkers**
School of Nutrition and Translational Research in Metabolism (NUTRIM), Division Gastroenterology-Hepatology, Maastricht University Medical Center+, Maastricht, Netherlands and others

■ **P782**

A new compatibility test for donor selection for faecal microbiota transplantation in Ulcerative Colitis

M. Ponce-Alonso, S. Garcia-Fernandez, L. Aguilera, E. Rodriguez-de-Santiago, J.R. Foruny, G. Roy, R. DelCampo, R. Canton, **A. Lopez-Sanroman**
Hospital Ramon y Cajal, Microbiology, Madrid, Spain and others

■ **P783**

Ciprofloxacin resistance in ESBL producing enterobacteriaceae colonising the gut in IBD patients

V. Skuja, K. Pekarska, Z. Straume, D. Rudzite, E. Lavrinoviča, L. Piekuse, H. Dauvarte, E. Vašuka, L. Dobelniece, P. Zalizko, A. Derovs, A. Krūmiņa, A. Lejnicks
Riga Stradins University, Department of Internal Medicine, Riga, Latvia and others

■ **P784**

A comparison study of the mucosa-associated microbiota between inflamed and non-inflamed sites in Ulcerative Colitis patients

A. Hirano, J. Umeno, H. Shibata, T. Kitazono, M. Esaki

Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan and others

■ **P785**

Association of bacteroidetes with endoscopic activity in patients with Inflammatory Bowel Disease (IBD)

I. Baston, R. Sueiro, L. Uribarri, R. Ferreiro, J.M. Leiro, J.E. Dominguez-Munoz, M. Barreiro de Acosta
University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain and others

■ **P786**

Correlation between the presence of bacteroidetes and faecal calprotectin for the detection of endoscopic activity in patients with Inflammatory Bowel Disease

I. Baston, R. Sueiro, R. Ferreiro, L. Uribarri, J.M. Leiro, J.E. Dominguez-Munoz, M. Barreiro de Acosta
University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain and others

■ **P787**

The microbiota and its role in anti-TNF therapy non-response

N.S. Ding, A. Perdones-Montero, M. Sarafian, D. Rees, L. Penez, E. Holmes, J. Marchesi, A. Hart
St Vincent's Hospital, Inflammatory Bowel Disease, Melbourne, Australia and others

■ **P788**

Microbiota related disease activity and distribution in subgroups of Inflammatory Bowel Disease

P. Ricanek, K. Rahul, Y. Ber, S. Vatn, L. Finnby, T. Lindahl, D. Bergemalm, A. Carsten, J. Söderholm, J. Jahnsen, F. Gomollon, J. Halfvarson, J. Satsangi, C. Casen, M.H. Vatn, IBD-Character consortium
Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and others

■ **P789**

Microbiome composition is altered in patients with IBD independent of endoscopic activity

K. Boland, W. Turpin, A. Mohammadi, K. Borowski, M.I. Smith, G. Nguyen, A.H. Steinhart, K. Croitoru, M. Silverberg

Mount Sinai Hospital, Zane Cohen Center for Digestive Diseases, Toronto, Canada

■ **P790**

Microbiota profile in pediatric IBD: Correlations with phenotype and disease activity

S. Gatti, R. Annibali, G. Del Baldo, E. Franceschini, E. Lionetti, V. Albano, T. Galeazzi, C. Catassi
Università Politecnica delle Marche, Department of Pediatrics, Ancona, Italy

■ **P791**

Activation of the aryl hydrocarbon receptor after simvastatin and recombinant antagonist of receptors of interleukin-1 treatment in a rat model of Inflammatory Bowel Disease

A. Kamyshnyi, V. Kamyshna, **A. Kozachuk**

Zaporozhye State Medical University, Zaporozhye, Ukraine

■ **P792**

Modulation of the fecal metagenome in patients with Crohn's Disease (CD)

M. Rojas-Feria, J.A. Fernández Caballero-Rico, H. Pastor Ramírez, M. Castro-Fernandez, N. Chueca Porcuna, L. Grande Santamaría, M. Romero-Gómez, F. García, J.A. Del Campo
Valme Hospital, UGC Digestive Disease, Seville, Spain and others

■ **P793**

Microbial composition in IBD may influence clinical symptoms independent of endoscopic activity

K. Boland, W. Turpin, A. Mohammadi, K. Borowski, B. Kabakchiev, M.I. Smith, G. Nguyen, A.H. Steinhart, K. Croitoru, M. Silverberg

Mount Sinai Hospital, Zane Cohen Center for Digestive Diseases, Toronto, Canada

■ **P794**

Alterations of intestinal microbiota in Ulcerative Colitis

N. Danilova, S. Abdulkhakov, **T. Grigoryeva**, V. Dubinkina, V. Odintsova, A. Tyakht, A. Pavlenko, A. Odintsova, R. Abdulkhakov, V. Govorun

Kazan State Medical University, Kazan, Russian Federation and others

Nurses poster presentations

■ N795

Fatigue in IBD must be compared to the background population - generation of normative data for the IBD-F

P. Bager, C. Vestergaard, T. Juul, J.F. Dahlerup

Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark and others

■ N796

Emotional and social functioning in patients with Crohn's Disease needs more attention

J. Wisse, C. Smids, W. Heida, H. Calsbeek, C. Horjus Talabur Horje, M. de Leest, M. Groenen, P. Wahab
Rijnstate Hospital, IBD centre, Gastroenterology and Hepatology, Arnhem, Netherlands and others

■ N797

Therapeutic drug monitoring after thiopurine initiation improves drug efficacy

W. Dijkstra-Heida, C. Smids, M. van Luin, G. Huisman- de Waal, M. de Leest, C. Horjus Talabur Horje, J. Wisse, P. Wahab, M. Groenen

Rijnstate Hospital, IBD centre, Gastroenterology and Hepatology, Arnhem, Netherlands and others

■ N798

Kinship stigma in community-dwelling people with Inflammatory Bowel Disease: Family acknowledgement matters

L. Dibley, E. Williams, P. Young, P. Ironside

King's College London, Florence Nightingale Faculty of Nursing & Midwifery, London, United Kingdom and others

■ N799

Inflammatory Bowel Disease affects sexual female desire and sexual female excitement

J. Barros, J. Baima, F. Renosto, R. Silva, E. Farineli, G. Batista, M. Dorna, R. Saad-Hossne, L. Sassaki
Paulista State University - Botucatu Medical School, Botucatu, Brazil

■ N800

Statistical comparison of predictors of quality of life in Inflammatory Bowel Disease

A. Rivera Sequeiros, E. Gil García, R. Chillón Martínez

Hospital San Juan de Dios del Aljarafe, Internal Medicine, Seville, Spain and others

■ N801

Patient opinion assessment of a comprehensive clinical tool to improve health-care in Inflammatory Bowel Disease. The Implica-2 project

L. Sanroman Alvarez, M. Figueira Alvarez, M.L. De Castr, V. Hernandez Ramirez, J.R. Pineda Mariño, S. Pereira Bueno, J. Martinez Cadilla, B. Romero Mosquera

Instituto University Hospital Complex Biomedical Research. Organizational Estructura of Xestión Integrated Vigo, Gastroenterology, Vigo, Spain

■ N802

Improving care for patients with perianal Crohn's disease; review of a perianal virtual clinic

H. Yarrow, P. Irving, A. Williams, F. Hibberts, I. Koumoutsos, A. Darakhshan, E. Westcott, J. Duncan
Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom

■ N803

Accelerated infusions of biosimilar infliximab are safe and well tolerated and monitoring post-infusion is not required

K. Robinson, A. Wright, L. Marshall, A. Lobo

Sheffield Teaching Hospitals NHS Trust, Gastroenterology, Sheffield, United Kingdom

■ N804

An evaluation of patient satisfaction with IBDoc calprotectin home test system

D. Fitzgerald, K. Sugrue, J. McCarthy, M. Buckley

Mercy University Hospital, IBD, Cork, Ireland and others

■ N805***Do we need to monitor patients after vedolizumab infusion?*****K. Robinson**, L. Marshall, A. Wright, A. Lobo

Sheffield Teaching Hospitals NHS Trust, Gastroenterology, Sheffield, United Kingdom

■ N806***Comparison of patient satisfaction between regular care and clinical trial care for IBD patients treated with biologics*****S. Stolte**, A. Aelvoet, J. Van der Geugten, M. Löwenberg, G. D'Haens

Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands and others

■ N807***The use of a pre-screening tool for anti TNFs in IBD in four North West NHS trusts: A study*****R. Campbell**, S. Gaskell, E. Nelson, R. Bloor, J. Hocking, T. Hickey, V. Geraghty, J. Hodgins

Stockport Acute Foundation Trust, Gastroenterology, Stockport, United Kingdom and others

■ N808***Cooking workshops as strategy of health promotion of patients with Inflammatory Bowel Diseases*****C. Zaltman**, L. Tavares, M. De Cnop, C. Grandin

Federal University of Rio de Janeiro, Internal Medicine, Rio de Janeiro, Brazil and others

■ N809***IBD control questionnaire: Validation and evaluation as part of a virtual biologic clinic (VBC) in Galway University Hospital, Ireland*****A. Keogh**, M. Burke

Galway University Hospital, Gastroenterology, Galway, Ireland

■ N810***Audit of patient satisfaction with telephone reviews for Inflammatory Bowel Disease*****K. Johns**

Withybush Hospital, Gastroenterology, Haverfordwest, United Kingdom

■ N811***Infliximab versus adalimumab: Clinical and endoscopy response in Ulcerative Colitis patients. A prospective study*****R.P.L. Silva**, G.C. Bissoli, E. Farinelli, C.F. Sibia, J. Barros, F.L. Renosto, R.S. Hossne, J.P. Baima, L.Y. Sasaki

Faculdade de Medicina de Botucatu, Botucatu, São Paulo, Brasil, Brazil and others

■ N812***Re-designing the IBD nurse service for children and families in Glasgow using digital working - a tertiary centre experience*****V. Garrick**, L. Curtis, L. Richmond

Children's Hospital, Glasgow, United Kingdom

■ N813***Reaction rates in patients transferred from biologic to bio-similar treatment for IBD*****G. Lloyd-Ford**, M. Gordon, A. Lewis

Aneurin Bevan University Health Board, Gastroenterology, Newport, United Kingdom

■ N814***Improvement in the treatment and management of patients affected by Inflammatory Bowel Disease: Hepatitis B and vaccination status*****F.M. Onidi**, G. Mocci, F. Cabras

Azienda Ospedaliera Brotzu, Cagliari, Italy

■ N815***IBD Team Climate Inventory (TCI): Finding solutions to team challenges*****M. Burke**, A. Keogh

Galway University Hospital, Gastroenterology, Galway, Ireland

■ **N816**

Anti-TNF therapy improves the quality of life in patients with Ulcerative Colitis

R.P.L. Silva, J.P. Baima, G.C. Bissoli, E. Farinelli, C.F. Sibia, J. Barros, R.B. Biondi, F.L. Renosto, R.S. Hossne, L.Y. Sassaki
Faculdade de Medicina de Botucatu, Botucatu, São Paulo, Brasil, Brazil and others

■ **N817**

Epidemiological profile of Crohn's Disease and Ulcerative Colitis in a Brazilian single centre.

E. Farinelli, A.F. Pagnin, **R.P.L. Silva**, C.F. Sibia, F.L. Renosto, J. Barros, J.P. Baima, R.S. Hossne, L.Y. Sassaki
Faculdade de Medicina de Botucatu, Botucatu, São Paulo, Brasil, Brazil and others

■ **N818**

A specialized IBD unit infusion center is preferred by patients

B. Koslowsky, B. Mazuz, E. Goldin, A. Bar-Gil Shitrit
Shaare Zedek Medical Center, Gastroenterology, Jerusalem, Israel

■ **N819**

Analysis of the role of nursing in an IBD unit

N. Ruiz, R. Camargo, G. Alcain, R. Carreño, D. Recio
Hospital Virgen de La Victoria, Gastroenterology, Malaga, Spain and others

■ **N820**

The value and perception of IBD patients on electronic newsletters as a mode of patient-medical team communication

O. Haj Natour, N. Orbach-Zingboim, B. Ungar, D. Skenizes, U. Kopylov, R. Eliakim, S. Ben-Horin
Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel

■ **N821**

Communication with IBD nurse is associated with disease severity but not with better adherence to treatment

C. Abraham, N. Ruhimovich, F. Benjaminov, F.M. Konikoff, T. Naftali
Meir Medical Center, Department of Gastroenterology & Hepatology, Kfar Saba, Israel and others

■ **N822**

Non-programmed assistance of IBD patients in our institution. Ratios of activity and effectiveness of IBD-nurse role

N. Cano Sanz, M. Sierra, P. Suarez, M.J. F. Gundín
Hospital Universitario de León - CAULE, Gastroenterology - IBD unit, León, Spain

■ **N823**

The linked project, creating network

E. Navarro Correal, L. Marín Sanchez
Vall d'Hebron university Hospital, Gastroenterology, Barcelona, Spain and others

■ **N824**

Impact of educational intervention on Inflammatory Bowel Disease nurse specialist

J. Barros, F. Renosto, R. Silva, J. Baima, E. Farinelli, R. Biondi, M. Dorna, R. Saad-Hossne, L. Sassaki
Paulista State University - Botucatu Medical School, Botucatu, Brazil

Educational programme

One of ECCO's aims is to promote education in the field of IBD and to improve the quality of care for IBD patients throughout Europe. Thus prior to and during the 12th Congress of ECCO in Barcelona ECCO offers the following educational activities:

15th IBD Intensive Advanced Course

Date:	February 15-16, 2017
Time:	IBD Advanced Course: Feb 15, 2017: 08:00-15:45 February 16, 2017: 08:00-12:30 Industry sponsored satellite symposium: Feb 15, 2017: 16:00-17:00
Organisation:	EduCom
Target audience:	Junior gastroenterologists
Registration:	Upon invitation
CME accreditation:	9 CME credits, upon return of an evaluation form filled in online

Wednesday, February 15, 2017

Programme overview (as of January 16, 2017)

Room 111, Level 1, CCIB

07:45 - 08:00	Arrival & distribution of voting pads
08:00 - 08:10	1: Welcome Julián Panés, Barcelona, Spain Gerassimos Mantzaris, Athens, Greece
08:10 - 08:30	2: Pre-course test Peter Irving, London, United Kingdom
08:30 - 09:30	Session 1: Pathogenesis Lead discussant: James Lindsay, London, United Kingdom
08:30 - 08:50	3: Exposome Jonas Halfvarson, Örebro, Sweden
08:50 - 09:10	4: Genetics Miles Parkes, Cambridge, United Kingdom
09:10 - 09:30	5: Inflammatory pathways Yehuda Chowers, Haifa, Israel
09:30 - 09:50	Coffee break
09:50 - 11:10	Session 2: Drug management sessions. Part I: Conventional drugs Lead discussant: Pascal Juillerat, Bern, Switzerland
09:50 - 10:10	6: 5-ASA compounds Gerhard Rogler, Zurich, Switzerland
10:10 - 10:30	7: Thiopurines Peter Irving, London, United Kingdom
10:30 - 10:50	8: Methotrexate Pascal Juillerat, Bern, Switzerland
10:50 - 11:10	9: Steroids Stephan Vavricka, Zurich, Switzerland

Wednesday, February 15, 2017, cont.

Programme overview (as of January 16, 2017)

Room 111, Level 1, CCIB

11:10 - 12:00		Session 2: Drug management sessions. Part II: Biologics Lead discussant: Peter Irving, London, United Kingdom
	11:10 - 11:30	10: Anti-TNF agents Filip Baert, Roeselare, Belgium
	11:30 - 11:45	11: Vedolizumab James Lindsay, London, United Kingdom
	11:45 - 12:00	12: Ustekinumab Marc Ferrante, Leuven, Belgium
12:00 - 12:30		Lunch break
12:30 - 14:00		Session 3: Seminars: Part I: Special clinical situations
	12:30 - 13:15	EITHER: 13a: Managing IBD and pregnancy Janneke van der Woude, Rotterdam, The Netherlands Iris Dotan, Tel Aviv, Israel Room 111, Level 1, CCIB OR 13b: Managing extraintestinal manifestations of IBD Stephan Vavricka, Zurich, Switzerland Peter Lakatos, Budapest, Hungary; Montreal, Canada Room 118, Level 1, CCIB
	13:15 - 14:00	EITHER: 14a: Managing IBD and pregnancy Janneke van der Woude, Rotterdam, The Netherlands Iris Dotan, Tel Aviv, Israel Room 111, Level 1, CCIB OR 14b: Managing extraintestinal manifestations of IBD Stephan Vavricka, Zurich, Switzerland Peter Lakatos, Budapest, Hungary; Montreal, Canada Room 118, Level 1, CCIB
14:00 - 14:15		Coffee break
14:15 - 15:45		Session 3: Seminars: Part II: Long term management
	14:15 - 15:00	EITHER: 15a: Managing complications associated with anti-TNF therapy Shomron Ben-Horin, Ramat Gan, Israel Room 111, Level 1, CCIB OR 15b: Perform endoscopy and IBD incl. chromo-endoscopy, balloon dilatation Pierre Michetti, Lausanne, Switzerland Marc Ferrante, Leuven, Belgium Room 118, Level 1, CCIB
	15:00 - 15:45	EITHER: 16a: Managing complications associated with anti-TNF therapy Shomron Ben-Horin, Ramat Gan, Israel Room 111, Level 1, CCIB OR 16b: Perform endoscopy and IBD incl. chromo-endoscopy, balloon dilatation Pierre Michetti, Lausanne, Switzerland Marc Ferrante, Leuven, Belgium Room 118, Level 1, CCIB
16:00-17:00		Industry Sponsored IBD Intensive Advance Course satellite symposium Please refer to pages page 194

Thursday, February 16, 2017

Programme overview (as of January 16, 2017)

Room 111, Level 1, CCIB

08:00 - 10:00	Session 4: Interactive case discussions Lead discussant: Peter Irving, London, United Kingdom	
08:00 - 08:50	17: Case-based discussion: Fistulising Crohn's Disease: Medical and surgical approaches Case presentation: Antonio López-Sanromán, Madrid, Spain Discussion: Paulo Kotze, Curitiba, Brasil	
08:50 - 09:00	Discussion	
09:00 - 09:50	18: Case-based discussion: The patient with severe inflammatory Crohn's Disease Case presentation: Pieter Hindryckx, Ghent, Belgium Discussion: Laurence Egan, Galway, Ireland	
09:50 - 10:00	Discussion	
10:00 - 10:20	Coffee break	
10:20 - 12:15	Session 5: Special cases scenarios Lead discussant: Pascal Juillerat, Bern, Switzerland	
10:20 - 10:40	19: Pre- and postoperative management of Crohn's Disease Glen Doherty, Dublin, Ireland	
10:40 - 11:25	20: Case based discussion: Investigation and management of mild/moderate Crohn's Disease Case presentation: Tim Raine, Cambridge, United Kingdom Discussion: Jane Andrews, Adelaide, Australia	
11:25 - 11:45	21: Management of refractory pouchitis Iris Dotan, Tel Aviv, Israel	
11:45 - 12:15	22: Medical management of acute severe Ulcerative Colitis Charlie Lees, Edinburgh, United Kingdom	
12:15 - 12:30	Feedback and closing remarks Peter Irving, London, United Kingdom Pascal Juillerat, Bern, Switzerland	

8th N-ECCO School

Date:	February 15, 2017
Time:	08:30-16:15
Organisation:	N-ECCO
Target audience:	IBD nurses – new to the specialty, Dietitians
Registration:	Upon invitation
CME accreditation:	n.a.

Wednesday, February 15, 2017

*Programme overview (as of January 16, 2017) –
Room 131+132, Level 1, CCIB*

08:30 - 08:45	1: Welcome & Introduction Usha Chauhan, Hamilton, Canada
08:45 - 12:15	Session 1: Diagnosis and assessment Usha Chauhan, Hamilton, Canada Nicolette Wierdsma, Amsterdam, The Netherlands
08:45 - 09:30	2: Diagnosis, anatomy and physiology in IBD Marc Ferrante, Leuven, Belgium
09:30 - 10:00	3: Psychosocial implications of living with IBD Kay Greveson, London, United Kingdom
10:00 - 10:30	4: Nutritional assessment in IBD Konstantinos Gerasimidis, Glasgow, United Kingdom
10:30 - 10:45	Coffee break
10:45 - 11:15	5: Surgery in IBD Janindra Warusavitarné, London, United Kingdom
11:15 - 11:45	6: Medical treatment Konstantinos Katsanos, Ioannina, Greece
11:45 - 12:15	7: Adherence Palle Bager, Aarhus, Denmark
12:15 - 13:15	Lunch break

Wednesday, February 15, 2017, cont.

*Programme overview (as of January 16, 2017) –
Room 131+132, Level 1, CCIB*

13:15 - 14:50	Session 2: Case studies – Disease management Kay Greveson, London, United Kingdom Nicolette Wierdsma, Amsterdam, The Netherlands	
13:15 - 14:05	EITHER: 8a: Workshop 1 – UC Management (Group A) Andreas Sturm, Berlin, Germany Room 131+132, Level 1, CCIB OR: 9a: Workshop 2 – CD Management (Group B) Pieter Hindryckx, Ghent, Belgium Room 130, Level 1, CCIB	
14:05 - 14:50	EITHER: 8b: Workshop 1 – UC Management (Group B) Andreas Sturm, Berlin, Germany Room 131+132, Level 1, CCIB OR: 9b Workshop 2 – CD Management (Group A) Pieter Hindryckx, Ghent, Belgium Room 130, Level 1, CCIB	
14:50 - 15:05	Coffee break	
15:05 - 16:05	Session 3: Multidisciplinary management in IBD Kay Greveson, London, United Kingdom Nicolette Wierdsma, Amsterdam, The Netherlands	
15:05 - 15:35	10: Nutritional management in IBD Rotem Sigall-Boneh, Tel Aviv, Israel	
15:35 - 16:05	11: Nursing roles in IBD management Kathleen Sugrue, Cork, Ireland	
16:05 - 16:15	12: Closing remarks Usha Chauhan, Hamilton, Canada	

2nd School for Clinical Trialists

Date:	February 15, 2017
Time:	08:00-11:30
Organisation:	ClinCom
Target audience:	Clinical trial coordinators, IBD nurses and Allied health professionals
Registration:	For registered participants only. No onsite registration
CME accreditation:	3 CME credits, upon return of an evaluation form filled in online

Wednesday, February 15, 2017

*Programme overview (as of January 16, 2017) –
Room 124+125, Level 1, CCIB*

<i>Understanding the different types of clinical trials</i>	
08:00 - 08:15	1: Welcome & Introduction Alessandro Armuzzi, Rome, Italy
08:15 - 09:30	Session 1 Edyta Zagórowicz, Warsaw, Poland
	08:15 - 09:00 2: Clinical trial design and sample size Tim Raine, Cambridge, United Kingdom
	09:00 - 09:30 3: How to optimise recruitment to clinical trials in IBD Charlie Lees, Edinburgh, United Kingdom
09:30 - 10:00	Coffee break
10:00 - 11:20	Session 2 Javier Gisbert, Madrid, Spain
	10:00 - 10:30 4: Setting up and running large nationwide IBD trials Laurent Beaugerie, Paris, France
	10:30 - 11:00 5: Tips & tricks for the IBD clinical research team Liese Gijbels, Leuven, Belgium Karen Rans, Leuven, Belgium
	11:00 - 11:20 6: What does the future hold for IBD clinical trials? Silvio Danese, Milan, Italy
11:20 - 11:30	7: Summary & closing remarks John Mansfield, Newcastle upon Tyne, United Kingdom



European
Crohn's and Colitis
Organisation

ECCO Educational Workshops 2017

ECCO Workshops



50th ECCO Workshop
Dubai, **UAE** - March 4, 2017



51st ECCO Workshop
Seoul, **Republic of Korea** - June 15, 2017



52nd ECCO Workshop
Kaunas, **Lithuania** - September 15, 2017



53rd ECCO Workshop
Bucharest, **Romania** - September 28, 2017



54th ECCO Workshop
Cardiff, **United Kingdom** - November 17, 2017



55th ECCO Workshop
Krakow, **Poland** - December 8, 2017



REPUBLIC OF KOREA **51**

UNITED ARAB EMIRATES
50

Spreading standards in IBD:
Your presence counts!

Scan and contact the ECCO Office
www.ecco-ibd.eu



4th N-ECCO Research Forum

Date:	February 15, 2017
Time:	13:00-17:00
Organisation:	N-ECCO
Target audience:	IBD nurses and Allied health professionals
Registration:	For registered participants only. No onsite registration
CME accreditation:	n.a.

Wednesday, February 15, 2017

*Programme overview (as of January 16, 2017) –
Room 124+125, Level 1, CCIB*

13:00 - 13:10	1: Welcome & Introduction Palle Bager, Aarhus, Denmark
13:10 - 14:00	Research methodology: Examples from current research Karen Kemp, Manchester, United Kingdom Palle Bager, Aarhus, Denmark
13:10 - 13:25	2: Systematic review Dawn Farrell, Cork, Ireland
13:25 - 13:45	3: Development of a questionnaire Wladzia Czuber-Dochan, London, United Kingdom
13:45 - 14:00	4: Measurement of conditions Randi Opheim, Oslo, Norway
14:00 - 16:45	International IBD nursing research projects: Brief introduction of project ideas by senior researchers Karen Kemp, Manchester, United Kingdom Palle Bager, Aarhus, Denmark
14:00 - 14:07	5: Fatigue in Europe Wladzia Czuber-Dochan, London, United Kingdom
14:08 - 14:14	6: Fatigue and physical function in IBD Dawn Farrell, Cork, Ireland
14:15 - 14:22	7: Improving bowel symptoms and control for people with IBD Lesley Dibley, London United Kingdom
14:23 - 14:30	8: Burden of IBD Palle Bager, Aarhus, Denmark
14:30 - 15:00	Coffee break
15:00 - 16:25	9: Workshops: International IBD nursing research projects – ‘pre investigators meetings’ Development towards final research protocols
16:25 - 16:45	10: Short presentation of status from the workshops
16:45 - 17:00	11: Learning from today: How to proceed? Palle Bager, Aarhus, Denmark

2nd ECCO Endoscopy Workshop

Date:	February 15, 2017
Time:	ECCO Endoscopy Workshop: 13:00-18:00 Industry sponsored satellite symposium: 11:45-12:45
Organisation:	EduCom
Target audience:	Physicians, Surgeons, Paediatricians
Registration:	For registered participants only. No onsite registration
CME accreditation:	3 CME credits, upon return of an evaluation form filled in online

Wednesday, February 15, 2017

*Programme overview (as of January 16, 2017) –
Room 122+123, Level 1, CCIB*

11:45 - 12:45	Industry sponsored satellite symposium Please refer to page 194
13:00 - 13:15	1: Welcome & Introduction Julián Panés, Barcelona, Spain Gerassimos Mantzaris, Athens, Greece 2: Pre-course test
13:15 - 14:15	3: Session 1: Assessment of endoscopic activity: Clinical trials and routine practice Chairs: Alessandro Armuzzi, Rome, Italy Konstantinos Katsanos, Ioannina, Greece Speaker: James Lindsay, London, United Kingdom
14:15 - 15:15	4: Session 2: Endoscopic surveillance for IBD associated colorectal cancer Chairs: Antonio López-Sanromán, Madrid, Spain James Lindsay, London, United Kingdom Speaker: Vito Annese, Florence, Italy
15:15 - 15:45	Coffee break
15:45 - 16:45	5: Session 3: Endoscopic therapeutic intervention in IBD Chairs: Peter Irving, London, United Kingdom Marc Ferrante, Leuven, Belgium Speaker: Nik Sheng Ding, Melbourne, Australia
16:45 - 17:45	6: Session 4: Small bowel endoscopy: Capsule vs. balloon enteroscopy Chairs: Peter Lakatos, Budapest, Hungary; Montreal, Canada Edyta Zagórowicz, Warsaw, Poland Speaker: Rami Eliakim, Tel Aviv, Israel
17:45 - 18:00	7: Post-course test & concluding remarks Gerassimos Mantzaris, Athens, Greece

3rd Advanced ECCO: EduCational COurse for Industry

Date:	February 15, 2017
Time:	14:00-18:00
Organisation:	ClinCom
Target audience:	Corporate & Non-Corporate Members
Registration:	For registered participants only. No onsite registration
CME accreditation:	n.a.

Wednesday, February 15, 2017

*Programme overview (as of January 16, 2017) –
Room 113, Level 1, CCIB*

14:00 - 14:05	1: Welcome Julián Panés, Barcelona, Spain
14:05 - 14:55	2: Session 1: Preclinical models in IBD drug development Silvio Danese, Milan, Italy Panel discussion: Gerhard Rogler, Zurich, Switzerland Andy Whitney, Foster City, United States (Gilead) Philippe Clement-Lacroix, Romainville, France (Galapagos)
14:55 - 15:45	3: Session 2: Proof of concept studies Séverine Vermeire, Leuven, Belgium Panel discussion: Stefan Schreiber, Kiel, Germany Allan Olson, San Diego, United States (Celgene) Miguel Forte, Valbonne-Sophia Antipolis, France (International Society of Cellular Therapy)
15:45 - 16:15	Coffee break
16:15 - 17:05	4: Session 3: Learning for GI from other IMIDs Bruce Sands, New York, United States Gerd-Rüdiger Burmester, Berlin, Germany Panel discussion: Chris Gasink, Malvern, United States (Janssen) Wojciech Niezychowski, Collegeville, United States (Pfizer) Elmer Schabel, Bonn, Germany (EMA)
17:05 - 17:55	5: Session 4: Treatment, strategies, trials Peter Irving, London, United Kingdom Panel discussion: John Mansfield, Newcastle upon Tyne, United Kingdom Ana Lacerda, Chicago, United States (AbbVie) Rebecca Curtis, London, United Kingdom (Takeda)
17:55 - 18:00	6: Closing remarks Silvio Danese, Milan, Italy

3rd Y-ECCO Basic Science Workshop

Date:	February 15, 2017
Time:	12:30-15:30
Organisation:	Y-ECCO
Target audience:	Physicians, Paediatricians, Surgeons, IBD nurses
Registration:	For registered participants only. No onsite registration
CME accreditation:	3 CME credits, upon return of an evaluation form filled in online

Wednesday, February 15, 2017

*Programme overview (as of January 16, 2017) –
Room 120+121, Level 1, CCIB*

12:30 - 12:35	1: Introduction Isabelle Cleynen, Leuven, Belgium
12:35 - 13:50	Session 1: Genetics in IBD – moving beyond GWAS Miles Parkes, Cambridge, United Kingdom Dominik Bettenworth, Münster, Germany
12:35 - 13:05	2: State of the art Miles Parkes, Cambridge, United Kingdom
13:05 - 13:20	3: Abstract 1: Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in Inflammatory Bowel Disease - IBD Character Alex Adams, Edinburgh, United Kingdom Please refer to P061 on page 75
13:20 - 13:35	4: Abstract 2: Metagenomics and metabolomics of patients with Inflammatory Bowel Disease and their unaffected relatives Maaïke Vancamelbeke, Leuven, Belgium Please refer to P774 on page 153
13:35 - 13:50	5: Abstract 3: Complete metabonomic and microbiota profiling identifies biomarkers for anti-TNF therapy response Nik Sheng Ding, Melbourne, Australia Please refer to P018 on page 70
13:50 - 14:10	Meet the speakers break
14:10 - 15:25	Session 2: Identifying novel targets in IBD using patient samples Jeff Barrett, Cambridge, United Kingdom Nik Sheng Ding, Melbourne, Australia
14:10 - 14:40	6: State of the art Jeff Barrett, Cambridge, United Kingdom
14:40 - 14:55	7: Abstract 4: The genetic risk in ER stress and autophagy translates into quantifiable epithelial ER stress levels in IBD patients Wiebe Vanhove, Leuven, Belgium
14:55 - 15:10	8: Abstract 5: Molecular profiling of early Crohn's Disease reveals a prominent role for WNT5A Sare Verstockt, Leuven, Belgium
15:10 - 15:25	9: Abstract 6: Transcriptomic profiling of intestinal macrophages isolated from patients reveals a profound gene expression reprogramming underlying IBD pathogenesis" Suranga Dharmasiri, Southampton, United Kingdom
15:25 - 15:30	Closing remarks and Y-ECCO best abstract awards Isabelle Cleynen, Leuven, Belgium

10th Y-ECCO Career Workshop

Date:	February 15, 2017
Time:	16:00-18:00
Organisation:	Y-ECCO
Target audience:	Physicians, Paediatricians, Surgeons, IBD nurses
Registration:	For registered participants only. No onsite registration
CME accreditation:	2 CME credits, upon return of an evaluation form filled in online

Wednesday, February 15, 2017

*Programme overview (as of January 16, 2017) –
Room 120+121, Level 1, CCIB*

<i>Successful grant writing skills</i>	
16:00 - 16:10	1: Welcome & Introduction Nuha Yassin, London, United Kingdom
16:10 - 16:40	Session 1: Grant Writing – How to get started Chairs: Isabelle Cleynen, Leuven, Belgium Dominik Bettenworth, Münster, Germany
16:10 - 16:25	2: Designing the ideal project Séverine Vermeire, Leuven, Belgium
16:25 - 16:40	3: Grant Writing – Tips and tricks Gerhard Rogler, Zurich, Switzerland
16:40 - 17:35	Session 2: Group Session – Designing a successful project Tim Raine, Cambridge, United Kingdom Dominik Bettenworth, Münster, Germany Isabelle Cleynen, Leuven, Belgium Nuha Yassin, London, United Kingdom
16:40 - 17:00	Group session – Design project suitable for funding application
17:00 - 17:35	4: Feedback on projects and announcement of winning project Séverine Vermeire, Leuven, Belgium Gerhard Rogler, Zurich, Switzerland Helen Terry, St. Albans, United Kingdom (CCUK)
17:35 - 18:00	Session 3: Grant Writing – Examples of successful projects Nik Sheng Ding, London, United Kingdom
17:35 - 17:50	5: Examples of funded IBD projects by charities Helen Terry, St. Albans, United Kingdom (CCUK)
17:50 - 18:00	6: Thank you and Prizes Nuha Yassin, London, United Kingdom Tim Raine, Cambridge, United Kingdom
18:00	7: Close – Y-ECCO Networking

6th S-ECCO IBD Masterclass in collaboration with ESCP

Date:	February 16, 2017
Time:	08:00-17:00
Organisation:	S-ECCO in collaboration with ESCP
Target audience:	Surgeons, Physicians, IBD nurses
Registration:	For registered participants only. No onsite registration
CME accreditation:	6 CME credits, upon return of an evaluation form filled in online



Thursday, February 16, 2017

Programme overview (as of January 16, 2017) – Room 113, Level 1, CCIB

<i>Difficult decision making in IBD</i>	
08:00 - 08:10	1: Welcome Oded Zmora, Tel Aviv, Israel
08:10 - 09:50	Session 1: Difficult decision making in Ulcerative Colitis Fabrizio Michelassi, New York, United States Yehuda Chowers, Haifa, Israel
08:10 - 08:40	Debate 1: Timing of surgery in Acute Severe Colitis
08:10 - 08:20	2: Save the colon – medical treatments Silvio Danese, Milan, Italy
08:20 - 08:30	3: Save the patient – early surgery Antonino Spinelli, Milan, Italy
08:30 - 08:40	Discussion
08:40 - 09:10	Debate 2: Surgery for Ulcerative Colitis revisited
08:40 - 08:50	4: Ileorectal anastomosis is an attractive option Yves Panis, Clichy, France
08:50 - 09:00	5: Ileoanal pouch is universally best André D'Hoore, Leuven, Belgium
09:00 - 09:10	Discussion
09:10 - 09:40	The technique
09:10 - 09:20	6: Top down pouch surgery Tom Øresland, Oslo, Norway
09:20 - 09:30	7: Bottom up pouch surgery Janindra Warusavitarne, London, United Kingdom
09:30 - 09:40	Discussion
09:40 - 09:50	8: Video: TAMIS total proctocolectomy and ileoanal pouch Anders Tøttrup, Aarhus, Denmark
09:50 - 10:20	Coffee break

Thursday, February 16, 2017, cont.

*Programme overview (as of January 16, 2017) –
Room 113, Level 1, CCIB*

10:20 - 12:00	Session 2: The art and science of IBD surgery André D'Hoore, Leuven, Belgium Oded Zmora, Tel Aviv, Israel
10:20 - 10:30	9: Update on the RICCO study Léon Maggiori, Clichy, France
10:30 - 10:40	10: Update on the ACCURE trial (UK part) Thomas Pinkney, Birmingham, United Kingdom
10:40 - 10:50	11: Abstract 1: The role of intestinal transplant in patients with complicated Inflammatory Bowel Disease (IBD): The Cambridge experience Sze Pheh Yeap, Cambridge, United Kingdom Please refer to DOP079 on page 65
10:50 - 11:00	12: Abstract 2: Smooth Seton® for perianal fistulas: A knot-less solution Merle Stellingwerf, Amsterdam, The Netherlands Please refer to P551 on page 128
11:00 - 11:10	13: Abstract 3: Does biologic therapy increase the risk for fistula-associated mucinous adenocarcinoma in long standing perianal Crohn's Disease? Silvio Laureti, Bologna, Italy Please refer to DOP058 on page 59
11:10 - 11:20	14: Abstract 4: A multi-institutional report of postoperative outcomes in vedulizumab-treated patients undergoing major abdominal operations for Inflammatory Bowel Disease Amy Lightner, Rochester, United States Please refer to P357 on page 107
11:20 - 11:40	15: Imaging in the peri-operative management Yoram Bouhnik, Clichy, France
11:40 - 12:00	16: Surgical techniques to reduce recurrence rates in Crohn's Disease Fabrizio Michelassi, New York, United States
12:00 - 13:00	Lunch break
13:00 - 15:00	Session 3: Difficult decision making in Crohn's Disease Yves Panis, Clichy, France Janindra Warusavitarne, London, United Kingdom
13:00 - 13:30	Debate 3: Post successful percutaneous drainage of abscess
13:00 - 13:10	17: Surgery for all Michel Adamina, Winterthur, Switzerland
13:10 - 13:20	18: Still place for medical therapy Shomron Ben-Horin, Ramat Gan, Israel
13:20 - 13:30	Discussion
13:30 - 14:00	Debate 4: Anal fissure and hemorrhoids in Crohn's patients
13:30 - 13:40	19: Hands off Peter Irving, London, United Kingdom
13:40 - 13:50	20: Take the knife Paulo Kotze, Curitiba, Brazil
13:50 - 14:00	Discussion

Thursday, February 16, 2017, cont.

*Programme overview (as of January 16, 2017) –
Room 113, Level 1, CCIB*


14:00 - 14:30		Debate 5: The ileocolonic anastomosis
14:00 - 14:10	21: Side to side: Isoperistaltic vs. antiperistaltic	Gianluca Sampietro, Milan, Italy
14:10 - 14:20	22: Hand-assist vs. single port	Christianne Buskens, Amsterdam, The Netherlands
14:20 - 14:30	Discussion	
14:30 - 15:00		Video contest: How do I do lap ileocolic resection? (including preoperative and postoperative management)
14:30 - 14:37	23: My technique	Oded Zmora, Tel Aviv, Israel
14:37 - 14:44	24: My technique	Nuha Yassin, London, United Kingdom
14:44 - 14:51	25: My technique	Monica Millan, Barcelona, Spain
14:51 - 15:00	Discussion	
15:00 - 15:30		Coffee break
15:30 - 15:55		Session 4: Cutting edge topics in IBD Antonino Spinelli, Milan, Italy Paulo Kotze, Curitiba, Brazil
15:30 - 15:40	26: Stem cells for surgeons	Daan Hommes, Los Angeles, United States
15:40 - 15:55	27: IBD surgery: Last resort or another option	Willem Bemelman, Amsterdam, The Netherlands
15:55 - 16:55		Session 5: Decision making on the edge – consultants' corner Alessandro Armuzzi, Rome, Italy Fabrizio Michelassi, New York, United States Yves Panis, Clichy, France Krisztina Gecse, Budapest, Hungary
15:55 - 16:15	28: Perianal fistula	Hagit Tulchinsky, Tel Aviv, Israel
16:15 - 16:35	29: Crohn's pancolitis	Christoph Isbert, Würzburg, Germany
16:35 - 16:55	30: Acute Colitis	Giuseppe Sica, Rome, Italy
16:55 - 17:00		Closing remarks Janindra Warusavitarne, London, United Kingdom



European
Crohn's and Colitis
Organisation

Barcelona
Spain

Abstracts of the 12th Congress of ECCO



Record number: 922 accepted abstracts

Presentation format of ECCO'17 Barcelona abstracts

- **Oral presentations** of the best 38 abstracts in the Scientific Programme
- **Digital oral presentations** of 90 abstracts on Thursday and Friday afternoon
5 minute oral presentations in 5 rooms on Level 1 each day
- **Abstract USB drives** distributed at the ECCO Booth
- **Hard copy poster presentations** of all other accepted abstracts in the poster exhibition area
- **Guided poster tour** during Friday lunchtime

Scan and contact the ECCO Office
www.ecco-ibd.eu



4th ECCO Ultrasound Workshop

Date:	February 16, 2017
Time:	07:30-12:30
Organisation:	EduCom in collaboration with EFSUMB and ESGAR
Target audience:	Physicians with routine experience in intestinal ultrasound (IUS) and participants of the intestinal ultrasound training programme
Registration:	For registered participants only. No onsite registration
CME accreditation:	3 CME credits, upon return of an evaluation form distributed during the course



Thursday, February 16, 2017

*Programme overview (as of January 16, 2017) –
Room 122+123, Level 1, CCIB*

07:30 - 07:45	1: Welcome & Introduction Julián Panés, Barcelona, Spain
07:45 - 10:15	Session 1 Chairs: Gerhard Rogler, Zurich, Switzerland Christian Maaser, Lueneburg, Germany Andrea Laghi, Rome, Italy
07:45 - 08:00	2: Lecture: Ultrasound findings in Crohn's Disease and Ulcerative Colitis: Active vs. inactive Christian Maaser, Lueneburg, Germany
08:00 - 09:00	3: Part 1: Interactive video presentation of ultrasound cases of IBD: Active or inactive? Anil K. Asthana, Melbourne, Australia
09:00 - 09:15	4: Lecture: Mural and extramural complications of Crohn's Disease Torsten Kucharzik, Lueneburg, Germany
09:15 - 10:15	5: Part 2: Interactive video presentation of ultrasound cases of IBD: Mural and extramural complications of Crohn's Disease Kerri Novak, Calgary, Canada
10:15 - 10:30	Coffee break
10:30 - 12:00	Session 2 Chairs: Emma Calabrese, Rome, Italy Torsten Kucharzik, Lueneburg, Germany Jordi Rimola, Barcelona, Spain
10:30 - 10:45	6: Lecture: Role of bowel ultrasound in the postoperative Crohn's Disease Giovanni Maconi, Milan, Italy
10:45 - 11:00	7: Lecture: The role of contrast enhanced ultrasound and sonoelastography in IBD Odd Helge Gilja, Bergen, Norway
11:00 - 12:00	8: Part 3: Interactive video presentation of ultrasound cases of IBD: Postoperative Crohn's Disease Stephan Vavricka, Zurich, Switzerland
12:00 - 12:25	9: Post-course test
12:25 - 12:30	10: Final remarks Giovanni Maconi, Milan, Italy

2nd ECCO-AOCC Forum: Learning from the Masters

Date: February 16, 2017
Time: 09:00-12:00
Organisation: ECCO Governing Board
Target audience: Physicians, Surgeons
Registration: For registered participants only. No onsite registration
CME accreditation: n.a.



Thursday, February 16, 2017

*Programme overview (as of January 16, 2017) –
Room 118+119, Level 1, CCIB*

<i>Learning from the Masters</i>	
Session 1	
09:00 - 10:15	Julián Panés, Barcelona, Spain Mamoru Watanabe, Tokyo, Japan
09:00 - 09:15	1: Welcome & introduction Julián Panés, Barcelona, Spain
09:15 - 09:45	2: Topic: Surveillance colonoscopy for CRC in IBD Kenji Watanabe, Osaka, Japan
09:45 - 10:15	3: Endoscopic and imaging features of CD, intestinal TB, and Bechet disease: Is instantaneous diagnosis feasible? Jie Zhong, Shanghai, China
10:15 - 10:45	Coffee break
Session 2	
10:45 - 12:00	Marc Ferrante, Leuven, Belgium Jiaming Qian, Beijing, China
10:45 - 11:25	4: Topic: Magnetic resonance, Balloon enteroscopy or Capsule endoscopy for examination of the small bowel in Crohn's Disease – Tandem Talk Jeong-Sik Byeon, Seoul, Korea Rami Eliakim, Tel Aviv, Israel
11:25 - 11:55	5: Topic: Endoscopic balloon dilatation for stricturing CD Martin Götz, Tübingen, Germany
11:55 - 12:00	6: Closing remarks Suk-Kyun Yang, Seoul, Korea

5th SciCom Workshop: Methodology on Research

Date: February 16, 2017
Time: 09:00-12:00
Organisation: SciCom
Target audience: Basic scientists and interested clinicians
Registration: For registered participants only. No onsite registration
CME accreditation: 3 CME credits, upon return of an evaluation form filled in online

Thursday, February 16, 2017

*Programme overview (as of January 16, 2017) –
 Room 131+132, Level 1, CCIB*

Methodology on Research	
09:00 - 10:20	Session 1 Charlie Lees, Edinburgh, United Kingdom Florian Rieder, Cleveland, United States
09:00 - 09:05	1: Welcome & Introduction Charlie Lees, Edinburgh, United Kingdom
09:05 - 09:30	2: How to set-up a successful translational IBD unit – Providing the frame for future discovery Britta Siegmund, Berlin, Germany
09:30 - 09:55	3: Studying the microbiota – Bacteria and beyond Dirk Haller, Freising, Germany
09:55 - 10:20	4: Omics analysis – Can we see the forest for the trees Jeff Barrett, Cambridge, United Kingdom
10:20 - 10:40	Coffee break
10:40 - 12:00	Session 2 Britta Siegmund, Berlin, Germany Azucena Salas, Barcelona, Spain
10:40 - 11:05	5: Transgenic animal models in IBD – Tricks you cannot read in the manuscripts Arthur Kaser, Cambridge, United Kingdom
11:05 - 11:30	6: Studying drug response – translation of system biology to systems medicine Stefan Schreiber, Kiel, Germany
11:30 - 11:55	7: Recreating the intestine ex vivo – Where are we on the way to the artificial gut (organoids, etc.) Azucena Salas, Barcelona, Spain
11:55 - 12:00	8: Closing remarks Florian Rieder, Cleveland, United States

11th N-ECCO Network Meeting

Date:	February 16, 2017
Time:	N-ECCO Network Meeting: 09:00-17:00 Industry sponsored satellite symposium: 12:45-13:45
Organisation:	N-ECCO
Target audience:	IBD Nurses – advanced level
Registration:	For registered participants only. No onsite registration
CME accreditation:	n.a.

Thursday, February 16, 2017

*Programme overview (as of January 16, 2017) –
Room 112, Level 1, CCIB*

09:00 - 09:15	1: Welcome & Introduction Karen Kemp, Manchester, United Kingdom
09:15 - 10:30	Session 1: Quality care in IBD Kay Greveson, London, United Kingdom Adriana Rivera Sequeiros, Seville, Spain
09:15 - 09:45	2: Quality indicators in IBD Marian O'Connor, London, United Kingdom
09:45 - 10:00	3: Remote monitoring in IBD Kathleen Sugrue, Cork, Ireland
10:00 - 10:30	4: Patient Reported Outcomes (PRO'S) Karen Kemp, Manchester, United Kingdom
10:30 - 11:00	Coffee break
11:00 - 12:30	Session 2: Special considerations in IBD Usha Chauhan, Hamilton, Canada Francisca Murciano Gonzalo, Barcelona, Spain
11:00 - 11:30	5: Fertility and pregnancy in IBD Janneke van der Woude, Rotterdam, The Netherlands
11:30 - 12:00	6: Travel vaccines in IBD Kay Greveson, London, United Kingdom
12:00 - 12:30	7: Low Fodmap in IBD Kevin Whelan, London, United Kingdom
12:30 - 14:00	Lunch break (Self Guided Poster Round)
12:45 - 13:45	Industry Sponsored N-ECCO Network Meeting satellite symposium Please refer to page page 194

Thursday, February 16, 2017, cont.

Programme overview (as of January 16, 2017) –

Room 112, Level 1, CCIB

Session 3: Abstracts	
14:00 - 14:45	Karen Kemp, Manchester, United Kingdom Palle Bager, Aarhus, Denmark
14:00 - 14:15	8: NO001: Clinical and psychological factors associated with Erectile Dysfunction in Inflammatory Bowel Disease patients Barros, J. , Baima, J., Renosto, F., Sibia, C., Silva, R., Farinelli, E., Andriolli, G., Dorna, M., Saad-Hossne, R., Sasaki, L. Paulista State University - Botucatu Medical School, Botucatu, Brazil
14:15 - 14:30	9: NO002: Decision-making about emergency and planned stoma surgery for IBD: A qualitative exploration of patient and clinician perspectives Dibley, L.¹ , Czuber-Dochan, W. ¹ , Duncan, J. ² , Artom, M. ¹ , Burch, J. ³ , Wade, T. ¹ , Verjee, A. ⁴ , Cann, D. ⁴ , Warusavitarne, J. ³ , Norton, C. ¹ ¹ King's College London, Florence Nightingale Faculty of Nursing & Midwifery, London, United Kingdom, ² Guy's & St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom, ³ St Mark's Hospital, Harrow, Gastroenterology, London, United Kingdom, ⁴ Patient & Public Involvement Team, London, United Kingdom
14:30 - 14:45	10: NO003: IBD nurses as integral part of a multidisciplinary IBD team: Prospective study on view on patient outcomes Coenen, S.¹ , Weyts, E. ¹ , Geens, P. ¹ , Vermeire, S. ¹ , Ferrante, M. ¹ , Noman, M. ¹ , Ballet, V. ¹ , Vanhaecht, K. ² , Van Assche, G. ¹ ¹ UZ Leuven, Gastroenterology, Leuven, Belgium, ² UZ Leuven, Quality, Leuven, Belgium
14:45 - 15:15	Coffee break
Session 4: Medical management of IBD	
15:15 - 16:30	Kathleen Sugrue, Cork, Ireland Ester Navarro Correal, Barcelona, Spain
15:15 - 15:45	11: Therapeutic algorithms for IBD management Axel Dignass, Frankfurt, Germany
15:45 - 16:30	12: Mono vs. combo therapy Laurent Peyrin-Biroulet, Vandoeuvre-Lès-Nancy, France Charlie Lees, Edinburgh, United Kingdom
16:30 - 17:00	Closing remarks, N-ECCO in 2017 and beyond Karen Kemp, Manchester, United Kingdom

4th P-ECCO Educational Course

Date:	February 16, 2017
Time:	10:00-12:00
Organisation:	P-ECCO
Target audience:	Paediatricians, Physicians, Surgeons, IBD nurses
Registration:	For registered participants only. No onsite registration
CME accreditation:	2 CME credits, upon return of an evaluation form filled in online

Thursday, February 16, 2017

*Programme overview (as of January 16, 2017) –
Room 120+121, Level 1, CCIB*

10:00 - 12:00	<i>Clinical challenges in paediatric IBD</i> Salvatore Cucchiara, Rome, Italy Dan Turner, Jerusalem, Israel
10:00 - 10:05	<i>1: Welcome & Introduction</i> Dan Turner, Jerusalem, Israel
10:05 - 10:25	<i>2: Treat to target in paediatric IBD – same as in adults?</i> Patrick van Rheeën, Groningen, The Netherlands
10:25 - 10:50	<i>3: Cannabis in adolescents – any role?</i> Richard Russell, Glasgow, United Kingdom
10:50 - 11:15	<i>4: Bone health in IBD – does it concern paediatricians?</i> Dan Turner, Jerusalem, Israel
11:15 - 11:40	<i>5: New treatments targeting the microbiota (FMT, antibiotics) – a case-based discussion</i> Jarosław Kierkuś, Warsaw, Poland
11:40 - 12:00	<i>6: Vedolizumab in children and other biologics after TNF – what can we extrapolate? A case-based discussion</i> Hankje Escher, Rotterdam, The Netherlands

2nd H-ECCO IBD Masterclass

Date:	February 16-17, 2017
Time:	February 16, 2017: 13:30-17:10 February 17, 2017: 08:00-11:40
Organisation:	H-ECCO Working Group, endorsed by ESP
Target audience:	Histopathologists, Clinicians
Registration:	For registered participants only. No onsite registration
CME accreditation:	6 CME credits, upon return of an evaluation form filled in online



Thursday, February 16, 2017

*Programme overview (as of January 16, 2017) –
Room 129+130, Level 1, CCIB*

13:30 - 13:35	1: Welcome & Introduction Roger Feakins, London, United Kingdom
13:35 - 15:00	Session 1: Diagnosis Magali Svrcek, Paris, France James Lindsay, London, United Kingdom
13:35 - 13:50	2: What clinicians expect from pathologists James Lindsay, London, United Kingdom
13:50 - 14:00	3: What pathologists expect from clinicians Paula Borralho, Lisbon, Portugal
14:00 - 14:15	4: IBD – endoscopic features Gionata Fiorino, Rozzano, Italy
14:15 - 14:35	5: IBD in biopsies Roger Feakins, London, United Kingdom
14:35 - 15:00	6: Pathology of IBD in resections Neil Shepherd, Cheltenham, United Kingdom
15:00 - 15:30	Coffee break
15:30 - 17:10	Session 2: Mimics of IBD Paula Borralho, Lisbon, Portugal Neil Shepherd, Cheltenham, United Kingdom
15:30 - 15:45	7: Clinical mimics of IBD Laurent Beaugerie, Paris, France
15:45 - 16:05	8: Relationships between diverticulosis and IBD Vincenzo Villanacci, Brescia, Italy
16:05 - 16:25	9: Microscopic colitis and IBD Karel Geboes, Leuven, Belgium
16:25 - 16:45	10: Infection, drugs, and other pathological mimics of IBD Roger Feakins, London, United Kingdom
16:45 - 17:10	11: Dysplasia (with interactive cases) Magali Svrcek, Paris, France Vincenzo Villanacci, Brescia, Italy

Friday, February 17, 2017

Programme overview (as of January 16, 2017) –

Room 129+130, Level 1, CCIB

08:00 - 09:40	Session 3: Recent advances Vincenzo Villanacci, Brescia, Italy Fernando Magro, Porto, Portugal
08:00 - 08:25	12: Pathologists' role in clinical trials (Tandem talk) Fernando Magro, Porto, Portugal Paula Borralho, Lisbon, Portugal
08:25 - 08:55	13: Hot topics Magali Svrcek, Paris, France
08:55 - 09:10	14: Pathogenesis of fibrosis and fistulas in IBD Roger Feakins, London, United Kingdom
09:10 - 09:40	15: Prognostic factors for IBD – clinical and pathological (Tandem talk) Paula Borralho, Lisbon, Portugal Laurent Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France
09:40 - 10:10	Coffee break
10:10 - 11:35	Session 4: Outside the colon Roger Feakins, London, United Kingdom Peter Irving, London, United Kingdom
10:10 - 10:30	16: Extraintestinal manifestations of IBD Peter Irving, London, United Kingdom
10:30 - 10:50	17: Upper GI pathology in IBD Paula Borralho, Lisbon, Portugal
10:50 - 11:10	18: Ileal pathology in IBD and related disease Vincenzo Villanacci, Brescia, Italy
11:10 - 11:25	19: Pathology of IBD in primary sclerosing cholangitis Magali Svrcek, Paris, France
11:25 - 11:35	20: The ideal IBD pathology report Roger Feakins, London, United Kingdom
11:35 - 11:40	Closing remarks Roger Feakins, London, United Kingdom

2nd D-ECCO Workshop

Date:	February 17, 2017
Time:	08:30-12:30
Organisation:	D-ECCO Working Group
Target audience:	Dietitians, IBD nurses, physicians
Registration:	For registered participants only. No onsite registration
CME accreditation:	3 CME credits, upon return of an evaluation form filled in online

Friday, February 17, 2017

*Programme overview (as of January 16, 2017) –
Room 118+119, Level 1, CCIB*

08:30 - 08:35	1: Welcome Rotem Sigall-Boneh, Tel Aviv, Israel
08:35 - 09:40	Session 1: Nutritional science in IBD Rotem Sigall-Boneh, Tel Aviv, Israel Nicolette Wierdsma, Amsterdam, The Netherlands
08:35 - 08:55	2: Biology of SCFA Konstantinos Gerasimidis, Glasgow, United Kingdom
08:55 - 09:15	3: Food additives - a role in IBD? Arie Levine, Tel Aviv, Israel
09:15 - 09:35	4: Diet and microbiome Jeroen Raes, Ghent, Belgium
09:35 - 09:40	Q&A
09:40 - 10:00	Coffee break
10:00 - 11:05	Session 2: Clinical nutrition in IBD Kevin Whelan, London, United Kingdom Arie Levine, Tel Aviv, Israel
10:00 - 10:20	5: The role of diet in pre- and post-surgical management Miranda Lomer, London, United Kingdom
10:20 - 10:40	6: Enteral nutrition in adults: Has anything changed? Walter Reinisch, Vienna, Austria
10:40 - 11:00	7: Case presentation – dietitian's view Nicolette Wierdsma, Amsterdam, The Netherlands
11:00 - 11:05	Q&A
11:05 - 11:20	Coffee break
11:20 - 12:25	Session 3: Diet and nutritional aspects of IBD Miranda Lomer, London, United Kingdom Konstantinos Gerasimidis, Glasgow, United Kingdom
11:20 - 11:40	8: Calcium, Vitamin K2 and Vitamin D Tibor Hlavaty, Bratislava, Slovakia
11:40 - 12:00	9: EEN – not what you are used to Rotem Sigall-Boneh, Tel Aviv, Israel
12:00 - 12:20	10: Food related quality of life and the patient's perspective on diet Kevin Whelan, London, United Kingdom
12:20 - 12:25	Q&A
12:25 - 12:30	11: Closing remarks Konstantinos Gerasimidis, Glasgow, United Kingdom



European
Crohn's and Colitis
Organisation

Barcelona
Spain

Face-to-face with ECCO



Meet the ECCO Officers

Stop by the ECCO Booth during the coffee breaks

- Have a chat with the ECCO Officers in an informal atmosphere
- Engage in lively discussions about IBD and ECCO's Initiatives
- Explore the e-CCO Learning Platform
- Learn about UR-CARE

Scan and contact the ECCO Office
www.ecco-ibd.eu



Date of preparation: December 2016 PHEM/IMM/1216/0001 JanssenPharmaceutica NV



paid advertisement by Janssen Pharmaceutica

BRINGING INNOVATIONS TO LIFE

Our dedication to doctors, nurses and patients means we are always looking towards the future of healthcare.

See how our pioneering research is making a real difference to patients' lives **today** and discover what this means for **tomorrow**.

Visit us at booth number 18 or www.janssen.com/immunology

Experience & *Innovation*

janssen  Immunology

PHARMACEUTICAL COMPANIES OF 

Industry sponsored satellite symposia

Industry sponsored satellite symposia are organised by pharmaceutical companies. These symposia are open to all congress participants. Responsibility for the programme content remains with the sponsor.

Satellite symposia organisers have been made aware that satellite symposia must not be of any promotional nature.

ECCO has scheduled parallel satellite symposia on Thursday, February 16, 2017 at 11:30-12:30 and at 17:45-18:45, on Friday, February 17, 2017 at 07:15-08:15 and at 18:30-19:30, and on Saturday, February 18, 2016 at 07:15-08:15. Furthermore, parallel educational lunchtime satellite symposia are scheduled for Friday, February 17, 2017 at 12:40-13:20.

Satellite symposia are held in the main Plenary Hall on the Ground Level, respectively in the Parallel Hall (Room 116+117) on Level 1 of CCIB.

Educational lunchtime satellite symposia are held in the main Plenary Hall on the Ground Level, respectively in the Parallel Hall (Room 116+117, Level 1), Room 111 (Level 1) and Room 113 (Level 1) of CCIB.

The programmes of satellite symposia are not affiliated with ECCO. Please note that due to compliance reasons, non-prescribing delegates might not have access to industry sponsored satellite symposia.

Industry sponsored satellite symposia – Scientific programme

Thursday, February 16, 2017

Satellite symposium 1a – Organiser:		Pfizer
Meeting room:		Plenary Hall, Ground Level, CCIB
11:30 - 12:30	Patient and clinical perspectives: Understanding current pitfalls and recognising new therapeutic possibilities in Ulcerative Colitis Chair: Stephen Hanauer, Chicago, United States	
	11:30 - 11:35	Welcome and introduction
	11:35 - 11:50	The patient journey of living with Ulcerative Colitis Alessandro Armuzzi, Rome, Italy
	11:50 - 12:05	Unmet need, challenges and limitations of current management of Ulcerative Colitis Peter Irving, London, United Kingdom
	12:05 - 12:20	Beyond biologics: Emerging therapies in Ulcerative Colitis Stephen Hanauer, Chicago, United States
	12:20 - 12:30	Audience Q&A

Industry sponsored satellite symposia – Scientific programme

Thursday, February 15, 2017, cont.

Satellite symposium 1b – Organiser: Pfizer	
Meeting room: Parallel Hall (Room 116+117), Level 1, CCIB	
11:30 - 12:30	Talking points in IBD: - Evidence based switching to biosimilars - A pathway towards personalised medicine Chair: James Lindsay, London, United Kingdom



Debate topic 1

11:30 - 12:00	Biosimilars in IBD: To switch or not to switch? Peter Lakatos, Budapest, Hungary; Montreal, Canada Expert Panel Debate
----------------------	---

Debate topic 2

12:00 - 12:30	Personalised medicine in IBD: Rhetoric or reality? Walter Reinisch, Vienna, Austria Expert Panel Debate
----------------------	--

Satellite symposium 2a – Organiser: AbbVie	
Meeting room: Plenary Hall, Ground Level, CCIB	
17:45 - 18:45	Tackling the burden of IBD Chair: Subrata Ghosh, Birmingham, United Kingdom



17:45 - 17:50	Welcome and Introduction Subrata Ghosh, Birmingham, United Kingdom
17:50 - 18:05	Beyond the symptoms: Societal impact of IBD David T. Rubin, Chicago, United States
18:05 - 18:20	Patient in focus: The personal burden of IBD Subrata Ghosh, Birmingham, United Kingdom
18:20 - 18:35	Reducing the burden: Successful management of IBD Edouard Louis, Liege, Belgium
18:35 - 18:45	Summary and Q&A Subrata Ghosh, Birmingham, United Kingdom Panel

Satellite symposium 2b – Organiser: Shire	
Meeting room: Parallel Hall (Room 116+117), Level 1, CCIB	
17:45 - 18:45	Optimising the IBD journey from early intervention to management of intestinal failure Chair: Remo Panaccione, Calgary, Canada



Session 1

17:45 - 17:48	Welcome and introduction Remo Panaccione, Calgary, Canada
17:48 - 18:00	Are we getting the most from our IBD medicines? Peter Irving, London, United Kingdom
18:00 - 18:12	Defining evidence-based therapeutic goals for treat-to-target in IBD Remo Panaccione, Calgary, Canada
18:12 - 18:17	Q&A Remo Panaccione, Calgary, Canada

Session 2

18:25 - 18:28	Welcome and introduction Remo Panaccione, Calgary, Canada
18:28 - 18:40	Short bowel syndrome and intestinal failure in IBD: Current challenges and treatment options Jean-Frédéric Colombel, New York, United States
18:40 - 18:45	Q&A Remo Panaccione, Calgary, Canada

Industry sponsored satellite symposia – Scientific programme

Friday, February 17, 2017

Satellite symposium 3a – Organiser:		Takeda
Meeting room:		Plenary Hall, Ground Level, CCIB
07:15 - 08:15	Changing the game in Ulcerative Colitis: Impact of gut-selective therapy Chair: Jean-Frédéric Colombel, New York, United States	
	07:15 - 07:20	Welcome and introduction Jean-Frédéric Colombel, New York, United States
	07:20 - 07:30	Resetting expectations for therapy in Ulcerative Colitis Jean-Frédéric Colombel, New York, United States
	07:30 - 07:45	Remission in Ulcerative Colitis: Has it been achieved and for how long? Brian Feagan, London, Canada
	07:45 - 08:05	Meeting expectations for therapy: Do gut-selective biologics deliver? Stefan Schreiber, Kiel, Germany
	08:05 - 08:15	Panel discussion/Q&A Jean-Frédéric Colombel, New York, United States

Satellite symposium 3b – Organiser:		Tillotts
Meeting room:		Parallel Hall (Room 116+117), Level 1, CCIB
07:15 - 08:15	Mild-to-moderate IBD management: Challenges beyond inflammation Chair: Gerhard Rogler, Zurich, Switzerland	
	07:15 - 07:25	Welcome Gerhard Rogler, Zurich, Switzerland
	07:25 - 07:45	Treatment of Mild to Moderate IBD in the elderly Ian Arnott, Edinburgh, United Kingdom
	07:45 - 08:05	The relevance of PROs and biomarkers in clinical practice Jonas Halfvarson, Orebro, Sweden
	08:05 - 08:10	Panel discussion/Q&A
	08:10 - 08:15	Closing remarks Gerhard Rogler, Zurich, Switzerland

Lunchtime Satellite symposia – Scientific programme

Friday, February 17, 2017


Satellite symposium LS1 – Organiser:		Takeda
Meeting room:		Plenary Hall, Ground Level, CCIB
12:40 - 13:20	Targeting disease progression in Crohn's Disease: Defeating an unrelenting enemy Chair: Iris Dotan, Tel Aviv, Israel	
	12:40 - 12:45	Welcome and introduction Iris Dotan, Tel Aviv, Israel
	12:45 - 13:00	Slowing progression of Crohn's Disease: Decisive treatment for early and long-term remission Remo Panaccione, Calgary, Canada
	13:00 - 13:15	Early use of gut-selective therapy in Crohn's Disease for long-term remission Iris Dotan, Tel Aviv, Israel
	13:15 - 13:20	Q&A Iris Dotan, Tel Aviv, Israel

Lunchtime Satellite symposia – Scientific programme

Friday, February 17, 2017, cont.



Satellite symposium LS2 – Organiser: MSD	
Meeting room: Parallel Hall (Room 116+117), Level 1, CCIB	
12:40 - 13:20	It's time to get Ulcerative Colitis under continuous control Chair: Gert Van Assche, Leuven, Belgium
	<p>12:40 - 12:50 Introduction: Why do we need to achieve continuous control of disease activity in Ulcerative Colitis? Gert Van Assche, Leuven, Belgium</p> <hr/> <p>12:50 - 13:20 Interactive discussion: Benefit of Continuous Clinical Response (CCR) for patients and HCPs. PRO2 and other outcome measures for Ulcerative Colitis patients Gert Van Assche, Leuven, Belgium James Lindsay, London, United Kingdom</p>

Lunch symposium LS3 – Organiser: Nikkiso	
Meeting room: Room 111, Level 1, CCIB	
12:40 - 13:20	New treatment option in second-line Ulcerative Colitis patients Chair: Wolfgang Kruis, Cologne, Germany Axel Dignass, Frankfurt, Germany
	<p>12:40 - 12:45 Welcome and introduction Wolfgang Kruis, Cologne, Germany Axel Dignass, Frankfurt, Germany</p> <hr/> <p>12:45 - 13:10 Novel Leukocyte/Thrombocyte Apheresis for induction of remission in Ulcerative Colitis – a controlled, randomized pilot study Wolfgang Kruis, Cologne, Germany</p> <hr/> <p>13:10 - 13:15 An open label, multicentre, post marketing clinical investigation on the efficacy and safety of twice-a-week leukopheresis in Mild to Moderate active Ulcerative Colitis: An interim analysis Alessandro Armuzzi, Rome, Italy Gionata Fionino, Milan, Italy</p> <hr/> <p>13:15 - 13:20 Questions & Answers/Discussion/Closing remarks Wolfgang Kruis, Cologne, Germany Axel Dignass, Frankfurt, Germany</p>

Lunch symposium LS4 – Organiser: Celltrion	
Meeting room: Room 113, Level 1, CCIB	
12:40 - 13:20	Witness the evolving landscape of IBD treatment driven by evidence Chair: Stefan Schreiber, Kiel, Germany
	<p>12:40 - 12:45 Welcome & Opening Stefan Schreiber, Kiel, Germany</p> <hr/> <p>12:45 - 12:55 Perceptual evolution on Biosimilar mAb Walter Reinisch, Vienna, Austria</p> <hr/> <p>12:55 - 13:05 3.4 CD: Another step towards evidence based extrapolation Young Ho Kim, Seoul, Republic of Korea</p> <hr/> <p>13:05 - 13:15 NOR-SWITCH: Another step towards evidence based switching Jørgen Jahnsen, Oslo, Norway</p> <hr/> <p>13:15 - 13:20 Panel Discussion</p>

Industry sponsored satellite symposia – Scientific programme

Friday, February 17, 2017

Lunch symposium 4a – Organiser:		TiGenix/Takeda
Meeting room:		Plenary Hall, Ground Level, CCIB
18:30 - 19:30	Perianal Crohn's Disease: Exploring a serious burden Chair: Michael Kamm, Melbourne, Australia	
	18:30 - 18:40	Crohn's Disease and complex perianal fistula: The scope of the problem and understanding the burden Michael Kamm, Melbourne, Australia
	18:40 - 19:05	Multidisciplinary perspectives on the management of complex perianal fistula: Current challenges Gert Van Assche, Leuven, Belgium Andre D'Hoore, Leuven, Belgium Michael Kamm, Melbourne, Australia
	19:05 - 19:17	View to the future: Potential new approaches to manage complex perianal fistula Alessandro Armuzzi, Rome, Italy
	19:17 - 19:30	Panel discussion and concluding remarks Michael Kamm, Melbourne, Australia

Lunch symposium 4b – Organiser:		Janssen
Meeting room:		Parallel Hall (Rooms 116+117), Level 1, CCIB
18:30 - 19:30	Raising the bar: Defining the new era of Crohn's Disease management Chair: Subrata Ghosh, Birmingham, United Kingdom	
	18:30 - 18:35	Welcome and overview of learning objectives Subrata Ghosh, Birmingham, United Kingdom
	18:35 - 18:45	Unmet needs: How new ideas will make progress Subrata Ghosh, Birmingham, United Kingdom
	18:45 - 19:00	Long term management: Tailoring treatment to patient profiles and objectives markers Iris Dotan, Tel Aviv, Israel
	19:00 - 19:20	A new era in treatment: IL-12/23 in IBD therapy Matthieu Allez, Paris, France
	19:20 - 19:30	Questions and closing remarks Subrata Ghosh, Birmingham, United Kingdom Matthieu Allez, Paris, France

International Symposia and Workshops

*Scientific Dialogue
in the Interest of
Therapeutic Progress*



Workshop
**Future Perspectives in Hepatology:
From Basics to Clinics**
Essen, Germany
January 19 – 20, 2017



Symposium 206
**From the New and Complex Concepts
to the Real Patient: Science and Clinic**
Madrid, Spain
March 31 – April 1, 2017



Symposium 207
**Mucosal Microbiome and Mucosal
or Systemic Dysfunction:
Mechanisms, Clinical Manifestations
and Interventions**
Brisbane, Australia
May 19 – 20, 2017

IX Gastro-Conference

Berlin, Germany
October 4 – 7, 2017



Symposium 208
**Eosinophilic Esophagitis –
Medical and Dietary Treatment**
Berlin, Germany
October 4 – 5, 2017



Symposium 209
**IBD 2017 – Therapeutic
and Biological Barriers**
Berlin, Germany
October 6 – 7, 2017



Workshop
**Workshop on Oral, Gastrointestinal
and Pulmonary GvHD**
Regensburg, Germany
November 17 – 18, 2017

FALK FOUNDATION e.V.



Leinenweberstr. 5
79108 Freiburg
Germany

Congress Department
Tel.: +49 (0)761/1514-125
Fax: +49 (0)761/1514-359
E-Mail: symposia@falk-foundation-symposia.org
www.falk-foundation-symposia.org

2017

Industry sponsored satellite symposia – Scientific programme

Saturday, February 18, 2017

Satellite symposium 5a – Organiser: Pfizer	
Meeting room: Plenary Hall, Ground Level, CCIB	
07:15 - 08:15	Evolving Patient and physician expectations in UC Management Chair: Corey Siegel, New Hampshire, United States
	07:20 - 07:35 Beyond the bowel: Clinical needs of patients with Ulcerative Colitis Iris Dotan, Tel Aviv, Israel
	07:35 - 07:50 Beyond traditional patient engagement: Enhancing communication and shared decision making Corey Siegel, New Hampshire, United States
	07:50 - 08:05 Beyond current therapies and treatment strategies: What can we do to optimise patient outcomes? Stefan Schreiber, Kiel, Germany

Satellite symposium 5b – Organiser: Boehringer Ingelheim	
Meeting room: Parallel Hall (Rooms 116+117), Level 1, CCIB	
07:15 - 08:15	What would the world look like if everybody had Inflammatory Bowel Disease? Chair: Walter Reinisch, Vienna, Austria
 Boehringer Ingelheim	07:15 - 07:30 Opening and introduction Walter Reinisch, Vienna, Austria
	07:30 - 08:10 Interdisciplinary discussion: What would an IBD-focused world look like? Discussants: Sam Cleasby, Sheffield, United Kingdom Niels Vande Castele, San Diego, United States Göran Lindahl, Gothenburg, Sweden Sherrilyn Roush, London, United Kingdom
	08:10 - 08:15 Summary: What can we bring back to our world? Walter Reinisch, Vienna, Austria



What if

everyone in the world had IBD?

Join us for the
Boehringer Ingelheim
satellite symposium

**From 7:15 am to 8:15 am
on Saturday 18 February**

**Parallel Hall
Room 116 & 117**

Breakfast will
be served

*This programme is not
affiliated with ECCO*




**Boehringer
Ingelheim**




Industry sponsored satellite symposia – Educational programme

Wednesday, February 15, 2017 – ECCO Endoscopy Workshop

Satellite symposium organiser:		Medtronic
Meeting room:		Room Room 122+123, Level 1, CCIB
11:45 - 12:45	Impact of capsule endoscopy (CE) on Crohn's management: A pan-intestinal capsule for a pan-intestinal disease Chairs: Vito Annese, Florence, Italy	
	11:45 - 12:05	The significance of small bowel involvement in Crohn's Disease Joerg Albert, Frankfurt, Germany
	12:05 - 12:25	Endoscopic assessment of bowel mucosal activity: Role of capsule endoscopy to monitor Crohn's Disease patient Bruno Rosa, Guimarães, Portugal
	12:25 - 12:45	A pan-intestinal tool for a pan-intestinal disease Rami Eliakim, Tel Aviv, Israel

Wednesday, February 15, 2017 – IBD Intensive Advanced Course

Satellite symposium organiser:		Vifor Pharma
Meeting room:		Room 111, Level 1, CCIB
16:00 - 17:00	Case-based learning; managing iron deficiency in different clinical IBD-patient situations Chair: Stephan Vavricka, Zurich, Switzerland	
	16:00 - 16:05	Welcome and introduction Stephan Vavricka, Zurich, Switzerland
	16:05 - 16:20	Iron deficiency pathways Jan Wehkamp, Tübingen, Germany
	16:20 - 16:50	Special clinical situations (patient cases)
	16:20 - 16:35	Managing iron deficiency in a newly diagnosed acute IBD patient Antonio López San Román, Madrid, Spain
	16:35 - 16:50	Managing iron deficiency in a chronic IBD patient Philip Esters, Frankfurt, Germany
	16:50 - 17:00	Summary and conclusions Stephan Vavricka, Zurich, Switzerland

Thursday, February 16, 2017 – N-ECCO Network Meeting

Satellite symposium organiser:		Takeda
Meeting room:		Room 112, Level 1, CCIB
12:45 - 13:45	IBD Nursing in the real world Chair: Usha Chauhan, Hamilton, Canada	
	12:45 - 12:50	Introduction to IBD nursing today Usha Chauhan, Hamilton, Canada
	12:50 - 13:00	Plenary session: Understanding and communicating complex immunology concepts Alexander Moschen, Innsbruck, Austria
	13:00 - 13:15	Plenary session: Understanding IBD patient psychology Yoram Inspector, Harrow, United Kingdom
	13:15 - 13:40	Interactive panel discussion: IBD nursing in the real world Michaela Schara, Dreistetten, Austria Yoram Inspector, Harrow, United Kingdom Alexander Moschen, Innsbruck, Austria
	13:40 - 13:45	Q&A session and concluding remarks Usha Chauhan, Hamilton, Canada



Congress information

Badges

Badges must be worn at all times throughout the entire congress and during social events. The coloured stripes on the name badges have the following significance:

- Congress delegates, Faculty members, Press
- Exhibitors, Participants of educational activities only
- Congress day ticket holders
- Congress Organiser, Staff

Banks and ATM

Banks are usually open from 8:30-14:00 (Monday-Friday), and remain closed on weekends. There will be ATMs at the nearby shopping mall and all over the city of Barcelona. At the airport and main station and along the main streets you will find currency exchange offices.

Business centre

A business centre with copy and fax services (at a charge) is located at Hilton Diagonal Mar next to the CCIB.

Certificate of attendance

All registered delegates can download and print their certificate of attendance in their individual user area in the online registration system after the congress.

Cloakroom

The cloakroom can be found in the Foyer of the Rambla on Level S0 of the CCIB. Neither the CCIB nor the congress organisers may be held liable for any loss of belongings dropped off at the cloakroom.

Congress bags

All registered delegates with a badge and a bag voucher are entitled to receive an ECCO'17 congress bag. With the fair trade bags by Township, ECCO supports their mission in creating a sustainable economic opportunity for women in South Africa's township communities. Please note that exhibitors are not entitled to receive a bag. Please note that congress bags for non-prescribers do not include any advertisements related to prescription-only medicines.

Coffee breaks

Coffee breaks are always served in the exhibition hall on the Ground level. This year ECCO offers coffee and pastries free of charge, snacks and lunch are served at cash catering stations. Attendees of the educational lunchtime symposia on Friday will be offered lunch prior to or after the symposium. Water fountains are available throughout the congress venue.

Congress documentation

Abstract USB drives

The congress bags include a voucher for the abstract USB drive with all abstracts. To obtain abstracts on an ECCO USB drive, please visit the ECCO Booth in the foyer on Level 1.

Abstracts – Online access

All abstracts can be found online (www.ecco-ibd.eu) as well as on your smart phones (mobile version of the ECCO Website) and the digital & website edition of JCC – Journal of Crohn's and Colitis. Further, computer access points will be available in the Banquet hall (Level 2) for looking up abstracts online.

Online streaming (post-event)

Members of ECCO can access the presentations of the 12th Congress of ECCO after the event - online at www.ecco-ibd.eu in the e-Library of the e-CCO Learning platform. Presentation availability is subject to speaker authorisation.

Congress organiser

OCEAiN – Organisation, Congress, Emotion, Association, iNnovation GmbH*

ECCO Office

Ungargasse 6/13

1030 Vienna, Austria

Phone: +43-(0) 1-710 22 42

Fax: +43-(0) 1-710 22 42-001

E-mail: ecco-congress@ecco-ibd.eu

Web: www.ecco-ibd.eu/ecco17



European
Crohn's and Colitis
Organisation

*service provider fully owned by European Crohn's and Colitis Organisation

Congress venue

CCIB

Plaça de Willy Brandt, 11-14

08019 Barcelona, Spain

www.ccib.es



Credit cards

All major cards are widely accepted, though in some small shops or hotels, there might occur an extra charge (2-6%). When paying by credit card for your shopping, you will be asked to show an identification document. Please have your ID card or passport with you all the time, otherwise they may refuse to accept your credit card as payment.

Currency

The Spanish currency is the Euro (EUR). Major credit cards are accepted at most large businesses. When you are exchanging your currency, you need your passport or official ID card. If you don't have it with you, the bank may refuse to exchange your currency.

Disclaimer

Please note that in the event of a cancellation of the congress by the organisers in case of force majeure, the registration fee, hotel deposit and any other service ordered through the registration will be partially refunded or forfeited, subject to the commitments of the congress organiser at that time. You may wish to insure yourself directly against such a risk.

ECCOlogical

At ECCO, we believe that our commitment to more eco-friendly & sustainable meetings will benefit our host destinations by leaving a minimum ecological footprint and will elevate the delegate experience.

Traditionally, congresses and exhibitions are renowned for producing lots of unnecessary waste. At the 12th Congress of ECCO, we actively demonstrate our commitment to greener meetings as best as we can with a number of measures. For details please refer to the ECCO Congress website (www.ecco-ibd.eu/ecco17).



Face-to-face with ECCO

Following the great success of the “Face-to-face with ECCO” in the previous years, this year’s “Face-to-face with ECCO” will again be held at the ECCO Booth (Entrance Hall) during the coffee breaks.

Please stop by the ECCO Booth to have a chat with ECCO Officers in an informal atmosphere and to engage in lively discussions about IBD and ECCO’s initiatives!

Floor plans

Please refer to page 208-210.

General regulations

Visitors of the 12th Congress of ECCO are kindly asked to adhere to the following rules and regulations:

- Entrance to the 12th Congress of ECCO and affiliated events is granted only with the congress badge. Entrance to the “ECCO Interaction: Hearts and Minds” is only granted with an entrance ticket.
- The congress organiser may not be held liable for any theft and/or loss of visitors’ individual property. It is the visitors’ sole responsibility to keep their belongings safe.

Industry exhibition

Please refer to page 204.

Information on Barcelona

For information on Barcelona, such as tours, restaurants, museums, churches/synagogues please refer to the desk “Barcelona information” in the entrance hall.

Insurance and liability

Neither the congress organiser nor the CCIB will assume any responsibility whatsoever for damage or injury to persons or property during the congress. Participants are recommended to arrange their personal travel and health insurance.

Internet access

Internet access is provided by Pfizer in the Internet Lounge located in the Banquet Hall. Please limit the viewing time to max. 5 minutes per person. Free WiFi is provided in the Entrance Hall and in the Plenary Hall. Please use the network ECCO2017, no password is required.

Language

The official language of the congress is English. No simultaneous translation will be provided.




European
Crohn's and Colitis
Organisation

Barcelona
Spain

ECCO e-Guide

Stop by for
a try @ the
ECCO Booth



Congress special: Updated edition 2017

- A new resource within the e-Learning Platform
- Brings utility to ECCO Guidelines
- Integrates all UC and CD Consensus Statements
- Disease calculators
- Algorithmic maps follow the patient journey
- Computer and tablet compatible
- Open access



Scan and visit
www.e-guide.ecco-ibd.eu



Lost and found

For lost and found service in the CCIB, please stop by the ECCO Booth (Entrance Hall) or the ECCO Congress Office (Room 133+134, Level 1).
For help in locating property lost outside the CCIB, please contact the registration desk.

Medical facilities

Medical assistance can be provided by qualified onsite staff in a first aid room located under escalator C on Level M0.

Photos, Filming and Recording

It is forbidden to film, take photos or record any presentation during the ECCO'17 scientific or educational programme and any poster presentation without the consent of the organiser (including smart phones, mobile devices, etc.).
Please note that the entire scientific programme as well as several educational activities will be recorded and published on ECCO's e-Learning platform after the congress and will be available for viewing for all ECCO Members free of charge. Further, all abstracts and presentations (subject to speaker authorisation) are included in the e-Library.

Poster exhibition

Please refer to page 40.

Programme changes

ECCO cannot assume liability for any changes in the ECCO'17 Congress programme and programmes of the educational activities due to external or unforeseen circumstances.

Public transportation



The CCIB is well served by Barcelona's metro system with El Maresme Fòrum station on the Yellow Line **L4** being only a few minutes' walk from the CCIB. Furthermore, the CCIB can be reached by bus (lines 7, 36,41,43 and 141) and the Trambesòs tram line (Forum station).



Registration and accommodation

All registration procedures for the 12th Congress of ECCO have been conducted online. In case you wish to register onsite please refer to the registration desk in the entrance hall on the ground level where you will be assisted with your queries.

Registration desk and ECCO Congress Office

Opening hours of the ECCO Congress Office and the registration desk at the CCIB:

Wednesday, February 15, 2017	07:00 - 19:00
Thursday, February 16, 2017	07:00 - 19:00
Friday, February 17, 2017	07:00 - 19:00
Saturday, February 18, 2017	07:00 - 13:00

The registration desk can be found in the entrance hall of the CCIB. The ECCO Congress Office is located in Room 133+134, Level 1.

Registration fees

Fee in EURO (including 21% Spanish VAT)	Early registration until November 3, 2016	Late registration until February 1, 2017	Onsite registration after February 1, 2017
ECCO Member Congress registration fees:			
<i>Regular/Regular (Y-ECCO) Member Congress fee</i>	250.-	320.-	400.-
<i>Nurse Member Congress fee</i>	55.-	95.-	145.-
<i>Affiliate Member Congress fee¹</i>	55.-	95.-	145.-
Non-Member Congress registration fees:			
<i>Non-Member Congress fee</i>	605.-	685.-	770.-
<i>Nurse Non-Member Congress fee²</i>	355.-	395.-	545.-
<i>Affiliate Non-Member Congress fee³</i>	355.-	395.-	545.-
<i>Patient Advocate Congress fee⁴</i>	55.-	55.-	55.-

¹Students/PhD Students registering at the Affiliate Member Congress fee must upload a certificate of their Student/PhD Student status during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

²Nurses registering at the Nurse Non-Member Congress fee must upload a certificate of their current nurse status and registration number during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

³Students/PhD Students and delegates with the following professions may register for the Affiliate Non-Member Congress fee: Dietitian, Pharmacist, Psychologist. All delegates registering at this fee must upload a certificate of their professional status/Student or PhD Student status during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

⁴Patient Advocates registering at this fee must upload a proof of their membership of a Patient Advocate Association during the registration process. If no certificate is being uploaded, the registration process cannot be completed. Please note that you might not have access to industry sponsored satellite symposia.

Registration fee for delegates includes:

- Access to all scientific sessions and satellite symposia
- Access to poster exhibition
- Access to industry exhibition
- Free copy of all congress documentation
- Certificate of attendance
- Access to congress abstracts
- Congress bag
- Coffee break

Please note that in order to pick-up a pre-paid ticket, the passport/ID of the delegate must be shown.

Speakers' centre

The speakers' centre is located in the VIP Room on Level M1 (accessible via the entrance hall). Speakers are asked to hand in their power point presentation preferably three hours prior to the presentation. The presentation will be transferred to the central congress server and will be available on a special congress notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook. Technical staff will be happy to assist.

In order to facilitate the process and reinforce the 2nd slide policy, faculty speakers are reminded to disclose their potential conflicts of interest in their Power Point slides in line with UEMS regulations. Based on the submitted Col form of each speaker, a draft Col slide has been prepared and is made available in the Speakers' centre with a reminder that if the respective presentation does not yet include a disclosure form, the slide draft should be checked/amended and included in the Power Point slides.

Opening hours of the Speakers' centre at the CCIB:

Wednesday, February 15, 2017	07:00 - 18:00
Thursday, February 16, 2017	07:00 - 18:30
Friday, February 17, 2017	06:45 - 19:00
Saturday, February 18, 2017	06:45 - 13:00

ECCO Business meetings

Upon invitation only.

Tuesday, February 14, 2017

<i>UR-CARE Meeting</i>	13:30 - 16:00	Room M213 (Level M2)
<i>Y-ECCO Meeting</i>	14:00 - 16:00	Room M220 (Level M2)
<i>ClinCom Meeting</i>	16:30 - 18:30	Room M219 (Level M2)
<i>EduCom Meeting</i>	16:30 - 18:30	Room M220 (Level M2)
<i>D-ECCO WG Meeting</i>	16:30 - 18:30	Room M221 (Level M2)
<i>UR-CARE Study Project Meeting</i>	16:00 - 18:00	Room M213 (Level M2)
<i>GB Update on ECCO Guidelines</i>	18:00 - 18:30	Room M213 (Level M2)
<i>GuiCom Meeting</i>	19:00 - 21:00	Room M213 (Level M2)
<i>SciCom Meeting</i>	19:00 - 21:00	Room M220 (Level M2)
<i>EpiCom Meeting</i>	19:00 - 21:00	Room M219 (Level M2)
<i>N-ECCO Meeting</i>	19:00 - 21:00	Room M221 (Level M2)

Wednesday, February 15, 2017

<i>ECCO-OUP Meeting</i>	11:15 - 12:45	Room M214 (Level M2)
<i>Biocycle Consortium Meeting</i>	12:00 - 15:00	Room 129 (Level 1)
<i>S-ECCO Meeting</i>	15:45 - 17:45	Room M213 (Level M2)
<i>H-ECCO WG Meeting</i>	15:45 - 17:45	Room M221 (Level M2)
<i>P-ECCO Meeting</i>	16:15 - 17:45	Room M214 (Level M2)
<i>N-ECCO National Representatives Meeting</i>	17:45 - 19:45	Room 131+132 (Level 1)
<i>Operational Board Meeting</i>	18:15 - 20:15	Room M213 (Level M2)

Thursday, February 16, 2017

<i>JCC Associate Editors Meeting with OUP</i>	07:15 - 08:45	Room 128 (Level 1)
<i>PIBD C&M Investigators' Meeting</i>	07:30 - 09:00	Room 120+121 (Level 1)
<i>ClinCom National Study Group Meeting</i>	08:00 - 10:00	Room 129+130 (Level 1)
<i>EBMT meets ECCO</i>	09:00 - 10:00	Room 128 (Level 1)
<i>Governing Board Meeting</i>	10:30 - 12:15	Room 128 (Level 1)
<i>EpiCom Study Group Meeting</i>	10:15 - 12:45	Room 129+130 (Level 1)
<i>General Assembly</i>	19:00 - 20:00	Room 112 (Level 1)
<i>Strategic Council Meeting</i>	20:00 - 20:30	Room 112 (Level 1)

Friday, February 17, 2017

<i>JCC Editorial Board Meeting</i>	07:15 - 08:15	Room 111 (Level 1)
<i>IOIBD Meeting</i>	10:30 - 11:00	Room 128 (Level 1)
<i>I-CARE Meeting</i>	11:00 - 12:30	Room 113 (Level 1)
<i>VEDOKIDS Investigators' Meeting</i>	12:30 - 13:30	Room 128 (Level 1)
<i>AOCC-ECCO Meeting</i>	18:20 - 19:20	Room 128 (Level 1)

Industry exhibition

Opening hours


Thursday, February 16, 2017	12:00 – 18:00
Friday, February 17, 2017	09:30 – 18:00
Saturday, February 18, 2017	09:30 – 13:00

List of exhibitors & sponsors

Company	Booth number
<i>AbbVie</i>	2
<i>AbbVie</i>	19
<i>Biogen</i>	29
<i>Boehringer Ingelheim Pharma</i>	21
<i>BÜHLMANN Laboratories</i>	10
<i>Calpro</i>	25
<i>Celgene</i>	8
<i>Celltrion</i>	5
<i>Cisbio Bioassays</i>	39
<i>DiaSorin</i>	12
<i>Dr. Falk Pharma</i>	15
<i>Eurospital</i>	40
<i>European Federation of Crohn's and Colitis Associations</i>	31
<i>Ferring</i>	28
<i>Genetic Analysis</i>	35
<i>Gilead</i>	11
<i>Grifols</i>	24
<i>Immundiagnostik AG</i>	30
<i>Inova Diagnostics</i>	36
<i>Janssen</i>	18

Company	Booth number
<i>La Lettre de l' Hepato-gastroenterologue (EDIMARK)</i>	27
<i>Medtronic</i>	26
<i>Mendes</i>	37
<i>MSD</i>	7
<i>Nikkiso</i>	22
<i>ORGENTEC Diagnostika</i>	38
<i>Origin Sciences</i>	34
<i>Pfizer</i>	16, 20
<i>R-Biopharm</i>	13
<i>Robarts Clinical Trials B.V</i>	23
<i>Roche</i>	14
<i>Sandoz</i>	4
<i>Shield Therapeutics</i>	3
<i>Shire</i>	6
<i>Takeda</i>	1
<i>Theradiag</i>	32
<i>Tillotts</i>	17
<i>Vifor Pharma</i>	9
<i>Wisepress</i>	33

Exhibition plan



Corporate Members

ECCO gratefully acknowledges the support of the following ECCO Corporate Members:

abbvie

Biogen

Celgene

BÜHLMANN

HEALTHCARE
CELLTRION

DyFalk

COSMO
Pharmaceuticals

ETHICON
PART OF THE Johnson-Johnson FAMILY OF COMPANIES

GILEAD
Advancing Therapeutics.
Improving Lives.

FERRING
PHARMACEUTICALS

GRIFOLS

Janssen
PHARMACEUTICAL COMPANIES
OF Johnson-Johnson

Hospira
A Pfizer Company

Lilly

mundipharma

NestléHealthScience

MSD

Otsuka

nograPharma

Pfizer

SANDOZ A Novartis
Division

SHIELD
THERAPEUTICS

Roche

TIGENIX
Living Medicines

Takeda

Shire

TILLOTTS PHARMA
ZERIA GROUP

Vifor Pharma



ECCO Interaction: Hearts and Minds

ECCO Interaction: Hearts and Minds is THE event at ECCO to see and be seen, to network and engage. Anyone who has been to a previous ECCO Congress knows that it is a must and everyone is welcome, but places are limited.

“Step into the IBD Future”: This year’s edition of the ECCO Interaction: Hearts and Minds will be held at the prestigious Museu Nacional d’Arts de Catalunya.

Date: Friday, February 17, 2017

Start time: 20:30

Venue: Museu Nacional d’Arts de Catalunya, Palau Nacional, Parc de Montjuïc, 08038 Barcelona

How to get to Museu Nacional d’Arts de Catalunya from the CCIB by using public transportation:

Take the metro **L4** from “El Maresme/Fòrum” in direction to “Trinitat Nova” and get off at the station “Urquinaona”. Then change to metro **L1** in direction to “Hospital de Bellvitge” and get off at the station “Espanya”.

When leaving the metro station, walk along Avenida Reina Maria Christina and take the escalators up to Museu Nacional d’Art de Catalunya.

Tickets need to be picked up at the registration desk “ECCO Interaction: Hearts and Minds” which is located in the entrance hall of the CCIB.

Access to the event is strictly granted with ECCO Interaction tickets only. Please make sure to bring your ticket with you. **No ticket sale onsite at the Museu Nacional!**

Y-ECCO Networking Corner

- Unique opportunity to meet key opinion leaders from the Governing Board and Operational Board of ECCO and to network with fellow Y-ECCO Members
- Where/When
 - At the ECCO Interaction: Hearts and Minds 2017
 - Museu Nacional
 - 20:30-21:00
- Welcome drinks served
- Join the main interaction following this great event
- Make sure you are registered and have your ticket with you!


Floor plans

CCIB, Ground level

- Plenary Hall: Scientific sessions, satellite symposia
- Industry exhibition, catering (Exhibition hall)
- Registration area
- ECCO Booth, e-Terminals
- ECCO Members' Lounge


CCIB, Level S0

- Cloakroom




CCIB, Level M1

- Speakers' centre (VIP Room)




CCIB, Level 1


- 15th IBD Intensive Advanced Course, 6th Scientific Workshop (Room 111)
- 15th IBD Advanced Course – Breakout (Room 118)
- 11th N-ECCO Network Meeting (Room 112)
- 3rd Advanced Industry Course, 6th S-ECCO IBD Masterclass (Room 113)
- 2nd School for Clinical Trialists, 4th N-ECCO Research Forum (Room 124+125)
- 2nd ECCO Endoscopy Workshop, 3rd ECCO Ultrasound Workshop (Room 122+123)
- 3rd Y-ECCO Basic Science Workshop, 10th Y-ECCO Career Workshop, 4th P-ECCO Educational Course, (Room 120+121)
- AOCC-ECCO Forum, 2nd D-ECCO Workshop (Room 118+119)
- 2nd H-ECCO IBD Masterclass (Room 129+130)
- 8th N-ECCO School, 5th SciCom Workshop: Methodology on Research (Room 131+132)
- 8th N-ECCO School – Breakout (Room 130)
- Scientific programme Session 9 (Room 111)
- Digital oral presentations (Room 111, 113, Room 114, Room 115, Room 118+119)
- Satellite symposia (Room 111, Room 112, Room 113, Room 116+117)
- ECCO Congress Office (Room 133+134)



CCIB, Level 2

- Poster exhibition
- Internet lounge and abstract printing





AIBD | 2017

ADVANCES in INFLAMMATORY
BOWEL DISEASES

SAVE THE DATE FOR 2017
NOVEMBER 9–11, 2017 | ORLANDO, FLORIDA
WALT DISNEY WORLD DOLPHIN HOTEL

CHAIRS

RICHARD P. MACDERMOTT, MD
Emeritus Professor of Medicine
Albany Medical Center
Albany, New York

STEPHEN B. HANAUER, MD
Northwestern Feinberg
School of Medicine
Chicago, Illinois

MIGUEL D. REGUEIRO, MD
University of Pittsburgh
School of Medicine
Pittsburgh, Pennsylvania



REGISTRATION IS NOW OPEN!
Take advantage of BIG savings through Early Registration rates.

VISIT WWW.ADVANCESINIBD.COM

Index of authors

(bold = first author)

- A**abakken, L. P429
Aaltonen, G. **P264**
Aaltonen, J. P515
Aantjes, M. P559
Abbara, A. P439
Abbasi, F. P743
Abdulganieva, D. **P011**, P163
Abdulhakov, R. P794
Abdulhakov, S. P011, P794
Abdullhaq, M. P173
Abel, A. P283
Abitbol, V. DOP011, DOP027, P471
Abraham, C. **N821**
Abu Dayyeh, B. P263
Abu Hashem, R. DOP073 P544, P588
Accomando, S. P412
Acton, N. P219, P479, P591, **P707**
Adams, A. OP022, **P061**
Adams, J. DOP077, DOP078, P369
Adedokun, Q.J. P119, P446
Adegbola, S. **P005**, P126, P245, P398
Adler, J. OP021
Admyre, C. **P080**, P106
Adomakoh, N. P390
Aelvoet, A. P196, N806
Affronti, M. P387, P613
Afif, W. P157, P342, P626, P677, P763
Afonso, J. P198, **P248**
Agrawal, D. DOP020
Agréus, L. P735
Aguas, M. **P205**, **P365**, P480, P607, DOP016
Aguilar Meleró, P. P545
Aguilar, H. P511
Aguilera, L. P782
Aguilera, M. P033, P034
Aguirre, U. P202
Aharoni Golan, M. P619
Ahmad, O.F. P614
Ahmad, T. DOP048, P413, P550, P648
Ahmed, R. **P670**
Ahn, H. P734
Ahn, S.H. P755
AIM Jr. Internal Fistula Study Group P493
Ainsworth, M.A. P584, P643
Aird, R. P037
Aissaoui, M. P206, P260, P266, P289
Aissat, Y. P206, P260, P266, P289
Ajioka, Y. P133
Akagi, M. P518
Akbar, A. P211, P432
Akbar, S. P614
Akinola, O. P275
Akpınar, H. P401
Aksan, A. **P620**
Aksoy, E. P029
Akyol, A. P029
Akyüz, F. P401
Al Khoury, A. **P495**
Al Nabhani, Z. **DOP087**
Al-Bakir, I. DOP047
Al-Darmaki, A. P134
Al-Farhan, H. **P134**
Al-Saffar, K.A. P606
Alakkari, A. P594
Alan, N. **P470**
Alan, P. DOP006
Alba, C. DOP063
P538, P598
Albano, E. P335
Albano, F. P790
Albano, V. P299
Albergaria, A. P301
Alberizzi, P. P190, P281, P642
Alberto, L. P607
Alcaide, N. N819
Alcain, G. P683
Alcover, M.M. P021, P143, P201
Aldeguer, X. P698
Aletaha, D. **P138**, **P729**
Alexakis, C. P051
Alexandre, N. DOP061
Alexeeva, O. **DOP070**, P091, P437, P462, P679
Alfaro, I. P475, P605, P633
DOP063, **P314**, P327
Alferi, M. DOP008
Algaba, A. P539
Alghamdi, A. P173
Alibrandi, A. P503
Aljadhli, E. P373
Allande, M.J. P617
Allegretta, L. OP004, OP030, DOP025, DOP027, DOP032, DOP084, P156, P420, P719, P740, P772
Allers, C. P240, P494
Allez, M. DOP013, P122, P123, P272, P572, P628
Allin, B.S.R. P245
Allocca, M. **P277**, P366, P475, P506, P534, P605, P633
Almendros, R. P186
Almeida, C. DOP081
Almer, S. P364
Aloi, M. P158, P278, P302, P404, P526
Alonso, M. P529
Alonzo, D. P047
Alperovich, G. P353, P669
Altwegg, R. DOP011, DOP025, DOP034, P310, P358, P667
Alvariño, A. P557, P632
Alves, A.L. P137
Alves, I. DOP081
Alvisi, P. P302
Alyousef, H. P173
Amato, A. OP005
Ambrosio, L. P552
Ametzazurra, A. **P503**, P605
Amil Dias, J. P257
Amininejad, L. P438, P560
Amiot, A. DOP011, DOP025, DOP027, P051, P608
P260, P266, P289
Amir, Z.c. DOP057
Amitai, M. **P143**, **P201**
Amoedo, J. P224
Amurrio, C. P023, P688, P704
Ananthakrishnan, A. P714
Ancona, N. P117
Andersen, B. DOP083
Andersen, V. P722
Anderson, C. OP001
Anderson, S. P220, P444
Andersson, R.E. P724
Andreu Plaza, J. P433
Andrews, E. P704
Andrews, J. OP007, OP036, P170, P238, P341, P392, P577
NO001
Andriolli, G. OP005, P117, P621
Andriulli, A. P433
Angel Rey, J.M. P372
Angelo, C. P193
Angueira, T. P734
Aniwan, S. P113
Annamalai, T. OP005, DOP001
Annese, V. P790
Annibali, R. OP005
Annunziata, M.L. DOP008
Ansalone, C. P235
Ansaloni, L. P152
Antal-Szalmás, P. DOP057
Anupindi, S. **DOP066**
Anzai, H. P226
Aoucheta, D. DOP032
Aparicio, T. P159, P231
Arai, M.

- Arajol, C. P546
 Araki, M. P419
 Aranda, R. OP014
 Arasaradnam, R. P512, P593
 Araújo, R. P255, P284
 Ardizzone, S. P301, P473
 Arebi, N. P391, P490, P694, P695, P718, P727, P745
 Aredas, E. P354
 Arenas, A. P354
 Arenas-Hernandez, M. P444
 Arenaza, A.P.Z. P220
 Argüelles-Arias, F. P327, P423, P618
 Arias, L. P327, P607
 Ariede, J.R. P760
 Arijis, I. P035, P067, P095
 Arikan, D. P353
 Arima, S. P107
 Arinelli, R. P449
 Arkkila, R. P639, P685
 Armbruster, F.-P. P474
 Armuzzi, A. OP005, P211, P240, P366, P440, P494, P574, P652, P654, P738, OP029
 Arnott, I. P125, P333, P416, P586
 Arpino, V. P460
 Arranz Hernández, L. P629
 Arreba, M.P. P202, P503
 Arribas López, M.R. P697
 Arroyo, M. DOP016
 Arsenescu, R. P275
 Artom, M. P251, P555, NO002
 Aruljothy, A. P495
 Arulmani, U. OP011, P468
 Arvanitidis, K. P097
 Asakura, H. DOP073
 Askling, J. OP024
 Assa, A. **DOP057**, P158, **P194**, P278, P302, P404, P414
 Assadsangabi, A. P525
 Astegiano, M. P178, P301
 Atherton, R. P513
 Atkinson, N. DOP065
 Atreja, A. **P554**, P705
 Atreya, R. **DOP073**, P080, P326, P501
 Atri, M. P273
 Atrott, K. DOP089, P052, P064, P102
 Attar, A. P051, **P608**
 Atuğ, Ö. P401
 Aulló, C. P314
 Auzolle, C. OP004, DOP032, P156, **P420**, P772
 Avallone, E.V. P530
 Avedano, L. P328
 Aviello, G. **DOP085**
 Avitzour, M. P689, P721
 Avni-Biron, I. DOP016, P188, P478, P708
 Avni, T. P160, P624
 Avouac, J. P471
 Awasthi, A. P512
 Axelrod, R. P689, P721
 Axler, J. DOP026
 Ayada, I. P070
 Aygalenq, P. P310
 Ayrizono, M.L.S. P025, P038
 Azad, A. P050
 Azagra, I. P202
 Azevedo, L. P299
 Azzarone, A. P621
Babicki, A. P576
 Bachlitzanaki, M. P709
 Badescu, A. P139
 Bae, J.-H. P582
 Baek, D.H. P228
 Baert, F. DOP069, P347, P438
 Bager, P. **N795**
 Bagnoli, S. P407
 Bahí, A. P021, P143, P201
 Bai, L. P113
 Baillet, P. **P272**
 Baillie, S. P614
 Baima, J. NO001, N799, N811, N816, N817, N824
 Baird, A. P109, OP007
 Bajer, L. **P259**
 Bajor, A. P533
 Baker, A.-M. **DOP047**
 Baker, D. **P443**, P681
 Bakker, T. P716
 Balaban, D.V. **P323**
 Baldaia, C. DOP014, P135, P168, P362, P385, P453, P636
 Balderramo, D. **P717**
 Balestrieri, P. P440
 Balicer, R. P721
 Balint, A. **P317**, **P580**, P739
 Ballet, V. OP020, DOP050, P496, P637, P686, NO003
 Balzola, S. P717
 Bamba, S. P325, P493
 Bamias, G. P627
 Bampton, P. P691
 Banai, J. P331, P592, P739
 Banaszekiewicz, A. P346, P404
 Banaszekiewicz, P. P576
 Banayan, E. **P553**
 Banerjee, E. **P179**
 Banerjee, R. P241
 Banskota, S. P030, P057
 Bantleon, F.I. **P283**
 Bao, X. OP037
 Bar Orr, I. **P257**
 Bar-Gil Shitrit, A. DOP016, P307, P366, N818
 Barakat, F. P086
 Baranovsky, A. OP023, DOP075
 Barastegui, R. DOP070, P437, P462, P679
 Barba, A.A. P103
 Barbosa, M. P294
 Barlow, P. P082
 Barmias, G. DOP056
 Barnes, M. P458
 Barnich, N. DOP086, P156, P772
 Barocas, M. DOP023
 Barone, M. P335
 Barosa, R. P368
 Barrachina-Sancho, M.D. P009, P015, P087, P092, P120, P224
 Barreau, F. P100
 Barreiro-de Acosta, M. OP013, DOP039, DOP063, **P183**, P186, P204, P280, P285, P327, P397, P423, P505, **P583**, P603, P618, P736, P785, P786
 Barrera-Ochoa, C. P144
 Barret, M. P471
 Barrett, J. OP001
 Barrio, J. DOP063, P186, P327
 Barrios, A. P205
 Barros, J. **NO001**, **N799**, N811, N816, N817, **N824**
 Barrow, V. **P659**
 Barthoulot, M. P221
 Bartolo, O. DOP016
 Bas, J. P546
 Bassel, M. DOP022
 Bastida, G. P205, P365, **P528**
 Baston, I. **P785**, **P786**
 Batista, G. N799
 Batra, A. P065
 Battat, R. **P626**, **P763**
 Baudry, C. DOP032
 Baumann, C. P338
 Baumgart, D.C. OP009, P326, P366
 Baumgartner, K. P547
 Bay-Jensen, A.-C. DOP051, P089, P671
 Baycheva, M. P219, P479, P591, P707
 Bayless, T. P488
 Bayliss, M. P558
 Bazarah, S. P173
 Bazerbachi, F. P263
 Bazzoli, F. P581
 Başaranoğlu, M. P401
 Beale, A. P458
 Beau P. P396
 Beaugerie, L. OP003
 Beaumont, M. P056, P079
 Bechi, P. P687

- Becc, M. OP017
 Beelen, E.M.J. **DOP040**
 Beetens, J. P610
 Beggs, A. OP002, P079
 Beglinger, C. P569
 Beiderwellen, K. P176
 Beijns, E.M. P696
 Belgers, E. P132
 Belgian IBD research and development group P438, P347
 Belhocine, K. P260, P266, P289
 Belkhdjia, H. P608
 Bell, A. P501
 Bell, S. P734
 Bellaguarda, E. P410
 Bellanova, M. P581
 Bellicco, M. P074, P585
 Bellini, M. P598
 Bello, C. P169
 Belluardo, N. P412
 Belluzzi, A. P581
 Belousova, E. **P163**, P517
 Beltrán, B. P186, P365
 Bemelman, W. OP015, DOP042, DOP055, P066, P241, P476, P524, P551, P650
 Ben Avraham, S. **P262**, P484
 Ben Mustapha, N. P405
 Ben-Bassat, O. P188, P451, P478
 Ben-Horin, S. P160, P181, P211, P240, P246, **P341**, P366, P400, P402, P428, P441, P481, P494, P624, P721, P779, N820
 Ben-Shachar, S. P243, **P757**
 Benchimol, E. P460, P689, P721, P734
 Bendtsen, F. DOP003, P703, P769
 Bendtzen, K. P584, P643
 Bene, L. P331, P592
 Bengs, S. P017
 Benjamin, P. P360
 Benjaminov, F. P345, N821
 Bennek, E. P041
 Benninga, M. DOP017, P297, P297, P524
 BenShoshan, M. P779
 Benson, A. P451
 Benyamini, Y. P210, P300
 Benítez, J.M. DOP016, **P327**, P545
 Benítez-Rodríguez, B. P319
 Ber, Y. DOP016, P788
 Berakova, K. P339
 Berenguer, D. P683
 Bereswill, M. DOP018, P329, P353, P669
 Berg, S. P381, P669
 Berga, K.-A. P552
 Bergemalm, D. OP022, P061, P788
 Berger, A.-E. P226
 Berger, C. **P474**
 Bergey, F. DOP049, **P316**
 Bergmann, M. P722
 Berkane, S. P260, P266, P289
 Bermejo, F. DOP063, P314
 Bernabeu, P. **P529**
 Bernardes, C. **P519**
 Bernardo, D. **P110**
 Bernardo, S. DOP014, **P322**, **P453**
 Berner Hansen, M. OP035
 Bernklev, T. P710
 Bernsen, M. P590
 Bernstein, C. P341, P451, P734
 Bernstine, H. P188
 Bernset, I.P. DOP062, P710
 Bertani, L. P440, P538, **P598**
 Bessissow, T. P157, P342, P495, P624, P626, P677, P763
 Bethune, R. P413
 Bettenworth, D. P162, P171, P738
 Betts, M. P271
 Bewshae, C. P550
 Beydogan, H. P735
 Bezzio, C. P574, P652
 Bhagat, S. DOP052
 Bhalra, N. DOP068, P056, P670
 Bhandari, A. P001
 Bhayat, F. DOP024, P442, P647, **P668**
 Bholah, M.H. P655
 Bian, S. **DOP028**, P496
 Biancheri, P. P032
 Biancone, L. OP005, P301, P332
 Biasci, D. DOP048
 Bibani, N. **P378**, **P631**
 Biedermann, L. P130, P304, P566, P711, P712, P719, P740
 Bielawski, J.P. DOP007, P775
 Bierla, J. P265
 Bigonzi, E. DOP041
 Bijns, E. P690
 Billiet, T. P258
 Bilsborough, J. P050
 Biondi, R. N816, N824
 Biscaglia, G. P117
 Bishop-Bailey, A. P512
 Bismuth, M. P358
 Bisschops, R. P275
 Bissoli, G.C. N811, N816
 Biswas, S. DOP047
 Bitencourt Pascoal, L. P038
 Bittl, M. **P171**
 Bitton, A. P157, P342, P626, P677, P734, P763
 Bjarnason, I. P129
 Björnsson, E. P758
 Black, C. P211, **P222**, **P240**, P494
 Blackwell, S. P245
 Blad, W. P770
 Blake, A. DOP024, P442, P647, P668
 Blanc, P. P358
 Blanpid, C. P100
 Blaut, M. P065
 Bloemendaal, F. **DOP036**
 Bloemsaat-Minekus, J. P665
 Blom, H. P533
 Blom, M. P639, P685
 Blomster, T. P515
 Bloom, S. P043, P045, P220, P376, P513
 Bloor, R. N807
 Boal Carvalho, P. P136
 Boaz, M. P295, P409, P484
 Bochicchio, S. P103
 Bodelier, A. P781
 Bodger, K. P241
 Boeing, H. P722
 Bogaerts, J. **DOP067**
 Bohm, M. DOP023
 Boirivant, M. P024
 Boitard, J. DOP034
 Boivineau, L. **DOP034**
 Bojarski, C. **P101**
 Bokemeyer, B. DOP026, P501
 Boland, B. DOP023
 Boland, K. **P269**, **P311**, **P789**, **P793**
 Boldorini, R. P178
 Bolstad, N. DOP062
 Boltin, D. P708
 Bolton, M. P093
 Bommelaer, G. DOP013, DOP086, P122, P123, P272, P572, P628
 Bonderup, O. P533, **P720**
 Bonfiglio, F. P061
 Bonifacio, C. P277
 Bonnart, C. P100
 Bonnaud, G. P310
 Bonnet, J. DOP032
 Bonovas, S. P506, P534
 Boone, J. P176
 Boonen, A. OP017
 Bor, R. P279, P317, P580, P675, P739
 Borchert, K. **P456**
 Borges, L. P415
 Borges, V. P519
 Borovsky, N. P689, P721
 Borowski, K. P789, P793
 Borralho, P. OP016
 Borren, N. **P023**, **P688**, **P704**
 Borruel, N. P350, **P683**
 Bortlik, M. P532
 Borys-Iwanicka, A. P504, P510
 Bosca-Watts, M.M. P211, P240, P494
 Boschi, L. DOP041

- Boshuizen, R. P114, P663
 Bosmans, J. OP015
 Boss, A. P522
 Bossa, F. OP005, P117, P574,
 P621, P652
 Bossuyt, P. OP015, **P258**,
 P347, P438
 Bosó, V. P365
 Botella, B. DOP063
 Botezelli, J.D. P025, P038
 Bots, M. P726
 Bots, S. **DOP017**, **P611**
 Boubaker, J. P405
 Boucekikine, T. P260, P266, P289
 Boudet, J.M. P423
 Bouguen, G. DOP011, DOP013,
 DOP027, P310
 Bouhmidi, A. P193
 Bouhnik, Y. DOP025, DOP027, **P051**,
 P142, P420, P522, P608
 Boukhadra, N. P310
 Boulton, R. DOP068
 Bounab, N. P260, P266, P289
 Boureille, A. P310
 Bourgaux, J.F. DOP034
 Bourl, S. P439
 Bourke, B. DOP085
 Bourrier, A. DOP011, DOP025,
 DOP027
 Boutaleb, A. **P206**, P260,
 P266, P289
 Boutron-Ruault, M.-C. P722
 Bouvier, D. DOP086
 Boyapati, R. P037, **P055**
 Bozada García, J.M. P634
 Bozcan, S. P214, P282, **P678**
 Bozina, N. P575
 Bradford, M. DOP036
 Braga Neto, M.B. **P263**
 Braithwaite, A.M. P528
 Branche, J. P608
 Branco, J.C. **P714**
 Brandimarte, G. P530
 Brandse, J. P114
 Brant, S. P488
 Brant, S.R. P269
 Brassard, P. P157, P734
 Braun, S. P456
 Brayshaw, N. DOP019
 Brcic, I. **P547**
 Breiderhoff, T. P063
 Breitenmoser, F. P130
 Brejnrod, A. DOP008
 Bresler, L. P338
 Breslin, N. P208, P276, P602
 Bressler, B. P597, P625
 Breunig, I. P131
 Breynaert, C. P035
 Brezina, J. P259
 Brieau, B. P471
 Briggs, E. P303
 Brinar, M. P742, P747
 Brink, M. OP015
 Brixl, H. DOP027
 Brodmerkel, C. DOP046, DOP052,
 DOP053, P077, P465
 P345, P409, P561
 Broide, E. **P756**
 Broly, F. P194, P302, P414
 Bronsky, J. P511
 Brookes, M. P156, P780
 Brot, L. OP020
 Brouwers, E. P303
 Brown, A. P443, P245, P681
 Brown, S. **DOP059**
 Bruckner, R.S. P263
 Bruining, D. P326
 Bruns, T. DOP020
 Bruss, A. OP036, P392, **P577**
 Bryant, R. P584, P643
 Brynskov, J. P529
 Buades, N. P181, P779
 Bubis, M. P153
 Bucci, L. P538
 Buccianti, P. P271
 Buchel, O. OP021
 Buckley, J. P578
 Buckley, M. N804
 Bucurica, S. P323
 Budzynska, A. **P189**
 Buer, L. **P514**
 Buetikofer, S. P130
 Buhl, S. P584, P643
 Buisson, A. DOP011, **DOP013**,
 DOP025, DOP027, **DOP086**,
 P122, **P123**, P156, P272, P315,
 420, P572, P608, P628, P772
 Bulmer, D. P086
 Bungay, H. P271
 Burch, J. NO002
 Burger, N. P039
 Burisch, J. DOP001, **DOP003**,
 P692, **P694**, **P695**, **P703**,
 P718, **P727**, P734, P745
 Burke, A.L. P170, P238
 Burke, M. N809, **N815**
 Burkitt, M. DOP049, DOP049
 Burling, D. P126, P398
 Burn, J. P398
 Burri, E. P130
 Burt, M. P535
 Bushmakin, A.G. P558
 Buskens, C. OP015, DOP042,
 P066, P476, P551, P650
 Busquets, D. P021, P143, P186,
 P201, P423, P480, P618
 Butera, A. **P024**
 Butler, A.J. DOP079
 Buttó, L. OP030
 Byeon, J.-S. P148, P252, P406,
 P482, P641
 Byer, J. P763
 Byrne, K. P261, P370, P578
 Bálint, A. P279, P675
 Bąk-Drabik, K. P504, P510
C
 Cabanne, A. P585
 Cabello Fernández, A. P693
 Cabras, F. N814
 Cabre, E. P367, P480, P562
 Cabriada, J.L. DOP063, P186,
 P202, P607
 Caccaro, R. OP005
 Cadiot, G. P272, P310
 Cagol, L. **P486**
 Cahill, L. P775
 Cai, J. DOP060
 Caillo, L. DOP034, P358, P608
 Caio, G. P301
 Calabrese, C. **P571**
 Calabrese, E. P332, P574, P652
 Calabrò, A. P301
 Calafiore, A. P571
 Calandrini, L. P571
 Calandruccio, G. P412
 Calatayud, S. P009, P015, P087,
 P092, P120
 Calcatera, F. P004
 Caldas, M. P110
 Calsbeek, H. N796
 Calvaruso, V. P658
 Calvert, C. P413
 Calvet, X. P186, P607
 Calvo, M. P603
 Camargo, M.G. P025
 Camargo, R. N819
 Caminero-Fernández, R. P110
 Cammarota, G. P019
 Campanati, L. **P235**
 Campbell, R. **N807**
 Campieri, M. P571, P581
 Campos, C. **P572**
 Campos, D. OP038, DOP044
 Camus, M. P471
 Cancela, E. P255, P284
 Caneparo, V. **P178**
 Cann, D. NO002
 Cannizzaro, R. P301
 Cano Sanz, N. **N822**
 Cano, N. P436
 Canton, R. P782
 Cantoro, L. OP005, P440
 Canzonieri, V. P301
 Cao, Q. P096, P568
 Capone, P. P646
 Caporaso, N. P646

Cappelleri, J.C.	P558	Cavazza, A.	P391	Chen, Y.	P054, P771
Cappello, M.	OP005, P412, P621, P658	Cazals-Hatem, D.	P522	Cheng, X.	P001
Caprioli, F.	DOP016, P574, P652	Cañas, M.	P183, P397, P736	Cheon, J.H.	DOP061, P341, P701
Carbonnel, F.	P140, P315, P722	Cañete, F.	P367, P562	Cheong, S.Y.	P377
Carding, S.R.	P093	Cea-Calvo, L.	OP013, DOP039, P183, P397, P583, P603, P736	Chermesh, I.	P484
Cardoneanu, A.	P139	Ceballos, D.	DOP063, P327, P423, P618	Chernin, E.	P749
Cardoso, H.	P049, P290, P308	Ceccarelli, L.	P538 , P598	Chevau, J.-B.	P608
Cardoso, M.	P714	Cecil, E.	P138, P729	Chew, T.S.	P434
Cardoso, R.	P255, P284	Celik, A.F.	P214, P282, P678	Chhaya, V.	P138, P729
Carella, M.	P117	Cenni, S.	P088	Chi, J.-H.	P098
Carlsen, A.	P429	Cernotova, V.	P750	Chiba, S.	P133
Carmagnola, S.	P473	Cerutti, R.	P301	Chiba, T.	P165
Carman, N.	DOP072 , P127, P268, P450 , P460	Cesarini, M.	P341	Chillón Martínez, R.	N800
Carmichael, M.S.	P434	Cesarkas, K.	P779	Chilukuri, P.	DOP023
Carmona, L.	P183, P397, P736	Chacón Martínez, S.	P433	Chiorean, M.	DOP077
Carneiro, A.J.	P741	Chadokufa, S.	P479 , P579, P591 , P707	Chiosa, A.M.	P203, P388
Carpelan-Holmström, M.	P264	Chalmers, I.	P167	Cho, J.M.	P237
Carrascosa, J.	P202	Champiat, S.	P315	Cho, J.	P177, P269
Carrat, F.	OP003	Chan, D.	P465	Cho, M.Y.	P044
Carrera Silva, A.	P074	Chan, G.	OP031	Choe, B.-H.	P674, P730
Carreras, E.	P437	Chan, G.	P403	Choe, Y.H.	DOP031, P487 , P500 , P542, P674, P730, P755
Carreño, R.	N819	Chan, S.	P722	Choi, C.H.R.	DOP047
Carrizzo, A.	P103	Chang, D.K.	P154	Choi, C.H.	P461 , P500
Carroccio, A.	P412	Chang, H.	P705, P733	Choi, C.W.	P324
Carroll, M.W.	P278	Chang, J.	OP021	Choi, H.	P483
Carsten, A.	P788	Chang, K.	P148, P406, P482, P641	Choi, H.-J.	P582
Carvalho, A.T.	P741	Chang, Y.-C.	P199	Choi, J.Y.	P755
Carvalho, D.	P519	Chao, C.-Y.	P342 , P495, P677	Choi, J.-S.	P582
Carvalho, J.	P190, P248, P281, P642	Chao, K.	P096	Choi, M.	P418
Carvalho, S.	P299	Chaparro, M.	DOP016 , P110, P186 , P327	Choi, M.-G.	P483
Carvello, M.	P004	Chapman, R.	DOP065	Choi, Y.S.	P656
Casado, R.	P423, P618	Chapman, R.W.	P271	Choi, Y.J.	P715
Casanova, M.	DOP016	Charland, K.	P699	Chong, L.	P182, P253, P274
Casciani, E.	P526	Charpentier, C.	DOP045, P221	Choong, L.M.	P129, P599
Casellas, F.	P350, P359, P423 , P618, P683	Chast, F.	P471	Choung, R.S.	P121
Casen, C.	P788	Chastek, B.	P330, P531	Chowers, Y.	P721
Cassieri, C.	P530	Chatu, S.	P129	Christ, C.	P521
Cassinotti, A.	P473	Chatzinacos, G.	P452	Christensen, B.	P410 , P454
Castaneda, D.	DOP043, DOP064	Chaudrey, K.	DOP023	Christodoulou, D.K.	P211, P240, P366, P494, P751
Castanheira, A.	P255, P284	Chaussade, S.	P471	Christopher, R.	DOP077, DOP078, P369
Castaña, A.	DOP012	Chavannes, M.	P157, P352	Chu, Y.	P075
Castaña-Rodríguez, N.	P589	Chavero, P.	P074, P585	Chueca Porcuna, N.	P792
Castiglione, F.	OP005, P153, P621, P646	Chaves, L.	P449	Chung-Faye, G.	P129
Castillo Espinosa, J.M.	P433	Chawla, T.P.	P296	Chung, B.	P079
Castro, D.	DOP057	Chen, B.	P402, P481	Chung, E.J.	P090
Castro, E.	P327	Chen, C.-L.	OP037	Chung-Faye, G.	P599
Castro-Fernandez, M.	P792	Chen, C.-Y.	P734	Chur-Hansen, A.	P170, P238
Castro, F.	P292	Chen, D.	P075	Church, P.	P127, P268, P460
Castro, J.	DOP070	Chen, G.	OP033	Church, P.C.	DOP072, P450
Castro-Laria, L.	P423, P618	Chen, L.A.	P558	Ciacci, C.	P103, P301
Castro, M.	DOP039, P327	Chen, M.-H.	P246, P394, P441, P653	Ciamberlano, B.	P024
Casén, C.	P778	Chen, M.	P244, P341, P400, P402, P428, P481	Ciardi, A.	P301
Catassi, C.	P790	Chen, N.	DOP018, P329	Cibor, D.	P287
Cathala, A.L.	DOP032	Chen, S.	OP025	Ciborowski, M.	P147
				Cicala, M.	P440
				Cid, J.	P437

- Cijevschi Prelipcean, C. P139, P203, P232, P320, P388, P601
 Cilissen, M. OP017
 Cilluffo, M.G. P008
 Cirillo, G. P088
 Citrano, M. P412
 Civitelli, F. P440, P526
 Claassens, J. DOP036
 Clair Willi, C. P719, P740
 Claire, P. **P360**
 Clark, M. OP004
 Clark, S. P541
 Clark, T. P648
 Claus, P. OP021
 Cleland, T. P023
 Clemente, J. OP037
 Clerc-Urmès, I. P338
 Cleynen, I. P067, P095, P738, P764, P774
 Cockroft, A. P129
 Codony, X. DOP088, P033
 Coelho Ludvig, J. DOP056
 Coenegrachts, J.-I. P347
 Coenen, S. **P180, NO003**
 Coffey, J.C. P026, P071, P216
 Coffin, B. DOP027
 Cohen, A. P626, P708
 Cohen, B. P213, P554
 Cohen-Dolev, N. **DOP009**, DOP037, P262, P484
 Cohen, D. P721
 Cohen, I. **P210, P300**
 Cohen, N. P689
 Cohen, R. P389, P454
 Cohen, S. **P302**, P409, P414
 Cohen, S. P526
 Cohen, Z. P311
 Coimbra, A. **P522**
 Cojocar, M. P207
 Coles, A. P550
 Colletti, R. OP025
 Collin, P. P218
 Collins, C.M. P058
 Collins, G.S. P270
 Collins, K.L. P170, P238
 Collins, M. **P315**
 Colombel, J.-F. OP009, OP010, OP019, OP037, DOP002, DOP003, DOP005, DOP015, **DOP019**, DOP021, DOP023, DOP064, P177, P119, P121, P209, P213, P381, P415, P554, P705, P733, P734
 Colombo, F. DOP042
 Comaneshter, D. P708
 Comas Redondo, C. P697
 Comas, D. P437
 Compernelle, G. OP020, DOP028, P637
 Conceição-Neto, N. **DOP080**
 Conlon, M. OP036, P392
 Conner, J. P311
 Connor, S. OP007
 Connors, J. P775
 Conort, O. P471
 Conroy, E. DOP085
 Consten, E. OP015
 Contaldo, A. P335
 Contente, L. P435, P723
 Conway, G. P688
 Cooney, R. DOP068, P351, P670
 Coope, A. **P025, P038**
 Cooper, B. P614
 Cooper, D. OP028
 Copenrath, E. DOP057
 Coppola, L. P301
 Corazza, G.R. P301
 Corazzari, E.S. P530
 Cordes, A.F. **P118, P162**
 Coriat, R. P471
 Cornillie, F. P119, P226
 Coron, E. P608
 Corrado, C. P530
 Corrales, G. P480
 Corraliza, A. OP004
 Corraliza, A.M. OP030, **DOP084**
 Correale, C. P004, P475, P605, P633
 Correia, A. DOP081
 Correia, L. DOP014, P124, P135, P168, P322, P362, P385, P453, P636
 Corritore, G. P117
 Corró, B.E. P506, P534
 Corsello, P. P004, P410
 Cortezzi, C.C. OP005
 Cortez Pinto, J. DOP014
 Coscia, M. DOP058
 Cosimo, P. P235
 Cosin-Roger, J. **P017**, P052, P072, **P102**
 Cosnes, J. DOP011
 Costa Santos, M.P. OP016
 Costa, F. OP005, P440, P538, P598
 Costache, R.S. P323
 Costantino, G. P539, P621
 Costello, S.P. P093
 Costello, S. **OP036, P392**, P577
 Cosin-Roger, J. P009
 Cotter, J. P136, P292, P294, P472
 Cottone, M. P318, P372, P387, P412, P613
 Coté-Daigneault, J. OP037
 Craven, R.A. P058
 Cravo, M. OP016
 Creanza, T. P117
 Cremer, A. **DOP069**, P560
 Cremers, I. P137
 Crispino, P. P530
 Critch, J. P460
 Croft, N. P086
 Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD) P321
 Croitoru, K. P223, P296, P311, P502, P789, P793
 Cronin, L. P170, P238
 Crook, K. P211, P432, P490
 Crooks, B. P242, P525
 Cross, W. DOP047
 Crotty, P. P208
 Crowley, E. DOP072, P127, P268, P450, **P460, P754**
 Cruz, M.L. OP034, OP035
 Cuatrecasas, M. P020, P522
 Cubero, F.J. P041
 Cucchiara, S. P526
 Cucuteanu, B. P320
 Cukovic-Cavka, S. P575, P742, P747
 Cukrowska, B. P265
 Cullen, G. P250, P261, P578, P594, P640
 Culver, E.L. **P271**
 Cummings, J.R.F. P006, P271
 Curtis, J. P448
 Curtis, L. N812
 Curtis, R. DOP026, P305, P470
 Cvanarova Småstuen, M. P778
 Cvanarova, M. P151, P710
 Cyrille, M. OP034, OP035
 Cytter Kuint, R. DOP057
 Czinderi, V. P317
 Czuber-Dochan, W. P251, P555, NO002
 Cárdenas Aranzana, M.J. P545
 Côté-Daigneault, J. **P213**
 Cúrdia Gonçalves, T. P136, **P294**, **P472**
 Çelik, A.F. P401
 Čuković-Čavka, S. P694, P695, P727
D'Alessio, S. P004
 D'Armiento, F.P. P301
 D'Aversa, F. P654
 D'Haens, G. OP014, OP015, OP031, OP032, DOP017, DOP021, DOP036, DOP074, **DOP075**, P007, P050, P066, P094, P114, P119, P209, **P353**, P522, P611, P640, P665, P669, N806
 D'Hoore, A. OP012, OP038, DOP042, DOP044, P229, P384, P445
 D'Incà, R. OP005, P301, P694, P695, P727, P745
 Dadalski, M. P265
 Daffra, P.R. **P140**
 Daher, S. **P451**
 Dahl, S.R. P710

Dahlerup, J.F.	P694, P695, P727, N795	De la Morena, F.	P110	Deng, J.	P054
Dahlke, K.	P065	De la Portilla, F.	OP009	Denis, M.A.	P732
Dalal, S.	P454	De la Puente, B.	DOP088, P033	Deora, V.	P651
Dall, A.	P700	De Lange, K.	OP001	Deraison, C.	P100
Dall, M.	P720	De Larrañaga, G.	PO74	DeRidder, L.	P414
Dalton, M.	P105	De Leest, M.	N796, N797	Derieppe, M.	P241
Danan, G.	DOP034	De Lima, A.	OP018	Derikx, L.	P663, P682
Danese, S.	OP005, OP009, OP032, DOP018, DOP021, P004, P050, P209, P211, P240, P277, P328 , P329, P475, P494, P506, P534, P605, P633	De Man, J.	P111	Deroover, L.	P774
Danielou, M.	P221	De Meij, T.	P297, P302, P414	Derovs, A.	P783
Danilenko, D.	P418	De Nitto, D.	P024, P530	Derwa, Y.	P622, P655
Danilova, N.	P794	De Palma, G.D.	P153	Deslandres, C.	P352
Daniluk, J.	P147	De Paula, J.A.	P140	Desobry, P.	P499
Daniluk, U.	P147 , P504, P510	De Ridder, L.	P158, P302	Desreumaux, P.	P772
Danlos, F.-X.	P315	De Salvo, C.	OP027	Desrivot, J.	P610
Daperno, M.	P275, P574, P652	De Souza, H.	P741	Detrez, I.	P226, P686
Dapoigny, M.	DOP013, P572	De Suray, N.	P732	Devadason, D.	P211, P432
Darakshshan, A.	P220, P507, N802	De Vallière, C.	P017, P052, P072, P102	Devaney, K.	P023
Dauvarte, H.	P783	De Ville de Goyet, L.	P732	Deviere, J.	P560
Davidov, Y.	P240, P494	De Villiers, W.J.S.	OP010	Devisscher, L.	P777
Davidson, R.	P439	De Vitis, I.	P654	Devière, J.	DOP069
Davidson, S.	P713	De Vos, M.	DOP069, P347, P777	Devriese, S.	P777
Davis, H.	DOP047	De Vries, A.C.	DOP040, P447	Dewey, F.	P754
Davis, J.	P670	De Vries, A.	P114, P226, P640	Dewey, J.	DOP076
Davis, M.	P698	De Vries, L.	P007	Dewint, P.	P438, P682
Davis, R.J.	P041	De Vroey, B.	P732	Dewit, O.	DOP011, P347, P732
Dawson, L.	P386	De Winter, B.	P111	Dharmasiri, S.	P006
Day, A.	P635	De-Meij, T.	P194	Di Bella, A.	P687
De Andrea, M.	P178	Debeuckelaere, C.	P258	Di Caro, S.	P220
De Boer, N.K.H.	DOP004, DOP040	Deboutte, W.	DOP080	Di Girolamo, M.	OP005
De Bortoli, N.	P538, P598	DeBruyn, J.	P460	Di Leo, A.	P335
De Bouvere, C.	P732	Decka, R.	P750	Di Martino, L.	OP027
De Bruyn, J.	P066 , P094	Decorti, G.	P084	Di Mitri, R.	P008, P318, P412
De Bruyn, M.	DOP050, P035, P078 , P095, P382	DeCrespigny, A.	P522	Di Sabatino, A.	OP005, P301
De Buck van Overstraeten, A.	OP012, OP038, DOP042, DOP044, P229, P258, P384, P445	Deekae, A.	P416, P586	Di Segni, A.	P779
De Carpi, J.M.	DOP037, P262	Deeks, J.	OP002	Di Silvestre, A.	P084
De Castro, M.	P455, P607, N801	Deepak, P.	P263, P616	Di Simone, M.	DOP041
De Cnop, M.	N808	Defagó, M.R.	P717	Dias de Castro, F.	P136, P472
De Cruz, P.	P773	Deiana, S.	P407	Dias, A.	DOP081
De Francisco, R.	DOP012	Dejaco, C.	P233	Dias Pereira, A.	DOP014
De Groof, J.	OP015 , P551	Dekeuleneer, X.	P180	Dias, C.B.	P025
De Hertogh, G.	OP033, OP038, DOP055, P077, P465, P468, P522	Dekkers, N.	P336	Dias, C.C.	P248
De Iudicibus, S.	P084	Del Baldo, G.	P790	Diaz, G.	P618
De Jong, D.J.	DOP004, DOP040, P663	Del Campo, J.A.	P792	Dibley, L.	NO002, N798
De Jong, E.	P682	Del Chierico, F.	P115	Diculescu, M.	P207
De Jong, J.	P524	Del Hoyo, J.	P205	Didita, A.	P232, P388
De Jong, M.	OP017	Del Rio, L.	P475	Diederer, K.	P297, P524
De Jonge, W.	P007, P069, P094, P716	Del Tedesco, E.	P310	Dieleman, L.	P552
De La Cruz Ramirez, M.D.	P634	DelCampo, R.	P782	Dieli, F.	P008
De La Fuente, J.	P616	Delin, J.	P364	Dienethal, A.	P179
De la Iglesia, D.	P505	Della Bella, S.	P004	Dierckx, T.	DOP080
		Della Valle, N.	P373	Dietrich, G.	P100
		Deltenre, P.	P566	Diez, M.C.	OP009
		Demcsák, A.	P279	Dignass, A.	P521
		Demir, N.	P214, P282, P678	Dignass, A.	P241, P326, P328, P466, P474, P620
		Demuth, D.	P330, P466, P531	Dijkstra, G.	OP017, DOP004
		Demyanova, E.	P638	Dijkstra, G.	DOP040, DOP051, P374, P671
		Denadai-Souza, A.	P100	Dijkstra-Heida, W.	N797
		Denecke, B.	P041		
		Deng, C.	DOP074		

- Dimarco, M. P613
 Dimitriu, A. **P207**
 Ding, N.S. **P018, P738, P787**
 DiNicola, C. P354
 Dinter, J. DOP073
 Dionne, S. **P085, P763**
 Dior, M. P471
 Dirrenberger, B. **P338**
 Diz-Lois Palomares, M. DOP016
 Djenidi, F. P420
 Do, E.J. P090
 Dobelniec, L. P783
 Dobos, G. P176
 Dogra, H. P086
 Doherty, G. DOP016, P250, P261, P355, P403, P511, P578, P594, P640
 Doherty, M.K. **DOP053**
 Dolin, P. P501, P511, P590
 Domachevsky, L. P188
 Domagala-Rodacka, R. P287
 Domenech, E. P607
 Dominguez-Munoz, J.E. P204, P280, P285, P505, P785, P786
 Domènech, E. OP013, DOP039, P367, P480, P562, P583, P603, P706
 Domínguez, J. P327
 Donday, M. DOP016, P186
 Dooley, B. P370
 Dorna, M. NO001, N799, N824
 Dorofeyev, A. DOP061
 Dorward, D. P055
 Dotan, I. P046, P158, P210, P243, P300, P366, P459, P612, P689, P721, P757
 Dotti, I. **P020**
 Doty, A. P356
 Dougados, M. P471
 Douglas, G. P775
 Dragoni, G. P407
 Dranga, M. P139, P203, P232, **P320, P388, P601**
 Drastich, P. P259
 Dray, X. P608
 Dreanic, J. P471
 Dreesen, E. OP020, DOP028, **P637**
 Drenth, J. P663
 Drexler, S. P776
 Driscoll, R. P241
 Drskova, T. P211, P404, P432
 Drug, V. P139
 Drvarov, O. DOP073, P544, P588
 Drygiannakis, I. P097
 Drylewicz, J. P267
 Du, Z. P759
 Dubinkina, V. P794
 Dubinsky, M. OP037, P161, P703
 Dubois, A. DOP086, P572
- Dubois, P. P129, P599
 Duchatellier, C.-F. P085
 Dudcos, B. DOP027
 Dudkowiak, R. P200
 Duerr, R. P269
 Dufour, G. **P358**
 Duggal, A. P684
 Duijvis, N.W. P094
 Dukler, A. P382
 Dulaj, P. **OP021, DOP023**
 Dulauroy, S. DOP087
 Duncan, J. NO002, N802
 Dunn, K.A. **DOP007, P775**
 Dunne, C. P026, P071, P216
 Dupas, J.-L. P221, P756
 Dupin, M. P310
 Duran, N. P354
 Durant, L. P093
 Duricova, D. P532, P694, P695, P727
 Duron, C. DOP013
 Durrant, C. P458
 Duru, G. P226
 Dushnitsky, D. P689, P721
 Dvorsky, M. P748
 Dziubak, R. P479
 Diaz Hernández, L. P629
 Diaz López, C. P463
 Díaz, A. P186
 Díaz, G. P423
 Díaz-Guerra, A. P110
- E**ast, J. OP026, DOP065
 Eberl, A. P515, **P639, P685**
 Eberl, G. DOP087
 ECCO Transition Topical Review Consensus Group DOP010
 Echarri, A. P186, P423, P618
 Eckhardt, G. P233
 Eckmann, L. P050
 Eder, P. P746
 Edir, A. P100
 Egan, L. P403, P511
 Ehehalt, R. **DOP022, DOP026**
 Eichner, S. OP025
 Ein Dor, A. P345, P561
 Eisele, C. OP037
 Eisenstein, S. P357
 Ekboom, A. OP024
 Ekk-Cierniakowski, P. P200
 El Bahrawy, A. P165
 El-Matary, W. P460, **P651**
 Elad, H. P757
 Elamin, A. P010
 Elawad, M. P579
 Eldridge, J. P128
 Eliadou, E. P525
 Eliakim, R. P160, P181, P366, P451, P624, P721, P779, N820
- Eliraz, E. OP028
 Elisei, W. P373
 Elizalde, J. P437
 Elkadi, A. P754
 Elkady, S.M. P220, P240, P494
 Elli, L. P301
 Elloumi, H. P378, P631
 Eillul, P. DOP001, P211, P240, P494, P694, P695, P727, P745
 Elosua González, A. **P508**
 Emmanuel, A. P535
 Emrich, S. DOP052
 Enck, P. P563
 EndCAP-C Consortium OP002
 Ende, K. P326
 Endo, K. P325
 Endo, Y. **P175**
 Engel, P. P713
 Engel, T. P160, P624
 Enomoto, N. P256
 Eom, Y.W. P044
 EpiCom studygroup P694, P695, P727
 Eriksson, C. **P364**
 Eriksson, J. OP024
 Errasti, A. P074
 Erzin, Y. P214, **P282, P678**
 Esaki, M. DOP071, P215, P523, P784
 Escher, J. DOP037, P257, P262, P414
 Eshuis, E. OP015
 Eslava, S. DOP060
 ESPGHAN Open IBD Interest Group P404
 Esplugues, J.V. P009, P015, P087, P092
 Esteller, M. P091
 Esters, P. P521
 Esteve, M. P423, P607, P618
 Estevens, D. P723
 Estévez-Gil, M. P455
 Etchevers, M.J. P140
 Eun, C.S. DOP061, **P060, P500**
 Ewara, E. P383
- F**adeeva, N. P536
 Fadgyas-Freyler, P. P623
 Faggiani, R. P373
 Fagundes, J.J. P025
 Faiz, O.D. P005, P126, P245, P398, P718
 Fallingborg, J. P533
 Falony, G. P767, P774
 Fandakova, I. P247
 Fantasia, L. P563
 Fantini, M.C. P332
 Farage Barhom, S. P779

Farinelli, E.	P760, NO001, N799, N811, N816, N817 , N824	Fettelschoss, A.	DOP089	Franco Leal, R.	P091
Farkas, K.	P279, P317, P331, P411, P580, P592, P675, P739	Feu, F.	P437	Francque, S.	P111
Faubel, R.	P205	Fidder, H.H.	DOP004	Francés, R.	P076
Faubion, W.	P050	Figueira Alvarez, M.	N801	Franke, A.	P759
Faul, P.	P026, P071	Filali, A.	P405	Fraser, A.	P458
Fausel, R.	P733	Filidou, E.	P097	Fraser, G.	P188
Feagan, B.	OP010, OP011, OP014, OP019 , OP032, OP033, OP034, OP035, DOP018, DOP019 , DOP021, DOP026, DOP033, DOP076, P050, P209, P241, P329, P442 , P465, P468 , P549	Filippi, J.	DOP025, DOP027, P310	Freeman, T.	P761
Feakins, R.	OP029, DOP056	Fillos, D.	P418	Frei, P.	P569, P711, P712
Fearnhead, N.S.	P240, P245, P494	Finezilber, Y.	P757	Freire, P.	P600
Fedorak, R.N.	P552	Finlayson, G.	P105	Freitas, T.	P642
Feichtenschlager, T.	P233	Finnby, L.	P788	French, D.	OP033
Feitosa, M.R.	P424	Finney-Hayward, T.	P363, P512, P543	Fresta, M.	P108
Fekih, M.	P405	Fiocca, R.	P301	Frey-Wagner, I.	P052, P064, P102
Felice, C.	OP029, P440, P654	Fiorino, G.	OP005, DOP006, DOP016, P004, P211, P240, P277, P366, P475 , P494, P506, P534, P605 , P633	Fried, M.	DOP089, P712
Felt-Bersma, R.	P744	Fisa, R.	P683	Friedman, A.	P609
Feng, H.	P773	Fischer, I.	P171	Friedman, G.	OP032, DOP074, P467
Feng, R.	P394, P653	Fish, J.	P127, P268	Friedman, M.	P158, P689 , P721
Feng, T.	P402, P481	Fishman, S.	DOP061, P459	Friedrich, M.	P063
Fenton, T.	P036	Fitzgerald, D.	N804	Fries, W.	OP005, P412, P539, P621
Ferenci, T.	P580, P675	Fitzpatrick, R.	P241	Friger, M.	P749
Fernandes, S.	P322, P453	Fleshner, P.	P553	Frigstad, S.O.	P533 , P710
Fernandes, S.	P642	Florena, A.M.	P301	Frivolt, K.	P486
Fernandez-Bañares, F.	P607	Flores, E.	DOP063	Froes, R.	P741
Fernandez-Gundin, M.	P436	Flourie, B.	DOP027	Frost, K.	P460
Fernández-Calderón, M.	P202	Focht, G.	P409, P689, P721	Frumento, P.	OP024
Fernández Caballero-Rico, J.A.	P792	Fociani, P.	P301, P473	Fuchssteiner, H.	P233
Fernández-Avilés, F.	P437	Foell, D.	P118	Fudim, E.	P181
Fernández, E.	P327	Foerster, D.	P456	Fuh, F.	P431
Fernández-Salazar, L.	DOP016, DOP063, P327	Fong, S.	P444	Fuhler, G.	P016
Ferracane, C.	P539	Fonseca Camarillo, G.	P042 , P164, P762, P765	Fujie, M.	P159
Ferrandis, P.	P632	Fontaine, F.	P347	Fujii, T.	P256, P325
Ferrante, M.	OP006, OP009, OP012, OP020, OP038, DOP028, DOP029, DOP044, DOP050, P035, P067, P095, P229, P258, P347, P382, P384, P438, P445, P496, P637, P686, P738, P767, P774, NO003	Fonteyne, P.	P004	Fujita, M.	P249
Ferreira, J.	P334	For the BERENICE Study Group	OP003	Fujiwara, Y.	P427
Ferreira, M.	P600	Ford, A.C.	P227, P343, P622, P655	Fukuda, A.	P040
Ferreira, M.	P600	Ford, C.	P599	Fumery, M.	DOP027, DOP045, P156, P221, P420, P448 , P694, P695, P727, P756, P772
Ferreiro, R.	P186, P204, P280, P285, P480, P505, P785, P786	Ford, M.	P371, P380, P520	Funakoshi, N.	P358
Ferrer Bradley, I.	DOP016	Forsyth, K.	P220	Furfaro, F.	P004, P277, P475, P506, P534, P605, P633
Ferrer, I.	DOP063, P557, P632	Forti, G.	P373	Furlan, D.	P301
Ferrer, L.	P717	Foruny, J.R.	P782	Furuzawa Carballeda, J.	P042
Ferrer-Picón, E.	P020	Foschi, D.	DOP042	Futatsuki, R.	P644
Ferrero, S.	P301	Fosser, C.	P113	Fyfe, M.	P032, P062
Ferslew, B.	P469	Foster, M.	P032 , P062, P684	Fábián, A.	P279, P317, P580, P675, P739
Festen, E.A.M.	DOP004	Foteinogiannopoulou, K.	P348	Färkkilä, M.	P457
Festi, D.	P581	Fotsing, G.	P396	Féres, O.	P424
		Fournier, S.	P566, P712, P719, P740	Förster, N.	P486
		Fowler, S.A.	P725		
		Fox, C.	DOP020	G adhok, R.	P614
		Fragaki, M.	P709	Gaetano, J.N.	P196, P410
		Frampton, M.	P758	Gaetano, T.	P699
		Franc, Y.	P304	Gagniere, C.	DOP011
		Franceschi, M.	P538	Gago, T.	P435, P723
		Franceschini, E.	P790	Galeazzi, T.	P790
		Franchimont, D.	DOP069, P560	Galien, R.	OP033
				Gallagher, C.	P184

Gallardo Valverde, J.M.	P463	Gawron-Kiszka, M.	P189, P746	Gisbert, J.P.	DOP016, DOP063, P110, P186, P328
Gallego, M.	DOP070, P437, P462, P679	Gaya, D.	DOP008, P027, P363, P543, P587 P635, P691, P734	Giudici, F.	P687
Gallina, S.	P373	Gearry, R.	OP005	Giuffrida, P.	P301
Gamar, I.	P260, P266, P289	Geccherle, A.	DOP055 , P145, P309, P331 , P411, P592, P623	Giugliano, F.P.	P088, P404
Ganther, J.	P063	Gecse, K.B.	NO003	Giuliani, A.	P024
Gao, L.-L.	OP010, P549	Geens, P.	P739	Giulii Capponi, M.	P235
Gao, X.	P096, P149	Gelley, A.	P412	Giunta, M.	P372
Garber, J.	P023, P688, P704	Genova, S.	DOP058	Giussani, M.	P235
García-Fernandez, S.	P782	Gentilini, L.	OP037	Gizis, M.	P627
García-Gil, J.	P143, P201	George, J.	N807	Glauben, R.	P063, P617
García-Planella, E.	P706	Geraghty, V.	DOP019, DOP021, DOP026, P209	Gleeson, M.	OP021
García, S.	P583	Geransar, P.	P654	Glerup, H.	P185, P522
García, V.	P528	Gerardi, V.	DOP006, P587	Glick Saar, E.	P779
García-Sánchez, V.	P545	Gerasimidis, K.	DOP008, P587	Glick, L.	P389
García-Tejero, I.	P480	Germain, A.	DOP042, P338	Gligorijevic, V.	P236
García Albert, A.M.	P433	Gerner, P.	P486	Glover, S.	P356
García Ortiz, J.M.	P634	Gervais, F.	P352	Gobbo Montoya, M.	P183, P397, P736
García Planella, E.	P603	Gervasi, S.	P108	Godat, S.	P566
García Sanchez, V.	P463	Gerß, J.	P162	Godino, A.	P186
García, C.	P224	Ghaly, S.	P691	Godny, L.	P046, P459, P612
García, F.	P792	Gharbi, O.	P378	Goel, G.	P023
García-García de Paredes, A.	P706	Gheorghie, C.	P207	Goess, C.	P170, P238
García-López, S.	P327, P618	Gheorghie, L.	P207	Goetz, M.	P275, P563
García-Olmo, D.	OP009	Ghione, S.	P661	Goishi, H.	P518
García-Paredes, R.	P433	Ghosh, S.	OP010, OP014, DOP068, P056, P079, P212, P275, P359 , P549	Goldberg, R.	OP028
García-Planella, E.	P327	Giannone, A.G.	P301	Goldby-Reffner, K.	OP021
García, S.	P607	Giannotta, M.	P694, P695, P727	Goldin, E.	OP009, P197, P217, P307, N818
García-Sánchez, V.	P327, P607	Gibson, D.	P355	Goldis, A.	OP023, DOP075, P694, P695, P727
García-Tercero, I.	P433	Gibson, P.	DOP030, P386, P410, P609	Goll, G.L.	DOP062
García, V.	OP013, DOP039, P583, P603	Giglio, M.C.	P153	Gollins, J.	DOP015
Gardenbroek, T.	OP015	Gil García, E.	N800	Golovics, P.A.	P145 , P309, P331, P411, P592, P623
Gardstein, B.	P470	Gil, A.	P074, P585	Gombošová, K.	P247
Garg, V.	P449, P698	Gilabert, P.	P143, P201, P546	Gomes de Sena, P.	OP016
Gargalianos-Kakolyris, P.	P390	Gilardi, D.	P277, P475, P506, P534, P605, P633	Gomollón, F.	OP022, P061, P186, P607, P788
Gargouri, D.	P378, P631	Giles, E.M.	OP070, P437, P462, P679	Gompertz, M.	DOP016, P462 , P679
Gargiglio, M.	P178	Gilroy, D.	P043, P045	Goncalves, S.	P074, P585
Garre, A.	DOP016, P186	Gils, A.	OP006, OP020, DOP028, DOP029, P226, P496, P560, P637, P686	Goncz, L.	P145, P309, P331, P411, P592, P623
Garrick, V.	N812	Gimesi-Orszagh, J.	P623	Gong, J.	DOP038
Garrido Martin, E.M.	P006	Giménez, P.	OP076	Gonsalves, A.	P196
Gartner, J.	P233	Giner, A.	DOP070, P437, P462, P679	Gonzaga-Jauregui, C.	P754
Gasbarrini, A.	OP027, P019, P115, P306, P498, P654	Ginsburg, P.M.	P590	Gonzalez Alvarado, M.N.	P013
Gasche, C.	P511	Gionchetti, P.	DOP041, DOP058, P571	Gonzalez Sueyro, R.C.	P140
Gasink, C.	OP010, DOP046, DOP052, P119, P465, P549	Giouleme, O.	P421, P452, P662	Gonzalez, F.	P358
Gaskell, S.	N807	Giráldez-Montero, J.M.	P280	Gonzalez-Lopez, J.	P280
Gaskin, K.	P073	Gisbert-Ferrándiz, L.	P009, P015, P087, P092, P120	Gonzalez-Navajas, J.M.	P076
Gassler, N.	P041	Gisbert, J.	P327, P738	Gonzalez, R.	P717
Gastroenterology Units. On behalf of the TEDDY study group	DOP016			González, A.J.	DOP012
Gasztanyi, B.	P331, P592			Gonçalves, A.R.	P453
Gatti, S.	DOP006, P790			Gonçalves, R.	P417
Gaugris, S.	P593			Gonçalves, T.	P292
Gauss, A.	P039			Goodhand, J.	P413, P550
Gavish, M.	P689, P721			Goodman, W.	OP027
Gavrilescu, O.	P139, P203, P232, P320, P388, P601				

Gordillo, J.	P706	Groner, S.	P131	Haberman, Y.	DOP054, P779
Gordon, H.	DOP001, P053 , P059, P070, P614, P770	Grosnar, D.	P188	Hadadi, A.	P173
Gordon, M.	N813	Grueber, M.	P719, P740	Haga, K.	P766
Goren, I.	P046 , P689, P721	Grung, P.	P057	Hagemann-Madsen, R.	P185, P522
Gornet, J.-M.	DOP011, DOP032	Grupo CEMEI (Cooperación para el		Hahm, K.-B.	P028
Goto, H.	P630	Estydio y Manejo de la Enfermedad		Hahnloser, D.	P566
Gottier, C.	DOP089, P768	Inflamatoria Intestinal) Córdoba,		Haj Natour, O.	N820
Goudkade, D.	P696, P737	Argentina	P717	Haji, A.	P535
Goulvestre, C.	P471	Grupo de Estudos de Doença		Halasz, J.	P134
Goutorbe, F.	DOP013, P123, P272, P572, P628	Inflamatória Intestinal	P124	Halfvarson, J.	OP022, P061, P364, P694, P695, P727, P788
Goutte, M.	DOP013, DOP086, P122, P123, P272, P572, P628	Grzybowska-Chlebowczyk, U.	P504, P510	Hall, B.	P380
Gouveia, C.	OP016	Gröchenig, H.P.	P233, P547	Hallas, J.	P720
Govani, S.	P303, P361	Guardiola, J.	P091, P143, P169, P183, P186, P201, P397, P546, P736	Haller, D.	OP004, OP030
Goverse, G.	P022	Gubatan, J.M.	P344	Halloran, B.	P552
Govorun, V.	P794	Guedj, E.	P010	Hamanaka, S.	P159, P231
Gower-Rousseau, C.	DOP045, P221, P734, P756	Guerra, I.	DOP016, P186, P314	Hamchaoui, F.	P206
Gracie, D.	P343	Guerreiro, H.	P435, P723	Hameeteman, W.	OP017
Gracie, D.J.	P622, P655	Guerrero Puente, L.N.	P545	Hamidouche, D.	P206, P260, P266, P289
Grafton, R.	P170, P238	Gugliemi, F.W.	OP005	Hamilton, A.L.	P773
Graham, R.	P469	Gui, X.	DOP068	Hamlin, P.J.	P227, P343, P525, P622, P648, P655
Graham, T.	DOP047	Gui, X.	P212, P275	Hammarlund, P.	P533
Grammatikos, N.	P452	Guidi, L.	OP005 , P440, P654	Hammer, T.	P692
Grande Santamaría, L.	P792	Guillen, M.C.	P683	Hammerman, O.	P451
Grandin, C.	N808	Guillon-Dellac, N.	DOP045	Hampe, J.	P326
Granja, A.	P314	Guillon, F.	DOP034	Han, D.S.	P060, P461, P701
Granovsky- Grisarú, S.	P197, P217	Guirola, M.A.	P350	Han, I.S.	P228
Gravito-Soares, E.	DOP016, DOP016	Gulart, A.	P449	Han, L.	P274
Graziani, C.	P019, P115 , P498	Gulati, S.	P535	Han, S.	P582
Greco, M.	P108	Gulletta, E.	P108	Han, S.-W.	P483
Green, A.	P458	Gulotta, G.	P191	Han, S.Y.	P228
Greenbaum, L.	P077	Gundín, M.J.	N822	Han, Y.-M.	P028
Greenberg, D.	P749	Gunn, M.C.	P434	Han, Z.	P672
Greenberg, G.	P615	Gunnarsson, J.	P364	Hanauer, S.	OP010, OP014, P119
Greener, T.	P426, P615	Guo, J.	P400 , P428	Hanigan, K.	P691
Greenup, A.	P597, P625	Guo, Z.	DOP038	Hansen, L.-F.	P158, P278
Greer, M.-L.	DOP057	Gupta, A.	P398	Hansen, M.B.	OP034
Grelack, A.	P663	Gut, I.	P061	Hansen, R.	DOP008, P158, P278, P587
Greuter, T.	P304	Gutermuth, B.	P303	Har-Noy, O.	P160, P341, P624
Grewal, C.S.	P596	Gutierrez, A.	DOP016	Hara, T.	P464
Grgic, D.	P742	Gutierrez, G.	P437	Harbord, M.	P770
Griebe, M.	P099	Gutierrez-Grobe, Y.	P144	Harder, B.	P418
Griffiths, A.	DOP057, P127, P268, P460, P754	Gutiérrez Mendizábal, P.	P508	Hardt, T.	P456
Grigoryeva, T.	P794	Gutiérrez, A.	OP013, DOP039, P076, P327, P529, P583, P603, P607	Haren, S.	OP021
Grill, J.-P.	P780	Gweon, T.-G.	P483	Haritunians, T.	P269
Grillo, F.	P301	Gómez Barbadillo, J.	P463	Harkin, G.	P403
Grimaud, J.C.	OP008, OP009, DOP025	Gómez Irwin, L.	P508	Harpaz, N.	P177
Grimble, G.	P376	Gómez García, R.	P327	Harrison, P.	OP023, OP033, DOP075
Grimstad, T.	P429, P710	Göktürk, H.S.	P401	Harrow, P.	P059
Grinspan, A.	P554			Harrower, T.	P550
Grip, O.	P364			Hart, A.	DOP046 , DOP047, DOP048, DOP055, P005, P018, P093, P126, P211, P220, P240, P245, P398, P432, P439, P494, P541, P555, P722, P743, P787
Gris, G.	DOP088, P033	H aaber, A.	P533		
Grisic, A.-M.	P485	Haas, J.S.	P456		
Groenen, M.	P014, P267, P313, N796, N797	Haas, T.	P233, P511		
		Haavardsholm, E.A.	DOP062	Hart, L.	P157

Harterry, K.	DOP065 , P370, P578	Herrera Justiniano, J.M.	P634	Hoque, S.	P501
Hartke, J.	DOP023	Herrera, C.	P683	Hordonneau, C.	DOP013, P122, P123, P272, P572
Hartleb, M.	P189, P746	Herrera-Najum, P.	P717	Horeman, T.	P551
Hartmann, F.	P326, P521	Hertervig, E.	P364	Horgan, G.	P578
Harustiaková, D.	P375	Hervás, J.	P224	Hori, K.	P150
Harvey, P.	P351	Hervías Cruz, D.	P193	Horiuchi, H.	P012
Hashimoto, S.	P107	Hervías, D.	P327	Horjus Talabur Horje, C.	P014, P267, P313, N796, N797
Hassan, C.	P526	Hester, K.	DOP020	Hornef, M.	P041
Hata, J.	P249	Heywood, N.	P245	Hornblow, R.	P079
Hata, K.	DOP066	Hibberts, F.	N802	Hornuss, D.	P039
Hatemi, I.	P214, P282, P678	Hibi, T.	DOP071, DOP073, P215, P293, P325, P493, P523	Horowitz, J.	P754
Hather, G.	P305 , P466	Hickey, J.	P593	Horsch, K.	P113
Hausmann, M.	P013, P102	Hickey, T.	N807	Hoshen, M.	P721
Hawkey, C.	OP004	Hicks, L.	P182 , P253 , P274	Hosomi, S.	P427
Hayashi, Y.	P419	Hida, N.	P150	Hossne, R.S.	P760, N811, N816, N817
Hayden, K.	DOP052	Hidayat, H.	P071, P216	Hoti, I.	P053, P070
Hayee, B.	P129, P535, P599, P667	Higgins, P.D.R.	OP031, P002, P303, P241, P361	Hou, H.W.	DOP082
Hayes, S.	DOP047	Higuera, R.	P202	Houze, P.	DOP032, P420
Hazel, K.	P371	Hindryckx, P.	P438, P752, P777	Hovde, Ø.	P710
Hazra, A.	DOP074	Hinojosa, E.	P557, P632	Hovell, C.	P379, P645, P649
He, C.-Y.	P672	Hinojosa, J.	P120, P557, P632	Howell, S.	OP036
He, H.	P149	Hinojosa, M.D.	P557, P632	Hoyles, L.	P093
He, Y.	P246, P441	Hirai, F.	P215	Hradsky, O.	P211, P432
Headon, B.	P609	Hirano, A.	P215, P784	Hrubá, V.	P532
Healey, P.	P467, P558	Hirasawa, K.	P133	Hrycek, C.	P170, P238
Heap, G.	P413, P550	Hirsch, A.	P389	Hsu, P.	OP073
Hebuter X.	OP023, DOP075, P501, P511, P590	Hirschfeld, G.	OP079	Hu, J.	OP037
Hedemann Nielsen, A.	P522	Hirschmann, S.	DOP073	Hu, J.	P149
Hedley, A.D.	P058	Hirten, R.	DOP023	Hu, M.	P073
Heerasing, N.	P413 , P550	Hisamatsu, T.	DOP071, P215, P293, P523	Hu, P.	P096, P149
Heida, A.	P374	Hishida, A.	P493	Huang, M.	P096
Heida, W.	N796	Hiyama, S.	P419	Huang, R.	P177
Heinrich, H.	P130	Hjortswang, H.	P364	Huang, S.	P002
Hellström, P.M.	P533,	Hlavaty, T.	P312, P567 , P750	Huang, V.W.	P552
	P606 , P735	Hlavatý, T.	P595	Huang, Y.	P096
Hemmrich-Stanisak, G.	P759	Ho, G.-T.	P037 , P055	Huang, Z.	P096
Henderson, P.	P082, P125, P167, P516, P700	Hoare, T.W.	P434	Hudesman, D.	DOP023, P357
Hendy, P.	P413, P550	Hobart, J.	P550	Huernos, S.	OP074, P585
Hendy, P.	P018, P093	Hocking, J.	N807	Huetson, P.	P735
Henneman, P.	P094	Hodgins, J.	N807	Huggett, B.	P479, P579, P591, P707
Henriksen, M.	P408	Hodson, J.	DOP068	Hughes, J.	P170, P238
Hering, L.	DOP089, P768	Hoekman, D.	DOP017, P297	Hughes, P.	OP036, P392
Hering, N.	P101	Hoeng, J.	OP010	Hugot, J.-P.	DOP086
Herman, A.	P418	Hoentjen, F.	DOP004, P663, P682	Huguet, J.M.	DOP016, P327, P423, P618
Herman-Sucharska, I.	DOP057	Hoffmann, P.	DOP035	Huguet, M.	P628
Hernandez Ramirez, V.	N801	Hojasak, I.	P404	Huh, G.	P715
Hernandez, A.	DOP063	Holler, B.	DOP073	Huhtala, H.	P218
Hernandez, C.	P009, P015, P087	Holm, A.	P048	Huisinga, W.	P485
Hernandez, V.	P694, P695, P727	Holmes, E.	P018, P182, P253, P787	Huisman- de Waal, G.	N797
Hernández Camba, A.	P629	Holvoet, T.	P777	Hummel, T.	P297
Hernández, A.M.	P503, P605	Hombres, D.W.	P354, P748	Huntzicker, E.	OP033
Hernández, C.	P092, P120	Honda, K.	P249	Huoponen, S.	P639, P685
Hernández-Martínez, A.	P327	Hong, E.	P377	Huorka, M.	P595, P750
Hernández-Tejero, M.	P314	Hong, S.N.	P154	Huppertz-Hauss, G.	P710
Hernández, V.	DOP001, P455	Honzawa, Y.	P012, P187	Hurst, R.D.	P389
Herrala, S.	P515	Hooper, K.	P082	Hussey, S.	DOP009, DOP037, P262
Herrera deGuise, C.	P350				

- Huynh, H. DOP072, P450, P460
Hwang, S.W. P148, P252, P406, P482, P641
Hyman, N. P389
Høivik, M. P151, P514, P710
Hübenthal, M. P759
Högenauer, C. **P390**
- I**
Iacob, R. P207
Iacucci, M. DOP068, **P212, P275**
Iade, B. DOP016
Iannone, A. **P335**
IBD Character Consortium OP022, P061, P788
IBD Studygroup from the Basque-Navarre Society of Gastrointestinal Diseases P202, P508
Iborra, M. **OP013**, P365, P583
Ichim, S. P207
Ido, A. P107
Ierardi, E. P335
IG-IBD P574, P652
Iglesias Flores, E. P327, P463, P545
Iida, T. P564
Iijima, H. P419
Iizuka, B. P464
Ijaz, U.Z. DOP008
Ikeuchi, H. P540
Im, J.P. P548
Imeneo, M. P108
Imhann, F. DOP004
Imperatore, N. P153, P646
ImproveCareNow Network OP025
Inayama, Y. P133
Inderson, A. P667
Indriolo, A. P235
Inflammatory Bowel Disease Genetics Consortium OP001
Iniesta, L. P683
Innes, A. P659
Inoue, E. P337, P489
Inoue, T. P419
Inouye, M. P773
Inserra, G. P412, P539
Ionita Radu, F. P323
Iovino, P. P103
Iqbal, S. OP029
Iqbal, T. **OP002**, DOP068, P056, P079, P670
Irani, N.R. **P270**
Iriarte, A. P202
Ironsides, P. N798
Irving, P. OP028, P220, P444, P684, N802
Isaksen, K. P429
Ishida, T. DOP071, P523
Ishihara, S. DOP066
Ishii, M. **P249**, P325, P666
- Ishikawa, D. **P766**
Israeli IBD Research Nucleus (IIRN) P779
Israeli, E. P451, P721
Ito, A. **P464**
Itoh, F. P666
Iturrriaga Goyon, E. P042, P164, P762, P765
Itzkowitz, S. DOP043, DOP064, P554
Ivanov, N. P010
Ivashkin, V. P390
Iwamoto, F. P256
Iwatani, S. P419
İşik, H. P620
- J**
Jabri, B. P196
Jackson, B. P691
Jacobson, K. P460
Jacobstein, D. OP010, DOP046, DOP052, P465, P549
Jagger, F. **P700**
Jahnsen, J. OP022, DOP062, P061, P710, P788
Jain, A. DOP020
Jairath, V. DOP033, P050
James, A. DOP026, P209
Jang, B.I. P321, P548, P657
Jansen, M. DOP047
Jantchou, P. P352
Jarocka-Cyrta, E. P346
Jarzebicka, D. P504, **P510**
Jauregui Amezaga, A. P437
Jawa, H. P173
Jeen, Y.J. P604
Jelakovic, M. P742, **P747**
Jelsness-Jørgensen, L.-P. P408, P710
Jeon, S.R. **P174**
Jeong, B.-S. **P030**, P057, P608
Jerber, L. P608
Jess, T. OP003
Jeuring, S. P316
Jeyarajah, J. P050
Jharap, B. OP037
Ji, G. P112
Ji, J.-S. P483
Ji, Z.-L. DOP082
Jia, Y.-I. P672
Jiang, M. P075
Jigarano, A.O. P203, P232, P388, **P601**
Jimenez, M. **P436**
Jiménez, C.E. P607
Jiménez, M. P110
Jiménez, S. DOP012
Jin, H. P098
Jinga, M. P323
Jo, H. P044
Jo, I.h. P068
- Johanns, J. OP010, DOP076, P549
John, L. P439
Johns, K. N810
Johnson, H. **P379**, P645, P649
Johnson, L.A. P002
Johnson, S. P698
Johnston, A. P227
Johnston, E. **P444**
Jokelainen, J. P515
Jonaitis, L. P759
Jonasson, J. P758
Jones, G.R. P416, P586
Jones, G. P443, P681
Jones, J.L. P725
Jonkers, D. OP017, DOP006, DOP049, P316, P690, P696, P737, P781
Joo, Y.-H. P068
Joossens, M. DOP080, P767
Jorquera, F. P436
Jostins, L. OP001
Jover, R. P529
Juan, G. **P557, P632**
Juanola, O. P076
Juillerat, P. P569, P719, P740
Julien, B. P360
Juliá, B. OP013, DOP039, P183, P397, P583, P603, P736
Julsgaard, M. DOP016
Jung, H.-K. P068
Jung, H.-J. P656
Jung, J. P027
Jung, K.W. P104
Jung, S.-A. P068
Jung, Y. P174, P461
Jussila, A. P218, P515
Juil, T. N795
Juzenas, S. **P759**
Jørgensen, K.K. **DOP062**
- K**
Kaakoush, N. P589
Kaaks, R. P722
Kabakchiev, B. P223, P296, P426, P502, P793
Kabir, M. **P220**, P513
Kadleckova, B. P339
Kaelin, M. P304
Kafalis, N. P452
Kagramanova, A. P536
Kaimakliotis, I. P694, P695, P727
Kaimakliotis, P. **P488**
Kajihara, T. P518
Kalabic, J. P353, P669
Kalei, A. P640
Kalla, R. **OP022**, P055, P061
Kamata, N. P325, P427, P493
Kamath, B.M. P127, P268



Kamikozuru, K.	P150	Kelly, C.	P430	Kim, K.O.	P321, P657
Kamm, M.	P589, P773	Kemp, K.	P525	Kim, K.-J.	P028 , P148, P252,
Kamperidis, N.	P391, P490	Kendall, A.	P043, P045		P482, P641
Kamyschna, V.	P791	Kennedy, E.	P311	Kim, K.	DOP031
Kamyszhnyi, A.	P791	Kennedy, N.	OP001, OP022,	Kim, M.J.	P487, P730
Kanagasundram, C.	P743		P037, P413	Kim, M.	P399
Kanai, T.	DOP071, P523	Kennedy, N.	P061, P550	Kim, N.	P715
Kane, S.	DOP023	Kenneth, C.	P525	Kim, S.-W.	P483
Kaneko, M.	DOP066	Keogh, A.	N809 , N815	Kim, S.-E.	P068
Kaneto, H.	P666	Keohane, S.	P141	Kim, S.	P487, P730
Kang, B.	DOP031, P542, P674,	Kerr, S.	P691	Kim, S.E.	P104
	P730, P755	Keränen, I.	P264	Kim, S.	P047
Kang, D.H.	P324	Keshav, S.	P271, P593	Kim, S.	P582
Kang, H.-E.	P030	Kevans, D.	P141, P184, P403,	Kim, T.J.	P154
Kang, J.W.	P377, P393		P491, P594	Kim, W.J.	P656
Kang, M.K.	P657	Key, T.	P722	Kim, Y.S.	P461, P701
Kang, S.-B.	P483	Keye, J.	P065	Kim, Y.H.	DOP061 , P701
Kaniewska, M.	P425	Khalid, J.M.	DOP019, DOP021,	Kim, Y.-H.	P154, P500
Kanis, S.	OP018		DOP022, DOP026, P209,	Kimura, H.	P133, P337, P489
Kanmura, S.	P107		P305, P442, P466, P470	Kimura, M.	P256
Kanwar, B.	P047		P023, P688, P704, P734	Kindermann, A.	P158, P278,
Kaplan, G.G.	P134, P212, P734	Khalili, H.	P239		P297, P524
Karakan, T.	DOP001	Khan, N.	P554	King, E.	OP025
Kariyawasam, V.	P386	Khan, S.	P378, P631	Kinnucan, J.	P410
Karlsen, L.N.	P429	Kharrat, J.	P722	Kiparissi, F.	P219, P479, P513,
Karlén, P.	P364, P501	Khaw, K.-T.	P448		P579, P591, P707
Karmiris, K.	DOP016, P211, P240,	Khera, R.	P157	Kirchgatterer, A.	P233
	P341, P494, P709	Kherad, O.	P451	Kirchgesner, J.	OP003
Karsdal, M.	DOP051, P089, P671	Khoury, T.	P026, P071	Kirkwood, C.D.	P773
Kaser, A.	DOP021, P209	Kiely, P.	DOP006, P265,	Kirschniak, A.	P563
Kashiwagi, H.	P464	Kierkus, J.	P504, P510, P746	Kishikawa, J.	DOP066
Kassim, O.	P454	Kiernan, M.	P071	Kiszka-Kanowitz, M.	P590
Kato, S.	DOP071, P523	Kiernan, M.G.	P026, P216	Kita, Y.	P150
Katsanos, K.H.	DOP001, DOP005,	Kiesslich, R.	P275	Kitazono, T.	P215, P784
	DOP006 DOP055, P211,	Kievit, L.	P694, P695, P727	Kiudelis, G.	P759
	P213, P240, P341, P366, P494,	Kievit, W.	P682	Kiyomatsu, T.	DOP066
	P694, P695, P727, P751	Killinger, Z.	P312	Kjaerulf, S.	DOP083
Katsikeros, R.	OP036, P392	Kim, A.	P241	Kjeldsen, J.	P089
Katsoula, A.	P421, P452, P662	Kim, B.D.	P748	Klag, T.	P563
Katsuno, T.	P159, P231	Kim, D.B.	P548	Klein, T.	P779
Katz, L.	P160, P624	Kim, D.J.	P604	Klersy, C.	P301
Kaur, D.	P596	Kim, D.-S.	P582	Kloft, C.	P485
Kav, T.	P029 , P401	Kim, E.R.	P154	Klopocka, M.	OP023, DOP075, P746
Kavadias, A.	P751	Kim, E.S.	P321 , P461	Knaus, U.G.	DOP085
Kavitt, R.T.	P192	Kim, E.Y.	P321	Knezevic Ivanovski, T.	P236
Kaviya, A.	DOP021, DOP026, P209	Kim, G.-U.	P148, P252, P406,	Knezevic Usaj, S.	P236
Kawagishi, K.	P225 , P570		P482, P641	Knezevic, T.	P569
Kawaguchi, T.	P325	Kim, H.M.	P701	Knight, R.	OP021
Kawai, K.	DOP066	Kim, H.J.	P487, P500	Knight, S.C.	P093
Kawai, M.	P150	Kim, H.G.	P174	Knittel, T.	P080, P106
Kawai, S.	P419	Kim, H.-S.	P044 , P548, P701	Knol, M.	P374
Kayhan, C.	P467	Kim, H.W.	P324	Knyazev, O.	P536
Kazemi-Shirazi, L.	OP009	Kim, J.H.	P104	Ko, B.M.	P174
Kecili, L.	P260, P266, P289	Kim, J.-E.	P730	Ko, D.-H.	P406
Keegan, D.	P261, P370, P578	Kim, J.-O.	P174	Ko, H.M.	P177
Keetarut, K.	P376	Kim, J.	P582	Kobayashi, K.	P225, P570
Keir, M.	P431, P522	Kim, J.K.	P656	Kobayashi, T.	P293, P325, P493
Kel, A.	P041	Kim, J.S.	P701	Koch, A.	P176
Kelly A.	P036	Kim, J.-A.	P030, P057	Koch, R.	P233

- Kochhar, G. DOP023
 Kocklar, G. P357
 Koelink, P. DOP036, P114
 Koens, L. P650
 Koganei, K. P644
 Koh, Y. P587
 Kohn, A. OP005, P440
 Koizumi, W. P570
 Kok, K. P220
 Kokkorou, M. P587
 Kokot, M. P328
 Kolar, M. **P532**
 Kolarčík, P. P247
 Kolaček, S. P158, P278
 Koletzko, S. DOP009, P486
 Kolho, K.-L. DOP037 P158, P194, P278, P409, P457
 Kolho, K. P414
 Koliani-Pace, J. DOP023
 Kolios, G. P097
 Kolios, S. P751
 Koller, T. P567, P595, P750
 Kollerova, J. P567
 Kondamudi, P.K. P051
 Kondragunta2, V. DOP020
 Konen, O. DOP057
 Konikoff, F.M. P345, P561, N821
 Konoplyanikov, A. P536
 Koo, E.J. P657
 Koo, J.S. **P604**
 Koot, B. P297
 Koporulina, M. P011
 Kopylov, U. **P160**, P181, P211, P240, P302, **P366**, P494, P624, P626, P763, P779, N820
 Korczowski, B. P504, P510
 Korf, H. **DOP050**, P050, P095
 Kori, M. P409
 Korlatowicz-Bilar, A. P504, P510
 Kornbluth, A. OP037
 Koseki, H. P231
 Koshikawa, Y. P012, P187
 Koshkin, S. P011
 Koslowsky, B. P197, P217, **P307, N818**
 Kosmidis, C. P627
 Kostas, A. P627
 Kot, J. P576
 Kotze, P. DOP055, P241
 Koulaouzidis, A. P160, P624
 Koumoutsos, I. N802
 Koumpouras, C. DOP053
 Koutroubakis, I. DOP055, P340, P348
 Kovacs, J. P375
 Kovács, A. P739
 Kowerzanow, J. P576
 Kozachuk, A. P791
 Krag, A. P089
 Krah, A. P486
 Krajčovičová, A. **P312**, P567, P595, P750
 Kretowski, A. P147
 Krishnaprasad, K. P691
 Kristof, T. P331, P592
 Kroeker, K.I. P552
 Krogfeldt, K.A. P769
 Krogh, K. P185
 Krugliak Cleveland, N. **P196**
 Krummenerl, A. P501
 Krummenerl, T. P501
 Krustins, E. DOP001
 Krznarić, Z. P575, P742, P747
 Krzysciak, W. P287
 Kräuchi, S. P283
 Krūmiņa, A. P783
 Kucharzik, T. DOP073, P162, P171
 Kucinskiene, R. P404
 Kudriavtseva, E. P517
 Kuehbacher, T. OP023, DOP075, **P544, P588**
 Kuin, S. P611
 Kukulska, M. P746
 Kulig, K. P661
 Kulkarni, P. P418
 Kunisaki, R. P133, P337, **P489**
 Kunovic, A. P742
 Kupcinskas, J. P759
 Kupcinskas, L. P694, P695, P727, P759
 Kuroki, H. **P644**
 Kurti, Z. P145, P309, P331, **P411**, P592, P623
 Kuzma, M. P312
 Kvien, T.K. DOP062
 Kwak, S.G. P321
 Kwon, D.-H. P582
 Kwon, E.J. P148, P482
 Kühbacher, T. DOP073, **DOP078**, P369
 Küh, A. P065
 Kühn, T. P722
 Kühnel, A. P101
 Kündig, T. DOP089
 Kürti, Z. P675
 La Fortezza, R.F. P335
 Labenz, C. P712
 Laberrenne, E. DOP045
 Labidi, A. **P405**
 Lacey, P. P354
 Laclé, M.M. DOP067
 Lada, S. P279
 Ladic, A. **P575**
 Laghouati, S. P315
 Lagkouvardos, I. OP030
 Lago, P. DOP081, P299
 Lahad, A. DOP054, P779
 Laharie, D. DOP011, DOP025, DOP027, P254, P310, P499, P680
 Lahat, A. DOP061, P181
 Lahiff, C. **OP026**
 Lainka, E. P486
 Laino, G. P538, P598
 Lakatos, P. P331, P739, P592, P145, P152, P309, P411, P623, P675, P694, P695, P727, P734
 Lakatos, P.L. P590
 Lal, S. P699
 Laliberte, M.-C. P280
 Lamas, M.J. OP001
 Lamb, C. P572
 Lambert, C. P103
 Lamberti, G. P315
 Lambotte, O. DOP022
 Lambrelli, D. P776
 Lamkanfi, M. P096
 Lan, P. P724
 Landerholm, K. P654
 Landi, R. P780
 Landman, C. P178
 Landolfo, S. P504, P510
 Landowski, P. P157
 Laneuville, J. DOP059, P017, P768
 Lang, S. P326
 Langbein, C. P544, P588
 Langel, N. DOP001, P694, P695, P727
 Langholz, E. **P176**
 Langhorst, J. P775
 Langille, M.G. P547
 Langner, C. **P108**
 Larussa, T. DOP023
 Lasch, K. DOP077, DOP078, P369
 Lassen, C. P023
 Lassen, K. P301
 Latella, G. P117
 Latiano, A. P117
 Latiano, T. P699
 Latour, M. P577
 Lau, S. P176
 Lauenstein, T. P720
 Lauge Nielsen, G. P777
 Laukens, D. P162
 Laumeyer, T. P338
 Laurent, V. **DOP058**, P571
 Laureti, S. P621
 Lauria, A. **P261**
 Lavelle, A. P783
 Lavrinoviča, E. OP032
 Lawendy, N. **OP007**, P691
 Lawrance, I.C. P460
 Lawrence, S. P403
 Layden, J. DOP018, P329
 Lazar, A. P590

- Lazarev, M. P275, P488
 Le Bal'ch, E. **P780**
 Le Bourhis, L. **OP004**, DOP084
 Le Jeunne, C. P471
 Leal, R.F. P025, P038
 Lebenheim, L. **P101**
 Lebensztejn, D. P147
 Lebovic, G. P699
 Lecca, G. P530
 Lechat, E. P456
 Ledder, O. P158, P194, P409, **P414**
 Leddin, D. P734
 Lederman, N. P689, P721
 Lee, A.R. P060
 Lee, B.I. P461
 Lee, B.-I. P483
 Lee, C.H. P073
 Lee, D.H. P715
 Lee, D.-W. P604
 Lee, E.Y. P321
 Lee, H.J. P730, P755
 Lee, H. P461
 Lee, H.-S. P406, P482, P641
 Lee, H.S. P321
 Lee, J. OP001, **DOP048**
 Lee, J.H. P730
 Lee, J.H. DOP031
 Lee, J.H. P487, P500
 Lee, J.M. **P548**
 Lee, J.-H. P730
 Lee, K.M. DOP061
 Lee, K.-M. P483, P548
 Lee, K. DOP031, P542, P674, P755
 Lee, K.E. **P068**
 Lee, M. P443
 Lee, M. P681
 Lee, M.J. P245
 Lee, M.S. P174
 Lee, S.J. DOP061, P487, P500
 Lee, S.D. **DOP077**
 Lee, S.G. P028
 Lee, S.-Y. P755
 Lee, S. P393
 Lee, S.-H. P500
 Lee, S.-H. **P148**, P641
 Lee, S.H. P098
 Lee, S.Y. DOP061, P487
 Lee, S. P500
 Lee, Y.J. P321
 Lee, Y.M. P730
 Lee, Y. P730
 Lee, Y. P393
 Lee, Y.R. P060
 Leedham, S. DOP047
 Leek, A. P297
 Lees, C.W. P416, P586
 Lefevre, C. **P396**
 Legnani, P. OP037, P213
 Leibovici, H. P708
 Leibovici-Weissman, Y. P708
 Leibovitzh, H. **P188**
 Leiro, J.M. P785, P786
 Leitao, K.Ø. P429
 Leite, S. P136, P642
 Lejnicks, A. P783
 Lekkerkerker, A. **P418**
 Lemieux, C. P157, P342, P677
 Lenker, E. P118
 Lenti, M.V. **P227**, **P525**, P648
 Lentjes, E. P722
 Leo Carnerero, E. P634
 Leo, E. P327
 Leone, D. P506, P534
 Leong, R. OP073
 Lepistö, A. P264
 Lerang, F. **P408**
 Leshno, M. P243
 Leskova, Z. P312, P567, **P595**, P750
 Lethebe, B.C. P212, P275
 Leung, Y. P212
 Levchenko, O. DOP061
 Levesque, B. OP014, DOP033, P050
 Levhar, N. P181, P779
 Levi, Z. P708
 Levin, A. DOP036
 Levine, A. DOP001, DOP006, DOP007, DOP009, **DOP037**, P257, P262, P295, **P409**, P414, P484, P758
 Levison, S. P036, P525
 Levy, Z. P721
 Lewis, A. N813
 Lewis, A. **OP029**
 Lewis, J.D. P501, P511, P590
 Lewis, N. DOP048
 Lewis, W. P288
 Ley, D. P756
 Leyden, J. P594
 Li Yim, A.Y. P094
 Li, C. OP014
 Li, J. P155
 Li, J. **P356**
 Li, K.-K. DOP068
 Li, K. DOP046, **DOP052**, **P077**, **P465**
 Li, W. P725
 Li, X. OP019
 Li, X. P075
 Li, X. P244
 Li, Y. **DOP038**
 Li, Y. P155
 Li, Z. P244
 Liang, J. P075, P096
 Liaskou, E. P079
 Liautard, J. DOP034
 Liberal, R. P230, P417
 Lichtenstein, G. DOP076, P501, P511, P590
 Lichtenstein, L. P188, **P478**, **P708**
 Lie Høivik, M. P728
 Liefferinckx, C. DOP069, **P560**
 Lightner, A. **P357**
 Lightowler, D. OP007
 Lim, D. P093
 Lim, W.-C. **P660**
 Lima, J. P299
 Lima, M. DOP081
 Limdi, J. P242, P512, P525
 Limketkai, B. **DOP002**
 Limsrivilai, J. **P303**
 Lin, B.-R. P199
 Lin, H. P660
 Lin, L. P096
 Lin, Z. P568
 Lindahl, T. P778, P788
 Lindley, K. P219
 Lindsay, J. OP029, P059, P086, P363, P543
 Lindsay, J.O. OP004, P053, P070, P467, P558, P614
 Lindsjö, I. P422
 Lindstrom, J. OP022
 Linea, C. P372
 Linke, K. P746
 Lionetti, E. P790
 Lionetti, P. DOP009, P257, P661
 Lipowska, A.M. P192
 LIRIC study group OP015
 Lissner, D. DOP016, **P617**
 Litta, F. **P306**
 Little, R. **P609**
 Liu, B. P037
 Liu, B. P361
 Liu, D. P001, P113
 Liu, E. P525
 Liu, J. P568
 Livovsky, D.M. P197, P307
 Lix, L.M. P725
 Llaó, J. P186
 Llaó, J. P423, P480, P607, P618, P706
 Lloyd-Ford, G. **N813**
 Lo Presti, E. **P008**
 Lo Sasso, G. P010
 Lobaton, T. DOP016, **P367**, P528, **P562**
 Lobo, A. P245, P328, P443, P511, P681, N803, N805
 Loddenkemper, C. P617
 Lodyga, M. **P746**
 Loftus, E.V. OP034, OP035, DOP021, DOP023 **P209**, P263, P353, P357, P466, **P669**, P734
 Loh, G. P065
 Loirat, D. P315
 Loitto, V. P048
 Lolli, E. P332

- Lombardi, G. OP028
Lomer, M. DOP006, P507
Longhi, M.S. P344
Looney, C. P431
Lopes, S. P600
Lopes, S. P049, P230, P234, P290, P308, P417
Lopetuso, L.R. **OP027**, P019, P115, **P498**
Lopez-Diaz, J. P204, **P505**
Lopez-Sanroman, A. P782
Lophaven, S.N. P692
Lord, G. OP028
Lorente Poyatos, R. P193
Lorente, R. P327
Lorentzen, M. DOP062
Lorenzetti, R. P373
Lorenzo, A. P204, P280, P285, P505
Lores, T. **P170**, **P238**
Losurdo, G. P335
Lotti, M. P235
Louis, E. DOP015, DOP069, P169, P501, P511, P590
Loureiro, R. P519
Lourenco, N. DOP032
Lourenço, L. P714
Lovasz, B.D. P145, **P309**, P331, P411, **P592**, P623
Love, M. P670
Low, E.N.D. **P031**
Lowenberg, M. DOP004
Lowerison, M.W. P212, P275
Lowery, A.J. P026, P071, P216
Lozano, J.J. P091
Lozano, M. P437
Lu, B. P047
Lu, T. P418, P522
Lubbers, T. P132
Luben, R. P722
Luber, R. **P386**
Lucafò, M. **P084**
Lucendo Villarín, A.J. P193
Ludvigsson, J.F. OP024
Ludwiczek, O. P233
Luglio, G. **P153**
Luinetti, O. P301
Luiz, R. P741
Lukas, M. P532
Lukas, M. P532
Lukin, D. DOP023
Luna, T. DOP020
Lundin, K.E. DOP062
Lung, P.F. P126, P245, P398
Luo, C. P146
Luo, M. DOP023
Luo, X. P400
Luo, Y. OP001
Luypaerts, A. P774
Luzza, F. P108
- Lv, H. P083, P155
Lykiardopoulos, B. P364
Lynge, E. P692, P734
Lyons, P. DOP048
Lázár, G. P317
López, A. P462, P679
López-Estévez, S. **DOP088**, **P033**, **P034**
López-García, A. DOP070, DOP084, P437
López-San Román, A. DOP016, P706
López-Serrano, A. **P224**
López-Serrano, P. DOP016
Löwenberg, M. DOP017, P611, N806
Łazowska-Przeorek, I. P504, P510
- M**a, L. **P083**
Maa, J.-F. P381
Maaser, C. **DOP001**, DOP073, P171
Mac Carthy, F. P491
Macaluso, F.S. **P372**, P387, **P412**, **P613**
Macaulay, D. P676
MacCarthy, F. P141, P403
Macciomei, M.C. P301
Maccioni, A. P301
Maccioni, F. P526
MacDonald, T. P032
Macedo, G. P049, P198, P230, P234, P290, P308, P417
Mach, T. P287
Machiels, K. **OP038**, **DOP044**, DOP080, P767
Machkova, N. P532
Macias-Ceja, D.C. **P009**, P015, P087, P092, P120
Maciejewska, K. P425
Macinga, P. P259
MacIntyre, B. **P775**
Maciua, R. OP011, P395, P431, P468
Mack, D. P460
Macken, E. DOP069
MacKenzie, T. P161
MacLellan, A. P775
MacMathuna, P. P403, P594
Macconi, G. P211, P240, P494
Macpherson, A.J. P719, P740
MacRae, H. P311
Macri, G. P407
Maddipati, K.R. P004
Madian, A. P165
Maeda, S. P133
Maedler, C. P157
Maes, P. DOP080
Magalhães, J. P292
Maggi, P.M. P661
- Maggiori, L. DOP042, P142, P476
Magill, L. OP002
Magnano, A. P412
Magnusson, K.-E. P048
Magro, F. DOP016, P049, P198, P230, P234, P248, P290, P308, P694, P695, P727
Magri, G. P412
Maguregui, A. P633
Maharshak, N. P046, P243, P612
Mahdi, G. P775
Maher, S. P558
Maheshwari, P. **P380**
Mahida, Y. P390
Mahiou, H. P206, P260, P266, P289
Mahmmod, N. OP017
Maia, L. P299
Maida, M. P613
Maillard, M.H. P298
Maillet, M. DOP032
Mailänder-Sánchez, D. **DOP083**
Maisano, S. P372
Maiz, A. P202
Majlingová, S. P247
Majorová, E. **P247**
Makanyanga, J. OP036, P392
Makarchuk, P. **P517**
Malagón, M. P143, P201
Malakos, Z. P751
Malecka-Panas, E. P746
Malek, N. DOP083, P563
Malickova, K. P532
Maljaars, J. OP017, P336, P667
Maljaars, P. P559
Maller, E. OP031
Malmborg, P. OP024
Malmström, G.-H. P422
Mamantopoulos, M. **P776**
Mamie, C. P013
Mamona, C. P221
Man, R. OP093
Mana, F. P347
Manabe, N. P249
Manca, R. P301
Mancebo Giménez, A. P048
Manceñido Marcos, N. DOP016, **P697**
Machancoses, F. P319
Mandić, A.D. **P041**
Manetti, N. OP005
Manganis, C. P271
Mangiola, F. P115
Manichanh, C. OP038, DOP044
Mannens, M.M. P094
Manser, C. P569
Mansfield, J. OP001, OP011, P659, P738
Manship, T.A. P416, P586
Mantaka, A. **P340**

Mantzaris, G.J.	DOP001, DOP016	Martins dos Santos, V.	DOP049,	Mazuz, B.	P197, N818
Manuchehri, A.	P467, P558		P316	Mazza, M.	P571
Manzanares Martin, B.	P545	Martins, C.	P137	Mazzuoli, S.	P621
Manzini, R.	DOP089	Martins, D.	P691	Mañosa, M.	P367, P480 , P562
Mao, R.	P244, P246 , P394, P400, P402, P428, P441 , P481, P653	Martins, D.	P255, P284	Mc Kiernan, S.	P491
Marabelle, A.	P315	Martín Arranz, M.D.	OP013, DOP039, P327, P423, P583, P603, P618	Mc Namara, D.	P184, P208, P276
Marano, C.	DOP076, P077, P446	Martín de Carpi, J.	DOP016, P414	McBride, J.	P431, P468
Marasco, R.	P108	Martin, G.	DOP016	McCarthy, J.	N804
Marchesa, P.	P372	Martín, M.D.	P528	McCarthy, N.	P059
Marchesi, J.	P770, P787	Martínez, M.D.	P528	McCarthy, N.E.	P070
Marchi, P.	P492	Martínez Dueñas, J.L.	P463	McCartney, A.L.	P093
Marchi, S.	P538, P598	Martínez, A.	P475, P503, P605, P633	McCartney, S.	P043, P045, P220, P363 , P513, P543
Marcolongo, M.M.	P140	Martínez-Cadilla, J.	P455	McCoy, K.	P776
Marcos-Pinto, R.	DOP081, P299	Martínez, C.	P437	McDonald, E.	P727
Marcus, V.	P157	Martínez, E.	P367, P562	McDonald, J.	P770
Marelli-Berg, F.	OP028	Martínez-González, S.	DOP012	McDonald, S.	DOP047
Maria, N.	P360	Martínez-León, M.	DOP057	McFarlane, A.	DOP030
Marik, A.	P279	Martínez, V.	DOP088, P033, P034	McGovern, D.	P050, P269
Marin Sanchez, L.	N823	Maruoka, D.	P159, P231	McGowan, M.	P587
Marin, A.C.	P110	Marín, I.	P423	McGreal-Bellone, A.	P141
Marin-Jimenez, I.	P618	Marín-Jiménez, I.	DOP016, P183, P397 , P736	McHugh, K.	P699
Marin, P.	P437	Masala, G.	OP722	McHugh, L.	P370
Marinaki, A.	P444	Masamunt, M.	DOP070, DOP084, P091, P437, P462, P679	McInnes, I.	P027
Marini, J.C.	P226	Masching, A.	P619	McKiernan, S.	P141, P403, P594
Marino, M.V.	P191	Mascialino, B.	P702	McKinney, E.	DOP048
Marion, J.F.	P213	Masclee, A.	OP017, P690, P781	McLain-Smith, S.	P512
Markovic, S.	P236	Masclee, A.A.M.	P696, P737	McLaughlin, J.	P058
Marks, D.	P043 , P045	Maser, E.	OP037, P554	McLaughlin, S.	P379, P645, P649
Markus, T.	OP017	Mashei, C.	P392	McNair, A.G.K.	P245
Marot, A.	P566	Massari, A.	P473	McNamara, D.	P594, P602
Maroto, N.	P557, P632	Massey, D.C.	DOP079	McShane, C.	P491
Marques da Costa, P.	P124, P168	Massimino, L.	P004	Meaney, J.	P141
Marques, M.	P049, P290, P308	Masucci, L.	P019	Meckel, K.	P196
Marquez Galan, J.L.	P634	Matalon, S.	P345, P561	Medcalf, L.	P129, P599
Marqués-Miñana, M.R.	P365	Mateescu, R.-B.	DOP061	Medhus, A.W.	P514
Marrache, A.M.	P383	Mateus, C.	P315	Medina Medina, R.	P545
Marreiros, A.	P435, P723	Mathis, K.	P357	Medina, B.	P360
Marshall, J.	P443, P681	Matsui, T.	DOP071, P215, P523	Medina, J.	P463
Marshall, J.K.	P383, P699	Matsumoto, H.	P249	Mege, D.	DOP042, P142, P476
Marshall, L.	N803, N805	Matsumoto, T.	DOP071, P215, P523	Meglicka, M.	P265
Marsiano, N.	DOP059	Matsumoto, Y.	P040	Mehta, S.	OP002
Marteau, P.	DOP011, DOP025, P390, P420, P772	Matsumura, T.	P159, P231	Mehta, S.	OP029, P220, P513
		Matsuoka, K.	P256 , P293	Mehta, V.	P596
Martelli, L.	P338	Matsuura, M.	P012, P165, P187	Meij, V.	DOP067
Martelossi, S.	P084	Matteoli, G.	P022	Meijer, S.	P522
Martens, L.	P776	Mattheakis, L.	P001, P113	Meisner, S.	P066
Martin de Carpi, J.	P257	Matthews, G.	OP002	Meissner, J.	P241
Martin, F.	P010	Matthias, A.T.	P764	Melberg, H.O.	P728
Martin, R.	P550	Matthijssens, J.	DOP080	Mele, L.	OP031
Martin, S.W.	DOP074	Matthys, C.	P767	Melgar, S.	DOP006
Martinelli, M.	P088, P278, P404	Matucci, A.	P661	Melhem, H.	P102
Martinez Cadilla, J.	DOP016, N801	Matz, E.	P689, P721	Melia, J.	P488
Martinez-Jimenez, T.	P433	Maul, J.	P326	Mellotte, G.	P491
Martinez-Medina, M.	OP030	Mayer, A.	P233	Mendes, S.	P600
Martinez, P.	DOP047	Mayorgas, A.	OP030	Mendolaro, M.	P621
Martinez-Vinson, C.	P302	Mazurak, N.	P563	Menichetti, J.	P506, P534
Martino, G.	P117			Mera, A.	P285
Martino, M.	P301			Meraviglia, S.	P008

- Merino Alonso, F.J. P629
 Merino, O. DOP016, DOP063, P202, P327, P607
 Merlos, M. DOP088
 Meroni, E. P022
 Merrick, V. **P125**
 Mertens, J. DOP073
 Mescoli, C. P301
 Meserve, J. DOP023
 Mesonero, F. P327, P480, P528
 Messadeg, L. DOP013
 Metwaly, A. **OP030**
 Meucci, G. OP005
 Meuleners, L. OP023, DOP075
 Miao, Y. P549
 Michetti, P. DOP027, P298
 Michon, I. P390
 Michot, J.-M. P315
 Micic, D. P410, P454
 Middleton, S.J. DOP079
 Miehsler, W. P233
 Miele, E. P088, P404
 Migliora, P. P301
 Mihai, C. P139, P203, P232, P320, **P388**, P601
 Mitheller, P. P331, P592, P739
 Mikocka-Walus, A. P170, P238
 Milanski, M. P025, P038
 Milassin, A. P279, P317, P580, P675, P739
 Milgrom, R. P296
 Miller, B. P242
 Milling, S. DOP008, P027
 Millson, B. P699
 Minami, N. **P012**, P187
 Minda, K. DOP022, P305
 Minet Quinard, R. DOP086
 Minguez, M. DOP039
 Ministro, P. P255, P284
 Minoo, P. P212
 Minsart, C. P560
 Miquel, J.O. P021
 Miraglia del Giudice, E. P088
 Mirsepasi-Lauridsen, H.C. P769
 Misra, R. P018, **P718**, **P745**
 Misselwitz, B. P013, P017, P064, P072, P130, P304, P711, P712
 Mitchell, H. P589
 Mitiche, A. P206, P260, P266, P289
 Mitrova, K. P532
 Mitselos, I. P751
 Mitsuhashi, S. P344
 Miura, T. P518
 Miyakawa, M. P249, P564, P666
 Miyazaki, T. P150
 Mo, M. OP035
 Mocanu, I. P368
 Mocchi, G. P373, N814
 Moccio, F. P008, P318, P574, P652
 Modino, Y. P183, P397, P736
 Mohamed, G. **P208**
 Mohammadi, A. P789, P793
 Mokhtar, N. P031
 Molina, G. P436
 Molina, I. P683
 Molnar, T. P279, P317, P331, P411, P580, P592, **P675**, P739
 Moloney, M. P026, P071, P216
 Molteni, P. P473
 Molto, A. P471
 Monast, C. DOP053
 Moniuszko, A. P425
 Monsinjon, M. P142
 Montalbano, L.M. P372
 Montalvo, I. P202
 Monte-Boquet, E. P365
 Monteiro, S. **P136**, P294, P472
 Monteleone, G. P301, P332
 Monteserin, L. P436
 Montoro, M.A. P607
 Montserrat, A. P528
 Mooiweer, E. DOP064
 Moon, C.M. P068
 Moon, J.S. P487
 Moon, W. **P104**, P461
 Moore, J. P005
 Moorghen, M. DOP047
 Moote, D. DOP057
 Moparty, R. P511
 Mora-Gutierrez, I. P110
 Mora, M. P557, P632
 Morais, L.R. DOP012
 Morais, R. P230, P417
 Moral, I. DOP063
 Moraleja-Yudejo, I. P327
 Morales Barrios, J.A. P629
 Moran, C. P380, P578, P594
 Moran, G.W. P105, P128, P341, P590
 Moran, N. P276
 Morandeira-Rego, F. P546
 Moreels, T. DOP069, P347, P732
 Moreira, A. P741
 Moreira, J. P741
 Moreira, M.J. P136, P292, P294, P472
 Moreno-Osset, E. P224
 Morgan, S. P220
 Morinaga, S. P293
 Morreale, G.C. **P658**
 Mortensen, C.O. P769
 Mortensen, J.H. DOP051
 Motta, P. P089, **P671**
 Mortier, K. **P333**
 Morton, D. OP002
 Moscardiello, M. OP031
 Mosli, M. **P173**
 Moss, A. P344
 Motoya, S. DOP071, P249, **P523**, P564, P666
 Mottet, C. P569
 Motwani, M. P043, P045
 Moun, B. P151, P501, P511, P514, P590, P710, P728, P734
 Mountfield, R. OP036, P577, P691
 Moura Santos, P. DOP014, P135, P168, P362, P385, P453, P636
 Moura, C. P168
 Mouradides, C. P732
 Moutsianas, L. **OP001**
 Mouzaki, M. DOP072, P450
 Mozer-Glassberg, Y. P409
 Mpalomenos, D. P751
 Mpalatagiannis, G. P751
 Mu, J. P146
 Muhammed, R. P211, P351, P432
 Muise, A. P127, P268, P754
 Mukhametova, D. P011
 Mukherjee, A. **DOP074**
 Mulcahy, H. P250, P261, **P370**, P578, P594, P640
 Mullane, D. P430
 Muller Kobold, A. P374
 Mumolo, G. P538, P598
 Mumtaz, S. DOP068, P655
 Munari, S. P386
 Muncan, V. P066
 Munck, L. P713
 Munkholm, P. P692, P694, P695, P718, P727, P745
 Murasugi, S. P464
 Murono, K. DOP066
 Murray, C. P363, P543
 Murray, J. P121, P616
 Murray, S. P081
 Murrells, T. P251
 Murugesan, S. P590
 Muscat, M. P240, P494
 Mussini, C. P315
 Muñagorri Santos, A.I. P508
 Muñoz Villafraña, M.C. P508
 Muñoz, C. P607
 Muñoz, D. P205
 Muñoz, M.d.C. P503
 Muñoz-Villafraña, M. P327
 Myrelid, P. **P724**
 Myriam, L. P360
 Myung, S.-J. P090, P148, P252, P406, P482, P641
 Márquez, L. P607
 Mössner, J. DOP073
 Mørk, C. DOP062
 Müller, W. DOP049
 Münch, A. P048

- N**achury, M. OP009, DOP011, P156, P310
 Naftali, T. DOP016, P345, P451, P561, N821
 Nagahori, M. DOP071, P256, P523
 Nagami, Y. P427
 Nagore, D. P475, P503, P605, P633
 Nagornyykh, B. P163
 Nagtegaal, I.D. P682
 Nagy, F. P279, P317, P331, P580, P675, P739
 Nahon, S. P310, P471
 Naik, S. DOP020
 Naimimohasse, S. P141
 Nair, M.V. P211, P432
 Nair, N. OP037
 Naito, Y. DOP071, P523
 Nakagawa, T. DOP071, P159, P231, P523
 Nakamura, S. P150
 Nakano, M. P293
 Nakase, H. DOP071, P012, P165, P187, P523, P564, P666
 Nakmouche, M. P206, P260, P266, P289
 Nakstad, B. P778
 Nam, T.-g. P030, P057
 Nanan, B. P073
 Nanan, R. P073
 Nancey, S. DOP011, DOP025, P156, P226, P310, P420, P590, P772
 Nantes Castillejo, Ó. P508
 Nantes, O. P327
 Nardone, O. OP005
 Nardone, O.M. P646
 Narula, N. DOP005, P223, P296, P415, P502, P699
 Nasu, Y. P107
 Nasuno, M. P249, P564, P666
 Navarro Correal, E. N823
 Navarro, B. P205, P365
 Navarro, E. P463, P683
 Navarro-Llavat, M. P423, P618
 Navarro, P. P240, P528
 Navas-López, V.M. P158, P278, P404
 Naviglio, S. P084
 Nawrot, T. P690, P696
 Nazarian, A. P273
 Nazefah, A.H. P031
 Neary, B. P355
 Nedd, K. P511
 Nedeljkovic Protic, M. P236
 Neeman, T. P537
 Negreira, S. P074, P585
 Nelson, E. N807
 Nencini, F. P661
 Neovius, M. OP024
 Nerkens, W. P551
 Nesi, G. P301
 Neuman, H. P275
 Neuman, S. P181, P779
 Neurath, M.F. DOP073, P326
 Ney, D. P486
 Ng, S. P734
 Ng, S.C. DOP024
 Ngiu, C.S. P031
 Nguyen, D. P469
 Nguyen, G. P223, P296, P502, P311, P789, P793
 Nicolaou, A. P043, P045
 Nicolas, D. P360
 Nielsen, A.H. P185
 Nielsen, K. P734
 Nielsen, K.R. P694, P695, P727
 Nieri, C. P538
 Nierkens, S. P267
 Niess, J. P076
 Niezychowski, W. OP031, OP032, DOP074
 Nihjuis, A. OP029
 Nimmo, E. P061
 Nip, K. P456
 Nir, E. OP028, DOP059
 Nishida, Y. P427
 Nishikawa, T. DOP066
 Nishio, A. P150
 Nishio, M. P133, P337, P489
 Nissen, L.H. P682
 Nissim-Eliraz, E. DOP059
 Niu, X. OP037
 Niv, Y. P708
 Nivet, D. P254
 Noble, A. P093, P775
 Noble, C.L. P416, P586
 Nojima, M. DOP071, P325, P523, P666
 Noman, M. OP006, OP020, NO003
 Noor, N. DOP048
 Nordberg, N. OP022
 Nordenvall, C. P724
 Nordkild, P. DOP083
 Norman, G.L. P152
 Northover, M. P220
 Norton, C. P251, P555, NO002
 Nos, P. P205, P365
 Nosegbe, U. P424
 Novacek, G. P233
 Novak, K. P134, P212
 Novák, J. P739
 Nowak, A. P105
 Nowakowska-Duława, E. P189
 Noyes, A. P418
 Nozaki, R. P630
 Nozawa, H. DOP066
 Nugent, M. P430
 Nugent, S. P430
 Null, K.D. P330, P531
 Nunberg, M. DOP054
 Nunes, A.C.-R. P049, P234, P290, P308
 Nunes, G. P368
 Nuta, P. P323
 Nuti, F. DOP009, P257
 Nuutinen, H. P515
 Nyboe Andersen, N. OP003
 Nys, K. P095
 Nyári, T. P279
 Nørager, C.B. P185
OLeary, D.P. P071
 O'Brien, C. P761
 O'Byrne, S. DOP019, DOP021, P209
 O'Connell, G. P670
 O'Connell, J. P141, P403, P491, P594
 O'Connor, A. P227, P343, P648
 O'Connor, M. P241, P490
 O'Hanlon, D.V. P507
 O'Leary, D.P. P026, P216
 O'Morain, C. P594
 O'Shea, C. P359
 O'Toole, A. P371, P380, P403, P520, P594
 O'Toole, D. P141
 O'Toole, K. OP021
 Obara, N. P644
 Obialo, N. P072
 Obritin, H. P272
 Ocklind, A. OP022
 Odes, S. P749
 Odes, S. P721
 Odintsova, A. P011, P163, P794
 Odintsova, V. P794
 Ogashiwa, T. P133, P337, P489
 Ogueta Fernández, M.Á. P508
 Oh, E.H. P252, P406, P482
 Oh, K. P252, P482
 Oh, S. P073
 Oh, Y.S. P395
 Ohmori, S. P565
 Ohmori, T. P565
 Ohse, M.C. P131
 Ohta, Y. P159, P231
 Ohtsuka, K. P175, P256
 Okabayashi, S. P293
 Okabe, M. P012, P187
 Okada, T. P325
 Okawa, K. P133
 Oke, S. P541
 Okimoto, K. P159, P231
 Oksanen, P. P218, P694, P695, P727
 Olbjørn, C. P778
 Oldenburg, B. DOP004, DOP040, DOP064, DOP067, P722, P726
 Olesen, M.L. DOP051, P089, P671

- Olinga, P. DOP051, P671
 Oliva, S. **P526**
 Olivares, D. DOP063, P480, P528
 Oliveira, A. P714
 Oliveira, A.P. P137
 Oliveira, M.H. OP016
 Olivera, P. P338
 Oliverio, M. P108
 Ollero Pena, V. P186
 Olsen, A. P722
 Olsen, I.C. DOP062
 Olson, A. OP014
 Oltra-Camps, L. P120
 Oltra, L. P557
 Oluseyi, A. P212
 Olén, O. **OP024**, P734
 Omassoli, J. P274
 Omdal, R. P429
 Omori, T. P464
 On behalf of the BIOCYCLE group
 DOP015
 On behalf of the SEGURTB study
 group from GETECCU DOP063
 On, A. P409
 Onali, S. P332
 Ong, S.H. P456
 ONIDI, F.M. **N814**
 Onodera, K. P564, P666
 Oomen, M. P524
 Oostenbrug, L. P690
 Opdenakker, G. P078, P382
 Opramolla, A. P646
 Opstelten, J. **P722, P726**
 Orbach-Zingboim, N. N820
 Orchard, T. P182, P253, P274, P770
 Ordas, I. **P607**
 Ordás, I. DOP070, P091,
 P437, P462, P679
 Orfanoudaki, E. P348
 Orlandi, A. P301
 Orlandini, B. **P407**
 Orlando, A. OP005, P318, P372, P387,
P412, P574, P613, P652
 Orlando, E. P387, P613
 Orlando, R. P387, P412, P613
 Orlanski Meyer, E. P158, **P278**
 Orsoni, P. OP008
 Ortiz-Masia, D. P009, **P015**,
P087, P092, P120
 Ortíz, J. P503
 Orzechowski, H.-D. DOP022
 Osada, T. P766
 Osipenko, M. DOP061
 Osmane, R. P206, P260, P266, P289
 Ossum, A. **P151**
 Ost rov, A. P590
 Otake, H. P133, P337, P489
 Otani, K. DOP066, P427
 Otley, A.R. P775
 Otley, A. P460
 Otobero, E. P554
 Ott, C. P734
 Ouakaa, A. P378, P631
 Ouchchane, L. DOP086
 Overton, J. P754
 Overvad, K. P722
 Owczarek, D. P287
 Owen, L. P439
 Oyón Lara, D. P508
 Ozaki, R. **P293**
 Ozer, C. P029
 O'Toole, A. DOP016
 O'Brien, C. DOP076
 O'Morain, C. DOP001
 Öberg, D. P364
 Över Hamzaoglu, H. P401
 Pacci, M. P661
 Padullés, A. P546
 Padullés, N. P546
 Paese, P. P621
 Pageaux, G.-P. P667
 Pagnin, A.F. N817
 Pahlkalla, T. P639
 Pai, R. OP014
 Paiano, P. P373
 Pajala, M. P515
 Pajares Villarroya, R. P697
 Pajares, R. P327
 Palaniappan, S.K. P380
 Palatka, K. P331, P580, P592, P739
 Palli, D. P722
 Palm, Ø. P151
 Palmela, C. **OP016, DOP043**,
 DOP064, **P177**
 Palmieri, O. **P117**
 Palo, W. DOP024, P442, P647
 Palumbo, O. P117
 Pan, Y. OP033
 Panaccione, R. DOP018, DOP021,
 P134, P209, P212, P329,
 P353, **P381**, P669, **P698**
 Panadero, A. P183, P397, P736
 Panchal, H. OP037
 Panic Tonucci, T. P440
 Panis, Y. DOP042, P142, P476
 Panyor, G. P235
 Panés, J. OP004, **OP009**, OP030,
 OP031, OP032, DOP070,
 DOP076, DOP084, P020,
 P050, P091, P437, P462,
 P467, P522 P558, P607, P679
 Paolino, D. P108
 Paoluzi, P. P530
 Papa, A. P440, **P654**
 Papadakis, K. P616
 Papatheodoridis, G. P627
 Papay, P. P233
 Papi, C. P301, P574, P652
 Papoff, P. P526
 Papoutsopoulou, S. DOP049
 Papp, M. P152, P331, P592
 Pappalardo, B. DOP018,
 P329, P359
 Parambir, D. P357
 Paramsothy, R. P589
 Paramsothy, S. **P589**
 Paredes, J.M. P224
 Parello, A. P306
 Parfenov, A. P536
 Parian, A. DOP002, P488
 Pariente, B. DOP025, DOP027,
 DOP045, P221, P420
 Parihar, V. P380
 Parihar, V. P403
 Parikh, M. DOP023
 Parisi, I. **P513**
 Park, C.H. P060
 Park, D.I. P461, P500
 Park, J.H. P487
 Park, J.-M. P028
 Park, K. OP025
 Park, M.I. P104
 Park, S.H. P148, P252, P406,
 P482, P548, P641
 Park, S.J. P104
 Park, S.J. P548
 Park, S. P377, P393
 Park, Y.S. P715
 Parkes, M. OP001, DOP048, P764
 Parmar, R.S. P211, P432
 Paroni Sterbini, F. P019
 Parra, R.S. **P424**
 Pascal, V. DOP044
 Paschos, P. **P421, P662**
 Pascoal, L.B. P025
 Pascual, A. P224
 Pascual, J. P475, P503, P605
 Pashankar, D. OP025
 Paspatis, G. P709
 Pastor Ramírez, H. P792
 Pastorelli, L. P178
 Paszek, P. DOP049
 Patai, A. P331, P592
 Patchett, S. P371, P403, P520, P594
 Patel, A. DOP020, P511
 Patel, D. **P239**
 Patel, H. P761
 Patel, H. **P330, P531**
 Patel, K.V. P507
 Patel, N. OP021
 Pathmakanthan, S. DOP068,
 P056, P670
 Patita, M. P368

- Paturelli, M. P621
 Paul, S. **P226**, P254
 Paulli, M. P301
 Pauwels, R.W.M. **P447**
 Pavlenko, A. P794
 Pavli, P. P537, P673, P761
 Pavlidis, P. **P129**, P599
 Payer, J. P312, P567
 Pecere, S. P115
 Pecoraro, G.M. P008, **P318**
 Pedersen, N. P694, P695, P727
 Pedroto, I. P299
 Peek-Kuijt, N. **P559**
 Peerani, F. P213, **P705**
 Peeters, M. OP020, DOP028
 Peitsch, M. P010
 Peixe, P. DOP016
 Peixoto, A. DOP016, P049, **P230**,
 P234, P290, P308, **P417**
 Pekarska, K. P783
 Pekow, J. P196, P410, P454
 Peleg, S. P409
 Pellegrino, S. P412
 Peltrini, R. P153
 Pemberton, J. P357
 Penders, J. P781
 Penenberg, D. OP014
 Penez, L. P018, P787
 Peng, K. P761
 Penna, A. P373
 Peppelenbosch, M. P016
 Perdigoto, D. **P600**
 Perdones-Montero, A. P018, P787
 Pereira Bueno, S. N801
 Pereira da Silva, J. DOP014
 Pereira, B. DOP013, P122, P123,
 P272, P572, P628
 Pereira, M. DOP081, **P299**
 Pereira, S. P455
 Peres, S. P074
 Perez, E.Y. P192
 Perez-Pampin, E. **P285**
 Perfetti, V. P301
 Perminow, G. P778
 Perrey, A. P572
 Perrone, L. P088
 Pesegova, M. DOP061
 Peter, I. OP037
 Peters, D.A. P185
 Peters, P. P233
 Petersen, A.M. P769
 Petersen, F. P171
 Petersson, J. DOP018, P329,
 P353, P381, P669
 Petito, V. **P019**, P115, P498
 Petralia, F. P121
 Petruzzellis, C. OP005
 Petruzziello, C. P332
 Petryka, R. OP023, DOP075
 Petryszyn, P. **P200**
 Petrášová, M. P247
 Peyrin-Biroulet, L. **OP011**, DOP018,
 DOP025, DOP027, DOP045,
 DOP078, P277, P328, P329,
 P338, P359, **P369**, P466,
 P468, P499, P608
 Peña-Sánchez, J.N. **P725**
 Peñalva, M. P607
 Peñate, M. DOP063
 Pfeffer-Gik, T. **P459**, **P612**
 Philandrianos, C. OP008
 Phillips, B. **P010**
 Phillips, R.K. P005, P126, P245, P398
 Piazza, O. P103
 Pica, R. P024, P530
 Picard, O. P181, P779
 Picchio, M. P373
 Piekuse, L. P783
 Pieper, D.H. P777
 Pierik, M. OP017, OP022, DOP004,
 DOP049, P061, P132, P316,
 P682, P690, P781
 Pierik, M.J. DOP040, P696, P737
 Pierre, D. P360
 Piessevaux, H. P732
 Pietrowska, K. P147
 Pineda Mariño, J.R. N801
 Pineda, J.R. P327, P455
 Pineton de Chambrun, G. DOP034,
 P358
 Pinho, J. P255, P284
 Pinho, R. P190, P281, P642
 Pinho, S. DOP081, P299
 Pinkney, T.D. P724
 Pinotti, R. DOP005
 Pinto, J. P124
 Pinto-Lopes, P. **P198**
 Piontini, A. P004
 Piotrowicz, G. **P576**
 Piotrowski, P. P200
 Pippias, M. P716
 Piqueras, M. DOP016, P607
 Pittet, V. P711
 Pittet, V. **P298**
 Pituch-Zdanowska, A. **P346**
 Pizarro, T.T. OP027, P498
 Pizzoferrato, M. P115
 Piñero, P. **P076**
 Placida, R. P108
 Planell, N. DOP070P020,
 P025, **P091**
 Plasmeijer, E. P682
 Platzer, R. P233
 Plevris, N. **P416**, **P586**
 Plocek, A. P504, P510
 Podmanicky, D. P339, **P375**
 Poggioli, G. DOP041, DOP058, P571
 Poiasina, E. P235
 Polanco, A. P224
 Polihrom, A. P418
 Politis, D. P751
 Pollack, P. P465, P549
 Pollok, R. P138, P729
 Polomack, B. DOP087
 Polyak, S. P501
 Ponanta-Gawron, K. P661
 Ponce-Alonso, M. **P782**
 Ponchon, T. P608
 Ponferrada, A. DOP063
 Poniewierka, E. P746
 Ponsioen, C.Y. DOP004
 Ponsioen, C. OP015, DOP017,
 P611, P716
 Ponsioen, C.I.J. DOP040
 Ponte, A. **P190**, **P281**, **P642**
 Pontes García, A. **P463**
 Pontikos, N. P758
 Popa, I. P203, P388, P601
 Popa, I.V. **P232**
 Popa, R.C. **P203**, P232, P388
 Popp, A. P323
 Portela, F. P600
 Porter, C. P121
 Portillo, I. P202
 Porto - ECCO GROWTH CD study
 group DOP037, P262
 Portovedo, M. P025
 Posovszky, C. P414, P486
 Potokar, J. P458
 Pottegård, A. P720
 Pouderoux, P. P358
 Pouillon, L. **OP006**
 Poullenot, F. **P254**, P499, P680
 Poveda-Andrés, J.L. P365
 Powles, S. P182, P253, **P274**
 Pozuelo del Río, M. OP038
 Pranzo, G. P373, P621
 Pratesi, S. P661
 Praticò, C. P571
 Pratt, J. OP025
 Pratt, L.-T. DOP057
 Preiss, J.C. P326, P617
 Premuzic, V. **P742**
 Previtali, A. DOP021
 Prieux-Klotz, C. P471
 Prijic, R. P742, P747
 Princen, F. P121
 Principi, B. P621
 Principi, M. OP005, DOP016, P335
 Privat, J. P608
 Privitera, A.C. P412, P621
 Probert, C. DOP049, P525
 Procopio, A. P108
 Proença, L. P642
 Prokop, L. P448
 Pronio, A. P024
 Proserberg, M. DOP003, P703, P769

- Prosser, R. P691
 Protheroe, A. **P081**
 Protic, M. P341, **P569**
 Protopotopov, M. P163
 Ptak, J. OP021
 Pugliese, D. DOP016, P211, P240, P366, **P440**, P494, P654
 Puolanne, A.-M. **P457**
 Putignani, L. P115
 Pérez Hernández, F. P629
 Pérez-Calle, J. P327
 Pérez, J. DOP016
 Pérez-Martínez, I. DOP012
 Pérez-Viejo, E. P314

Qari, Y. P173
 Qian, J. P083, P096, P155
 Qiu, Y. **P394, P653**, P672
 Qiu, Z. P075
 Qu, X. P376
 Quaranta, G. P019
 Queiros, P. P435, P723
 Quertinmont, E. P560
 Quevrain, E. P780
 Quince, C. DOP008
 Quraisi, M.N. DOP068, **P056, P079**

Racine, A. P722
 Radeke, H.H. P620
 Radford-Smith, G. OP007, P691
 Radice, S. P277, P475, P605, P633
 Radke, M. P486
 Rae, J. P418
 Raes, J. DOP080, P078, P767, P774, P776
 Rafaat, M.N. P165
 Raffals, L. OP021, P263
 Rafferty, H. P648
 Rafiz, A.R. P031
 Rafter, N. P355
 Rahier, J.F. DOP016, DOP069, P438
 Rahman, F. P043, P045, P220
 Rahman, S. P059
 Rahul, K. P788
 Raiden, K. P717
 Raimundo Fernandes, S. **DOP014**, **P124, P135, P168**, **P362, P385, P636**
 Raine, T. P738
 Rainero, G. P140
 Rainteau, D. P780
 Raja Ali, R.A. P031
 Raker, J. **P599**
 Raluy-Callado, M. P470
 Ram, G.V. P606
 Ramirez-Montagut, T. P431
 Ramirez, V. P745
 Ramos Silva, F. P038
 Ramos, J. P519
 Ramos-Lora, M. P319, P693
 Ramírez, A. P091
 Ran, Z.-H. P241
 Rana-Khan, Q. DOP024, P647
 Rannem, T. P533
 Rao, K. P303
 Rao, N. P113
 Rao, V.L. P410
 Rapaccini, G.L. P440, P654
 Raselli, T. **P013**, P064
 Rashid, M. P775
 Rasmussen, M. **P584, P643**
 Rath, S. P171
 Ratto, C. P306
 Ravelli, P. P235
 Rawa, T. P746
 Razack, A. P222
 Rea, M. P646
 Rebull, M. P587
 Recalde, X. P605
 Recio, D. N819
 Reddi, D. OP093
 Reddy, S. P410
 Reenaers, C. DOP011, P438
 Rees, D. P787
 Reggiani Bonetti, L. P301
 Regula, J. P746
 Reicht, G. P233
 Reilly, M. P380
 Reinmund, J.-M. DOP013
 Reindl, W. P099
 Reinhard, C. P169
 Reinisch, W. OP009, OP032, OP034, OP035, DOP055, P119, P353, P390, P485, P610, P669
 Reis, C. P299
 Reis, C.A. DOP081
 Reis, J. P714
 Reis, P.P. P760
 Remzi, F. P357
 Renieri, V. P340
 Renna, S. P318, P372, P387, P412, P613
 Renosto, F. NO001, N799, N824
 Renosto, F.L. P760, N811, N816, N817
 Renzi, N. DOP058
 Reyes, N. P436
 Reymond, M. DOP013, P122, P123, P272, P572, P628
 Rezus, E. P139
 Ribeiro, S. P137
 Riboni, R. P301
 Ricanek, P. OP022, P061, **P788**
 Ricard, J. P254
 Ricart, E. OP004, DOP070, DOP084, P091, P437, P462, P679
 Ricchiuti, A. P598
 Ricci, M.Q. P590
 Ricciardelli, C. P373, P621
 Ricciuto, A. DOP072, **P127, P268**, P450, P460
 Richard, M.P. OP009
 Richards, S. P052
 Richmond, L. P414, N812
 Rickenbacher, A. P017
 Riddle, M. P121
 Ridge, A. P184
 Ridgeway, L. P276
 Rieder, F. P341
 Riera, C. P683
 Riestra, S. DOP012, DOP063
 Riggs, J.B. DOP089
 Rimola, J. P522
 Rincón, L. P193
 Ring, C. P065
 Ringold, R. P382
 Rioux, J.L. P269
 Rispens, T. P665
 Rispo, A. P153, P574, P621, P646, P652
 Ristimäki, A. P264
 Rita Carvalho, J. P168
 Rita Gonçalves, A. DOP014, P135, P168, P362, P385, P636
 Ritchie, K.J. P773
 Rivera Sequeiros, A. **N800**
 Rivera, N. P503
 Rivero, M. P603
 Rivière, P. **P229, P499, P680**
 Rizzello, F. DOP058, P571, P574, P652
 Rizzi, S.F. P335
 Rizzo, A. P004, P301
 Rizzuto, G. OP005, P387, P412, P613
 Roads, N. P288
 Robert, C. P315
 Roberts, C. P241
 Roberts-Thomson, I. OP036, P392
 Robinson, A.M. DOP018
 Robson, K. P329, P353, P381, P669
 Robles Rodríguez, J.L. **N803, N805**
 Robles-Alonso, V. P319
 Robles, V. P327
 Roblin, X. **P350**, P683
 Robson, S. OP023, DOP025, DOP027, DOP075, P226, P254, P310, P341, P366, P573
 Robson, S. P344
 Robu, G. P323
 Rocha, J.J.R.d. P424
 Roda, G. **DOP005**, P341
 Rodansky, E. P002
 Roder, M. P259
 Roderburg, C. P131
 Rodrigues, A. P190, P281, P414, P642
 Rodrigues, C. OP016, P714

- Rodrigues, J. P190, P281, P642
 Rodrigues, M. P772
 Rodrigues-Pinto, E. P049
 Rodriguez, C. DOP016
 Rodriguez-de-Santiago, E. P782
 Rodriguez, E. P528
 Rodriguez-Justo, M. DOP047
 Rodriguez-San Pedro, L. P618
 Rodriguez-Lago, I. **P202**
 Rodriguez Díaz, C.Y. P629
 Rodríguez Glez., G.E. **P629**
 Rodríguez Gutiérrez, C. P508
 Rodríguez Lago, I. P508
 Rodriguez Lozano, A. P433
 Rodriguez-Marin, J. P529
 Rodríguez-Alonso, L. P546
 Rodríguez-Lago, I. DOP016
 Rodríguez, L. P091
 Rodríguez-Moranta, F. P546
 Rodríguez-Prada, J.-I. P455
 Rodríguez, R. P546
 Rodríguez-San Pedro, L. P423
 Rodríguez, V. P683
 Roessler, A. P171
 Rogai, F. OP005, P407
 Rogers, J. P554
 Rogers, P. P125
 Roggenbuck, D. P178
 Rogler, G. OP004, OP034, DOP0055, DOP056, DOP059, DOP089, P013, P017, P052, P064, P072, P102, P130, P298, P304, P522, P566, P569, P711, P712, P768
 Roine, R.P. P685
 Rojas-Feria, M. **P792**
 Rolland, C. P100
 Rolland-Fourcade, C. P100
 Romain, G. P360
 Romano, C. P404, P412
 Romano, M. P084
 Romberg-Camps, M. OP017, P690
 Romero Mosquera, B. N801
 Romero, C. OP013, DOP039, P183, P397, P583, P603, P736
 Romero-Gómez, M. P792
 Ron, Y. P243, P366, P612
 Roncero García-Escribano, Ó. P193
 Roncero, O. P186
 Ronchi, F. P776
 Roque Ramos, L. **P368**, P733
 Rosa, I. P315
 Rosa, I. DOP014, P248
 Roseira, J. **P435, P723**
 Rosenberg, L. P344
 Rosenblum, J. P689, P721
 Rosenfeld, G. P597, P625
 Rosenstiel, P. DOP049
 Rosenthal, R. P063
 Roseth, A. P169, **P422**
 Rosiñol, L. P437
 Rossel, J.-B. P711
 Rossi, A. P055
 Rossi, F. P372
 Rossiter, A. P056, P079
 Rossiter, G. OP019
 Rothlin, C. P074
 Rottoli, M. **DOP041**
 Roubrocks, S. P041, P131
 Rove, J.B. P778
 Rovira, M. P437
 Rowan, C. P370, P403
 Rowan, C.R. **P250, P594, P640**
 Rowley, A. P032, P062, P684
 Roy, G. P782
 Roy, S. P131
 Royo, V. P327
 Rubek Nielsen, K. P692
 Rubertà, F. P235
 Rubin, D. DOP021, P196, P209, P454, P589
 Rubin, D.T. OP011, DOP019, P192, P389, P410, P467, P468, **P558**, P619
 Rubín de Célix, C. P314
 Ruchkina, I. P536
 Rudas, G. P309
 Rudbeck-Thomsen, D. DOP016
 Rudzite, D. P783
 Rueffer, A. P176
 Ruemmele, F. P414
 Rugge, M. P301
 Ruhimovich, N. P345, P561, N821
 Ruiz-Aguello, M.B. P633
 Ruiz, E. P503
 Ruiz, N. **N819**
 Ruiz, P.A. P017, P102
 Rundquist, S. P364
 Ruppert, J. P474
 Russell, N.K. DOP079
 Russell, R.K. DOP008, DOP037, P262, P333, P363, P543, P587
 Russo, G. P008
 Russo, I. **P103**
 Russo, P. P519
 Rustemović, N. P747
 Rutgeerts, P. OP006, OP010, OP038, DOP044, P067, P119, P229, P381, P446, P465
 Rutka, M. P279, P317, P331, P411, P580, P592, P675, **P739**
 Ruiz-Frutos, C. P319
 Ryan, B. P208, P276, P594, P602
 Ryan, B. P403
 Ryan, E. P250, P640
 Ryzewska, G. P390, P425, P576, P746
 Ryoo, E. P487
 Ryu, D.G. P324
 Räsänen, P. P685
 Saad-Hossne, R. NO001, N799, N824
 Sabatier, F. OP008
 Sabaté, J.-M. P499
 Sabbah, M. P378, P631
 Sabbahi, H. P173
 Sabino, J. OP038, DOP044, DOP050, P078, P767, P774
 Saccenti, E. P316
 Sacco, M. P153
 Sachs, M.C. OP024
 Sacleux, S.-G. **DOP045**
 Saddy Rodrigues Coy, C. P091
 Saeys, Y. P776
 Saez-Villafaña, M. P436
 Safroneeva, E. P566
 Sagar, V.M. DOP068
 Sahami, S. P524
 Sahari, B. P132
 Sahebally, S.M. P026, P071, P216
 Sahnán, K. P005, **P126**, P211, P240, **P245, P398**, P432, P494
 Saibeni, S. OP005, **P574, P652**
 Sailer, A.W. P064
 Saiote, J. P519
 Sairo, H. **P218**
 Saito, E. P293
 Saito, K. P159
 Sakemi, R. P666
 Sakuraba, A. P454, P676
 Salah, A. P266, P289
 Salamon, A. DOP061, P331, P592, P739
 Salamone, G. P191
 Salas, A. OP004, OP030, DOP070, DOP084, P020, P050, P091, P437
 Salemme, M. P301
 Salgueiro Rodríguez, I. P545
 Salice, M. P571
 Salinas Moreno, S. P697
 Salmoral Luque, R. P193
 Salteniene, V. P759
 Salueña, I. P193
 Salupere, R. P694, P695, P727, P745
 Salvador, F. P683
 Salvador, P. P009, P015, P087, **P092**, P120
 Saló, J. P021
 Samaan, M.A. P220
 Sambuelli, A. **P074, P585**
 Sampietro, G. DOP042, P301
 Samuel, S. P128
 Sanchez-Elsner, T. P006
 Sandall, A.M. **P507**

- Sandborn, W.J. OP010, OP014, OP032, OP033, OP034, OP035, DOP019, DOP021, DOP023, DOP033, DOP074, DOP076, P050, P119, P209, P381, **P395, P446**, P448, P465, P676
- Sanderson, J. OP028, P220, P444, P507
- Sandri, G. P301
- Sands, B. OP010, OP019, DOP021, **DOP076**, P209, P241, P554
- Sands, B.E. OP032, DOP023, P467
- Sanfratello, A. P658
- Sang Tse, C. P357
- Sanguinetti, M. P019
- Saniabadi, A. P518
- Sanroman Alvarez, L. **N801**
- Santacana, E. P546
- Santeusanio, G. P301
- Santiago, A. OP038, DOP044
- Santini, D. P301
- Santos, L. P714
- Santos, P. P168
- Saoula, H. P206, **P260, P266, P289**
- Saphina, N. P011
- Sapienza, C. P372, P387, P613
- Sarafian, M. P018, P787
- Saralaya, R. P113
- Sarbagili-Shabat, C. P484
- Sarbagili-Shabat, C. P262, **P295**, P409
- Sargalt, L. P528
- Sarid, O. **P749**
- Saritas Yuksel, E. DOP006
- Saro, C. DOP063
- Sarter, H. DOP045, P221, P756
- Sartini, A. P581
- Sartor, B. P037
- Sasaki, F. P107
- Sasaki, K. DOP066
- Sasaki, L.Y. P760, NO001, N799, N811, N816, N817, N824
- Sathananthan, D. P577
- Sato, T. P150
- Satsangi, J. OP004, OP022, P037, P055, P061, P125, P353, P416, P586, P669, P788
- Sauder, K. P361
- Sautel, C. DOP013
- Sauter, M. P130
- Savarino, E. DOP016
- Savelkoul, P. P781
- Savin, A. P203, P388
- Savoye, G. DOP045, P221, P756
- Sawney, T. P479, P591
- Saxena, S. P138, P729
- Scaioli, E. **P581**
- Scaldaferrri, F. OP027, P019, P115, P306, P498
- Scannone, D. P498
- Scanzi, J. DOP013
- Scaringi, S. P687
- Scarpulla, G. P412
- Scharl, M. DOP056, DOP059, DOP089, P711, P712, P768
- Scharl, S. P711, P712
- Schemerold, L. P676
- Scherl, A. P468, P522
- Schiavoni, E. P115
- Schils, N. OP012, **P445**
- Schirbel, A. **P116**
- Schloss, P.D. DOP053
- Schmelczler, G. P064
- Schmelz, R. P326
- Schmickler, M.-N. P180
- Schmidt, C. **P326**
- Schmidt, F. **P065**
- Schneider, M. P283
- Schneider, T. P617
- Schneider, X. P130
- Schoeman, M. OP036, P577
- Schoeman, S. P577
- Schoenefuss, F. **DOP035**
- Schoepfer, A. P304, P566, P569
- Schouten, W.R. DOP040
- Schramm, C. DOP073
- Schreiber, S. OP023, OP032, OP026, DOP075, P381, P395, **P466**, P544, P588
- Schreiner, P. **P711**
- Schubert, S. DOP022, P501
- Schuit, F. P067
- Schulze, H. P326, P474, **P521**
- Schulzke, J.-D. P101
- Schumann, M. P065, P101
- Schumm, L.P. P269
- Schuster, T.B. P283
- Schwartz, D. P341, P694, P695, P727, P749
- Schwarzinger, M. OP003
- Schwillie-Kiuntke, J. P563
- Schöpfer, A. P719, P740
- Scimeca, D. P117
- Scott, G. **P288**
- Scott, J.A. P242
- Scotta, C. OP028
- Scribano, M.L. DOP061
- Scrivero, B. OP005
- Sebastian, S. DOP055, **P211**, P222, P240, P245, P363, P366, **P432, P494**, P501, P511, P543, **P590**
- Sebepos-Rogers, G. P614
- Sebkova, L. DOP016, P621
- Segal, A. P043, P045, P758
- Segal, J. P093, **P541, P743**
- Segal, J.P. P220
- Seibold, F. P569
- Seidman, E. P085, P626, P763
- Seksik, P. DOP011, P156, 420, P772, P780
- Selinger, C. P211, P227, **P648**, P343, P494, P525, **P440**
- Selinger, L. P181
- Sellge, G. **DOP049**, P041, P131
- Semmler, J. P474
- Sempere, L. P076, P529
- Seno, H. P012, P040, P187
- Sensky, T. P359
- Seo, G.S. **P098**
- Seo, H. P148, P406, P482, **P641**
- Seo, M. P148, P252, P406, P482, P641
- Seow, C.H. P134, P212
- Seppen, J. P069
- Serban, D. P404
- Serghini, M. P405
- Sergienko, R. P749
- Serra, K. **P546**
- Serra-Pagès, M. P143, P201
- Serrano, A. P314
- Serrano, M. P143, P201
- Serrero, M. **OP008**, DOP027
- Sessa, F. P301
- Setoyama, H. P107
- Setsuko Ayrizono, M.d.L. P091
- Seuwen, K. P017, P052, P072
- Severine, B. P360
- Severino, F.E. P760
- Severs, M. DOP004
- Seward, E. P220
- Sezgin, O. P401
- Sgambato, A. P019
- Sgambato, D. P571
- Shachmon, E. P409
- Shackelton, L. P050
- Shafraan, I. DOP021, P209, P590
- Shah, A. DOP068
- Shah, N. P219, P278, P414, P479, P579, P591, P707
- Shah, S.C. DOP043, DOP064, **P734**
- Shah, Y. P239
- Shahini, E. P335
- Shaikh, O. **P351**
- Shaini, E. P621
- Shaji, S. P745
- Shamaly, H. P409
- Shamir, R. P194
- Shand, A.G. P416, P586
- Shaoul, R. P409, P414
- Sharkey, L.M. DOP079
- Sharma, A. P512
- Sharma, N. DOP068
- Sharma, Y. P269
- Shashidhar, H. OP025
- Shaw, I. P363, P543
- Sheibani, R. DOP049

- Shen, B. DOP023, P357
 Shergill-Bonner, R. P219, **P707**
 Sheridan, J. P250, P261, P578
 Sherlock, M. P460
 Sherman, C. P469
 Sherwood, R. P129
 Shetzline, M. P442
 Shiba, M. P427
 Shibata, H. P784
 Shibata, W. P133
 Shibuya, T. P766
 Shih, I.-L. P199
 Shim, H. P134
 Shim, K.-N. P068
 Shimizu, T. P037
 Shimoyama, T. P497, P540
 Shin, D. **P377, P393**
 Shin, S.A. P028
 Shinichiro, S. P493
 Shinozaki, M. **P349**
 Shinzaki, S. P325, P419
 Shiotani, A. P249, P666
 Shirin, H. P345, P561
 Shitrit, A. P345, P561
 Shitrit, A.B.-G. **P197, P217**
 Shmidt, E. DOP023
 Shouval, D. DOP054, P356, P779
 Shpigel, N. OP028, DOP059
 Shraim, R. P446
 Shrumpf, E. P271
 Shteyer, E. P278, P409
 Shulmann, S. P501
 Shums, Z. P152
 Shuttleworth, E. **P036**
 Siakavellas, S. **P627**
 Siau, K. DOP068
 Sibia, C.F. **P760**, NO001, N811, N816, N817
 Sicilia, B. P528
 Sidelmann Brinch, K. DOP083
 Sider, S. P479, P579, P591, P707
 Siebert, S. P027
 Sieczkowska-Golub, J. **P504**
 Sieczkowska, J. P510
 Siegel, C. OP021, **DOP015**, DOP023, **DOP060**, P161, P241
P501, P511, P590, P703
 Siegel, L.S. P161
 Siegmund, B. DOP056, P063, P065, P101, P326, P501, P511, P590, P617
 Sierra-Ausin, M. P436
 Sierra, M. DOP016, N822
 Siersema, P. P722, P726
 Sigall Boneh, R. **DOP006**, DOP007, DOP009, P262, **P484**
 Sike, R. OP023, DOP075
 Silano, M. P301
 Silva, A. P255, P284
 Silva, A.P. P190, P281, P642
 Silva, F.A.R. P025
 Silva, J. P190, P281, P642
 Silva, M. **P049**, P230, **P234**, **P290**, **P308**, P417
 P760, NO001, N799, **N811**, **N816**, N817, N824
 Silver, A. OP029, DOP047
 Silverberg, M. P050, P223, P269, P273, P296, P311, P426, P502, P615, P789, P793
 Simmen, S. P102
 Simon, E. **P128**
 Simon, M. DOP027, DOP032
 Sinagra, E. P372
 Sincic, B. P734
 Singh, A. P448
 Singh, A. P357
 Singh, S. P525
 Singh, S. P410
 Singh, S. P448
 Singh, S. DOP023
 Sipeki, N. **P152**
 Sipponen, T. P366, P515, P639, P685
 Siringo, S. P412
 Sirohi, S. P032, P062, P684
 Sitkin, S. P638
 Sivri, B. P029
 Sjöberg, K. P713
 Sjöberg, M. P364
 Skammelos, A. DOP005, **P751**
 Skehan, S. P261
 Skelly, M. P026, P071, P216
 Skenizes, D. N820
 Skiecevičienė, J. P759
 Skinner, L. OP021
 Sklerovsky Benjaminov, F. P561
 Skovsen, K. P769
 Skuja, V. **P783**
 Skup, M. DOP018, P329, P449, P669, P676, P698, P735
 Sladek, M. DOP009, DOP037, P404, P661
 Sladek, M.. P194
 Slavcev, A. P259
 Slinger, K. P649
 Slomin-Nevo, V. P749
 Smedby, K.E. OP024
 Smedley, C. P036
 Smeets, H. DOP017
 Smets, F. P158
 Smids, C. **P014**, **P267**, **P313**, N796, N797
 P758
 Smith, A. P758
 Smith, K. DOP048
 Smith, M. P527
 Smith, M.I. P050, P789, P793
 Smith, P. P525
 Smith, P. P758
 Smith, S. DOP068
 Smith, S.J. P507
 Smith, V. P047
 Smits, L. **P663**
 Smola, I. P746
 Snapper, S. P356, P753
 So, S. P666
 Sobrero, M.J. P140
 Sofia, M.A. **P192**
 Sokol, H. **P156**, P772
 Solanke, Y. P032, **P062**, P684
 Solcia, E. P301
 Solina, G. P301, P318, P372
 Sollazzo, V. P153
 Solà Tapias, N. **P100**
 Song, E.M. P148, P252, P406, P482, P641
P228, P324
 Song, G.A. P656
 Song, K.-H. P617
 Sonnenberg, E. **P291**
 Sono, M. P596
 Sood, A. P655
 Sood, R. P504, P510
 Sordyl, B. **P471**
 Soret, P.-A. P315
 Soria, J.-C. P389
 Sossenheim, P.H. **P452**
 Soufleris, K. P315
 Soularue, E. P248
 Sousa, H. P190, P281, P642
 Sousa, M. **P255**, **P284**
 Sousa, P. DOP059, **DOP089**, P102, P052, P064, **P768**
 Spalinger, M. DOP030, P310, P386, P609
 Sparrow, M. P511
 Spearman, D. P659
 Speight, A. **DOP004**
 Spektor, L. P002
 Spence, J. P050
 Spencer, D. P259
 Spicak, J. P102
 Spielmann, P. DOP055, P004
 Spinelli, A. **P556**, **P664**
 Spizzo, P. P069
 Sridhar, A. **DOP030**
 Srinivasan, A. P129
 Srirajaskanthan, R. **P527**
 St.Clair Jones, A. **P276**, P403
 Stack, R. P180
 Staes, D. P039
 Staffer, S. P053, P059, P070
 Stagg, A. DOP009, P088, P404
 Staiano, A. **P022**
 Stakenborg, M. **DOP026**, P326, P390
 Stallmach, A. P139
 Stanciu, C. DOP083
 Stange, E.F. P200
 Staniak, A.

- Stansfield, C. P525
 Staples, J. P754
 Stasi, E. DOP016
 Stassen, L. **P132**
 Stawicka, A. P346
 Steenholdt, C. P584, P643
 Steenkamer, J. P066
 Stefanescu, C. DOP011, DOP025, P156, P772
 Stefanich, E. P418
 Stefanov, V. P375
 Stefánsson, T. P734
 Stein, D. DOP020, P667
 Stein, D. DOP022
 Stein, J. P179, P456, P474, P521, P620
 Steiner, C. **P002**
 Steiner, P. P233
 Steiner, S. **OP025**
 Steiner, A. P076
 Steinhagen, P.R. P366
 Steinhart, A.H. P223, P273, P296, P415, P502, P789, P793
 Steinhart, H. P615
 Steinhilber, F. P341
 Stellingwerf, M. DOP042, P476, **P551**
 Stempak, J. P311
 Stevens, C. P082
 Stidham, R.W. P303, P361
 Stijnen, T. P336, P667
 Stitt, L. P050
 Stocco, G. P084
 Stockfisch, T. P121
 Stoker, J. P522
 Stokkers, P. OP015
 Stolte, S. **N806**
 Stone, C.D. P341
 Stone, J. OP037
 Stoot, J. P132
 Stoyanova, K. OP023, DOP075
 Straumann, A. P566
 Straume, Z. P783
 Strauss, R. DOP076, P077, P121
 Streetz, K. P041, P131
 Stremmel, W. **P039**
 Strid, H. DOP001, P364
 Strik, A. **P114, P665**
 Stringfield, S. P357
 Strisciuglio, C. **P088**, P158, P194, P404
 Strohl, M. P626
 Strongili, K. P764
 Stuchlik, S. P595
 Stuhmann, N. P039
 Sturdik, I. P312, P567, **P750**
 Sturm, A. P116
 Sturt, J. P251
 Ståhlhammar, J. P735
 Stefanescu, C. P051
 Su, C.
 Su, M.
 Suarez, P.
 Suarezfarinas, M.
 Subramaniam, K.
 Subramanian, S.
 Sudel, B.
 Sueiro, R.
 Sugaya, T.
 Sugita, A.
 Sugiyama, K.
 Sugrue, K.
 Sulleiro, E.
 Sullivan, B.A.
 Sultan, K.
 Sulz, M.
 Sun, Y.
 Sung, H.-Y.
 Sung, M.
 Suraci, E.
 Sutton, R.
 Suzuki, K.
 Suzuki, R.
 Suzuki, Y.
 Suárez, A.
 Suárez-Lledó, M.
 Suárez, M.J.
 Svaton Lirhus, S.
 Svolos, V.
 Svorcan, P.
 Swaminath, A.
 Swann, J.
 Sweeney, L.
 SWIBREG SVEAH study group
 Swinnen, T.
 Swoger, J.
 SysmedIBD EU research consortium
 Szafarska-Poplawska, A.
 Szalay, B.
 Szamosi, T.
 Szapary, P.
 Szczekliak, K.
 Szczepanik, M.
 Szczepanski, M.
 Szepes, Z.
 Szucs, M.
 Szántó, K.
 Szűcs, D.
 Sáenz Gallo, M.
 Sánchez-Montalvá, A.
 Söderholm, J.
 Söderman, C.
 Sørensen, N.
 Śpiewak, J.
 Şentürk, Ö.
 Soltys, K.
 OP031, OP032, DOP074, P467
 P149
 P436, N822
 P177
P537, P673
 P511, P525
 OP025
 P785, P786
 P325
 P644
 P249, P564
 N804
 P683
 OP034, OP035
 DOP023
 P712
 P096
 P582
 P699
 P108
P552
 DOP073
 P666
 DOP071, P523
 DOP012
 P437
 P224
P728
DOP008
 P236
 DOP023
 P182, P253
 P555
 P364
 P180
 OP021
 DOP049, DOP059
 P504, P510
 P411, P592
 P331, P592, P739
 DOP076
P287
 P504, P510
 P265
 P279, P317, P331, P580, P592, P675, P739
 P317, P580
 P279
 P279
 P634
 P683
 OP022, P061, P788
 P364, P501
 P769
 P189
 P401
 P595
 Šturdík, I.
 Šusterová, I.
Tabbers, M.
 Tacconi, C.
 Tadbiri, S.
 Tae, C.H.
 Taida, T.
 Taira, K.
 Takahashi, M.
 Takano, M.
 Takano, S.
 Takase, A.
 Takehara, T.
 Takenaka, K.
 Talavera, A.
 Talikka, M.
 Tamborska, A.
 Tamim, H.
 Tamminen, K.
 Tan, W.
 Tanaka, A.
 Tanaka, F.
 Tanaka, H.
 Tanaka, T.
 Tang, H.T.
 Tang, J.
 Tang, K.
 Tang, M.T.
 Tang, W.
 Taniere, P.
 Tanigawa, T.
 Tanis, P.
 Tanoue, S.
 Tanuma, T.
 Tanzanu, M.
 Tapete, G.
 Taranath, R.
 Tardillo Marín, C.A.
 Targan, S.
 Tari, R.
 Tartera Diaz, H.
 Tasset, C. OP023, OP033, DOP075
 Tatro, A.R. P395
 Tatsumi, K. P644
 Tattersall, S. P525
 Tauziet, E. P780
 Tavares de Sousa, H. P435, P723
 Tavares, L. N808
 Taxonera, C. DOP016, DOP039, **DOP063**, P186, P327
 Taylor, K. P609
 Taylor, M. **P684**
 Tcybarevich, I. **P052, P072**
 Te Velde, A.A. P066, **P094**
 Teare, G.F. P725

- Tedjo, D. **P781**
 Tee, D. OP036, P577
 Teich, N. P326, P590
 Teich, V. **P449**
 Teixeira, C. **P137**
 Tekin, F. P401
 Telesco, S.E. DOP053, P121
 Temko, D. DOP047
 Ten Hove, J.R. DOP043,
DOP064, DOP067
 Teng, G. P166
 Teniente, A. P367, P562
 Teo, S.-M. P773
 Terai, S. DOP073
 Terpin, M.M. OP005
 Terry, H. P241
 Tessone, L. P074
 Testa, A. **P646**
 Tesè, I. P318
 Tew, W. P431
 Tezel, A. P401
 Thakkar, R. DOP018, P329
 Thapaliya, G. P105
 The ADJUST study group P325
 The DIAMOND study group P523
 The I-CARE Study Group **P509**
 The Nor-Switch Study Group
 DOP062
 Thenet, S. P780
 Theodoraki, E. **P348**
 Theodoropoulou, A. P709
 Thi, A.A. P128, **P439**
 Thiis-Evensen, E. P778
 Thomann, A. **P099**
 Thomann, P. P099
 Thomas, S. P334
 Thommes, J. OP011
 Thompson, B. P413
 Thompson, K. OP021
 Thompson, K.D. DOP015, **P161**
 Thompson, N. P659
 Thomson, M. P211, P432
 Thorkilgaard, T. P769
 Tian, Y. P166
 Tian, Y. **P112**
 Tighe, D. **P602**
 Timeus, S. **P492**
 Tirado, P. P074, P585
 Tiszlavicz, L. P739
 Tjønneland, A. P722
 Tobin, A.M. P184
 Todoroff, A. P547
 Tokushige, K. P464
 Tole, S. OP011
 Tolusso, B. P440
 Tomer, G. P334
 Tominaga, K. P427
 Tomlinson, I. DOP047
 Tommasini, A. P084
 Tomás-Pérez, M. P683
 Tomé, L. P600
 Tonelli, F. P301
 Tonini, G.E. P275
 Topf-Olivestone, C. **P158**, P278
 Tops, S. OP020, P637
 Torgutalp, M. P029
 Torocsik, D. P580
 Torp, R. P710
 Torregrosa Lloret, M. P433
 Torrella Cortés, E. P433
 Torres, E. P463
 Torres, J. OP016, **OP037**, DOP005,
 DOP043, DOP064, **P121**,
 P177, P705, P733
 Torres, N. P503, P605
 Torres, P. DOP016, P706
 Tortora, R. P646
 Tosca, J. P327, P480
 Toshimitsu, F. P493
 Toth, G.T. P331, P592
 Toubeau, J.-F. P560
 Towbin, A. DOP057
 Toya, Y. P325
 Toyonaga, T. P293
 Tozer, P.J. P005, P126, P245, P398
 Trabulo, D. P137
 Trad, D. P378, P631
 Trakal, J. P717
 Tran, A. P196
 Tran-Minh, M.-L. **DOP032**, P420
 Trang-Poisson, C. DOP025
 Tranter, M. **P086**
 Trapani, D. P301
 Trapero, A. P327
 Trautwein, C. DOP049, P041, P131
 Travis, M. P036
 Travis, S. OP026, **DOP018**, P241,
 P270, P271, **P329**, P442,
 P512, P577, P668, P684
 Treasure, P. P058
 Trenkel, S. P486
 Treton, X. P156, P772
 Trichopoulou, A. P722
 Trifan, A. P139
 Trigo Salado, C. P634
 Trivedi, P. **DOP068**
 Trokan, L. DOP077, DOP078, P369
 Troncone, E. OP005
 Trovattello, N. P412
 Trunicka, P. P259
 Truta, B. P488
 Trznadel, A. P200
 Träger, C. P769
 Tréton, X. P142
 Tsadok Perets, T. P708
 Tsapas, A. P421, P662
 Tse, C.S. **P616**
 Tselepis, C. P079
 Tsiianos, E. P751
 Tsuchiwata, S. DOP074
 Tsujii, Y. P630
 Tucci, L. P108
 Tulchinsky, H. P046, P210,
 P278, P300, P459
 Tumino, R. P722
 Tumova, J. P129
 Turcan, S. P694, P695, P727
 Turck, D. P756
 Turina, M. P017
 Turk, N. P742, P747
 Turner, D. DOP007, DOP037,
 DOP054, DOP057, P158, P278, P302,
 P409, P414, P689, P721
 Turpin, W. P789, P793
 Tursi, A. **P373**, P621
 Tvedt-Gundersen, E. P429
 Tweedale, M. P673
 Twomey, P. P250
 Tyakht, A. P794
 Tyrrell, H. OP011
 Tzampouras, N. P751
 Tzivinikos, C. P211, P432
 Törkvist, L. OP022, P061
 Törüner, M. **P401**
Uchino, M. P540
 Udupa, V. **P109**
 Ueda, W. P133
 Ueno, F. P175
 Uhlig, H. P414
 UK inflammatory bowel disease
 (IBD) audit steering group P333
 Ullman, T. DOP043, DOP064,
 213, P554
 Umeda, S. P293
 Umegae, S. P497
 Umeno, J. **P215**, P325, P784
 Ungar, B. **P181**, P366, N820
 Ungaro, F. **P004**
 Ungaro, R. DOP003, DOP005,
 P705, **P733**
 Ungureanu, I. P203, P320,
 P232, P388, P601
 Urbano, A. P437
 Urbanski, S. P212
 Urbonas, V. P404
 Uribarri, L. P785, P786
 Urlep, D. P414
 Usai, P. P301
 Usiskin, K. OP019
 Ünsal, B. P401
Vaartjes, I. P726
 Vakhitov, T. P638

- Valatas, V. P097
 Valats, J.-C. P358
 Valdivieso, B. P205
 Vale Rodrigues, R. DOP014
 Valente, A. DOP014, P135, P168, P362, P385, P453, P636
 Vallicelli, C. DOP041
 Valpiani, D. P694, P695, P727
 ValVano, M.R. P621
 Van Amesfoort, J. **P650**
 Van Arnim, U. P326
 Van Assche, G. OP006, OP009, OP012, OP020, OP038, DOP028, DOP029, DOP044, DOP050, P035, P095, P229, P258, P382, P384, P445, P496, P522, P637, P686, P767, NO003
 Van Biervliet, S. P194
 Van Bodegraven, A. OP017, P132, P744
 Van de Vondel, S. **P438**
 Van de Vrie, W. P665
 Van de Wiele, T. **P777**
 Van Deen, W. P241
 Van den Bossche, L. P777
 Van den Brink, G. DOP036, DOP055, P050, P066, P114, P611
 Van den Cruys, K. P180
 Van den Heuvel, T. P316, P682, **P690**
 Van den Heuvel, T.R.A. P696
 Van der Aa, A. OP023, OP033, DOP075
 Van der Geugten, J. N806
 Van der Giessen, J. **P016**
 Van der Goten, J. P067
 Van Der Merwe, S. P767
 Van der Meulen, A. P336, P667, P682
 Van der Meulen-de Jong, A.E. OP017, DOP004, DOP040, P559
 Van der Woude, C.J. OP018, DOP004, DOP040, P016, P241, P447
 Van Domselaar, M. DOP016, DOP063, P327
 Van Dongen, H. OP015
 Van Esch, A. P663
 Van Gossium, A. DOP069, P560
 Van Haaften, W.T. **DOP051**, P671
 Van Hamersveld, P. P007, P069
 Van Hauwermeiren, F. P776
 Van Herk, E.H. P020
 Van Hoek, B. P667
 Van Hoeve, K. DOP016
 Van hooland, T. P180
 Van Kaem, T. OP033, P610
 Van Koolwijk, E. P014, P313
 Van Langenberg, D. DOP030
 Van Limbergen, J. DOP007, P775
 Van Lochem, E. P014, P267, P313
 Van Lommel, L. P067
 Van Luin, M. N797
 Van Megen, Y. P665
 Van Ranst, M. DOP080
 Van Rheenen, P. **DOP010**, P374
 Van Rosendaal, A. P682
 Van Schaik, F. P722
 Van Spaendonck, H. **P111**
 Van Stappen, J. **P384**
 Van Stappen, T. **DOP029**, P637
 Van Steenberghe, S. P496
 Van Tubergen, A. OP017
 Van Viegen, T. P050
 Van Wagenveld, B. OP015
 Van Welden, S. P777
 Van-der Hofstadt, C. P529
 Vanbeckevoort, D. P258, P384
 Vancamelbeke, M. P067, **P774**
 Vande Casteele, N. OP006, DOP029, **DOP033**, P050
 Vanden Branden, S. P438
 Vanden Bussche, J. P777
 Vandeputte, D. P078
 Vandermeulen, G. P774
 Vandervoort, J. P347
 Vanhaecht, K. NO003
 Vanhaecke, L. P777
 Vanhoutte, F. P610
 Vanhove, W. **P095**
 Vanni, E. P178
 Vanoli, A. P301
 Vanslebrouck, R. P522
 Vara, A. DOP070, P462, P679
 Vardas, E. P709
 Vardi, H. P749
 Varga, G. P118
 Variola, A. OP005
 Vass, N. P279
 Vassallo, R. P412
 Vasseur, F. P756
 Vasudevan, A. DOP030
 Vatn, M. OP022, P061
 Vatn, M.H. P778, P788
 Vatn, S. OP022, P061, P788
 Vavricka, S. P102, **P130**, P304, P566, P569, P711, P712, P719, P740
 Vaysse, T. DOP025, P140
 Vaz, A.M. P435, P723
 Vazeille, E. DOP086
 Vašuka, E. P783
 Vecchi, M. P178, P275
 Vecchione, C. P103
 Vega-López, A. P327
 Vega, R. P043, P045, P220, P513
 Vegh, Z. P145, P309, P331, P411, P592, P623, P694, P695, P727
 Vegni, E. **P506, P534**
 Vela González, M. P629
 Veljkovic, E. P010
 Velloso, L.A. P038
 Velosa, J. DOP014, P135, P168, P322, P362, P385, P453, P636
 Ventharn, N. OP022, P055, P061
 Ventimiglia, M. P372, P387, P412
 Ventra, A. OP005
 Ventura, A. P084
 Vera, M. P186, P607
 Veran, J. OP008
 Verbeek, S. DOP036
 Verbeke, K. P774
 Verdejo Gil, C. **P193**
 Verdier, J. DOP049, P041, **P131**
 Veres, G. DOP009, P152
 Vergniol, J. P499
 Vergnolle, N. P100
 Verhaegh, B. P690
 Verhaegh, B.P.M. **P696, P737**
 Verjee, A. P245, NO002
 Vermehren, J. P486
 Vermeire, S. OP006, OP012, OP014, OP020, **OP023**, OP032, **OP033**, OP034, OP035, OP038, **DOP021**, DOP028, DOP029, DOP044, DOP050, DOP069, DOP075, DOP076, DOP080, P035, P050, P067, P078, P095, P180, P209, P229, P241, P258, P382, P384, P445, P467, P496, P558, **P610**, P637, P686, P767, P774, NO003
 Vermet, C. **P573**
 Vernia, P. P530
 Verreault, A. P352
 Verreth, A. DOP016
 Verschuren, M. P722
 Verseijden, C. P007
 Verstockt, B. **P035**, P067, **P664**
 Verstockt, S. P035, **P067**
 Vervoordeldonk, M. P069
 Verwey, M. P559
 Vester-Andersen, M. DOP003, **P769**, P703
 Vestergaard, C. N795
 Vetrano, S. P004, P050
 Vicente, R. DOP016
 Vicente, R. P423, P528, P618
 Vicuña, M. P480
 Vidarsson, G. DOP036
 Vieira Teixeira, F. DOP056
 Vieira, A.I. P368
 Vieira-Silva, S. P767, P774, P776
 Viennot, S. DOP011, P310
 Vigen, L. P713
 Vijayan, S. P160
 Vikström, E. P048
 Vila, M. **P021**
 Vilanova, M. DOP081

- Vilchez-Vargas, R. P777
 Villanacci, V. P275, P301
 Villoria, A. DOP016
 Vinayaga-Pavan, M. **P758**
 Vinci, E. P412, P621
 Vincze, A. P331, P592, P739
 Vind, I. DOP003, P703, P769
 Viola, A. **P539**
 Viola, F. P440, P526
 Visee, C. OP008
 Viso, D. P436
 Visscher, A. P744
 Visser, R. DOP036
 Visvanathan, S. P091
 Vital, M. P777
 Vitale, A. P088
 Vitor, S. DOP016
 Viña Romero, M.M. P629
 Vogelsang, H. P233
 Voisin, A.-L. P315
 Volchkova, E. P517
 Vollebregt, P. **P744**
 Volta, U. P301
 Von Euler-Chelpin, M.C. P692
 Vong, C. DOP074
 Vora, A. P702
 Vradelis, S. P097
 Vucelic, B. P742
 Vuitton, L. DOP011, P608
 Vultaggio, A. P661
 Vutcovici, M. P734
 Yyas, N. P177
 Vázquez, J.M. P327
 Vázquez-Morón, J.M. **P319, P693**
 Végh, Z. P675, P734
- W**aars, S. **P336**
 Wade, K. P379, **P649**
 Wade, T. NO002
 Wadman, E. DOP052
 Wagner, R.H. P102
 Wahab, P. P014, P267, P313, N796, N797
 Wahed, M. P391
 Waldhör, T. P233
 Waldner, M.J. DOP073
 Waldron, D. P026, P071, P216
 Waldschmitt, N. OP030
 Waljee, A. P303, **P361**
 Walker, G. P413, P550
 Walker, J. P451
 Wall, C. **P635**
 Wallis, Y. OP002
 Walls, D. DOP015
 Walsh, C.M. DOP072, P450
 Walsh, L. **P071**
 Walsh, L.G. P026, P216
 Walsh, C. P032, P062, P684
- Walters, T. P460
 Walters, T. P127, P268
 Walters, T.D. DOP072, P450
 Wang, A. P676
 Wang, D. DOP082
 Wang, H. P083
 Wang, H. P166
 Wang, J.-M. DOP082
 Wang, J. DOP080
 Wang, K. P112
 Wang, L.M. OP026, DOP047, P270
 Wang, P. P121
 Wang, W. P075
 Wang, W. OP031
 Wang, X. P096
 Wang, Z. **P146**
 Wangermez, M. P396
 Ward, M. P386, P609
 Ward, S. DOP068
 Wardi, J. P295
 Wardle, R. **P105**, P128
 Warner, B. P444
 Warner, N. P754
 Warusavitarn, J. P005, P126, NO002
 Wasilewska, A. P661
 Wasko-Czopnik, D. P610
 Watabe, K. P419
 Watanabe, K. **DOP071**, P215, P427, P523
 Watanabe, M. DOP071, P175, P256, P523
 Watanabe, S. P766
 Watanabe, T. DOP066, P427, P540
 Waters, D. OP036, P392
 Watson, D. DOP008
 Wathayalage, R. P537
 Watts, G. **P512**
 Waugh, J. P434
 Weaver, A. P241
 Weaver, S. P379, P645, P649
 Webb, D.-L. P606
 Webber, S. P032, P062, P684
 Weber, A. P522
 Weersma, R.K. DOP004
 Wehkamp, J. DOP083, P563
 Wei, S.C. **P199**
 Weihe, P. P692
 Weinlage, T. P118
 Weiss, B. DOP054, P278, P779
 Weisshof, R. **P619**
 Weizman, A.V. P223, P296, P311, P502
 Welting, O. P007, P069
 Wenzl, H. P233
 Werner, L. **DOP054**
 Werner, S. DOP020
 Westcott, E. P220, N802
 Westera, L. **P050**
 Westerouen van Meeteren, M. **P667**
 Weyts, E. NO003
- Whelan, K. DOP006
 White, M. DOP049
 Whiteman, D. P691
 Whiteoak, S. **P645**
 Whitley, L. P513
 Widjaja, C. OP021
 Widlak, M.M. DOP068
 Wieckowska, N. P200
 Wieme, F. P180
 Wierdsma, N. DOP006
 Wierstra, K. P552
 Wild, G. P342, P677
 Wildenberg, M. DOP036, P007, P066, P114
 Wildenberg, M.E. P094
 Wilkens, R. **P185**
 Willemze, R. **P069, P716**
 Willert, R. P525
 Williams, A. P220, N802
 Williams, C.J. P655
 Williams, E. N798
 Williams, H. P182, P253, P274
 Williams, K. P196
 Williams, M. DOP047
 Williamson, K. DOP065
 Williet, N. **P310**, P573
 Wils, P. **DOP027**
 Wilson, D. P125, P167, P516, P700
 Wilson, S.R. P134
 Wine, E. DOP006, P158
 Winter, D. P109
 Winter, H.S. P158, P278
 Wisniewska-Jarosinska, M. OP023, DOP075
 Wisse, J. **N796**, N797
 Withers, D. P079
 Witteman, B. P722
 Wolf, C. P099
 Wolf, D. OP014, DOP026, P501, **P511**, P590
 Wolfson, P. P439
 Wolters, V. P297, P302
 Wolters, V. P414
 Wolthuis, A. OP012, OP038, DOP044, P258, P445
 Wong, J.-M. P199
 Wong, K. P552
 Wong, Z. P031
 Wood, P. **P516**
 Woodward, J.M. DOP079
 Woodworth, D. OP032
 Wright, A. N803, N805
 Wright, E.K. P773
 Wright, N. DOP047
 Wright, P. P027
 Wroblewski, K. P196
 Wu, K. P075, P096
 Wu, R. DOP082
 Wu, Y. **P691**

- Wullaert, A. P776
Wynne, B. P370
Wyse, J. P495
Wysoczanski, R. P043, **P045**
Wyss, A. P013, **P064**
- X**
Xavier, R. P023, P688
Xavier, S. **P292**
Xie, R. DOP074
Xin, Y. P083
Xu, B. **P075**
Xu, H. **P155**
Xu, L. P672
Xu, P.-P. **P672**
Xu, S. P446
Xu, T. P155
Xue, X. P096
- Y**
Yadav, A. **P520**
Yagel, S. DOP059
Yajnik, V. P023, P688, P704
Yakoubi, M. P631
Yamada, A. P325, P493
Yamada, K. P630
Yamada, S. P012, **P187**
Yamagami, H. P427
Yamaguchi, T. P419
Yamamoto Furusho, J.K. P042, P144, **P164**, P762, P765
Yamamoto, S. P012, P187
Yamamoto, T. **P497, P540**
Yamashita, M. P666
Yanagisawa, H. P666
Yanai, H. **P243**, P612, P757
Yanai, Y. P325
Yang, C.H. P657
Yang, D.-H. P148, P252, P406, P482, P641
Yang, F. DOP060
Yang, H. P096, P155
Yang, H.R. **P237**, P487
Yang, J. OP034
Yang, M. P676
Yang, S.-K. P148, P241, P252, P406, P482, P641
Yang, Z. DOP076
Yarlas, A. P558
Yarrow, H. **N802**
Yarur, A. **DOP020**, P410
Yassin, N. DOP055
Yassin, N.A. P738
Yasuda, K. DOP066
Yavzori, M. P181
Yazdanian, B. P738
Yazdi, A. P776
Yazumi, S. P291
Ye, B.D. DOP061, P148, P252, P406, P482, P548, P641, P701
- Ye, L. **P568**
Yeap, S.P. **DOP079**
Yen, R.-F. P199
Yerushalmi, B. P409
Yi, F. **P195, P286**
Yilmaz, B. P776
Yinda, C. DOP080
Ylisaukko-oja, T. **P515**
Yokoyama, J. DOP073
Yokoyama, K. P225, **P570**
Yokoyama, T. P540
Yokoyama, Y. **P150**, P325
Yoneyama, H. DOP073
Yonezawa, M. P464
Yoo, K. P068
Yoon, H. P715
Yoon, S.-R. P582
Yoon, S.-W. P582
Yoon, Y.S. P461
Yoshida, A. P175
Yoshihara, T. **P419**
Yoshimura, N. DOP071, P523
Yoshino, T. P291, P325, P493
Young, D. P160, P624
Young, P. N798
Yu, Y.S. P068
Yu, Z. P146
Yukawa, T. P427
Yuksel, E.S. DOP001
Yun, S.-H. P582
Yildirim, S. **P214**, P282, P678
- Z**
Zabana, Y. DOP016
Zaghiyan, K. P553
Zagórowicz, E. P504, P510, P738
Zakirov, R. P163
Zalizko, P. P783
Zallot, C. P499
Zaltman, C. **N808**
Zamanillo, D. P033
Zambonin, D. **P687**
Zamborsky, T. **P339**
Zambrano Perez, A. **P219**, **P579**, P591, P707
Zand, A. **P354, P748**
Zangerle-Murray, T. P027
Zanieri, F. P661
Zapata, E. P202
Zapater, P. P076
Zappa, M. P522
Zargari, A. P080, **P106**
Zarubova, K. P194
Zeegers, M.P. P690, P696
Zeitz, J. P102, P130, P711, **P712**
Zelikovic, E. P763
Zelinkova, Z. P339, P375
Zeng, L. P054, **P771**
- Zeng, Z.-R. P394, P653
Zenlea, T. P344
Zeppa, P. P103
Zerbib, F. P499, P680
Zeròncio, M. **P647**
Zezos, P. **P223, P273, P296, P502**
Zhan, X. OP019
Zhang, H. OP032, P467
Zhang, H. **DOP090**
Zhang, H. DOP076, P446
Zhang, H. P146
Zhang, K. P041
Zhang, K. P761
Zhang, M. P149
Zhang, S. P754
Zhang, S.-H. P394, P653
Zhang, W. **P166**
Zhang, X. P177
Zhang, Y. P096
Zhang, Y. P149
Zhao, L. P113
Zhao, R. P418, P522
Zhao, Y. P246
Zheng, D. **P402**
Zheng, J. P047
Zheng, Y. P166
Zhi, M. P149
Zhu, J. P361
Zhu, M. P146
Zhu, W. DOP038
Zhu, X. P096
Zhu, Y. DOP090
Zigman, N. P689, P721
Zinicola, T. P306
Zinkevich, O. P011
Zippi, M. P530
Zittan, E. P273
Zmeter, N. P192
Zmiri, Y. P206, P260, P266, P289
Zorn, M. P521
Zorzi, F. **P332**
Zouraq, I.A. P305
Zárate, F. P717

Imprint

Publisher

ECCO – European Crohn's and Colitis Organisation

OCEAiN – Organisation, Congress, Emotion, Association, iNnovation GmbH

Ungargasse 6/13

1030 Vienna, Austria

Phone: +43-(0)1-710 22 42

Fax: +43-(0)1-710 22 42-001

E-Mail: ecco@ecco-ibd.eu

Web: www.ecco-ibd.eu



European
Crohn's and Colitis
Organisation

To visit the ECCO website, please scan this code
or look at www.ecco-ibd.eu



Dieses Produkt entspricht dem Österreichischen Umweltzeichen für schadstoffarme Druckprodukte (UZ 24).
This product conforms to the standards of the Austrian Environmental Seal of Approval for environmentally
friendly printing products (UZ 24). Grasl Druck & Neue Medien, Bad Vöslau, UW-Nr. 715, www.fairprint.at





European
Crohn's and Colitis
Organisation

We keep you informed at all times!



More reasons to join the ECCO Family!

JCC

- 2015 Impact Factor: 6.585
- ECCO Guidelines and Topical Reviews
- ECCO Scientific Workshop Reviews
- JCC online only (website)
- Printed copies to be purchased at OUP

ECCO Website

- ECCO Activities & Events
- Congress abstracts

ECCO IBD Mobile App

- News on IBD at your fingertips

ECCO News

- All the inside stories of ECCO
- ECCO Calls, Elections and Activities
- Literature reviews

e-CCO Learning

- e-Courses
- e-Library
- Abstracts
- Documents, images
- Webcasts, podcasts

Scan and contact the ECCO Office
www.ecco-ibd.eu





Invitation

Talking points in IBD

12th Congress of ECCO
Thursday, 16th February 2017
11.30am - 12.30pm
Rm 116/117
Centre de Convencions
Internacional de Barcelona

A pathway
towards
personalized
medicine

Evidence-based
switching to
biosimilar
infliximabs

Chair
James Lindsay
London, United Kingdom



Expert
Panel



Chris Probert
Liverpool, UK



Stefan Schreiber
Kiel, Germany

TALKING POINT 1



Biosimilar infliximab in IBD: to switch or not to switch?

Peter Lakatos, Budapest, Hungary
and Montreal, Canada

TALKING POINT 2



Personalized medicine in IBD: rhetoric or reality?

Walter Reinisch, Vienna, Austria

Abbreviated Prescribing Information is available on the Pfizer stand (20)
This satellite symposium meeting is funded and organised by Pfizer
This programme is not affiliated with ECCO
PP-IFA-GLB-0452 | December 2016



Putting the patient first

